{"PMC7107872": [["Methods", [["Methods", "TREATMENT", 0, 7]]]], "PMC7122118": [["IsolationThe isolation of patients with suspected or documented infections\u2014to not spread to others\u2014has been discussed for hundreds of years.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Guidelines are many, methods are different, attitudes show vide variations, routines and procedures are still changing, regulations by law may be absent, and some healthcare professionals may be afraid of adverse outcomes of isolation [1\u201344].", [["procedures", "TREATMENT", 89, 99]]], ["Microbes that are spread in the environment, on the hands and equipment are invisible.", [["hands", "ORGANISM_SUBDIVISION", 52, 57], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["environment", "OBSERVATION_MODIFIER", 32, 43]]], ["The invisible agent does not call on attention before the infection; clinical disease, hospital infection or nosocomial infection is a factum that can be registered [23, 28, 29, 35\u201337].", [["infection", "DISEASE", 58, 67], ["infection", "DISEASE", 96, 105], ["nosocomial infection", "DISEASE", 109, 129], ["the infection", "PROBLEM", 54, 67], ["clinical disease", "PROBLEM", 69, 85], ["hospital infection", "PROBLEM", 87, 105], ["nosocomial infection", "PROBLEM", 109, 129], ["infection", "OBSERVATION", 58, 67], ["nosocomial", "OBSERVATION_MODIFIER", 109, 119], ["infection", "OBSERVATION", 120, 129]]], ["How to stop the transmission is often \u201cto believe and not believe\u201d in infection control.HistoryIsolation comes from the Latin word isolare, from solus meaning alone.", [["infection", "DISEASE", 70, 79], ["infection control", "TREATMENT", 70, 87], ["HistoryIsolation", "TREATMENT", 88, 104], ["infection", "OBSERVATION", 70, 79]]], ["Isola means a \u201cdeserted\u201d island, including Isola outside Venice, Isola di Santa Maria di Nazareth, where the first permanent quarantine hospital\u2014nazaretto changed to Lazaretto (Lazarus)\u2014was created in 1423 [45].", [["hospital\u2014nazaretto", "CHEMICAL", 136, 154], ["Isola di Santa Maria di Nazareth", "TREATMENT", 65, 97], ["the first permanent quarantine hospital\u2014nazaretto", "TREATMENT", 105, 154]]], ["It was the bubonic plague or the Black Death (1347\u20131352) and leprosy which triggered the need for isolation or quarantine that protected against people who were sick.", [["bubonic", "DISEASE", 11, 18], ["Death", "DISEASE", 39, 44], ["leprosy", "DISEASE", 61, 68], ["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["the bubonic plague", "PROBLEM", 7, 25], ["the Black Death", "PROBLEM", 29, 44], ["leprosy", "PROBLEM", 61, 68], ["isolation", "TREATMENT", 98, 107], ["quarantine", "TREATMENT", 111, 121], ["bubonic", "OBSERVATION_MODIFIER", 11, 18], ["plague", "OBSERVATION", 19, 25]]], ["Quarantine (from Italian quaranta = 40) was introduced in Southern Europe ca. year 1400, to isolate presumed infectious ships, persons, goods, food and equipment from other places at quarantine stations for 40 days, i.e. double the incubation period for most serious infectious diseases, also in our time.HistoryIn Norway, isolation was created primarily for leprous patients, probably by King Magnus Lagab\u00f8ter in Bergen, ca.", [["Quarantine", "CHEMICAL", 0, 10], ["infectious diseases", "DISEASE", 267, 286], ["leprous", "DISEASE", 359, 366], ["Quarantine", "CHEMICAL", 0, 10], ["patients", "ORGANISM", 367, 375], ["persons", "SPECIES", 127, 134], ["patients", "SPECIES", 367, 375], ["most serious infectious diseases", "PROBLEM", 254, 286], ["infectious", "OBSERVATION", 109, 119]]], ["1270, later on for the Black Death (approximately 1350), the white plague; tuberculosis, from the mid-1800s, at sanatoriums like Luster in Sogn and Glitre in Akershus or in separate isolation buildings at the hospital, like epidemic buildings at Ullev\u00e5l Hospital.HistoryDespite academic controversy about \u201cinfection or not\u201d from the late 1700s to the 1860s, the isolation treatment was used for presumably \u201cinfectious diseases\u201d like typhoid, cholera, scarlet fever, diphtheria, smallpox, plague, etc. Patients were isolated in hospital, at home or in own local epidemic houses in the country.", [["Death", "DISEASE", 29, 34], ["white plague", "DISEASE", 61, 73], ["tuberculosis", "DISEASE", 75, 87], ["infection", "DISEASE", 306, 315], ["infectious diseases\u201d", "DISEASE", 407, 427], ["typhoid", "DISEASE", 433, 440], ["cholera", "DISEASE", 442, 449], ["scarlet fever", "DISEASE", 451, 464], ["diphtheria", "DISEASE", 466, 476], ["smallpox", "DISEASE", 478, 486], ["plague", "DISEASE", 488, 494], ["Patients", "ORGANISM", 501, 509], ["Patients", "SPECIES", 501, 509], ["the Black Death", "PROBLEM", 19, 34], ["the white plague", "PROBLEM", 57, 73], ["tuberculosis", "PROBLEM", 75, 87], ["\u201cinfection", "PROBLEM", 305, 315], ["the isolation treatment", "TREATMENT", 358, 381], ["\u201cinfectious diseases", "PROBLEM", 406, 426], ["typhoid", "PROBLEM", 433, 440], ["cholera", "PROBLEM", 442, 449], ["scarlet fever", "PROBLEM", 451, 464], ["diphtheria", "PROBLEM", 466, 476], ["smallpox", "PROBLEM", 478, 486], ["plague", "PROBLEM", 488, 494], ["tuberculosis", "OBSERVATION", 75, 87], ["infection", "OBSERVATION", 306, 315], ["infectious", "OBSERVATION", 407, 417], ["typhoid", "OBSERVATION", 433, 440]]], ["Chronic carriers of typhoid bacteria (Salmonella typhi) were isolated alone at home or at the counties epidemic house by themselves (Smitteborg, \u201cinfection castle\u201d in Skreia, Norway, is still a local name).", [["typhoid bacteria", "DISEASE", 20, 36], ["infection", "DISEASE", 146, 155], ["typhoid bacteria", "ORGANISM", 20, 36], ["Salmonella typhi", "ORGANISM", 38, 54], ["Salmonella typhi", "SPECIES", 38, 54], ["Salmonella typhi", "SPECIES", 38, 54], ["typhoid bacteria", "PROBLEM", 20, 36], ["Salmonella typhi", "PROBLEM", 38, 54], ["typhoid bacteria", "OBSERVATION", 20, 36]]], ["The epidemic houses had access control and were monitored by the healthcare board mayor.", [["access control", "TREATMENT", 24, 38]]], ["Hygiene and infection control were very important since they had few curative agents.", [["Hygiene", "DISEASE", 0, 7], ["infection", "DISEASE", 12, 21], ["infection control", "TREATMENT", 12, 29], ["few curative agents", "TREATMENT", 65, 84], ["infection", "OBSERVATION", 12, 21]]], ["It was prepared vaccines and carried out partly or complete mass vaccinations against some infections.HistoryPulmonary tuberculosis was treated at sanatoriums in the mountains or at coast hospitals.", [["infections", "DISEASE", 91, 101], ["HistoryPulmonary tuberculosis", "DISEASE", 102, 131], ["vaccines", "TREATMENT", 16, 24], ["complete mass vaccinations", "TREATMENT", 51, 77], ["some infections", "PROBLEM", 86, 101], ["HistoryPulmonary tuberculosis", "PROBLEM", 102, 131], ["mass", "OBSERVATION", 60, 64], ["infections", "OBSERVATION", 91, 101], ["tuberculosis", "OBSERVATION", 119, 131]]], ["The patient did not come home until he was free from infection.", [["infection", "DISEASE", 53, 62], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["infection", "PROBLEM", 53, 62], ["infection", "OBSERVATION", 53, 62]]], ["During outbreaks of typhoid fever, diphtheria or scarlet fever, the patients were isolated in separate sick barracks or at home.", [["typhoid fever", "DISEASE", 20, 33], ["diphtheria", "DISEASE", 35, 45], ["scarlet fever", "DISEASE", 49, 62], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["typhoid fever", "PROBLEM", 20, 33], ["diphtheria", "PROBLEM", 35, 45], ["scarlet fever", "PROBLEM", 49, 62], ["typhoid", "OBSERVATION_MODIFIER", 20, 27], ["scarlet", "OBSERVATION_MODIFIER", 49, 56]]], ["To be a carrier of an infectious disease could lead to work prohibition and isolation.", [["infectious disease", "DISEASE", 22, 40], ["an infectious disease", "PROBLEM", 19, 40], ["isolation", "TREATMENT", 76, 85], ["infectious", "OBSERVATION", 22, 32]]], ["Schools were closed intermittently during outbreaks, and posters were put on houses with infectious disease as a warning.", [["infectious disease", "DISEASE", 89, 107]]], ["Disinfection of houses, clothing and all of its contents was completed after the termination of the isolation period, using chlorine and sulphur smoke.", [["chlorine", "CHEMICAL", 124, 132], ["sulphur", "CHEMICAL", 137, 144], ["chlorine", "CHEMICAL", 124, 132], ["sulphur", "CHEMICAL", 137, 144], ["chlorine", "SIMPLE_CHEMICAL", 124, 132], ["sulphur", "SIMPLE_CHEMICAL", 137, 144], ["clothing", "TREATMENT", 24, 32], ["chlorine", "TREATMENT", 124, 132], ["sulphur smoke", "OBSERVATION", 137, 150]]], ["Carbolic acid and hydrochloric acid were also used where sulphur fumes treatment failed.", [["Carbolic acid", "CHEMICAL", 0, 13], ["hydrochloric acid", "CHEMICAL", 18, 35], ["sulphur fumes", "CHEMICAL", 57, 70], ["Carbolic acid", "CHEMICAL", 0, 13], ["hydrochloric acid", "CHEMICAL", 18, 35], ["sulphur fumes", "CHEMICAL", 57, 70], ["Carbolic acid", "SIMPLE_CHEMICAL", 0, 13], ["hydrochloric acid", "SIMPLE_CHEMICAL", 18, 35], ["sulphur fumes", "SIMPLE_CHEMICAL", 57, 70], ["Carbolic acid", "TREATMENT", 0, 13], ["hydrochloric acid", "TREATMENT", 18, 35], ["sulphur fumes treatment", "TREATMENT", 57, 80]]], ["Bedding, clothing and fixtures that could not be washed or disinfected were often burned, with a financial compensation for this \u201coutlay.\u201d", [["clothing and fixtures", "TREATMENT", 9, 30]]], ["Patients who broke the isolation routines could be penalized and committed to further isolation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the isolation routines", "TREATMENT", 19, 41], ["further isolation", "TREATMENT", 78, 95]]], ["The society\u2019s need went first before each individual\u2019s needs [46].HistoryDuring the 20 years from 1911 to 1930, among approximately 2.4 million inhabitants in Norway, there were a total of 2,146,702 cases of acute laryngitis and bronchitis, 470,099 with acute gastroenteritis, 181,752 with \u201ccroup pneumonia,\u201d 89,100 cases of diphtheria, 75,000 with scarlet fever, 71,000 with rheumatic fever, 15,000 with typhoid and paratyphoid fever, 5300 with poliomyelitis and 3200 with dysentery! [46]HistoryKnowledge of infection, sanitation and housing conditions (less overcrowded), clean water, good personal hygiene, vaccinations and nutritional status were factors mitigating epidemic outbreaks beginning of the twentieth century.", [["laryngitis", "DISEASE", 214, 224], ["bronchitis", "DISEASE", 229, 239], ["acute gastroenteritis", "DISEASE", 254, 275], ["pneumonia", "DISEASE", 297, 306], ["diphtheria", "DISEASE", 325, 335], ["scarlet fever", "DISEASE", 349, 362], ["rheumatic fever", "DISEASE", 376, 391], ["typhoid and paratyphoid fever", "DISEASE", 405, 434], ["poliomyelitis", "DISEASE", 446, 459], ["dysentery", "DISEASE", 474, 483], ["infection", "DISEASE", 509, 518], ["acute laryngitis", "PROBLEM", 208, 224], ["bronchitis", "PROBLEM", 229, 239], ["acute gastroenteritis", "PROBLEM", 254, 275], ["\u201ccroup pneumonia", "PROBLEM", 290, 306], ["diphtheria", "PROBLEM", 325, 335], ["scarlet fever", "PROBLEM", 349, 362], ["rheumatic fever", "PROBLEM", 376, 391], ["typhoid", "PROBLEM", 405, 412], ["paratyphoid fever", "PROBLEM", 417, 434], ["poliomyelitis", "PROBLEM", 446, 459], ["dysentery", "PROBLEM", 474, 483], ["infection", "PROBLEM", 509, 518], ["vaccinations", "TREATMENT", 610, 622], ["acute", "OBSERVATION_MODIFIER", 208, 213], ["laryngitis", "OBSERVATION", 214, 224], ["bronchitis", "OBSERVATION", 229, 239], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["gastroenteritis", "OBSERVATION", 260, 275], ["pneumonia", "OBSERVATION", 297, 306], ["rheumatic", "OBSERVATION_MODIFIER", 376, 385], ["fever", "OBSERVATION", 386, 391], ["infection", "OBSERVATION", 509, 518]]], ["This demonstrates that most infectious diseases can be prevented and controlled, even without antibiotics.HistoryIn 1937, before the breakthrough of the penicillin, there were the most important precautions against infectious diseases in Norway: [1] isolation of the source of infection, [2] disinfection, [3] vaccination, [4] quarantine, [5] food hygiene and [6] eradication of insects [46].", [["infectious diseases", "DISEASE", 28, 47], ["penicillin", "CHEMICAL", 153, 163], ["infectious diseases", "DISEASE", 215, 234], ["infection", "DISEASE", 277, 286], ["penicillin", "CHEMICAL", 153, 163], ["penicillin", "SIMPLE_CHEMICAL", 153, 163], ["most infectious diseases", "PROBLEM", 23, 47], ["antibiotics", "TREATMENT", 94, 105], ["the penicillin", "TREATMENT", 149, 163], ["infection", "PROBLEM", 277, 286], ["most", "OBSERVATION_MODIFIER", 23, 27], ["infectious", "OBSERVATION", 28, 38], ["infection", "OBSERVATION", 277, 286]]], ["Airborne infection was estimated as \u201cthe most important form of spreading infections\u201d which may be correct even today [46, 47].HistoryThe last 125 years of isolation treatment carried out in Norway have been in separate houses and buildings until ca.", [["infection", "DISEASE", 9, 18], ["infections", "DISEASE", 74, 84], ["Airborne infection", "PROBLEM", 0, 18], ["spreading infections", "PROBLEM", 64, 84], ["isolation treatment", "TREATMENT", 156, 175], ["infection", "OBSERVATION", 9, 18], ["spreading", "OBSERVATION_MODIFIER", 64, 73], ["infections", "OBSERVATION", 74, 84]]], ["1960 when most infectious diseases were integrated into appropriate wards for the underlying diseases.", [["infectious diseases", "DISEASE", 15, 34], ["most infectious diseases", "PROBLEM", 10, 34], ["the underlying diseases", "PROBLEM", 78, 101], ["diseases", "OBSERVATION", 93, 101]]], ["In 1970 there was still isolate buildings where all kinds of infections were taken care of and with good routines.", [["infections", "DISEASE", 61, 71], ["infections", "PROBLEM", 61, 71], ["infections", "OBSERVATION", 61, 71]]], ["Today, this type of isolation is gone, with exception of some buildings in preparedness for strict isolation.Hospital Infections that Should Be Treated in IsolatesIn each third to fifth hospital bed, there is an infected patient, and each third patient is treated with resistance-driving antibiotics today [28, 29, 35, 48].", [["Infections", "DISEASE", 118, 128], ["patient", "ORGANISM", 221, 228], ["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 221, 228], ["patient", "SPECIES", 245, 252], ["strict isolation", "TREATMENT", 92, 108], ["driving antibiotics", "TREATMENT", 280, 299], ["infected", "OBSERVATION", 212, 220]]], ["Isolation units are therefore of great need.Hospital Infections that Should Be Treated in IsolatesIn Norway with 5.5 million inhabitants, ca.", [["Infections", "DISEASE", 53, 63], ["Isolation units", "TREATMENT", 0, 15]]], ["900,000 patients are treated annually in hospitals and about 50,000 receive hospital infections, resulting in at least 450,000 extra days in hospitals because of infection.", [["infections", "DISEASE", 85, 95], ["infection", "DISEASE", 162, 171], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["hospital infections", "PROBLEM", 76, 95], ["infection", "PROBLEM", 162, 171], ["infection", "OBSERVATION", 162, 171]]], ["Hospital infections with Staphylococcus aureus occur in 2% of the patients [28, 29].", [["infections", "DISEASE", 9, 19], ["Staphylococcus aureus", "DISEASE", 25, 46], ["Staphylococcus aureus", "ORGANISM", 25, 46], ["patients", "ORGANISM", 66, 74], ["Staphylococcus aureus", "SPECIES", 25, 46], ["patients", "SPECIES", 66, 74], ["Staphylococcus aureus", "SPECIES", 25, 46], ["Hospital infections", "PROBLEM", 0, 19], ["Staphylococcus aureus", "PROBLEM", 25, 46], ["Staphylococcus aureus", "OBSERVATION", 25, 46]]], ["Isolation treatment is laborious and expensive (ca.", [["Isolation treatment", "TREATMENT", 0, 19]]], ["Out of the 13,700 somatic beds in Norway in 2013, hospital infections charged ca.", [["infections", "DISEASE", 59, 69]]], ["20% of these, which would generate a need for ca.", [["ca", "PROBLEM", 46, 48]]], ["2740 infection beds.", [["infection", "DISEASE", 5, 14], ["infection", "OBSERVATION", 5, 14]]], ["However, the somatic bed capacity in Norway is steadily being reduced, which creates several problems in the healthcare.New and Old Microbes Increase the Need for IsolatesThere is an increased need of isolates for patients with infections, especially due to pulmonary tuberculosis, MRSA, VRE, Clostridium difficile (CD), multiresistant gram-negative bacteria and other \u201cmultidrug-resistant organisms\u201d (MDRO) [23, 24, 36, 37, 48\u201351].", [["pulmonary", "ANATOMY", 258, 267], ["infections", "DISEASE", 228, 238], ["pulmonary tuberculosis", "DISEASE", 258, 280], ["MRSA", "DISEASE", 282, 286], ["VRE", "DISEASE", 288, 291], ["Clostridium difficile", "DISEASE", 293, 314], ["CD", "DISEASE", 316, 318], ["patients", "ORGANISM", 214, 222], ["pulmonary", "ORGAN", 258, 267], ["Clostridium difficile", "ORGANISM", 293, 314], ["patients", "SPECIES", 214, 222], ["MRSA", "SPECIES", 282, 286], ["Clostridium difficile", "SPECIES", 293, 314], ["MRSA", "SPECIES", 282, 286], ["Clostridium difficile", "SPECIES", 293, 314], ["the somatic bed capacity", "PROBLEM", 9, 33], ["isolates", "TREATMENT", 201, 209], ["infections", "PROBLEM", 228, 238], ["pulmonary tuberculosis", "PROBLEM", 258, 280], ["MRSA", "PROBLEM", 282, 286], ["VRE", "PROBLEM", 288, 291], ["Clostridium difficile", "PROBLEM", 293, 314], ["multiresistant gram-negative bacteria", "PROBLEM", 321, 358], ["resistant organisms", "PROBLEM", 380, 399], ["reduced", "OBSERVATION_MODIFIER", 62, 69], ["several", "OBSERVATION_MODIFIER", 85, 92], ["problems", "OBSERVATION", 93, 101], ["Microbes", "OBSERVATION_MODIFIER", 132, 140], ["Increase", "OBSERVATION_MODIFIER", 141, 149], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["pulmonary", "ANATOMY", 258, 267], ["tuberculosis", "OBSERVATION", 268, 280], ["MRSA", "OBSERVATION", 282, 286], ["negative bacteria", "OBSERVATION", 341, 358]]], ["Global incidence of entero-pathogenic bacteria and imported resistant agents increases, and there is an ongoing microbial spread via food, animals, fish, water, supplies and the environment [48, 51].New and Old Microbes Increase the Need for IsolatesNew knowledge of transmission, robustness and ability to survive in the environment may reinforce the methods for isolation.", [["fish", "ORGANISM_SUBDIVISION", 148, 152], ["entero-pathogenic bacteria", "PROBLEM", 20, 46], ["entero-pathogenic bacteria", "OBSERVATION", 20, 46], ["resistant agents", "OBSERVATION", 60, 76], ["microbial spread", "OBSERVATION", 112, 128], ["Microbes", "OBSERVATION_MODIFIER", 211, 219], ["Increase", "OBSERVATION_MODIFIER", 220, 228]]], ["CD, originally defined as contact transmission, may also spread through the air [52].", [["CD", "DISEASE", 0, 2]]], ["CD problem increases, particularly in the United States where half a million patients are infected each year and 29,000 of them died in 2011 [53].", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["CD problem", "PROBLEM", 0, 10], ["increases", "OBSERVATION_MODIFIER", 11, 20]]], ["A special dangerous CD type (NAP1) is detected [53].New and Old Microbes Increase the Need for IsolatesThe incidence of new respiratory viruses like Human metapneumovirus, bocavirus, Human coronavirus, etc. increases.", [["respiratory viruses", "DISEASE", 124, 143], ["Human metapneumovirus", "DISEASE", 149, 170], ["Human coronavirus", "DISEASE", 183, 200], ["NAP1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Human", "ORGANISM", 149, 154], ["metapneumovirus", "ORGANISM", 155, 170], ["bocavirus", "ORGANISM", 172, 181], ["Human", "ORGANISM", 183, 188], ["coronavirus", "ORGANISM", 189, 200], ["Human", "SPECIES", 149, 154], ["metapneumovirus", "SPECIES", 155, 170], ["Human", "SPECIES", 183, 188], ["coronavirus", "SPECIES", 189, 200], ["Human metapneumovirus", "SPECIES", 149, 170], ["Human coronavirus", "SPECIES", 183, 200], ["Old Microbes", "PROBLEM", 60, 72], ["Isolates", "TREATMENT", 95, 103], ["new respiratory viruses", "PROBLEM", 120, 143], ["Human metapneumovirus", "PROBLEM", 149, 170], ["bocavirus", "PROBLEM", 172, 181], ["dangerous CD", "OBSERVATION_MODIFIER", 10, 22], ["Microbes", "OBSERVATION_MODIFIER", 64, 72], ["Increase", "OBSERVATION_MODIFIER", 73, 81], ["new", "OBSERVATION_MODIFIER", 120, 123], ["respiratory viruses", "OBSERVATION", 124, 143], ["metapneumovirus", "OBSERVATION", 155, 170]]], ["For the first time in more than 100 years, a highly pathogenic virus as Ebola has been introduced to Norway and to other countries in Europe.", [["Ebola", "DISEASE", 72, 77], ["Ebola", "ORGANISM", 72, 77], ["a highly pathogenic virus", "PROBLEM", 43, 68], ["virus", "OBSERVATION", 63, 68]]], ["Pandemic-actual viruses such as SARS, MERS, different types of bird flu, new outbreaks of Ebola and other viral haemorrhagic fevers show the need for isolation and emergency preparedness [30\u201334].New and Old Microbes Increase the Need for IsolatesChildren\u2019s diseases, who disappeared with vaccinations, like whooping cough, mumps, rubella and measles, are now increasing with outbreaks in areas with high vaccination rate in America and Europe [1].", [["SARS", "DISEASE", 32, 36], ["bird flu", "DISEASE", 63, 71], ["Ebola", "DISEASE", 90, 95], ["viral haemorrhagic fevers", "DISEASE", 106, 131], ["whooping cough", "DISEASE", 307, 321], ["mumps", "DISEASE", 323, 328], ["rubella", "DISEASE", 330, 337], ["measles", "DISEASE", 342, 349], ["bird flu", "ORGANISM", 63, 71], ["Ebola", "ORGANISM", 90, 95], ["Children", "SPECIES", 246, 254], ["Pandemic", "PROBLEM", 0, 8], ["actual viruses", "PROBLEM", 9, 23], ["SARS", "PROBLEM", 32, 36], ["MERS", "PROBLEM", 38, 42], ["bird flu", "PROBLEM", 63, 71], ["Ebola", "PROBLEM", 90, 95], ["other viral haemorrhagic fevers", "PROBLEM", 100, 131], ["vaccinations", "TREATMENT", 288, 300], ["whooping cough", "PROBLEM", 307, 321], ["mumps", "PROBLEM", 323, 328], ["rubella", "PROBLEM", 330, 337], ["measles", "PROBLEM", 342, 349], ["high vaccination rate", "TREATMENT", 399, 420], ["viruses", "OBSERVATION", 16, 23], ["bird flu", "OBSERVATION", 63, 71], ["Microbes", "OBSERVATION_MODIFIER", 207, 215], ["Increase", "OBSERVATION_MODIFIER", 216, 224]]], ["From 2014 to 2015, Europe had more than 22,000 measles cases [54].", [["measles", "DISEASE", 47, 54]]], ["By hospitalization, these need airborne infection isolation units.New and Old Microbes Increase the Need for IsolatesNoro-, rota- and sapoviruses and other types of virus gastroenteritis are highly infectious with vomiting and producing of aerosols, i.e. airborne infection.", [["infection", "DISEASE", 40, 49], ["gastroenteritis", "DISEASE", 171, 186], ["vomiting", "DISEASE", 214, 222], ["airborne infection", "DISEASE", 255, 273], ["airborne infection isolation units", "TREATMENT", 31, 65], ["Old Microbes", "PROBLEM", 74, 86], ["IsolatesNoro", "TEST", 109, 121], ["rota", "TREATMENT", 124, 128], ["sapoviruses", "TREATMENT", 134, 145], ["virus gastroenteritis", "PROBLEM", 165, 186], ["vomiting", "PROBLEM", 214, 222], ["airborne infection", "PROBLEM", 255, 273], ["airborne infection", "OBSERVATION", 31, 49], ["Microbes", "OBSERVATION_MODIFIER", 78, 86], ["Increase", "OBSERVATION_MODIFIER", 87, 95], ["virus gastroenteritis", "OBSERVATION", 165, 186], ["infectious", "OBSERVATION_MODIFIER", 198, 208], ["airborne infection", "OBSERVATION", 255, 273]]], ["Growing global outbreaks of norovirus may cause fast and widely spread of gastroenteritis among patients and personnel in health institutions and cause inactivity and stop of new admissions [55, 56].Particular Issues Around Infection and IsolationThe closure of wards or hospitals.", [["norovirus", "DISEASE", 28, 37], ["gastroenteritis", "DISEASE", 74, 89], ["norovirus", "ORGANISM", 28, 37], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["norovirus", "SPECIES", 28, 37], ["Growing global outbreaks of norovirus", "PROBLEM", 0, 37], ["gastroenteritis", "PROBLEM", 74, 89], ["Particular Issues", "PROBLEM", 199, 216], ["Infection", "PROBLEM", 224, 233], ["global", "OBSERVATION_MODIFIER", 8, 14], ["outbreaks", "OBSERVATION", 15, 24], ["norovirus", "OBSERVATION", 28, 37], ["widely", "OBSERVATION_MODIFIER", 57, 63], ["spread", "OBSERVATION_MODIFIER", 64, 70], ["gastroenteritis", "OBSERVATION", 74, 89], ["Infection", "OBSERVATION", 224, 233], ["closure", "OBSERVATION", 251, 258]]], ["Geriatric wards are usually closed during outbreaks.", [["Geriatric wards", "TREATMENT", 0, 15]]], ["The most frequent cause is outbreaks of norovirus, 44%, p < 0.001 and influenza/parainfluenza, 38.5%, p < 0.001 [16].Particular Issues Around Infection and IsolationIntensive care units (ICU) are often particularly vulnerable to infection.", [["norovirus", "DISEASE", 40, 49], ["influenza/parainfluenza", "DISEASE", 70, 93], ["infection", "DISEASE", 229, 238], ["parainfluenza", "ORGANISM", 80, 93], ["parainfluenza", "SPECIES", 80, 93], ["norovirus", "PROBLEM", 40, 49], ["influenza", "TEST", 70, 79], ["parainfluenza", "TEST", 80, 93], ["Particular Issues", "PROBLEM", 117, 134], ["IsolationIntensive care units", "TREATMENT", 156, 185], ["infection", "PROBLEM", 229, 238], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["norovirus", "OBSERVATION", 40, 49], ["Infection", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 229, 238]]], ["Cross-contamination between such patients is normal [57].", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["normal", "OBSERVATION", 45, 51]]], ["In a 16-bed ICU for adults, 430 patients were followed for 3950 patient days and cross-transmission was followed by genetic typing of the microbes [57].", [["adults", "ORGANISM", 20, 26], ["patients", "ORGANISM", 32, 40], ["patient", "ORGANISM", 64, 71], ["patients", "SPECIES", 32, 40], ["patient", "SPECIES", 64, 71]]], ["A total of 40 episodes of cross-transmission was demonstrated and dominated by Pseudomonas aeruginosa, other gram-negative bacilli and S aureus.", [["Pseudomonas aeruginosa", "ORGANISM", 79, 101], ["S aureus", "ORGANISM", 135, 143], ["Pseudomonas aeruginosa", "SPECIES", 79, 101], ["S aureus", "SPECIES", 135, 143], ["Pseudomonas aeruginosa", "SPECIES", 79, 101], ["S aureus", "SPECIES", 135, 143], ["cross-transmission", "PROBLEM", 26, 44], ["Pseudomonas aeruginosa", "PROBLEM", 79, 101], ["other gram", "TEST", 103, 113], ["S aureus", "PROBLEM", 135, 143], ["negative bacilli", "OBSERVATION", 114, 130], ["aureus", "OBSERVATION", 137, 143]]], ["Cross-transmission was associated with understaffing, use of nasogastric tube, ventilator and other multiple patient-to-nurse contacts and immune-compromised patients [57].", [["nasogastric tube", "ANATOMY", 61, 77], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 61, 77], ["patient", "ORGANISM", 109, 116], ["patients", "ORGANISM", 158, 166], ["patient", "SPECIES", 109, 116], ["patients", "SPECIES", 158, 166], ["nasogastric tube", "TREATMENT", 61, 77], ["ventilator", "TREATMENT", 79, 89], ["nasogastric tube", "OBSERVATION", 61, 77]]], ["Patients treated at understaffed ICUs were three times more likely to be infected; immunosuppressed had four times greater risk, and bronchoscopy-treated patients led five times higher risk [57].", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 154, 162], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 154, 162], ["bronchoscopy", "TEST", 133, 145], ["infected", "OBSERVATION", 73, 81]]], ["Intensive units often have no isolates, and if they have, they are not so much used because of staff shortages.Airborne Infection Isolation Units: \u201cHigh-Level Isolation Rooms\u201d ::: Lack of Infection IsolatesIn 2009, a European investigation was done as regards the number of \u201chigh-level isolation rooms\u201d (HIRs), i.e. airborne infection isolation units with negative pressure (not defined) with at least 6 air changes per hour and sluice (anteroom) [61].", [["infection", "DISEASE", 325, 334], ["isolates", "PROBLEM", 30, 38], ["Infection", "PROBLEM", 188, 197], ["a European investigation", "TEST", 215, 239], ["airborne infection isolation units", "TREATMENT", 316, 350], ["Infection", "OBSERVATION", 120, 129], ["Infection", "OBSERVATION", 188, 197], ["airborne infection", "OBSERVATION", 316, 334]]], ["This is a unit intended for high- risk infections like haemorrhagic viral infection, SARS, the starting phase of pandemic influenza, XDR (extended drug-resistant) tuberculosis, anthrax, plague, biological terrorism, etc. [61]Airborne Infection Isolation Units: \u201cHigh-Level Isolation Rooms\u201d ::: Lack of Infection IsolatesIn all, 16 European network countries (EUNID) with 211 hospitals and about 1790 isolation beds participated.", [["infections", "DISEASE", 39, 49], ["haemorrhagic viral infection", "DISEASE", 55, 83], ["SARS", "DISEASE", 85, 89], ["influenza", "DISEASE", 122, 131], ["XDR", "DISEASE", 133, 136], ["tuberculosis", "DISEASE", 163, 175], ["anthrax", "DISEASE", 177, 184], ["plague", "DISEASE", 186, 192], ["high- risk infections", "PROBLEM", 28, 49], ["haemorrhagic viral infection", "PROBLEM", 55, 83], ["SARS", "PROBLEM", 85, 89], ["pandemic influenza", "PROBLEM", 113, 131], ["XDR", "PROBLEM", 133, 136], ["tuberculosis", "PROBLEM", 163, 175], ["anthrax", "PROBLEM", 177, 184], ["plague", "PROBLEM", 186, 192], ["Infection", "PROBLEM", 302, 311], ["haemorrhagic", "OBSERVATION_MODIFIER", 55, 67], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infection", "OBSERVATION", 74, 83], ["tuberculosis", "OBSERVATION", 163, 175], ["Infection", "OBSERVATION", 302, 311]]], ["The total proportion of airborne infection isolates (HIR) per country were calculated per million inhabitants.", [["airborne infection", "DISEASE", 24, 42], ["airborne infection isolates", "PROBLEM", 24, 51], ["total", "OBSERVATION_MODIFIER", 4, 9], ["airborne infection", "OBSERVATION", 24, 42]]], ["The largest proportion of these isolation units were detected in Luxemburg, 31.5 per million; followed by Finland, 28.4; Sweden, 25.9; Ireland, 15.1; Denmark, 14.3; Italy, 12.3; and Estonia, 11.2 per million inhabitants.", [["these isolation units", "TREATMENT", 26, 47], ["Denmark", "TEST", 150, 157], ["Italy", "TEST", 165, 170], ["Estonia", "TEST", 182, 189], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["proportion", "OBSERVATION_MODIFIER", 12, 22], ["isolation units", "OBSERVATION", 32, 47]]], ["Spain, the Netherlands, Germany and the United Kingdom had the lowest share, 0.2, 0.2, 0.3 and 1.7 per million inhabitants, respectively [61].Airborne Infection Isolation Units: \u201cHigh-Level Isolation Rooms\u201d ::: Lack of Infection IsolatesMost countries used HEPA filter for air extraction from the isolates (9 out of 11).", [["Infection Isolates", "PROBLEM", 219, 237], ["HEPA filter", "TREATMENT", 257, 268], ["air extraction", "TREATMENT", 273, 287], ["the isolates", "TEST", 293, 305], ["Infection", "OBSERVATION", 151, 160], ["Infection", "OBSERVATION", 219, 228], ["air extraction", "OBSERVATION", 273, 287]]], ["Among 13 countries, 4 had localized airborne isolates (HIR) to own buildings or wards, in 4 was HIR in the same ward as other patient rooms, and in 5 both solutions were adopted [61].", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133]]], ["A total of 342 HIRs were equipped for intensive care, most in Italy (245 beds) and in Denmark (40 portable beds) [61].Airborne Infection Isolation Units: \u201cHigh-Level Isolation Rooms\u201d ::: Lack of Infection IsolatesAfter year 2000, HIRs have been used in Europe to approximately 10 imported haemorrhagic fever cases and 33 confirmed SARS cases.Airborne Infection Isolation Units: \u201cHigh-Level Isolation Rooms\u201d ::: Lack of Infection IsolatesIn the United States, there are three \u201chigh-level isolation units\u201d (HLIU), placed at the same level as laboratory with biosafety level (BSL) 3 and 4, in separate buildings, with limited and controlled access, negative air pressure and special treatment of sewage and garbage [62].Isolate: Design and Function ::: Lack of Infection IsolatesIsolates rely on \u201cevidence-based design,\u201d i.e. knowledge of the construction, design, materials, equipment, furnishing, standards, etc., which are considered as core elements of the infection prevention [63].", [["haemorrhagic fever", "DISEASE", 289, 307], ["SARS", "DISEASE", 331, 335], ["infection", "DISEASE", 958, 967], ["HIRs", "CANCER", 15, 19], ["intensive care", "TREATMENT", 38, 52], ["Infection Isolates", "PROBLEM", 195, 213], ["haemorrhagic fever cases", "PROBLEM", 289, 313], ["SARS cases", "TEST", 331, 341], ["Infection Isolates", "PROBLEM", 419, 437], ["air pressure", "TEST", 655, 667], ["Infection IsolatesIsolates", "PROBLEM", 758, 784], ["the infection prevention", "TREATMENT", 954, 978], ["Infection", "OBSERVATION", 127, 136], ["Infection", "OBSERVATION", 195, 204], ["Infection", "OBSERVATION", 351, 360], ["Infection", "OBSERVATION", 419, 428], ["air pressure", "OBSERVATION", 655, 667], ["Infection", "OBSERVATION", 758, 767], ["infection", "OBSERVATION", 958, 967]]], ["Solid evidence of the spread of infection is used to control good environmental measures, disinfection and proper use of the isolates [64\u201366].Isolate: Design and Function ::: Lack of Infection IsolatesInfection isolation involves admittance of the patient to a separate room with disinfection/bathroom, sluice or anteroom (see Fig. 21.1).", [["infection", "DISEASE", 32, 41], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 248, 255], ["the spread of infection", "PROBLEM", 18, 41], ["disinfection", "TREATMENT", 90, 102], ["Infection IsolatesInfection isolation", "PROBLEM", 183, 220], ["spread", "OBSERVATION_MODIFIER", 22, 28], ["infection", "OBSERVATION", 32, 41], ["Infection", "OBSERVATION", 183, 192], ["Isolates", "OBSERVATION_MODIFIER", 193, 201], ["Infection", "OBSERVATION", 201, 210]]], ["It is always an advantage with some negative pressure of infection isolates\u2014even for contact infection\u2014to avoid spread of infections outside the isolate.Isolate: Design and Function ::: Lack of Infection IsolatesA contact isolate has sluice, patient room and disinfection/bathroom, about.", [["infection", "DISEASE", 57, 66], ["infections", "DISEASE", 122, 132], ["patient", "ORGANISM", 242, 249], ["patient", "SPECIES", 242, 249], ["infection", "PROBLEM", 57, 66], ["infections", "PROBLEM", 122, 132], ["Infection", "PROBLEM", 194, 203], ["pressure", "OBSERVATION_MODIFIER", 45, 53], ["infection", "OBSERVATION", 57, 66], ["infections", "OBSERVATION", 122, 132], ["Infection", "OBSERVATION", 194, 203]]], ["The sluice should be at least 6 m2 with room for bed or stretcher and wash basin.", [["sluice", "ANATOMY", 4, 10], ["sluice", "CANCER", 4, 10]]], ["It shall have a defined clean side, space for clean clothes and unused PPE and a dirty side, for infectious waste and infectious waste bags or containers.Isolate: Design and Function ::: Lack of Infection IsolatesPatient room should be at least 20 m2, with the head end against the wall and about 2 m free zone on both long sides and from the foot end, to avoid too close contact with the patient.Isolate: Design and Function ::: Lack of Infection IsolatesDisinfection room, combined with bathroom, 8\u201310 m2, contains shower, toilet and wash basin, with plenty of space to be able to help the patient as needed.", [["head", "ANATOMY", 261, 265], ["wall", "ANATOMY", 282, 286], ["foot", "ANATOMY", 343, 347], ["head", "ORGANISM_SUBDIVISION", 261, 265], ["wall", "TISSUE", 282, 286], ["foot", "ORGANISM_SUBDIVISION", 343, 347], ["patient", "ORGANISM", 389, 396], ["patient", "ORGANISM", 592, 599], ["Patient", "SPECIES", 213, 220], ["patient", "SPECIES", 389, 396], ["patient", "SPECIES", 592, 599], ["clean clothes", "TREATMENT", 46, 59], ["a dirty side", "TREATMENT", 79, 91], ["infectious waste", "TREATMENT", 97, 113], ["infectious waste bags", "TREATMENT", 118, 139], ["Infection Isolates", "PROBLEM", 195, 213], ["wash basin", "TREATMENT", 536, 546], ["clean", "OBSERVATION", 24, 29], ["Infection", "OBSERVATION", 195, 204], ["wall", "ANATOMY_MODIFIER", 282, 286], ["foot", "ANATOMY", 343, 347], ["Infection", "OBSERVATION", 438, 447]]], ["It should also be equipped with decontaminator, preferably a well-sealed, throughput decontaminator from disinfection room to the sluice.", [["sluice", "CANCER", 130, 136], ["decontaminator", "TREATMENT", 32, 46]]], ["In throughput decontaminators (or autoclaves), infected equipment can be put in from the disinfection room and removed decontaminated in the sluice.", [["sluice", "ANATOMY", 141, 147], ["sluice", "CANCER", 141, 147], ["infected equipment", "TREATMENT", 47, 65]]], ["All throughput systems should be assured with complete sealing against air leakage.", [["air leakage", "PROBLEM", 71, 82], ["air leakage", "OBSERVATION", 71, 82]]], ["Avoid throughput cabinets between the sluice and disinfection room.Isolate: Design and Function ::: Lack of Infection IsolatesAll isolation unit surfaces must be smooth, robust and withstand disinfectants, both liquid and dry gaseous form.", [["sluice", "ANATOMY", 38, 44], ["Infection Isolates", "PROBLEM", 108, 126], ["All isolation unit surfaces", "TREATMENT", 126, 153], ["Infection", "OBSERVATION", 108, 117]]], ["Avoid tiles, gaps and joints where dirt can form the basis for growth and biofilms of microbes which may prevent effect of disinfection.Isolate: Design and Function ::: Lack of Infection IsolatesThere should be at least eight air changes per hour (> six air changes [61]), which is important to remove the infectious agent in the room air.", [["joints", "MULTI-TISSUE_STRUCTURE", 22, 28], ["Avoid tiles, gaps and joints where dirt", "PROBLEM", 0, 39], ["biofilms of microbes", "TREATMENT", 74, 94], ["disinfection", "PROBLEM", 123, 135], ["Infection Isolates", "PROBLEM", 177, 195], ["the infectious agent", "TREATMENT", 302, 322], ["joints", "ANATOMY", 22, 28], ["disinfection", "OBSERVATION", 123, 135], ["Infection", "OBSERVATION", 177, 186], ["air", "OBSERVATION", 226, 229], ["infectious", "OBSERVATION", 306, 316]]], ["Incoming air must enter on the wall or ceiling; air extraction shall go out by the floor (15 cm above), preferably in the disinfection room.", [["wall", "ANATOMY", 31, 35], ["wall", "TISSUE", 31, 35], ["air extraction", "TREATMENT", 48, 62], ["air", "OBSERVATION", 9, 12], ["air", "OBSERVATION", 48, 51]]], ["The isolate should have separate ventilation system so that the infection does not come across to other patients by setbacks in joint ventilation ducts.", [["joint ventilation ducts", "ANATOMY", 128, 151], ["infection", "DISEASE", 64, 73], ["patients", "ORGANISM", 104, 112], ["joint ventilation ducts", "MULTI-TISSUE_STRUCTURE", 128, 151], ["patients", "SPECIES", 104, 112], ["The isolate", "TREATMENT", 0, 11], ["separate ventilation system", "TREATMENT", 24, 51], ["the infection", "PROBLEM", 60, 73], ["setbacks in joint ventilation ducts", "PROBLEM", 116, 151], ["ventilation system", "OBSERVATION", 33, 51], ["infection", "OBSERVATION", 64, 73], ["joint", "ANATOMY", 128, 133], ["ventilation ducts", "OBSERVATION", 134, 151]]], ["Intake air should be a certain distance from the air outlet.", [["air outlet", "MULTI-TISSUE_STRUCTURE", 49, 59], ["air outlet", "OBSERVATION", 49, 59]]], ["HEPA filters should be set on air outlet, and procedures for maintenance and control should be established.Isolate: Design and Function ::: Lack of Infection IsolatesAirborne infection isolate is provided and formed as for a contact isolate.", [["infection", "DISEASE", 175, 184], ["HEPA filters", "TREATMENT", 0, 12], ["air outlet", "TREATMENT", 30, 40], ["procedures", "TREATMENT", 46, 56], ["maintenance and control", "TREATMENT", 61, 84], ["Infection IsolatesAirborne infection isolate", "PROBLEM", 148, 192], ["filters", "OBSERVATION", 5, 12], ["Infection", "OBSERVATION", 148, 157], ["Airborne infection", "OBSERVATION", 166, 184]]], ["The isolate should be organized for direct access from outside.", [["The isolate", "TREATMENT", 0, 11]]], ["In addition, the controlled and defined negative pressure is graded down from the sluice to the disinfection-bathroom compartment [22].", [["negative", "OBSERVATION_MODIFIER", 40, 48], ["pressure", "OBSERVATION_MODIFIER", 49, 57]]], ["Pressure is usually, \u221216 to \u221225 pascal relative to the corridor and the adjacent rooms.", [["Pressure", "TEST", 0, 8]]], ["In the sluice there is 6\u201310 pascal, in the patient room \u221216 to \u221225 pascal and disinfection room \u221225 pascal.", [["sluice", "ANATOMY", 7, 13], ["sluice", "CANCER", 7, 13], ["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50]]], ["The air will then be drawn from the cleanest room (sluice) to the dirtiest room (disinfection room), if the doors are closed.Isolate: Design and Function ::: Lack of Infection IsolatesThe most stable, controlled negative pressure may be made by doors opened outwards from the patient room to the sluice and further from the sluice to the corridor (see Fig. 21.1).", [["sluice", "ANATOMY", 296, 302], ["patient", "ORGANISM", 276, 283], ["sluice", "CANCER", 296, 302], ["patient", "SPECIES", 276, 283], ["Infection Isolates", "PROBLEM", 166, 184], ["air", "OBSERVATION", 4, 7], ["Infection", "OBSERVATION", 166, 175], ["most stable", "OBSERVATION_MODIFIER", 188, 199]]], ["The vacuum will suck the door even tighter to the door frame to hinder air leakage.", [["air leakage", "PROBLEM", 71, 82], ["vacuum", "OBSERVATION", 4, 10], ["air leakage", "OBSERVATION", 71, 82]]], ["Interlocked doors should be used so that only one door at a time may be opened into the patient room.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95]]], ["The stability is dependent on the number of air changes per hour.", [["stability", "OBSERVATION_MODIFIER", 4, 13], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["air changes", "OBSERVATION", 44, 55]]], ["The minimum and most stabile is 6 air changes per hour (6\u201312) [19, 22, 61].", [["minimum", "OBSERVATION_MODIFIER", 4, 11], ["most", "OBSERVATION_MODIFIER", 16, 20], ["stabile", "OBSERVATION_MODIFIER", 21, 28]]], ["Each air exchange reduces the pathogenic agents in the air substantially.", [["Each air exchange", "PROBLEM", 0, 17], ["the pathogenic agents", "TREATMENT", 26, 47], ["air exchange", "OBSERVATION", 5, 17], ["pathogenic agents", "OBSERVATION", 30, 47], ["air substantially", "OBSERVATION", 55, 72]]], ["All air expelled exits at the floor (15 cm above) and is gathered into an outgoing ventilation channel from the disinfection compartment.", [["air expelled", "OBSERVATION", 4, 16], ["ventilation channel", "OBSERVATION", 83, 102], ["disinfection compartment", "OBSERVATION", 112, 136]]], ["Avoid \u201cshortcuts\u201d of the air circulation.Isolate: Design and Function ::: Lack of Infection IsolatesAs for contact isolates, airborne infection isolates should have separate ventilation systems with no setbacks in ventilation ducts; external intake of air over the roof should be well away from the external air outlet over the roof, and all air from the unit is HEPA filtrated.", [["ventilation ducts", "ANATOMY", 214, 231], ["airborne infection", "DISEASE", 125, 143], ["ventilation ducts", "MULTI-TISSUE_STRUCTURE", 214, 231], ["air outlet", "MULTI-TISSUE_STRUCTURE", 308, 318], ["Infection IsolatesAs", "PROBLEM", 82, 102], ["contact isolates", "PROBLEM", 107, 123], ["airborne infection isolates", "PROBLEM", 125, 152], ["separate ventilation systems", "TREATMENT", 165, 193], ["setbacks in ventilation ducts", "PROBLEM", 202, 231], ["external intake of air over the roof", "TREATMENT", 233, 269], ["HEPA filtrated", "TREATMENT", 363, 377], ["air circulation", "OBSERVATION", 25, 40], ["Infection", "OBSERVATION", 82, 91], ["air", "OBSERVATION", 252, 255], ["external", "ANATOMY", 299, 307], ["air outlet", "OBSERVATION", 308, 318], ["roof", "ANATOMY_MODIFIER", 328, 332]]], ["Procedures for maintenance, disinfection and control of filters and ducts should be established.Isolate: Design and Function ::: Lack of Infection IsolatesCohort isolation of several patients with the same infectious agent may be appropriate.", [["ducts", "ANATOMY", 68, 73], ["ducts", "MULTI-TISSUE_STRUCTURE", 68, 73], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["disinfection", "TREATMENT", 28, 40], ["control of filters", "TREATMENT", 45, 63], ["ducts", "TREATMENT", 68, 73], ["Infection Isolates", "PROBLEM", 137, 155], ["ducts", "ANATOMY", 68, 73], ["Infection", "OBSERVATION", 137, 146], ["infectious", "OBSERVATION", 206, 216]]], ["It is a good initiative during pandemics.", [["good", "OBSERVATION_MODIFIER", 8, 12]]], ["The SARS epidemic released a rapid learning process where the Chinese built\u2014within a week\u2014a dedicated SARS hospital for 1000 patients in Beijing [33].", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 102, 106], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["The SARS epidemic", "PROBLEM", 0, 17]]], ["In a study from Brazil, all patients with proven MDROs (multidrug-resistant organisms) were transferred to a 34-bed unit for isolation treatment by a trained personnel, where personnel, patients and family were weekly taught about how to handle MDRO\u2019s by a special team [67].", [["MDROs", "DISEASE", 49, 54], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 186, 194], ["a study", "TEST", 3, 10], ["multidrug-resistant organisms", "PROBLEM", 56, 85], ["isolation treatment", "TREATMENT", 125, 144]]], ["After the intervention, the MDRO rate was significantly reduced, specially by the reduction of VRE.", [["VRE", "DISEASE", 95, 98], ["the intervention", "TREATMENT", 6, 22], ["the MDRO rate", "TEST", 24, 37], ["VRE", "PROBLEM", 95, 98], ["reduced", "OBSERVATION_MODIFIER", 56, 63], ["VRE", "OBSERVATION", 95, 98]]], ["Isolated patients had at least the same good treatment quality as not isolated patients [67].", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 79, 87]]], ["In Norway, cohort isolation was utilized in Trondheim during the first national outbreak of MRSA (1970\u20131974).", [["MRSA", "DISEASE", 92, 96], ["MRSA", "SPECIES", 92, 96], ["MRSA", "SPECIES", 92, 96], ["cohort isolation", "TREATMENT", 11, 27], ["MRSA", "PROBLEM", 92, 96], ["MRSA", "OBSERVATION", 92, 96]]], ["A total of 144 patients were infected (including 15 personnel), and 48 died (31.6%) directly or indirectly from the hospital epidemic [68].", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["The control of the outbreak came first when infected patients and personnel were cohort isolated in a separate isolation ward [68].Isolate: Design and Function ::: Lack of Infection IsolatesBarrier care of one infectious patient among other patients without infections on the same bedroom in dormitory is not recommended.Disinfection and Cleaning ::: Lack of Infection IsolatesA good standard of patient isolates depends on good daily cleaning and a thorough disinfection by termination of the isolation.", [["infections", "DISEASE", 258, 268], ["patients", "ORGANISM", 53, 61], ["patient", "ORGANISM", 221, 228], ["patients", "ORGANISM", 241, 249], ["patient", "ORGANISM", 396, 403], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 221, 228], ["patients", "SPECIES", 241, 249], ["patient", "SPECIES", 396, 403], ["Infection IsolatesBarrier care", "TREATMENT", 172, 202], ["infections", "PROBLEM", 258, 268], ["Infection IsolatesA", "PROBLEM", 359, 378], ["a thorough disinfection", "TREATMENT", 448, 471], ["the isolation", "TREATMENT", 490, 503], ["Infection", "OBSERVATION", 172, 181], ["Infection", "OBSERVATION", 359, 368]]], ["Long-time surviving bacteria, viruses and fungi should not be a risk for the next patient to be isolated, which may happen [69, 70].", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["Long-time surviving bacteria", "PROBLEM", 0, 28], ["viruses", "PROBLEM", 30, 37], ["fungi", "PROBLEM", 42, 47], ["bacteria", "OBSERVATION", 20, 28]]], ["MRSA, multiresistant Acinetobacter baumannii and other MDROs are contaminating bedding, bed and environment for months, if not removed [71].Disinfection and Cleaning ::: Lack of Infection IsolatesDisinfection of rooms and isolates are often not well enough done [64].", [["MRSA", "DISEASE", 0, 4], ["Acinetobacter baumannii", "ORGANISM", 21, 44], ["MRSA", "SPECIES", 0, 4], ["Acinetobacter baumannii", "SPECIES", 21, 44], ["MRSA", "SPECIES", 0, 4], ["Acinetobacter baumannii", "SPECIES", 21, 44], ["MRSA", "PROBLEM", 0, 4], ["multiresistant Acinetobacter baumannii", "PROBLEM", 6, 44], ["other MDROs", "PROBLEM", 49, 60], ["Infection Isolates", "PROBLEM", 178, 196], ["isolates", "PROBLEM", 222, 230], ["multiresistant", "OBSERVATION_MODIFIER", 6, 20], ["Acinetobacter baumannii", "OBSERVATION", 21, 44], ["Infection", "OBSERVATION", 178, 187]]], ["The terminal disinfection, removal and disinfection of all equipment in the room and disinfecting of all surfaces are important.", [["The terminal disinfection", "TREATMENT", 0, 25], ["removal", "TREATMENT", 27, 34], ["disinfection", "TREATMENT", 39, 51], ["all equipment", "TREATMENT", 55, 68], ["terminal", "OBSERVATION_MODIFIER", 4, 12], ["disinfection", "OBSERVATION", 13, 25], ["removal", "OBSERVATION_MODIFIER", 27, 34]]], ["Disinfectants (liquid) that are effective against all microbial agents are chloramine 5%, household bleach 10% or peracetic acid for 1 h.", [["chloramine", "CHEMICAL", 75, 85], ["peracetic acid", "CHEMICAL", 114, 128], ["chloramine", "CHEMICAL", 75, 85], ["peracetic acid", "CHEMICAL", 114, 128], ["Disinfectants", "SIMPLE_CHEMICAL", 0, 13], ["chloramine", "SIMPLE_CHEMICAL", 75, 85], ["peracetic acid", "SIMPLE_CHEMICAL", 114, 128], ["all microbial agents", "TREATMENT", 50, 70], ["chloramine", "TREATMENT", 75, 85], ["peracetic acid", "TREATMENT", 114, 128]]], ["Treatment with hot water (>85 \u00b0C) for 10 min is a very effective disinfection of equipment and textiles.", [["hot water", "TREATMENT", 15, 24]]], ["Different types of gas or steam disinfection (hydrogen-peroxide dry gas, chlorine gas, formaldehyde gas) may be effective for equipment and room disinfection [72\u201375].", [["hydrogen-peroxide", "CHEMICAL", 46, 63], ["chlorine gas", "CHEMICAL", 73, 85], ["formaldehyde gas", "CHEMICAL", 87, 103], ["hydrogen-peroxide", "CHEMICAL", 46, 63], ["chlorine", "CHEMICAL", 73, 81], ["formaldehyde", "CHEMICAL", 87, 99], ["hydrogen-peroxide", "SIMPLE_CHEMICAL", 46, 63], ["chlorine", "SIMPLE_CHEMICAL", 73, 81], ["formaldehyde", "SIMPLE_CHEMICAL", 87, 99], ["gas", "TEST", 19, 22], ["steam disinfection", "TREATMENT", 26, 44], ["hydrogen", "TREATMENT", 46, 54], ["peroxide dry gas", "TEST", 55, 71], ["chlorine gas", "TEST", 73, 85], ["formaldehyde gas", "TEST", 87, 103], ["gas", "OBSERVATION", 19, 22]]], ["Note that there is yet no gas treatment that is documented to kill Mycobacteria [76].Proper Patient in the\u00a0Right Place ::: Lack of Infection IsolatesThe isolates are often used incorrectly.", [["Patient", "SPECIES", 92, 99], ["gas treatment", "TREATMENT", 26, 39], ["Mycobacteria", "TEST", 67, 79], ["Infection Isolates", "PROBLEM", 131, 149], ["The isolates", "TREATMENT", 149, 161], ["no", "UNCERTAINTY", 23, 25], ["gas treatment", "OBSERVATION", 26, 39], ["Right", "ANATOMY_MODIFIER", 107, 112], ["Infection", "OBSERVATION", 131, 140]]], ["In the same ward and at the same time, patients without infection are placed on the isolates while infectious patients are not isolated.", [["infection", "DISEASE", 56, 65], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 110, 118], ["infection", "PROBLEM", 56, 65], ["without", "UNCERTAINTY", 48, 55], ["infection", "OBSERVATION", 56, 65]]], ["Although defined isolate treatment is determined and PPE used, it turns out that the patient is walking freely around in the ward, not really isolated.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["isolate treatment", "TREATMENT", 17, 34], ["PPE", "TREATMENT", 53, 56], ["isolate treatment", "OBSERVATION", 17, 34]]], ["Knowledge and practices increases understanding of disease control measures.Proper Patient in the\u00a0Right Place ::: Lack of Infection IsolatesSome patients that are both prone to infection and have serious infections, like cystic fibrosis patients, should be treated in isolates [77].Side Effects of Isolation ::: Lack of Infection IsolatesDepression, anxiety and anger get less visits and information by health professionals; more often fall injuries or other injuries, inferior care, etc. are claimed to be side effects of isolation [41, 43].", [["infection", "DISEASE", 177, 186], ["infections", "DISEASE", 204, 214], ["cystic fibrosis", "DISEASE", 221, 236], ["Depression", "DISEASE", 338, 348], ["anxiety", "DISEASE", 350, 357], ["injuries", "DISEASE", 441, 449], ["injuries", "DISEASE", 459, 467], ["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 237, 245], ["Patient", "SPECIES", 83, 90], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 237, 245], ["disease control measures", "TREATMENT", 51, 75], ["Infection Isolates", "PROBLEM", 122, 140], ["infection", "PROBLEM", 177, 186], ["serious infections", "PROBLEM", 196, 214], ["cystic fibrosis", "PROBLEM", 221, 236], ["Infection IsolatesDepression", "PROBLEM", 320, 348], ["anxiety", "PROBLEM", 350, 357], ["fall injuries", "PROBLEM", 436, 449], ["other injuries", "PROBLEM", 453, 467], ["inferior care", "TREATMENT", 469, 482], ["Right", "ANATOMY_MODIFIER", 98, 103], ["Infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 177, 186], ["serious", "OBSERVATION_MODIFIER", 196, 203], ["infections", "OBSERVATION", 204, 214], ["cystic", "OBSERVATION_MODIFIER", 221, 227], ["fibrosis", "OBSERVATION", 228, 236], ["Isolation", "OBSERVATION", 298, 307], ["Infection", "OBSERVATION", 320, 329]]], ["However, patients previously depressed and anxious at admission suffer no more under an isolation stay [39].", [["depressed", "DISEASE", 29, 38], ["anxious", "DISEASE", 43, 50], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["depressed and anxious", "PROBLEM", 29, 50]]], ["There is not shown differences between isolated and non-isolated patient, according to the patient\u2019s view of treatment, on the contrary [42].", [["patient", "ORGANISM", 65, 72], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 65, 72], ["patient", "SPECIES", 91, 98], ["treatment", "TREATMENT", 109, 118]]], ["But the patient satisfaction is the highest among those who are well informed [38].", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15]]], ["Most studies show that contact time with the medical doctor is approximately equal for isolated and non-isolated patients and approximately equally frequent [40, 43].", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Most studies", "TEST", 0, 12]]], ["Although MRSA or VRE infected patients, in one study, had more frequent falls and pressure ulcers, this was not reduced by removing the contact isolation, so that it was likely other factors which could contribute to such complications [78].Additional Costs for Transmitted Infections ::: Lack of Infection IsolatesOutbreaks are very costly and take up significant resources and healthcare for other patients [79].", [["MRSA", "CHEMICAL", 9, 13], ["VRE infected", "DISEASE", 17, 29], ["falls", "DISEASE", 72, 77], ["ulcers", "DISEASE", 91, 97], ["Infections", "DISEASE", 274, 284], ["patients", "ORGANISM", 30, 38], ["ulcers", "PATHOLOGICAL_FORMATION", 91, 97], ["patients", "ORGANISM", 400, 408], ["MRSA", "SPECIES", 9, 13], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 400, 408], ["MRSA", "SPECIES", 9, 13], ["MRSA", "PROBLEM", 9, 13], ["VRE", "PROBLEM", 17, 20], ["one study", "TEST", 43, 52], ["frequent falls", "PROBLEM", 63, 77], ["pressure ulcers", "PROBLEM", 82, 97], ["such complications", "PROBLEM", 217, 235], ["Infection Isolates", "PROBLEM", 297, 315], ["MRSA", "OBSERVATION", 9, 13], ["VRE", "OBSERVATION_MODIFIER", 17, 20], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["pressure", "OBSERVATION_MODIFIER", 82, 90], ["ulcers", "OBSERVATION", 91, 97], ["Infections", "OBSERVATION", 274, 284], ["Infection", "OBSERVATION", 297, 306]]], ["A patient infected with MRSA was at Ullev\u00e5l University Hospital, Norway, estimated to generate an additional charge of 526,000 NKR (ca. $75,100), including extended length, spread to a hospital employee, screening tests and antibacterial treatment in 1999 [36].", [["MRSA", "DISEASE", 24, 28], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["MRSA", "SPECIES", 24, 28], ["MRSA", "SPECIES", 24, 28], ["MRSA", "PROBLEM", 24, 28], ["screening tests", "TEST", 204, 219], ["antibacterial treatment", "TREATMENT", 224, 247], ["infected", "OBSERVATION", 10, 18], ["MRSA", "OBSERVATION", 24, 28]]], ["In 2002, in connection with a MRSA outbreak in neonatal ward at Ullev\u00e5l, the calculated additional costs were 375,000 NKR (ca. $53,500) per MRSA-positive patient, including isolation expenditure, disinfection and cleaning, screening and extra days in the hospital [24].", [["MRSA", "DISEASE", 30, 34], ["patient", "ORGANISM", 154, 161], ["MRSA", "SPECIES", 30, 34], ["MRSA", "SPECIES", 140, 144], ["patient", "SPECIES", 154, 161], ["a MRSA outbreak", "PROBLEM", 28, 43], ["MRSA", "PROBLEM", 140, 144], ["isolation expenditure", "TREATMENT", 173, 194], ["disinfection", "TREATMENT", 196, 208], ["MRSA", "OBSERVATION", 30, 34]]], ["Active screening and isolation of patients with MRSA are significantly and markedly cheaper for the healthcare than uncontrolled transmission which can result in serious infection and death [80].Anchoring Isolation Procedures in Laws, Regulations and Guidance ::: Lack of Infection IsolatesAnchoring isolation procedures in laws is essential to the implementation of isolation.", [["MRSA", "DISEASE", 48, 52], ["infection", "DISEASE", 170, 179], ["death", "DISEASE", 184, 189], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["MRSA", "SPECIES", 48, 52], ["MRSA", "SPECIES", 48, 52], ["Active screening", "TEST", 0, 16], ["isolation", "TREATMENT", 21, 30], ["MRSA", "PROBLEM", 48, 52], ["uncontrolled transmission", "PROBLEM", 116, 141], ["serious infection", "PROBLEM", 162, 179], ["death", "PROBLEM", 184, 189], ["Infection IsolatesAnchoring isolation procedures", "TREATMENT", 272, 320], ["isolation", "TREATMENT", 367, 376], ["MRSA", "OBSERVATION", 48, 52], ["serious", "OBSERVATION_MODIFIER", 162, 169], ["infection", "OBSERVATION", 170, 179], ["Infection", "OBSERVATION", 272, 281]]], ["Norway has several laws, regulations and guidance to control infections in healthcare facilities [2\u20137].", [["infections", "DISEASE", 61, 71]]], ["International studies have laid the basis for the Norwegian isolation measures and techniques [9\u201314, 17\u201320, 27].", [["International studies", "TEST", 0, 21], ["the Norwegian isolation measures", "TREATMENT", 46, 78]]], ["Simply to place patients in single rooms provides noticeable improvement in the spread of infection [81].Implementation and Execution: Failing? ::: Lack of Infection IsolatesThe implementation of good isolation measures and compliance is often weakened by confusion, lack of written procedures, lack of training, competence and understaffing.", [["infection", "DISEASE", 90, 99], ["confusion", "DISEASE", 256, 265], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["infection", "PROBLEM", 90, 99], ["Infection Isolates", "PROBLEM", 156, 174], ["good isolation measures", "TREATMENT", 196, 219], ["confusion", "PROBLEM", 256, 265], ["written procedures", "TREATMENT", 275, 293], ["spread", "OBSERVATION_MODIFIER", 80, 86], ["infection", "OBSERVATION", 90, 99], ["Infection", "OBSERVATION", 156, 165], ["good isolation", "OBSERVATION", 196, 210]]], ["A number of other factors also influence the attitude of healthcare professionals with regard to follow the hospital\u2019s infection control procedures, not least professional disagreement about the procedures.In emergency wards in the United States, only 45% of the wards used contact protection (gloves and gown) upon receipt of patients with diarrhoea or faecal incontinence, 84% for suspected CD, 49% for purulent skin infections, 79% for suspected MRSA and 63% by multiresistant gram-negative rods [21].It may be a big difference between what staff and others say they do and what happens in reality [82].", [["faecal", "ANATOMY", 354, 360], ["skin", "ANATOMY", 414, 418], ["infection", "DISEASE", 119, 128], ["diarrhoea", "DISEASE", 341, 350], ["faecal incontinence", "DISEASE", 354, 373], ["CD", "DISEASE", 393, 395], ["skin infections", "DISEASE", 414, 429], ["MRSA", "DISEASE", 449, 453], ["patients", "ORGANISM", 327, 335], ["faecal", "ORGANISM_SUBDIVISION", 354, 360], ["skin", "ORGAN", 414, 418], ["patients", "SPECIES", 327, 335], ["MRSA", "SPECIES", 449, 453], ["MRSA", "SPECIES", 449, 453], ["infection control procedures", "TREATMENT", 119, 147], ["the procedures", "TREATMENT", 191, 205], ["contact protection (gloves and gown", "TREATMENT", 274, 309], ["diarrhoea", "PROBLEM", 341, 350], ["faecal incontinence", "PROBLEM", 354, 373], ["purulent skin infections", "PROBLEM", 405, 429], ["MRSA", "PROBLEM", 449, 453], ["multiresistant gram", "TEST", 465, 484], ["skin", "ANATOMY", 414, 418], ["infections", "OBSERVATION", 419, 429], ["negative rods", "OBSERVATION", 485, 498]]], ["Among 470 persons who entered isolates, the compliance was higher by strict isolation infections (65%) than with other infectious conditions [83].", [["infections", "DISEASE", 86, 96], ["persons", "ORGANISM", 10, 17], ["persons", "SPECIES", 10, 17], ["strict isolation infections", "PROBLEM", 69, 96], ["other infectious conditions", "PROBLEM", 113, 140], ["infectious", "OBSERVATION", 119, 129]]], ["The compliance with isolation procedures increased significantly when more time was spent with the patient, being a visitor, and when the patient was on a strict isolation [83].", [["patient", "ORGANISM", 99, 106], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 99, 106], ["patient", "SPECIES", 138, 145], ["isolation procedures", "TREATMENT", 20, 40]]], ["The study pointed out the danger of increased demands for doctors and nurses due to savings can result in adverse effects such as reduced compliance with key routines as isolation [83].", [["The study", "TEST", 0, 9], ["adverse effects", "PROBLEM", 106, 121]]], ["Morgan et al. observed 7750 visits of a healthcare professional to isolated and non-isolated patients.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["Patients on contact isolation had 36% fewer visits and 18% less contact, and there were fewer visitors than non-isolated patients [84].", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 121, 129], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 121, 129], ["contact isolation", "TREATMENT", 12, 29]]], ["However, the staff implemented significantly more frequent handwashing after visit in isolates, 63%, than by visits with non-isolated patients, 47% [84].During the MRSA outbreak with ca 150 patients in Trondheim, Norway, 1970\u20131974, Kvittingen et al. described problems that may occur during epidemic and endemic conditions as \u201cdoctors more or less wholehearted support and scepticism to the measures made by the Hygiene Committee, discussions concerning the virulence and resistance development, what to do when a local outbreak paralyzes the department completely, information problems, lack of qualified personnel, etc.\u201d [68, 85].", [["MRSA", "DISEASE", 164, 168], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 134, 142], ["MRSA", "SPECIES", 164, 168], ["patients", "SPECIES", 190, 198], ["MRSA", "OBSERVATION", 164, 168]]], ["They stressed that \u201clarger hospitals should dispose well-planned isolation opportunities, both for patients who are infectious spreaders and perhaps equally important, to protect patients with reduced infection defence,\u201d and that \u201cpersonnel in management positions (should) provide effective and loyal support for infection control personnel\u201d [68].This was a very important observation done for more than 40 years ago.", [["infection", "DISEASE", 201, 210], ["infection", "DISEASE", 314, 323], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 179, 187], ["infectious spreaders", "PROBLEM", 116, 136], ["reduced infection defence", "PROBLEM", 193, 218], ["effective and loyal support", "TREATMENT", 282, 309], ["infectious", "OBSERVATION", 116, 126], ["infection", "OBSERVATION", 201, 210]]], ["It is still causing major problems during outbreaks and endemic situations when there may be a choice between shortcut thoughts about \u201ceconomy\u201d and infection control.", [["infection", "DISEASE", 148, 157], ["infection control", "TREATMENT", 148, 165], ["still causing", "UNCERTAINTY", 6, 19], ["infection", "OBSERVATION", 148, 157]]], ["Still, impression and experience is that staff working directly with the patients have great respect for contact and airborne routines, at least in Norway.Isolation Regimes and Recommendations ::: Lack of Infection IsolatesIsolation regimes and interpretation of these are an almost perpetual discussion which changes with endemic and epidemic conditions, economy and guesswork.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Infection IsolatesIsolation regimes", "TREATMENT", 205, 240], ["Infection", "OBSERVATION", 205, 214]]], ["Although isolation of patients with infectious diseases has been used for hundreds of years, there is little evidence in terms of endemic conditions [19\u201322].", [["infectious diseases", "DISEASE", 36, 55], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["infectious diseases", "PROBLEM", 36, 55], ["endemic conditions", "PROBLEM", 130, 148], ["infectious", "OBSERVATION", 36, 46], ["little evidence in", "UNCERTAINTY", 102, 120]]], ["The Norwegian isolation regimes are based mostly on guidelines from CDC [9\u201312, 17\u201321].", [["The Norwegian isolation regimes", "TREATMENT", 0, 31]]], ["In addition, an increasing number of guidelines are focusing on special isolation factors [19, 64\u201366, 69\u201373, 86].Isolation Regimes and Recommendations ::: Lack of Infection IsolatesCDC\u2019s isolation guideline is graded from high evidence, highly recommended as the IA, to no recommendation and unresolved questions or professional disagreement [19].", [["Infection", "PROBLEM", 163, 172], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["number", "OBSERVATION_MODIFIER", 27, 33], ["Infection", "OBSERVATION", 163, 172]]], ["Category IC is included in the legislation for patients and caregivers [19].", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Classification into categories is essential for the most important infection control measures in hospitals.", [["infection", "DISEASE", 67, 76], ["infection", "OBSERVATION", 67, 76]]], ["\u201cThese recommendations are designed to prevent transmission of infectious agents among patients and healthcare personnel in all settings where healthcare is delivered.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["infectious agents", "TREATMENT", 63, 80], ["infectious", "OBSERVATION", 63, 73]]], ["The CDC recommendations are changed over time [9\u201312, 17\u201319].Isolation Regimes and Recommendations ::: Lack of Infection IsolatesCDC/HICPAC system recommendations in categories in correspondence with investigations, theory and economic possibility; quoted [19].Isolation Regimes and Recommendations ::: Lack of Infection IsolatesSiegel JD et al. 2007 Guideline for isolation precautionsAdministrative Responsibility for Isolation TreatmentCDC\u2019s isolation guideline refers to the administrative responsibility around isolation treatment [19].", [["Infection", "PROBLEM", 110, 119], ["Infection Isolates", "PROBLEM", 310, 328], ["isolation precautions", "TREATMENT", 364, 385], ["Isolation TreatmentCDC\u2019s isolation guideline", "TREATMENT", 419, 463], ["isolation treatment", "TREATMENT", 515, 534], ["Infection", "OBSERVATION", 110, 119], ["Infection", "OBSERVATION", 310, 319]]], ["The hospital\u2019s management is responsible for ensuring the implementation of good practical measures and to be the driving force in the hospital\u2019s infection control preparedness.", [["infection", "DISEASE", 146, 155], ["good practical measures", "TREATMENT", 76, 99], ["infection control preparedness", "TREATMENT", 146, 176], ["infection", "OBSERVATION", 146, 155]]], ["This should particularly be done with regard to isolate patients, an extra burden, and also for the economy.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["an extra burden", "PROBLEM", 66, 81]]], ["Enough isolate capacity is to be provided in relation to citizens, patient categories, type of hospital activity and endemic/epidemic conditions.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["endemic/epidemic conditions", "PROBLEM", 117, 144]]], ["The isolates must be of good quality and design, and it should be enough airborne infection isolation units [19].Administrative Responsibility for Isolation TreatmentSome of the CDC-recommended administrative responsibilities are quoted here: [19]Administrative Responsibility for Isolation TreatmentCitation: \u201cHealthcare organization administrators should ensure the implementation of recommendations in this section:Incorporate prevention of transmission of infectious agents into the hospital\u2019s patient- and occupational safety programs.", [["infection", "DISEASE", 82, 91], ["patient", "ORGANISM", 498, 505], ["patient", "SPECIES", 498, 505], ["airborne infection isolation units", "TREATMENT", 73, 107], ["infectious agents", "TREATMENT", 460, 477], ["occupational safety programs", "TREATMENT", 511, 539]]], ["Category IB/IC.Make prevention of transmission of infectious agents a priority for the healthcare organization.", [["infectious agents", "TREATMENT", 50, 67], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["infectious", "OBSERVATION", 50, 60]]], ["Provide administrative support, including fiscal and human resources for maintaining infection control programs.", [["infection", "DISEASE", 85, 94], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["administrative support", "TREATMENT", 8, 30], ["fiscal and human resources", "TREATMENT", 42, 68], ["infection control programs", "TREATMENT", 85, 111], ["infection", "OBSERVATION", 85, 94]]], ["Category IB/IC.Include prevention of healthcare-associated infections as one determinant of bedside nurse staffing levels and composition, especially in high-risk units.", [["infections", "DISEASE", 59, 69], ["healthcare-associated infections", "PROBLEM", 37, 69], ["staffing levels", "TEST", 106, 121], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["infections", "OBSERVATION", 59, 69]]], ["Category IB/IC.Include infection control in daily treatment and care of patients.", [["infection", "DISEASE", 23, 32], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["infection control", "TREATMENT", 23, 40], ["daily treatment", "TREATMENT", 44, 59], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["infection", "OBSERVATION", 23, 32]]], ["Category IB.Delegate authority to infection control personnel or their designees (e.g., patient care unit charge nurses) for making infection control decisions concerning patient placement, transport and transfer -based precautions.", [["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 132, 141], ["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 171, 178], ["infection control decisions", "TREATMENT", 132, 159], ["patient placement", "TREATMENT", 171, 188]]], ["Category IC.Involve infection control personnel in decisions on facility construction and design, determination of airborne isolates and protective environment capacity needs, and environmental assessments.", [["infection", "DISEASE", 20, 29], ["airborne isolates", "TREATMENT", 115, 132], ["environmental assessments", "TEST", 180, 205]]], ["Category IB/IC.Ensure -- to provide clinical microbiology laboratory support, including a sufficient number of medical technologists trained in microbiology, \u2212--for monitoring transmission of microorganisms, planning and conducting epidemiologic investigations, and detecting emerging pathogens.", [["microorganisms", "PROBLEM", 192, 206], ["conducting epidemiologic investigations", "TEST", 221, 260], ["emerging pathogens", "PROBLEM", 276, 294], ["IC", "OBSERVATION_MODIFIER", 12, 14]]], ["Identify resources for performing surveillance cultures, rapid diagnostic testing for viral and other selected pathogens, preparation of antimicrobial susceptibility summary reports, trend analysis, and molecular typing of clustered isolates ---- use these resources according to facility-specific epidemiologic needs, in consultation with clinical microbiologists.", [["performing surveillance cultures", "TEST", 23, 55], ["rapid diagnostic testing", "TEST", 57, 81], ["viral and other selected pathogens", "PROBLEM", 86, 120], ["trend analysis", "TEST", 183, 197]]], ["Category IB.Provide -- resources to meet occupational health needs related to infection control -- evaluation and management of healthcare personnel with communicable infections.", [["infection", "DISEASE", 78, 87], ["communicable infections", "DISEASE", 154, 177], ["infection control", "TREATMENT", 78, 95], ["evaluation", "TEST", 99, 109], ["communicable infections", "PROBLEM", 154, 177]]], ["Category IB/IC.In all areas where healthcare is delivered, provide supplies and equipment necessary for the ---Standard Precautions, including hand hygiene products and personal protective equipment (e.g., gloves, gowns, face and eye protection).", [["hand", "ANATOMY", 143, 147], ["eye", "ANATOMY", 230, 233], ["eye", "ORGANISM_SUBDIVISION", 230, 233], ["Standard Precautions", "TREATMENT", 111, 131], ["hand hygiene products", "TREATMENT", 143, 164], ["personal protective equipment", "TREATMENT", 169, 198], ["gloves", "TREATMENT", 206, 212], ["gowns", "TREATMENT", 214, 219], ["face and eye protection", "TREATMENT", 221, 244], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["all", "OBSERVATION_MODIFIER", 18, 21], ["areas", "OBSERVATION_MODIFIER", 22, 27], ["eye", "ANATOMY", 230, 233]]], ["Category IB/IC.Provide ventilation systems required for a sufficient number of AIIRs (as determined by a risk assessment) and protective environments in healthcare facilities that provide care to patients for whom such rooms are indicated, according to published recommendations.", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["ventilation systems", "TREATMENT", 23, 42], ["a risk assessment", "TEST", 103, 120], ["IC", "OBSERVATION_MODIFIER", 12, 14]]], ["Category IB/IC.Involve infection control personnel in the selection and post-implementation evaluation of medical equipment and supplies and changes in practice that could affect the risk of HAI.", [["infection", "DISEASE", 23, 32], ["HAI", "DISEASE", 191, 194], ["post-implementation evaluation", "TEST", 72, 102], ["medical equipment", "TREATMENT", 106, 123], ["HAI", "PROBLEM", 191, 194], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["infection", "OBSERVATION", 23, 32]]], ["Category IC.Develop and implement policies and procedures to ensure that reusable patient care equipment is cleaned and reprocessed appropriately before use on another patient.", [["patient", "ORGANISM", 82, 89], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 82, 89], ["patient", "SPECIES", 168, 175], ["procedures", "TREATMENT", 47, 57], ["reusable patient care equipment", "TREATMENT", 73, 104]]], ["Category IA/IC.Develop and implement systems for early detection and management -----of potentially infectious persons at initial points of patient encounter in outpatient settings (e.g., triage areas, emergency departments, outpatient clinics, physician offices) and at the time of admission to hospitals and long-term care facilities (LTCF).", [["persons", "ORGANISM", 111, 118], ["patient", "ORGANISM", 140, 147], ["persons", "SPECIES", 111, 118], ["patient", "SPECIES", 140, 147], ["early detection", "TEST", 49, 64], ["management", "TREATMENT", 69, 79], ["infectious", "OBSERVATION", 100, 110]]], ["Category IB.Develop and implement policies and procedures to limit patient visitation by persons with signs or symptoms of a communicable infection.", [["communicable infection", "DISEASE", 125, 147], ["patient", "ORGANISM", 67, 74], ["persons", "ORGANISM", 89, 96], ["patient", "SPECIES", 67, 74], ["persons", "SPECIES", 89, 96], ["procedures", "TREATMENT", 47, 57], ["symptoms", "PROBLEM", 111, 119], ["a communicable infection", "PROBLEM", 123, 147], ["infection", "OBSERVATION", 138, 147]]], ["Screen visitors to high-risk patient care areas (e.g., oncology units, hematopoietic stem cell transplant [HSCT] units, intensive care units, other severely immune-compromised patients) for possible infection.", [["hematopoietic stem cell", "ANATOMY", 71, 94], ["infection", "DISEASE", 199, 208], ["patient", "ORGANISM", 29, 36], ["hematopoietic stem cell", "CELL", 71, 94], ["patients", "ORGANISM", 176, 184], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 176, 184], ["hematopoietic stem cell transplant", "TREATMENT", 71, 105], ["HSCT] units", "TREATMENT", 107, 118], ["intensive care units", "TREATMENT", 120, 140], ["infection", "PROBLEM", 199, 208], ["hematopoietic", "ANATOMY", 71, 84], ["stem cell", "OBSERVATION", 85, 94], ["possible", "UNCERTAINTY", 190, 198], ["infection", "OBSERVATION", 199, 208]]], ["Category IB.Identify performance indicators of the effectiveness of organization-specific measures to prevent transmission of infectious agents (Standard and Transmission-Based Precautions), establish processes to monitor adherence to those performance measures and provide feedback to staff members.", [["specific measures", "TREATMENT", 81, 98], ["infectious agents", "TREATMENT", 126, 143], ["those performance measures", "TREATMENT", 235, 261], ["infectious", "OBSERVATION", 126, 136]]], ["Citation ended.Administrative Responsibility for Isolation TreatmentA good and active hospital management is of major importance to stop the outbreak [23, 24, 37, 49, 50, 68, 87, 88].", [["Isolation TreatmentA", "TREATMENT", 49, 69], ["active hospital management", "TREATMENT", 79, 105]]], ["Ransj\u00f8 et al. attached the importance to the activity of the hospital management during outbreaks of multidrug-resistant microbes in Sweden [87].", [["multidrug-resistant microbes", "DISEASE", 101, 129], ["the hospital management", "TREATMENT", 57, 80]]], ["In Norway, an outbreak of VRE by a dialysis department spring 2011, at Ullev\u00e5l University Hospital, was expected from the department\u2019s critical building condition [23].", [["VRE", "DISEASE", 26, 29], ["VRE", "PROBLEM", 26, 29]]], ["A structural rehabilitation started then, with expansion of bed numbers, assisted by the hospital management.", [["A structural rehabilitation", "TREATMENT", 0, 27], ["the hospital management", "TREATMENT", 85, 108]]], ["One year later, all patients were VRE negative [23].", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["VRE", "TEST", 34, 37]]], ["A number of outbreaks at Ullev\u00e5l\u2019s premature intensive care unit during years have been linked to chronic understaffing, overcrowding, part-time work, lack of infection control practices and isolates, lack of information and a lack of management responsibilities [24, 37].Administrative Responsibility for Isolation TreatmentThe responsibility of the hospital management to prevent and combat outbreaks of infection should be clearly stated in the hospital\u2019s infection control program.Contact Isolation: \u201cContact Precautions\u201d (CP)CDC defines contact isolation, using gown and gloves when in contact with patients infected with resistant bacteria like MRSA and other MDROs (multidrug-resistant organisms), and single rooms are recommended [19].Contact Isolation: \u201cContact Precautions\u201d (CP)Direct contact contamination occurs when microbes are transmitted from an infected person to another without the \u201cintermediate stage\u201d in the environment.", [["infection", "DISEASE", 159, 168], ["infection", "DISEASE", 406, 415], ["infection", "DISEASE", 459, 468], ["MRSA", "CHEMICAL", 651, 655], ["MDROs", "CHEMICAL", 666, 671], ["patients", "ORGANISM", 604, 612], ["patients", "SPECIES", 604, 612], ["MRSA", "SPECIES", 651, 655], ["person", "SPECIES", 871, 877], ["MRSA", "SPECIES", 651, 655], ["infection control practices", "TREATMENT", 159, 186], ["Isolation Treatment", "TREATMENT", 306, 325], ["the hospital management", "TREATMENT", 347, 370], ["infection", "PROBLEM", 406, 415], ["infection control program", "TREATMENT", 459, 484], ["gown", "TREATMENT", 567, 571], ["gloves", "TREATMENT", 576, 582], ["resistant bacteria", "PROBLEM", 627, 645], ["MRSA", "PROBLEM", 651, 655], ["other MDROs (multidrug-resistant organisms", "PROBLEM", 660, 702], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["infection", "OBSERVATION", 159, 168], ["infection", "OBSERVATION", 406, 415], ["infection", "OBSERVATION", 459, 468], ["MRSA", "OBSERVATION", 651, 655]]], ["Microbes transferred to the hands can further spread to the own mouth, nose, hair, ears, clothing, etc. [89] Healthcare personnel is likely to be a \u201csource, vector or a victim\u201d of infections like MRSA [90, 91].Contact Isolation: \u201cContact Precautions\u201d (CP)Patients bring their own microbes into the hospital, with often large contact before a known infection [92\u201396].", [["mouth", "ANATOMY", 64, 69], ["nose", "ANATOMY", 71, 75], ["hair", "ANATOMY", 77, 81], ["ears", "ANATOMY", 83, 87], ["infections", "DISEASE", 180, 190], ["MRSA", "DISEASE", 196, 200], ["infection", "DISEASE", 348, 357], ["hands", "ORGANISM_SUBDIVISION", 28, 33], ["mouth", "ORGANISM_SUBDIVISION", 64, 69], ["nose", "ORGANISM_SUBDIVISION", 71, 75], ["hair", "MULTI-TISSUE_STRUCTURE", 77, 81], ["ears", "ORGAN", 83, 87], ["Patients", "ORGANISM", 255, 263], ["MRSA", "SPECIES", 196, 200], ["Patients", "SPECIES", 255, 263], ["infections", "PROBLEM", 180, 190], ["MRSA", "PROBLEM", 196, 200], ["a known infection", "PROBLEM", 340, 357], ["hands", "ANATOMY", 28, 33], ["mouth", "ANATOMY", 64, 69], ["nose", "ANATOMY", 71, 75], ["hair", "ANATOMY", 77, 81], ["ears", "ANATOMY", 83, 87], ["likely to be", "UNCERTAINTY", 133, 145], ["infection", "OBSERVATION", 348, 357]]], ["Therefore, rapid tests are recommended where possible to detect pathogens [80, 97].Contact Isolation: \u201cContact Precautions\u201d (CP)Indirect contact contamination happens when the microbes are transferred to an object in the environment and from there transmitted to other objects or people.", [["people", "ORGANISM", 280, 286], ["people", "SPECIES", 280, 286], ["rapid tests", "TEST", 11, 22], ["pathogens", "PROBLEM", 64, 73]]], ["Infectious patients themselves will have the agent on the body and clothes and transmit it to the environment.", [["body", "ANATOMY", 58, 62], ["patients", "ORGANISM", 11, 19], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["patients", "SPECIES", 11, 19], ["the body and clothes", "TREATMENT", 54, 74]]], ["The undetected microbes can spread quietly and calmly in many directions via equipment, rooms, surfaces and missing/incorrect procedures [98].", [["microbes", "OBSERVATION", 15, 23]]], ["This is often a large and persistent environmental problem and a threat to other patients [23, 24, 37, 49, 50, 57, 68\u201372, 87].", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["a large and persistent environmental problem", "PROBLEM", 14, 58], ["large", "OBSERVATION_MODIFIER", 16, 21], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["environmental", "OBSERVATION", 37, 50]]], ["The most typical spread occurs when people with contaminated hands are depositing microbes on equipment, machinery, knobs, door handles, uniforms, other textiles, furniture, toys, etc. [89\u201391]Contact Isolation: \u201cContact Precautions\u201d (CP)Fellow-patients on the same room are highly susceptible to infection [16, 20, 23, 24, 37, 57, 96\u201399].", [["infection", "DISEASE", 296, 305], ["people", "ORGANISM", 36, 42], ["hands", "ORGANISM_SUBDIVISION", 61, 66], ["patients", "ORGANISM", 244, 252], ["people", "SPECIES", 36, 42], ["patients", "SPECIES", 244, 252], ["infection", "PROBLEM", 296, 305], ["most typical", "OBSERVATION_MODIFIER", 4, 16], ["spread", "OBSERVATION", 17, 23], ["infection", "OBSERVATION", 296, 305]]], ["Infection can be spread further via equipment (BP apparatus, stethoscope, medicine tray, blood sugar test equipment, journal, etc.) and the personnel\u2019s uniform.", [["blood", "ANATOMY", 89, 94], ["sugar", "CHEMICAL", 95, 100], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["Infection", "PROBLEM", 0, 9], ["BP apparatus", "TEST", 47, 59], ["stethoscope", "TREATMENT", 61, 72], ["medicine tray", "TREATMENT", 74, 87], ["blood sugar test", "TEST", 89, 105]]], ["It is often brought to the ward office, to service rooms and to other personnel or patients.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["A long \u201cdomino\u201d chain of infections may follow infectious agents not stopped by simple hygienic measures and isolation [98].Contact Isolation: \u201cContact Precautions\u201d (CP)Contact infection may also be an airborne infection from patients coughing and sneezing by certain aerosol procedures, when cleaning the surfaces, by bedding and by strong air currents (e.g. by rapidly opening and closing doors) which dislodges dust from the lamps, shelves, etc. [44, 46, 47, 52, 100\u2013102] Therefore, a daily good housekeeping and good routines for final disinfection in isolates is very important to reduce the burden and risk of pathogenic microbes [22, 74].Contact Isolation: \u201cContact Precautions\u201d (CP)Contact infection prevention (CP)\u2014recommended by CDC [19].Contact Isolation: \u201cContact Precautions\u201d (CP)Some citations selected from Siegel et al. 2007; CDC guideline for isolation, where recommendations are in categories where IA is strongest recommendation.Contact Isolation: \u201cContact Precautions\u201d (CP)Selected citations: [19] \u201cIn acute care hospitals, place patients who require CP in a single-patient room when available.", [["infections", "DISEASE", 25, 35], ["infection", "DISEASE", 177, 186], ["infection", "DISEASE", 211, 220], ["coughing", "DISEASE", 235, 243], ["sneezing", "DISEASE", 248, 256], ["infection", "DISEASE", 698, 707], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 1050, 1058], ["patient", "ORGANISM", 1086, 1093], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 1050, 1058], ["patient", "SPECIES", 1086, 1093], ["A long \u201cdomino\u201d chain", "TREATMENT", 0, 21], ["infections", "PROBLEM", 25, 35], ["infectious agents", "TREATMENT", 47, 64], ["Contact infection", "PROBLEM", 169, 186], ["an airborne infection", "PROBLEM", 199, 220], ["patients coughing", "PROBLEM", 226, 243], ["sneezing", "PROBLEM", 248, 256], ["certain aerosol procedures", "TREATMENT", 260, 286], ["final disinfection in isolates", "PROBLEM", 534, 564], ["pathogenic microbes", "PROBLEM", 616, 635], ["CP", "PROBLEM", 1071, 1073], ["infections", "OBSERVATION", 25, 35], ["airborne", "OBSERVATION_MODIFIER", 202, 210], ["infection", "OBSERVATION", 211, 220], ["shelves", "ANATOMY", 435, 442]]], ["Category IB.When single-patient rooms are in short supply, apply the following principles for making decisions on patient placement: ---- Place together in the same room (cohort) patients who are infected or colonized with the same pathogen--.", [["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 114, 121], ["patients", "ORGANISM", 179, 187], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 114, 121], ["patients", "SPECIES", 179, 187], ["infected", "PROBLEM", 196, 204], ["infected", "OBSERVATION", 196, 204]]], ["Category IB.Wear gloves whenever touching the patient\u2019s intact skin or surfaces and articles in close proximity to the patient (e.g., medical equipment, bed rails).", [["skin", "ANATOMY", 63, 67], ["patient", "ORGANISM", 46, 53], ["skin", "ORGAN", 63, 67], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 119, 126], ["Wear gloves", "TREATMENT", 12, 23], ["medical equipment, bed rails", "TREATMENT", 134, 162], ["skin", "ANATOMY", 63, 67]]], ["Category IB.Wear a gown whenever anticipating that clothing will have direct contact with the patient or potentially contaminated environmental surfaces or equipment in close proximity to the patient.", [["patient", "ORGANISM", 94, 101], ["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 192, 199], ["a gown", "TREATMENT", 17, 23]]], ["Remove gown and observe hand hygiene before leaving the patient-care environment.", [["hand", "ANATOMY", 24, 28], ["hand", "ORGANISM_SUBDIVISION", 24, 28], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["gown", "TREATMENT", 7, 11]]], ["Category IB.Patient transport.", [["Patient", "SPECIES", 12, 19]]], ["In acute care hospitals and long-term care and other residential settings, limit transport and movement of patients outside of the room to medically-necessary purposes.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["long-term care", "TREATMENT", 28, 42], ["acute", "OBSERVATION_MODIFIER", 3, 8]]], ["Category II.When transport or movement in any healthcare setting is necessary, ensure that infected or colonized areas of the patient\u2019s body are contained and covered.", [["body", "ANATOMY", 136, 140], ["patient", "ORGANISM", 126, 133], ["body", "ORGANISM_SUBDIVISION", 136, 140], ["patient", "SPECIES", 126, 133], ["infected", "PROBLEM", 91, 99], ["infected", "OBSERVATION", 91, 99]]], ["Category II.Remove and dispose of contaminated PPE and perform hand hygiene prior to transporting patients on CP.", [["hand", "ANATOMY", 63, 67], ["hand", "ORGANISM_SUBDIVISION", 63, 67], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["contaminated PPE", "TREATMENT", 34, 50], ["hand hygiene", "TREATMENT", 63, 75], ["CP", "PROBLEM", 110, 112]]], ["Category II.Don clean PPE to handle the patient at the transport destination.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Category II.Handle patient-care equipment and instruments/devices according to Standard Precautions.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["care equipment", "TREATMENT", 27, 41], ["instruments/devices", "TREATMENT", 46, 65], ["Standard Precautions", "TREATMENT", 79, 99]]], ["Category IB/IC.In acute care hospitals and long-term care and other residential settings, use disposable noncritical patient-care equipment (e.g., blood pressure cuffs) or implement patient-dedicated use of such equipment.", [["blood", "ANATOMY", 147, 152], ["patient", "ORGANISM", 117, 124], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 117, 124], ["patient", "SPECIES", 182, 189], ["long-term care", "TREATMENT", 43, 57], ["care equipment", "TREATMENT", 125, 139], ["blood pressure cuffs", "TREATMENT", 147, 167], ["such equipment", "TREATMENT", 207, 221], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["acute", "OBSERVATION_MODIFIER", 18, 23]]], ["If common use of equipment for multiple patients is unavoidable, clean and disinfect such equipment before use on another patient.", [["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 122, 129], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 122, 129]]], ["Category IB [19].\u201dContact Isolation: \u201cContact Precautions\u201d (CP)Selected citation ended.Airborne and Droplets: IsolationSpread of pathogenic infectious agents through the air and droplets requires a defined negative pressure ventilation isolate and a system which reduces airborne infection in the patient\u2019s room.", [["infection", "DISEASE", 280, 289], ["patient", "ORGANISM", 297, 304], ["patient", "SPECIES", 297, 304], ["pathogenic infectious agents", "TREATMENT", 129, 157], ["a defined negative pressure ventilation isolate", "TREATMENT", 196, 243], ["airborne infection", "PROBLEM", 271, 289], ["pathogenic", "OBSERVATION_MODIFIER", 129, 139], ["infectious", "OBSERVATION", 140, 150], ["pressure ventilation", "OBSERVATION", 215, 235], ["airborne infection", "OBSERVATION", 271, 289]]], ["It is best done by air replacement 6\u201312 times an hour [19, 61].Airborne and Droplets: IsolationThe cause of airborne, pathogenic microbes may include:Transmitted to the air from infected airways by coughing, sneezing, sputum, watery eyes, talking, shouting, singing, etc., caused by influenza, parainfluenza and other respiratory viruses, tuberculosis, staphylococci, pneumococci, gram-negative rods, etc. [12, 19, 22, 46, 47]Transmitted to the air from infected gastrointestinal tract by vomiting, e.g. norovirus, rotavirus, sapovirus and entero-haemorrhagic E. coli (EHEC).Transmitted by splash and spray from pus, blood, tissue- particles, etc. in tiny droplets, particularly during surgery, punctures, suction, diathermy, gastroscopy, etc. [103, 104]From splashes and spills by invasive, aerosol-generating procedures like bronchoscopy.From accidents and spill by insertion or replacement of catheters in the blood and the urinary tract.By rapid removal of the bandage from pus and discharging wounds.By raise up of infected dust, skin cells and other contaminants by activities that create air currents, often in poorly cleaned rooms [44].Re-aerosolized pathogens from used textiles and equipment in the patient room or where these contaminated items are brought, for instance, to the ward\u2019s disinfection room or to the laundry.", [["airways", "ANATOMY", 187, 194], ["sputum", "ANATOMY", 218, 224], ["eyes", "ANATOMY", 233, 237], ["gastrointestinal tract", "ANATOMY", 463, 485], ["pus", "ANATOMY", 612, 615], ["blood", "ANATOMY", 617, 622], ["tissue", "ANATOMY", 624, 630], ["blood", "ANATOMY", 913, 918], ["urinary tract", "ANATOMY", 927, 940], ["pus", "ANATOMY", 978, 981], ["wounds", "ANATOMY", 998, 1004], ["skin cells", "ANATOMY", 1035, 1045], ["watery eyes", "DISEASE", 226, 237], ["influenza", "DISEASE", 283, 292], ["parainfluenza", "DISEASE", 294, 307], ["respiratory viruses", "DISEASE", 318, 337], ["tuberculosis", "DISEASE", 339, 351], ["staphylococci", "DISEASE", 353, 366], ["pneumococci", "DISEASE", 368, 379], ["Transmitted to the air from infected gastrointestinal tract", "DISEASE", 426, 485], ["vomiting", "DISEASE", 489, 497], ["entero-haemorrhagic E. coli", "DISEASE", 540, 567], ["accidents", "DISEASE", 845, 854], ["airways", "MULTI-TISSUE_STRUCTURE", 187, 194], ["parainfluenza", "ORGANISM", 294, 307], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 463, 485], ["rotavirus", "ORGANISM", 515, 524], ["entero-haemorrhagic E. coli", "ORGANISM", 540, 567], ["EHEC", "ORGANISM", 569, 573], ["pus", "ORGANISM_SUBSTANCE", 612, 615], ["blood", "ORGANISM_SUBSTANCE", 617, 622], ["tissue", "TISSUE", 624, 630], ["blood", "ORGANISM_SUBSTANCE", 913, 918], ["urinary tract", "ORGANISM_SUBDIVISION", 927, 940], ["pus", "ORGANISM_SUBSTANCE", 978, 981], ["wounds", "PATHOLOGICAL_FORMATION", 998, 1004], ["dust", "ORGANISM_SUBSTANCE", 1029, 1033], ["skin cells", "CELL", 1035, 1045], ["patient", "ORGANISM", 1209, 1216], ["skin cells", "CELL_TYPE", 1035, 1045], ["parainfluenza", "SPECIES", 294, 307], ["E. coli", "SPECIES", 560, 567], ["patient", "SPECIES", 1209, 1216], ["E. coli", "SPECIES", 560, 567], ["EHEC", "SPECIES", 569, 573], ["air replacement", "TREATMENT", 19, 34], ["airborne", "PROBLEM", 108, 116], ["infected airways", "PROBLEM", 178, 194], ["coughing", "PROBLEM", 198, 206], ["sneezing", "PROBLEM", 208, 216], ["sputum, watery eyes", "PROBLEM", 218, 237], ["influenza", "PROBLEM", 283, 292], ["parainfluenza", "PROBLEM", 294, 307], ["other respiratory viruses", "PROBLEM", 312, 337], ["tuberculosis", "PROBLEM", 339, 351], ["staphylococci", "PROBLEM", 353, 366], ["pneumococci", "PROBLEM", 368, 379], ["gram-negative rods", "PROBLEM", 381, 399], ["infected gastrointestinal tract", "PROBLEM", 454, 485], ["vomiting", "PROBLEM", 489, 497], ["e.g. norovirus", "PROBLEM", 499, 513], ["rotavirus", "PROBLEM", 515, 524], ["sapovirus", "PROBLEM", 526, 535], ["entero-haemorrhagic E. coli", "PROBLEM", 540, 567], ["pus", "PROBLEM", 612, 615], ["tiny droplets", "PROBLEM", 651, 664], ["punctures", "TREATMENT", 695, 704], ["suction", "TREATMENT", 706, 713], ["diathermy", "TREATMENT", 715, 724], ["gastroscopy", "TEST", 726, 737], ["generating procedures", "TREATMENT", 800, 821], ["bronchoscopy", "TREATMENT", 827, 839], ["replacement of catheters in the blood and the urinary tract", "TREATMENT", 881, 940], ["rapid removal", "TREATMENT", 944, 957], ["the bandage", "TREATMENT", 961, 972], ["pus", "PROBLEM", 978, 981], ["discharging wounds", "PROBLEM", 986, 1004], ["infected dust, skin cells", "PROBLEM", 1020, 1045], ["Re-aerosolized pathogens", "PROBLEM", 1144, 1168], ["air", "OBSERVATION", 169, 172], ["infected", "OBSERVATION", 178, 186], ["airways", "ANATOMY", 187, 194], ["watery eyes", "ANATOMY", 226, 237], ["respiratory", "ANATOMY", 318, 329], ["viruses", "OBSERVATION", 330, 337], ["negative rods", "OBSERVATION", 386, 399], ["air", "OBSERVATION", 445, 448], ["infected", "OBSERVATION", 454, 462], ["gastrointestinal tract", "ANATOMY", 463, 485], ["norovirus", "OBSERVATION", 504, 513], ["sapovirus", "OBSERVATION", 526, 535], ["E. coli", "OBSERVATION", 560, 567], ["splash", "OBSERVATION", 590, 596], ["pus", "OBSERVATION", 612, 615], ["blood", "ANATOMY", 617, 622], ["tissue", "ANATOMY", 624, 630], ["particles", "OBSERVATION_MODIFIER", 632, 641], ["tiny", "OBSERVATION_MODIFIER", 651, 655], ["droplets", "OBSERVATION", 656, 664], ["catheters", "OBSERVATION", 896, 905], ["blood", "ANATOMY", 913, 918], ["urinary tract", "ANATOMY", 927, 940], ["rapid", "OBSERVATION_MODIFIER", 944, 949], ["removal", "OBSERVATION", 950, 957], ["bandage", "OBSERVATION", 965, 972], ["pus", "OBSERVATION", 978, 981], ["discharging", "OBSERVATION_MODIFIER", 986, 997], ["wounds", "OBSERVATION", 998, 1004], ["infected", "OBSERVATION_MODIFIER", 1020, 1028], ["dust", "OBSERVATION", 1029, 1033], ["skin cells", "ANATOMY", 1035, 1045], ["air currents", "OBSERVATION", 1095, 1107]]], ["By massive contamination and poor routines for washing equipment and hospital textiles, this may cause a special problem of re-aerosols [105].Construction activity of all types without measures against airborne infection is influencing the airborne spread of bacteria, virus and fungi.", [["airborne infection", "DISEASE", 202, 220], ["massive contamination", "PROBLEM", 3, 24], ["washing equipment", "TREATMENT", 47, 64], ["hospital textiles", "TREATMENT", 69, 86], ["airborne infection", "PROBLEM", 202, 220], ["bacteria", "PROBLEM", 259, 267], ["virus", "PROBLEM", 269, 274], ["fungi", "PROBLEM", 279, 284], ["massive", "OBSERVATION_MODIFIER", 3, 10], ["contamination", "OBSERVATION", 11, 24]]], ["This must be taken into account when rebuilding and repairing buildings and ventilation ducts etc. [22, 105].", [["ventilation ducts", "ANATOMY", 76, 93], ["ventilation ducts", "MULTI-TISSUE_STRUCTURE", 76, 93], ["ventilation ducts", "OBSERVATION", 76, 93]]], ["If ignored, it may cause large problems like the outbreak of Bacillus cereus among 171 patients, most with sepsis, during 6 months of a large construction project next to the hospital [105].", [["Bacillus cereus", "DISEASE", 61, 76], ["sepsis", "DISEASE", 107, 113], ["Bacillus cereus", "ORGANISM", 61, 76], ["patients", "ORGANISM", 87, 95], ["Bacillus cereus", "SPECIES", 61, 76], ["patients", "SPECIES", 87, 95], ["Bacillus cereus", "SPECIES", 61, 76], ["large problems", "PROBLEM", 25, 39], ["Bacillus cereus", "PROBLEM", 61, 76], ["sepsis", "PROBLEM", 107, 113], ["sepsis", "OBSERVATION", 107, 113]]], ["Air samples showed growth of large quantities of Bacillus inside the hospital, the units and also isolates, and hospital textiles were heavily contaminated [105].Airborne and Droplets: IsolationOn a daily basis, the human inhales 10,000 particles or more via airways; many of these are bacteria, viruses and fungi but mostly come up again without causing disease.Airborne and Droplets: IsolationA solid documentation shows that airborne infection may occur at a variety of infectious diseases [12, 22, 31, 47, 52, 54, 58, 59, 85, 100\u2013119].", [["Air samples", "ANATOMY", 0, 11], ["airways", "ANATOMY", 259, 266], ["airborne infection", "DISEASE", 428, 446], ["infectious diseases", "DISEASE", 473, 492], ["human", "ORGANISM", 216, 221], ["airways", "MULTI-TISSUE_STRUCTURE", 259, 266], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["Air samples", "TEST", 0, 11], ["large quantities of Bacillus", "PROBLEM", 29, 57], ["hospital textiles", "TREATMENT", 112, 129], ["heavily contaminated", "PROBLEM", 135, 155], ["the human inhales", "TREATMENT", 212, 229], ["bacteria", "PROBLEM", 286, 294], ["viruses", "PROBLEM", 296, 303], ["fungi", "PROBLEM", 308, 313], ["disease", "PROBLEM", 355, 362], ["IsolationA solid documentation", "TEST", 386, 416], ["airborne infection", "PROBLEM", 428, 446], ["growth", "OBSERVATION_MODIFIER", 19, 25], ["large", "OBSERVATION_MODIFIER", 29, 34], ["quantities", "OBSERVATION_MODIFIER", 35, 45], ["Bacillus", "OBSERVATION_MODIFIER", 49, 57], ["airways", "ANATOMY", 259, 266], ["bacteria", "OBSERVATION", 286, 294], ["viruses", "OBSERVATION", 296, 303], ["airborne infection", "OBSERVATION", 428, 446]]], ["Rooms with MRSA-infected cases may have larger numbers of MRSA bacteria in air samples than in samples from surfaces [113, 114].", [["air samples", "ANATOMY", 75, 86], ["samples", "ANATOMY", 95, 102], ["MRSA-infected", "DISEASE", 11, 24], ["air samples", "ORGANISM_SUBSTANCE", 75, 86], ["MRSA", "SPECIES", 11, 15], ["MRSA", "SPECIES", 58, 62], ["MRSA", "SPECIES", 58, 62], ["MRSA", "PROBLEM", 11, 15], ["infected cases", "PROBLEM", 16, 30], ["MRSA bacteria in air samples", "PROBLEM", 58, 86], ["samples from surfaces", "TEST", 95, 116], ["MRSA", "OBSERVATION", 11, 15], ["infected", "OBSERVATION", 16, 24], ["larger", "OBSERVATION_MODIFIER", 40, 46], ["numbers", "OBSERVATION_MODIFIER", 47, 54], ["MRSA", "OBSERVATION_MODIFIER", 58, 62], ["bacteria", "OBSERVATION_MODIFIER", 63, 71], ["air", "OBSERVATION_MODIFIER", 75, 78]]], ["MRSA may even be spread to nearby located rooms, to patients not infected [113, 114].", [["MRSA", "DISEASE", 0, 4], ["patients", "ORGANISM", 52, 60], ["MRSA", "SPECIES", 0, 4], ["patients", "SPECIES", 52, 60], ["MRSA", "SPECIES", 0, 4], ["MRSA", "PROBLEM", 0, 4]]], ["The few existing units for airborne infection isolation mean that most patients, except for pulmonary tuberculosis, most often are admitted to contact isolation or single-patient rooms, with the use of PPE corresponding to airborne infection: gloves, infection-protecting gown, cap and surgical mask and sometimes room-bound shoes [22].Airborne and Droplets: IsolationAirborne Precautions (AP)\u2014recommended by CDC [19].Airborne and Droplets: IsolationSome citations selected from Siegel et al. 2007; CDC guideline for isolation.", [["pulmonary", "ANATOMY", 92, 101], ["infection", "DISEASE", 36, 45], ["pulmonary tuberculosis", "DISEASE", 92, 114], ["infection", "DISEASE", 232, 241], ["infection", "DISEASE", 251, 260], ["patients", "ORGANISM", 71, 79], ["pulmonary", "ORGAN", 92, 101], ["patient", "ORGANISM", 171, 178], ["PPE", "GENE_OR_GENE_PRODUCT", 202, 205], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 171, 178], ["airborne infection isolation", "TREATMENT", 27, 55], ["pulmonary tuberculosis", "PROBLEM", 92, 114], ["PPE", "TREATMENT", 202, 205], ["airborne infection", "PROBLEM", 223, 241], ["gloves", "TREATMENT", 243, 249], ["infection", "PROBLEM", 251, 260], ["cap and surgical mask", "TREATMENT", 278, 299], ["IsolationAirborne Precautions", "TREATMENT", 359, 388], ["infection", "OBSERVATION", 36, 45], ["pulmonary", "ANATOMY", 92, 101], ["tuberculosis", "OBSERVATION", 102, 114], ["airborne infection", "OBSERVATION", 223, 241], ["infection", "OBSERVATION", 251, 260], ["surgical mask", "OBSERVATION", 286, 299]]], ["Recommendations are in categories where IA is strongest recommendation.Airborne and Droplets: IsolationSelected citations: [19]Airborne and Droplets: Isolation\u201cIn acute care hospitals and long-term care settings, place patients who require Airborne Precautions in an AIIR (airborne infection isolate rooms) that has been constructed in accordance with current guidelines.", [["infection", "DISEASE", 282, 291], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["long-term care settings", "TREATMENT", 188, 211], ["Airborne Precautions", "TREATMENT", 240, 260], ["an AIIR (airborne infection isolate rooms", "TREATMENT", 264, 305]]], ["Category IA/IC.Provide at least six (existing facility) or 12 (new construction/renovation) air changes per hour.Direct exhaust of air to the outside.", [["air", "OBSERVATION", 131, 134]]], ["If it is not possible to exhaust air from an AIIR directly to the outside, the air may be returned to the air-handling system or adjacent spaces if all air is directed through HEPA filters.Whenever an AIIR is in use for a patient on Airborne Precautions, monitor air pressure daily with visual indicators (e.g., smoke tubes, flutter strips), regardless of the presence of differential pressure sensing devices (e.g., manometers).Keep the AIIR door closed when not required for entry and exit.When an AIIR is not available, transfer the patient to a facility that has an available AIIR.", [["patient", "ORGANISM", 222, 229], ["patient", "ORGANISM", 536, 543], ["patient", "SPECIES", 222, 229], ["patient", "SPECIES", 536, 543], ["HEPA filters", "TREATMENT", 176, 188], ["Airborne Precautions", "TREATMENT", 233, 253], ["air pressure", "TEST", 263, 275], ["visual indicators", "TEST", 287, 304], ["smoke tubes", "TREATMENT", 312, 323], ["flutter strips", "TREATMENT", 325, 339], ["differential pressure sensing devices", "TREATMENT", 372, 409], ["not possible", "UNCERTAINTY", 9, 21], ["air", "OBSERVATION", 33, 36], ["air", "OBSERVATION", 79, 82], ["air", "OBSERVATION", 152, 155]]], ["Category II.In the event of an outbreak or exposure involving large numbers of patients who require Airborne Precautions:Consult infection control professionals before patient placement to determine the safety of alternative room that do not meet engineering requirements for an AIIR.Place together (cohort) patients who are presumed to have the same infection(based on clinical presentation and diagnosis when known) in areas of the facility that are away from other patients, especially patients who are at increased risk for infection (e.g., immune-compromised patients).Use temporary portable solutions (e.g., exhaust fan) to create a negative pressure environment in the converted area of the facility.", [["infection", "DISEASE", 129, 138], ["infection", "DISEASE", 351, 360], ["infection", "DISEASE", 528, 537], ["patients", "ORGANISM", 79, 87], ["patient", "ORGANISM", 168, 175], ["patients", "ORGANISM", 308, 316], ["patients", "ORGANISM", 468, 476], ["patients", "ORGANISM", 489, 497], ["patients", "ORGANISM", 564, 572], ["patients", "SPECIES", 79, 87], ["patient", "SPECIES", 168, 175], ["patients", "SPECIES", 308, 316], ["patients", "SPECIES", 468, 476], ["patients", "SPECIES", 489, 497], ["patients", "SPECIES", 564, 572], ["Airborne Precautions", "TREATMENT", 100, 120], ["patient placement", "TREATMENT", 168, 185], ["the same infection", "PROBLEM", 342, 360], ["infection", "PROBLEM", 528, 537], ["temporary portable solutions", "TREATMENT", 578, 606], ["a negative pressure environment", "TREATMENT", 637, 668], ["infection", "OBSERVATION", 351, 360], ["infection", "OBSERVATION", 528, 537]]], ["Discharge air directly to the outside, away from people and air intakes, or direct all the air through HEPA filters before it is introduced to other air spaces.", [["people", "SPECIES", 49, 55], ["HEPA filters", "TREATMENT", 103, 115], ["air", "OBSERVATION", 10, 13], ["air intakes", "OBSERVATION", 60, 71], ["air", "OBSERVATION", 91, 94], ["air spaces", "OBSERVATION", 149, 159]]], ["Category II.Place the patient in an AIIR as soon as possible.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["If an AIIR is not available, place a surgical mask on the patient and place him/her in an examination room.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["a surgical mask", "TREATMENT", 35, 50]]], ["Once the patient leaves, the room should remain vacant for the appropriate time, generally 1 h, to allow for a full exchange of air.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["a full exchange of air", "TREATMENT", 109, 131]]], ["Category IB/IC.Instruct patients with a known or suspected airborne infection to wear a surgical mask and observe Respiratory Hygiene/Cough Etiquette.", [["airborne infection", "DISEASE", 59, 77], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["airborne infection", "PROBLEM", 59, 77], ["a surgical mask", "TREATMENT", 86, 101], ["Respiratory Hygiene", "TREATMENT", 114, 133], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["infection", "OBSERVATION", 68, 77]]], ["Once in an AIIR, the mask may be removed; the mask should remain on if the patient is not in an AIIR.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["the mask", "TREATMENT", 17, 25], ["the mask", "TREATMENT", 42, 50]]], ["Category IB/IC.Restrict susceptible healthcare personnel from entering the rooms of patients known or suspected to have measles (rubeola), varicella (chickenpox), disseminated zoster, or smallpox if other immune healthcare personnel are available.", [["measles (rubeola)", "DISEASE", 120, 137], ["varicella", "DISEASE", 139, 148], ["chickenpox", "DISEASE", 150, 160], ["disseminated zoster", "DISEASE", 163, 182], ["smallpox", "DISEASE", 187, 195], ["patients", "ORGANISM", 84, 92], ["rubeola", "CANCER", 129, 136], ["patients", "SPECIES", 84, 92], ["measles (rubeola)", "PROBLEM", 120, 137], ["varicella (chickenpox)", "PROBLEM", 139, 161], ["disseminated zoster", "PROBLEM", 163, 182], ["smallpox", "TREATMENT", 187, 195], ["IC", "OBSERVATION_MODIFIER", 12, 14], ["disseminated", "OBSERVATION_MODIFIER", 163, 175], ["zoster", "OBSERVATION", 176, 182]]], ["Category IB.Wear a fit-tested NIOSH-approved N95 or higher level respirator for respiratory protection when entering the room or home of a patient when the following diseases are suspected or confirmed:Infectious pulmonary or laryngeal tuberculosis or when infectious tuberculosis skin lesions are present and procedures that would aerosolize viable organisms (e.g., irrigation, incision and drainage, whirlpool treatments) are performed.", [["respiratory", "ANATOMY", 80, 91], ["pulmonary", "ANATOMY", 213, 222], ["laryngeal", "ANATOMY", 226, 235], ["skin lesions", "ANATOMY", 281, 293], ["Infectious pulmonary or laryngeal tuberculosis", "DISEASE", 202, 248], ["tuberculosis", "DISEASE", 268, 280], ["patient", "ORGANISM", 139, 146], ["pulmonary", "ORGAN", 213, 222], ["laryngeal", "ORGAN", 226, 235], ["skin lesions", "PATHOLOGICAL_FORMATION", 281, 293], ["patient", "SPECIES", 139, 146], ["N95", "TREATMENT", 45, 48], ["higher level respirator", "TREATMENT", 52, 75], ["respiratory protection", "TREATMENT", 80, 102], ["Infectious pulmonary or laryngeal tuberculosis", "PROBLEM", 202, 248], ["infectious tuberculosis skin lesions", "PROBLEM", 257, 293], ["procedures", "TREATMENT", 310, 320], ["viable organisms", "PROBLEM", 343, 359], ["irrigation", "TREATMENT", 367, 377], ["incision", "TREATMENT", 379, 387], ["drainage", "TREATMENT", 392, 400], ["whirlpool treatments", "TREATMENT", 402, 422], ["respiratory protection", "OBSERVATION", 80, 102], ["pulmonary", "ANATOMY", 213, 222], ["laryngeal", "ANATOMY", 226, 235], ["tuberculosis", "OBSERVATION", 236, 248], ["infectious", "OBSERVATION_MODIFIER", 257, 267], ["lesions", "OBSERVATION", 286, 293]]], ["Category IB.Smallpox (vaccinated and unvaccinated) --- Category II.No recommendation is made regarding the type of personal protective equipment (i.e., surgical mask or respiratory protection with a N95 or higher respirator) to be worn by susceptible healthcare personnel who must have contact with patients with known or suspected measles, chickenpox or disseminated herpes zoster.", [["respiratory", "ANATOMY", 169, 180], ["measles", "DISEASE", 332, 339], ["chickenpox", "DISEASE", 341, 351], ["herpes zoster", "DISEASE", 368, 381], ["patients", "ORGANISM", 299, 307], ["herpes zoster", "ORGANISM", 368, 381], ["patients", "SPECIES", 299, 307], ["herpes zoster", "SPECIES", 368, 381], ["Smallpox (vaccinated", "TREATMENT", 12, 32], ["personal protective equipment", "TREATMENT", 115, 144], ["surgical mask", "TREATMENT", 152, 165], ["respiratory protection", "TREATMENT", 169, 191], ["a N95", "TREATMENT", 197, 202], ["measles", "PROBLEM", 332, 339], ["chickenpox", "PROBLEM", 341, 351], ["disseminated herpes zoster", "PROBLEM", 355, 381], ["disseminated", "OBSERVATION_MODIFIER", 355, 367], ["herpes zoster", "OBSERVATION", 368, 381]]], ["Unresolved issue.In acute care hospitals and long-term care and other residential settings, limit transport and movement of patients outside of the room to medically-necessary purposes.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["long-term care", "TREATMENT", 45, 59], ["acute", "OBSERVATION_MODIFIER", 20, 25]]], ["Category II.If transport or movement outside an AIIR is necessary, instruct patients to wear a surgical mask, if possible, and observe Respiratory Hygiene/Cough Etiquette.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["a surgical mask", "TREATMENT", 93, 108]]], ["Category II.For patients with skin lesions associated with varicella or smallpox or draining skin lesions caused by M. tuberculosis, cover the affected areas to prevent aerosolization or contact with the infectious agent in skin lesions.", [["skin lesions", "ANATOMY", 30, 42], ["skin lesions", "ANATOMY", 93, 105], ["skin lesions", "ANATOMY", 224, 236], ["skin lesions", "DISEASE", 30, 42], ["varicella", "DISEASE", 59, 68], ["smallpox", "DISEASE", 72, 80], ["skin lesions", "DISEASE", 93, 105], ["M. tuberculosis", "DISEASE", 116, 131], ["patients", "ORGANISM", 16, 24], ["skin lesions", "PATHOLOGICAL_FORMATION", 30, 42], ["skin lesions", "PATHOLOGICAL_FORMATION", 93, 105], ["skin lesions", "PATHOLOGICAL_FORMATION", 224, 236], ["patients", "SPECIES", 16, 24], ["M. tuberculosis", "SPECIES", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["skin lesions", "PROBLEM", 30, 42], ["varicella", "PROBLEM", 59, 68], ["smallpox", "PROBLEM", 72, 80], ["draining skin lesions", "PROBLEM", 84, 105], ["M. tuberculosis", "PROBLEM", 116, 131], ["the affected areas", "PROBLEM", 139, 157], ["aerosolization", "PROBLEM", 169, 183], ["the infectious agent in skin lesions", "PROBLEM", 200, 236], ["skin", "ANATOMY", 30, 34], ["lesions", "OBSERVATION", 35, 42], ["varicella", "OBSERVATION", 59, 68], ["smallpox", "OBSERVATION_MODIFIER", 72, 80], ["draining", "OBSERVATION_MODIFIER", 84, 92], ["skin", "ANATOMY", 93, 97], ["lesions", "OBSERVATION", 98, 105], ["M.", "OBSERVATION_MODIFIER", 116, 118], ["tuberculosis", "OBSERVATION", 119, 131], ["prevent", "UNCERTAINTY", 161, 168], ["aerosolization", "OBSERVATION", 169, 183], ["infectious", "OBSERVATION_MODIFIER", 204, 214], ["skin", "ANATOMY", 224, 228], ["lesions", "OBSERVATION", 229, 236]]], ["Category IB.Healthcare personnel transporting patients who are on Airborne Precautions do not need to wear a mask or respirator during transport if the patient is wearing a mask and infectious skin lesions are covered.", [["skin lesions", "ANATOMY", 193, 205], ["infectious skin lesions", "DISEASE", 182, 205], ["patients", "ORGANISM", 46, 54], ["patient", "ORGANISM", 152, 159], ["skin lesions", "PATHOLOGICAL_FORMATION", 193, 205], ["patients", "SPECIES", 46, 54], ["patient", "SPECIES", 152, 159], ["Airborne Precautions", "TREATMENT", 66, 86], ["a mask", "TREATMENT", 107, 113], ["respirator", "TREATMENT", 117, 127], ["a mask", "TREATMENT", 171, 177], ["infectious skin lesions", "PROBLEM", 182, 205], ["infectious", "OBSERVATION_MODIFIER", 182, 192], ["skin", "ANATOMY", 193, 197], ["lesions", "OBSERVATION", 198, 205]]], ["Category II.Exposure management immunize or provide the appropriate immune globulin to susceptible persons as soon as possible following unprotected contact (i.e., exposed) to a patient with measles, varicella or smallpox: Category IA.Administer measles vaccine to exposed susceptible persons within 72 h after the exposure or administer immune globulin within 6 days of the exposure event for high-risk persons in whom vaccine is contraindicated.Administer varicella vaccine to exposed susceptible persons within 120 h after the exposure or administer varicella immune globulin (VZIG or alternative product), when available, within 96 h for high-risk persons in whom vaccine is contraindicated (e.g., immune compromised patients, pregnant women, newborns whose mother\u2019s varicella onset was <5 days before or within 48 h after delivery.Administer smallpox vaccine to exposed susceptible persons within 4 days after exposure.\u201d", [["measles", "DISEASE", 191, 198], ["varicella", "DISEASE", 200, 209], ["smallpox", "DISEASE", 213, 221], ["varicella", "DISEASE", 458, 467], ["varicella", "DISEASE", 553, 562], ["VZIG", "CHEMICAL", 580, 584], ["varicella", "DISEASE", 771, 780], ["globulin", "GENE_OR_GENE_PRODUCT", 75, 83], ["persons", "ORGANISM", 99, 106], ["patient", "ORGANISM", 178, 185], ["persons", "ORGANISM", 285, 292], ["immune globulin", "GENE_OR_GENE_PRODUCT", 338, 353], ["persons", "ORGANISM", 404, 411], ["varicella", "ORGANISM", 458, 467], ["persons", "ORGANISM", 499, 506], ["varicella", "ORGANISM", 553, 562], ["immune globulin", "GENE_OR_GENE_PRODUCT", 563, 578], ["VZIG", "SIMPLE_CHEMICAL", 580, 584], ["persons", "ORGANISM", 652, 659], ["patients", "ORGANISM", 721, 729], ["women", "ORGANISM", 740, 745], ["newborns", "ORGANISM", 747, 755], ["persons", "ORGANISM", 887, 894], ["varicella immune globulin", "PROTEIN", 553, 578], ["persons", "SPECIES", 99, 106], ["patient", "SPECIES", 178, 185], ["persons", "SPECIES", 285, 292], ["persons", "SPECIES", 404, 411], ["persons", "SPECIES", 499, 506], ["persons", "SPECIES", 652, 659], ["patients", "SPECIES", 721, 729], ["women", "SPECIES", 740, 745], ["persons", "SPECIES", 887, 894], ["Exposure management", "TREATMENT", 12, 31], ["the appropriate immune globulin", "TREATMENT", 52, 83], ["measles", "PROBLEM", 191, 198], ["measles vaccine", "TREATMENT", 246, 261], ["immune globulin", "TREATMENT", 338, 353], ["varicella vaccine", "TREATMENT", 458, 475], ["varicella immune globulin", "TREATMENT", 553, 578], ["VZIG", "TREATMENT", 580, 584], ["varicella onset", "PROBLEM", 771, 786], ["delivery", "TREATMENT", 827, 835], ["smallpox vaccine", "TREATMENT", 847, 863]]], ["Citation ended.Airborne and Droplets: Isolation\u201c--The environmental recommendations in these guidelines may be applied to patients with other infections that require Airborne Precautions\u201d.", [["infections", "DISEASE", 142, 152], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["other infections", "PROBLEM", 136, 152], ["Airborne Precautions", "TREATMENT", 166, 186]]], ["Selected citation ended.Strict Isolation for High-Risk and Dangerous PathogensParticularly dangerous or unknown infectious agents with high mortality need special treatment in high-risk isolates with separately, controlled ventilation and disinfection of air extraction/waste/water, etc. or in buildings separated from other patients and without common ventilation [22, 30\u201334].Strict Isolation for High-Risk and Dangerous PathogensDuring the Ebola epidemic from March 2014, health professionals and patients were not protected well enough since the WHO recommended procedures for close contact/droplet infection [120].", [["Ebola", "DISEASE", 442, 447], ["infection", "DISEASE", 602, 611], ["patients", "ORGANISM", 325, 333], ["patients", "ORGANISM", 499, 507], ["patients", "SPECIES", 325, 333], ["patients", "SPECIES", 499, 507], ["Strict Isolation", "TREATMENT", 24, 40], ["Dangerous Pathogens", "PROBLEM", 59, 78], ["high mortality", "PROBLEM", 135, 149], ["special treatment", "TREATMENT", 155, 172], ["high-risk isolates", "TREATMENT", 176, 194], ["ventilation", "TREATMENT", 223, 234], ["disinfection", "TREATMENT", 239, 251], ["air extraction", "TREATMENT", 255, 269], ["Strict Isolation", "TREATMENT", 377, 393], ["High-Risk", "PROBLEM", 398, 407], ["procedures", "TREATMENT", 565, 575], ["droplet infection", "PROBLEM", 594, 611]]], ["The WHO excluded risk of airborne transmission of Ebola, even though it was documented to be transferred via air to primates [120, 121].", [["Ebola", "DISEASE", 50, 55], ["Ebola", "ORGANISM", 50, 55], ["Ebola", "PROBLEM", 50, 55], ["airborne", "OBSERVATION", 25, 33], ["Ebola", "OBSERVATION", 50, 55]]], ["The uncertain infection control procedures of WHO were upgraded from September to October 2014 by the WHO and CDC, from contact/droplet infection 1 metre from the patient to strict isolation, but still without measures against airborne infection [121, 122].", [["infection", "DISEASE", 14, 23], ["infection", "DISEASE", 136, 145], ["airborne infection", "DISEASE", 227, 245], ["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170], ["droplet infection", "PROBLEM", 128, 145], ["strict isolation", "TREATMENT", 174, 190], ["airborne infection", "PROBLEM", 227, 245], ["infection", "OBSERVATION", 14, 23]]], ["The principle of \u201cprevention is better than cure\u201d was not in use.Strict Isolation for High-Risk and Dangerous PathogensThe same happened in connection with SARS in 2003 where WHO was recommending a low infection control level, contact/droplets 1 metre from the patient, and had to raise the disease control level up to strict isolation ca.", [["SARS", "DISEASE", 156, 160], ["infection", "DISEASE", 202, 211], ["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 261, 268], ["\u201cprevention", "TREATMENT", 17, 28], ["Strict Isolation", "TREATMENT", 65, 81], ["High-Risk", "PROBLEM", 86, 95], ["Dangerous Pathogens", "PROBLEM", 100, 119], ["a low infection control level", "PROBLEM", 196, 225], ["the disease control level", "PROBLEM", 287, 312], ["disease", "OBSERVATION", 291, 298]]], ["2 months later on [33].Strict Isolation for High-Risk and Dangerous PathogensHigh-risk infections are recorded almost daily around the world, like the pneumonic plague in Madagascar, outbreaks (partly nosocomial) of multidrug-resistant tuberculosis in all parts of the world and nosocomial outbreaks of Crimean-Congo haemorrhagic fever in Germany after import of ill US soldier from Afghanistan [123\u2013125].", [["High-risk infections", "DISEASE", 77, 97], ["pneumonic plague", "DISEASE", 151, 167], ["tuberculosis", "DISEASE", 236, 248], ["Crimean-Congo haemorrhagic fever", "DISEASE", 303, 335], ["Crimean-Congo haemorrhagic fever", "ORGANISM", 303, 335], ["Congo haemorrhagic fever", "SPECIES", 311, 335], ["Crimean-Congo haemorrhagic fever", "SPECIES", 303, 335], ["Strict Isolation", "TREATMENT", 23, 39], ["High-Risk", "PROBLEM", 44, 53], ["Dangerous Pathogens", "PROBLEM", 58, 77], ["High-risk infections", "PROBLEM", 77, 97], ["the pneumonic plague in Madagascar", "PROBLEM", 147, 181], ["multidrug-resistant tuberculosis", "PROBLEM", 216, 248], ["Congo haemorrhagic fever", "PROBLEM", 311, 335], ["pneumonic", "OBSERVATION_MODIFIER", 151, 160], ["plague", "OBSERVATION", 161, 167], ["resistant", "OBSERVATION_MODIFIER", 226, 235], ["tuberculosis", "OBSERVATION", 236, 248]]], ["Nearly each day, there are reported new cases of avian influenza, MERS, various haemorrhagic viruses or other dangerous microbes [1, 31\u201334].Strict Isolation for High-Risk and Dangerous PathogensSince 1945, there has been no need for strict isolation in Norway, with the exception of the imported healthcare professionals with Ebola in autumn 2014.Protective IsolationRisk of infection may occur when patients with greatly reduced infection defence are coming into contact with infected equipment, textiles or other patients, staff or visitors who have infection or are carriers of possible pathogenic microbes [19, 22, 126].Protective IsolationThe following conditions are particularly vulnerable to contamination, agranulocytosis, neutropenia; <0.5 in granulocytes or rapidly decreasing number < 2, severe burns, patients with severely weakened immune system due to the treatment with immunosuppressive, chemotherapy or radiation (transplants, cancer or leukaemia).", [["granulocytes", "ANATOMY", 753, 765], ["immune system", "ANATOMY", 846, 859], ["cancer", "ANATOMY", 945, 951], ["leukaemia", "ANATOMY", 955, 964], ["influenza", "DISEASE", 55, 64], ["haemorrhagic viruses", "DISEASE", 80, 100], ["Ebola", "DISEASE", 326, 331], ["infection", "DISEASE", 375, 384], ["infection", "DISEASE", 430, 439], ["infection", "DISEASE", 552, 561], ["agranulocytosis", "DISEASE", 715, 730], ["neutropenia", "DISEASE", 732, 743], ["burns", "DISEASE", 807, 812], ["cancer or leukaemia", "DISEASE", 945, 964], ["avian influenza", "ORGANISM", 49, 64], ["Ebola", "ORGANISM", 326, 331], ["patients", "ORGANISM", 400, 408], ["patients", "ORGANISM", 515, 523], ["granulocytes", "CELL", 753, 765], ["patients", "ORGANISM", 814, 822], ["cancer", "CANCER", 945, 951], ["leukaemia", "CANCER", 955, 964], ["granulocytes", "CELL_TYPE", 753, 765], ["avian influenza", "SPECIES", 49, 64], ["patients", "SPECIES", 400, 408], ["patients", "SPECIES", 515, 523], ["patients", "SPECIES", 814, 822], ["avian influenza", "PROBLEM", 49, 64], ["MERS", "PROBLEM", 66, 70], ["various haemorrhagic viruses", "PROBLEM", 72, 100], ["Strict Isolation", "TREATMENT", 140, 156], ["Dangerous Pathogens", "PROBLEM", 175, 194], ["strict isolation", "TREATMENT", 233, 249], ["infection", "PROBLEM", 375, 384], ["greatly reduced infection defence", "PROBLEM", 414, 447], ["infection", "PROBLEM", 552, 561], ["pathogenic microbes", "PROBLEM", 590, 609], ["Protective Isolation", "TREATMENT", 624, 644], ["contamination", "PROBLEM", 700, 713], ["agranulocytosis", "PROBLEM", 715, 730], ["neutropenia", "PROBLEM", 732, 743], ["granulocytes", "PROBLEM", 753, 765], ["severe burns", "PROBLEM", 800, 812], ["severely weakened immune system", "PROBLEM", 828, 859], ["immunosuppressive", "TREATMENT", 886, 903], ["chemotherapy", "TREATMENT", 905, 917], ["radiation (transplants", "TREATMENT", 921, 943], ["cancer", "PROBLEM", 945, 951], ["leukaemia", "PROBLEM", 955, 964], ["new", "OBSERVATION_MODIFIER", 36, 39], ["influenza", "OBSERVATION", 55, 64], ["haemorrhagic", "OBSERVATION_MODIFIER", 80, 92], ["viruses", "OBSERVATION", 93, 100], ["no need for", "UNCERTAINTY", 221, 232], ["infection", "OBSERVATION", 375, 384], ["infection", "OBSERVATION", 430, 439], ["agranulocytosis", "OBSERVATION", 715, 730], ["rapidly", "OBSERVATION_MODIFIER", 769, 776], ["decreasing", "OBSERVATION_MODIFIER", 777, 787], ["severe", "OBSERVATION_MODIFIER", 800, 806], ["burns", "OBSERVATION", 807, 812], ["cancer", "OBSERVATION", 945, 951], ["leukaemia", "OBSERVATION", 955, 964]]], ["This heterogeneous group is growing due to a more advanced treatment and more cancer and transplant cases.", [["cancer", "ANATOMY", 78, 84], ["cancer", "DISEASE", 78, 84], ["cancer", "CANCER", 78, 84], ["a more advanced treatment", "TREATMENT", 43, 68], ["transplant cases", "TREATMENT", 89, 105], ["heterogeneous", "OBSERVATION_MODIFIER", 5, 18], ["group", "OBSERVATION", 19, 24], ["cancer", "OBSERVATION", 78, 84]]], ["They should be protected against infection from \u201coutside\u201d by treatment in protective isolation in a clean room with anteroom or sluice and with HEPA-filtered air in a positive pressure room [19, 22, 126\u2013131].Protective IsolationCDC recommends that by allogeneic haematopoietic stem cell transplantation (HSCT), the patients should be treated in protective isolation, especially to protect against fungal infections such as Aspergillus; Category IB.", [["sluice", "ANATOMY", 128, 134], ["haematopoietic stem cell", "ANATOMY", 262, 286], ["infection", "DISEASE", 33, 42], ["fungal infections", "DISEASE", 397, 414], ["haematopoietic stem cell", "CELL", 262, 286], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["infection", "PROBLEM", 33, 42], ["HEPA", "TREATMENT", 144, 148], ["Protective IsolationCDC", "TREATMENT", 208, 231], ["allogeneic haematopoietic stem cell transplantation", "TREATMENT", 251, 302], ["protective isolation", "TREATMENT", 345, 365], ["fungal infections", "PROBLEM", 397, 414], ["Aspergillus", "PROBLEM", 423, 434], ["allogeneic haematopoietic stem cell transplantation", "OBSERVATION", 251, 302]]], ["[19]Protective Isolation\u201cAs defined by the American Institute of Architecture, air quality for HSCT patients is improved through a combination of environmental controls that include [1] HEPA filtration of incoming air, [2] directed room air flow, [3] positive room air pressure relative to the corridor, [4] well-sealed rooms (including sealed walls, floors, ceilings, windows, electrical outlets) to prevent flow of air from the outside, [5] ventilation to provide \u226512 air changes per hour, [6] strategies to minimize dust (e.g., scrub-able surfaces rather than upholstery and carpet, and routinely cleaning crevices and sprinkler heads), and [7] prohibiting dried and fresh flowers and potted plants in the rooms of HSCT patients.", [["flowers", "ANATOMY", 676, 683], ["patients", "ORGANISM", 100, 108], ["flowers", "ORGANISM_SUBDIVISION", 676, 683], ["patients", "ORGANISM", 723, 731], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 723, 731], ["Protective Isolation", "TREATMENT", 4, 24], ["environmental controls", "TREATMENT", 146, 168], ["HEPA filtration", "TREATMENT", 186, 201], ["room air flow", "TEST", 232, 245], ["room air pressure", "TEST", 260, 277], ["ventilation", "TREATMENT", 443, 454], ["dust", "PROBLEM", 519, 523], ["scrub", "TREATMENT", 531, 536], ["carpet", "TREATMENT", 578, 584], ["routinely cleaning crevices and sprinkler heads", "TREATMENT", 590, 637]]], ["The latter is based on molecular typing studies that have found indistinguishable strains of Aspergillus terreus in patients with haematologic malignancies and in potted plants in the vicinity of the patients\u201d [19].In protective isolate should intake air be HEPA filtered which removes 99.97% of particles larger than or equal 0.3 \u03bcm in diameter; Category IB.", [["haematologic malignancies", "ANATOMY", 130, 155], ["Aspergillus terreus", "DISEASE", 93, 112], ["haematologic malignancies", "DISEASE", 130, 155], ["Aspergillus terreus", "ORGANISM", 93, 112], ["patients", "ORGANISM", 116, 124], ["malignancies", "CANCER", 143, 155], ["patients", "ORGANISM", 200, 208], ["Aspergillus terreus", "SPECIES", 93, 112], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 200, 208], ["Aspergillus terreus", "SPECIES", 93, 112], ["molecular typing studies", "TEST", 23, 47], ["Aspergillus terreus", "PROBLEM", 93, 112], ["haematologic malignancies", "PROBLEM", 130, 155], ["HEPA filtered", "TREATMENT", 258, 271], ["Aspergillus terreus", "OBSERVATION", 93, 112], ["malignancies", "OBSERVATION", 143, 155], ["Category IB", "OBSERVATION", 347, 358]]], ["[19]The room should be at positive pressure relative to the corridor with a pressure difference of 12.5 pascal or more; Category IB.", [["a pressure difference", "TEST", 74, 95]]], ["[19]The pressure should be monitored visually every day; Category IA [19].The room must be sealed so that no outside air to seep in; Category IB.", [["The pressure", "TEST", 4, 16], ["sealed", "OBSERVATION", 91, 97]]], ["[19]Use smooth surfaces, avoiding textile furniture and the like, and perform good cleaning; Category II [19].Do not use carpeting in corridors or rooms in the area; Category IB.", [["smooth surfaces", "TREATMENT", 8, 23], ["avoiding textile furniture", "TREATMENT", 25, 51], ["Category IB", "OBSERVATION", 166, 177]]], ["[19]The patient should be at least possible out of the room, the necessary examinations, etc., to be implemented in the shortest possible time; Category IB.", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["the necessary examinations", "TEST", 61, 87]]], ["[19, 22, 126, 130, 131]If necessary, use respiratory protection if out of isolation; Category II [19, 130].Staff are using adequate infection control equipment if the patient has infection; Category IA/IB.", [["infection", "DISEASE", 132, 141], ["infection", "DISEASE", 179, 188], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["respiratory protection", "TREATMENT", 41, 63], ["adequate infection control equipment", "TREATMENT", 123, 159], ["infection", "PROBLEM", 179, 188], ["infection", "OBSERVATION", 132, 141], ["infection", "OBSERVATION", 179, 188]]], ["[19]Patients with respiratory infection\u2014at the same time they need protective isolation\u2014should be transferred to a defined airborne isolate.", [["respiratory", "ANATOMY", 18, 29], ["Patients", "ORGANISM", 4, 12], ["Patients", "SPECIES", 4, 12], ["respiratory infection\u2014at", "PROBLEM", 18, 42], ["protective isolation", "TREATMENT", 67, 87]]], ["If HEPA filters are lacking on the air intake to the airborne infection isolation units, a portable system of the HEPA filter may be used in the room to remove fungal spores and bacteria; Category II [19].Protective IsolationAvoid transfers outside the isolate [130, 131].", [["spores", "ANATOMY", 167, 173], ["infection", "DISEASE", 62, 71], ["HEPA filters", "TREATMENT", 3, 15], ["the airborne infection isolation units", "TREATMENT", 49, 87], ["a portable system", "TEST", 89, 106], ["the HEPA filter", "TREATMENT", 110, 125], ["fungal spores", "PROBLEM", 160, 173], ["bacteria", "PROBLEM", 178, 186]]], ["A retrospective, case-control study of immunocompromised patients in Switzerland showed that when invasive fungal infection occurred, the mortality was over 20% [131].", [["fungal infection", "DISEASE", 107, 123], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["case-control study", "TEST", 17, 35], ["invasive fungal infection", "PROBLEM", 98, 123], ["invasive", "OBSERVATION_MODIFIER", 98, 106], ["fungal", "OBSERVATION_MODIFIER", 107, 113], ["infection", "OBSERVATION", 114, 123]]], ["An outbreak of fungal infection among 29 patients on a haematological department showed that the more often the patient was transferred to other departments/was outside the isolate, the more frequently he was infected with invasive fungi [131].", [["fungal infection", "DISEASE", 15, 31], ["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 112, 119], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 112, 119], ["fungal infection", "PROBLEM", 15, 31], ["invasive fungi", "PROBLEM", 223, 237], ["outbreak", "OBSERVATION_MODIFIER", 3, 11], ["fungal", "OBSERVATION_MODIFIER", 15, 21], ["infection", "OBSERVATION", 22, 31]]], ["With more than five patient transfers outside protective isolates, the risk of fungal infection was sixfold higher than if staying in protective isolation.", [["fungal infection", "DISEASE", 79, 95], ["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["outside protective isolates", "TREATMENT", 38, 65], ["fungal infection", "PROBLEM", 79, 95], ["protective isolation", "TREATMENT", 134, 154], ["fungal", "OBSERVATION_MODIFIER", 79, 85], ["infection", "OBSERVATION", 86, 95]]], ["If the patient was transferred during neutropenia, the risk increased by nearly sevenfold [131].Protective IsolationBuilding activities.", [["neutropenia", "DISEASE", 38, 49], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["neutropenia", "PROBLEM", 38, 49], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["IsolationBuilding activities", "OBSERVATION", 107, 135]]], ["Fungal spores are always released during construction activity and may become airborne also in risk areas where severely immunocompromised patients are located [105, 126, 130].", [["spores", "ANATOMY", 7, 13], ["Fungal spores", "CELL", 0, 13], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Fungal spores", "PROBLEM", 0, 13], ["severely immunocompromised", "PROBLEM", 112, 138], ["severely", "OBSERVATION_MODIFIER", 112, 120], ["immunocompromised", "OBSERVATION", 121, 138]]], ["Infectious agents may be spread via air, textiles and equipment with deposition of fungal spores and other microbes during the construction period.", [["spores", "ANATOMY", 90, 96], ["Infectious agents", "TREATMENT", 0, 17], ["fungal spores", "PROBLEM", 83, 96], ["air", "OBSERVATION", 36, 39], ["fungal spores", "OBSERVATION", 83, 96]]], ["Fungal spores follow air currents far away [105].", [["spores", "ANATOMY", 7, 13], ["Fungal spores", "PROBLEM", 0, 13]]], ["Construction activity must therefore be coordinated with appropriate departments and wards so that the patient area is shielded.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["Air from construction places should not leak into patient areas and be taken out directly from the building in such a way that it does not re-enter through the systems for intake of air.Protective IsolationLeakage of water in buildings.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["leak into patient areas", "PROBLEM", 40, 63], ["leak", "OBSERVATION", 40, 44], ["air", "OBSERVATION", 182, 185]]], ["Fungal growth in patient room walls is due to neglected maintenance of buildings for many years and usually comes from water leakage from the old pipes, roof leaks or poorly maintained bathrooms.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["Fungal growth", "PROBLEM", 0, 13], ["water leakage", "PROBLEM", 119, 132], ["roof leaks", "PROBLEM", 153, 163], ["growth", "OBSERVATION_MODIFIER", 7, 13], ["roof leaks", "OBSERVATION", 153, 163]]], ["Patients should not stay in rooms with suspected fungal growth and decay!Protective IsolationControl of fungi should be implemented in protective isolates and storages for such isolates once a year or more frequently when suspected water leaks and rot.", [["Patients", "ORGANISM", 0, 8], ["rot", "ORGANISM_SUBDIVISION", 248, 251], ["Patients", "SPECIES", 0, 8], ["fungal growth", "PROBLEM", 49, 62], ["Protective IsolationControl of fungi", "TREATMENT", 73, 109], ["water leaks and rot", "PROBLEM", 232, 251], ["leaks", "OBSERVATION", 238, 243]]], ["The requirement is 0 fungal spores per 1000 litres of air using the SAS-slit sampler.Protective IsolationPatients must be protected against infections during care and treatment [19, 22, 132\u2013134].Protective IsolationCleaning and disinfection of rooms, surfaces and equipment between infection susceptible patients must be extra careful since many\u2014at the same time\u2014have serious infections, including resistant bacteria.", [["infections", "DISEASE", 140, 150], ["infection", "DISEASE", 282, 291], ["infections", "DISEASE", 376, 386], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 304, 312], ["0 fungal spores", "PROBLEM", 19, 34], ["the SAS-slit sampler", "TREATMENT", 64, 84], ["Protective IsolationPatients", "TREATMENT", 85, 113], ["treatment", "TREATMENT", 167, 176], ["Protective IsolationCleaning", "TREATMENT", 195, 223], ["infection", "PROBLEM", 282, 291], ["serious infections", "PROBLEM", 368, 386], ["resistant bacteria", "PROBLEM", 398, 416], ["0 fungal", "OBSERVATION_MODIFIER", 19, 27], ["IsolationCleaning", "OBSERVATION", 206, 223]]], ["Despite a good cleaning, abundant amounts of microbes may be detected in the environment and the equipment after cleaning [135, 136].Protecting Staff Against Serious InfectionHealthcare professionals who treat infectious patients may be highly exposed to infection, although they really should be protected [3, 6\u20138, 19, 22, 137, 138].Protecting Staff Against Serious InfectionAt the beginning of the SARS epidemic in 2003, 90% of SARS patients were the hospital personnel who had taken care of the first SARS patients [33].", [["infection", "DISEASE", 255, 264], ["SARS", "DISEASE", 400, 404], ["SARS", "DISEASE", 430, 434], ["SARS", "DISEASE", 504, 508], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 435, 443], ["patients", "ORGANISM", 509, 517], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 435, 443], ["patients", "SPECIES", 509, 517], ["Serious Infection", "PROBLEM", 158, 175], ["infection", "PROBLEM", 255, 264], ["good", "OBSERVATION_MODIFIER", 10, 14], ["cleaning", "OBSERVATION", 15, 23], ["abundant", "OBSERVATION_MODIFIER", 25, 33], ["amounts", "OBSERVATION_MODIFIER", 34, 41], ["microbes", "OBSERVATION", 45, 53], ["may be", "UNCERTAINTY", 54, 60], ["Infection", "OBSERVATION", 166, 175], ["infection", "OBSERVATION", 255, 264]]], ["During the Ebola outbreak in 2014, healthcare workers were again severely attacked by the disease and death in the first phase, until a more protective personal protective equipment system was in place [34, 120\u2013122].", [["Ebola", "DISEASE", 11, 16], ["death", "DISEASE", 102, 107], ["the disease and death", "PROBLEM", 86, 107]]], ["There is still a great variety in international guidelines in terms of personal protection equipment (PPE) by Ebola virus for healthcare workers [121].", [["Ebola virus", "DISEASE", 110, 121], ["Ebola virus", "ORGANISM", 110, 121], ["Ebola virus", "SPECIES", 110, 121], ["Ebola virus", "SPECIES", 110, 121], ["personal protection equipment", "TREATMENT", 71, 100], ["great", "OBSERVATION_MODIFIER", 17, 22], ["variety", "OBSERVATION_MODIFIER", 23, 30]]], ["The WHO, United Kingdom and CDC defined Ebola as non-airborne infection in 2014 and still does the same in 2017 [121].", [["Ebola", "DISEASE", 40, 45], ["infection", "DISEASE", 62, 71], ["Ebola", "ORGANISM", 40, 45], ["Ebola", "PROBLEM", 40, 45], ["non-airborne infection", "PROBLEM", 49, 71], ["Ebola", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 62, 71]]], ["None of these recommended respiratory protection for suspected Ebola infection in August\u2013September 2014, at least half a year after the start of the epidemic.", [["Ebola infection", "DISEASE", 63, 78], ["Ebola", "ORGANISM", 63, 68], ["respiratory protection", "TREATMENT", 26, 48], ["suspected Ebola infection", "PROBLEM", 53, 78], ["Ebola", "OBSERVATION_MODIFIER", 63, 68], ["infection", "OBSERVATION", 69, 78]]], ["Only the United Kingdom recommended respirator mask for confirmed Ebola.", [["Ebola", "DISEASE", 66, 71], ["Ebola", "ORGANISM", 66, 71], ["respirator mask", "TREATMENT", 36, 51], ["Ebola", "PROBLEM", 66, 71], ["Ebola", "OBSERVATION", 66, 71]]], ["There was no covering of the head or neck, not either during aerosol-generating procedures!Protecting Staff Against Serious InfectionIn October 2014, the CDC upgraded the PPE measures to strict isolation measures for proven Ebola infection, while the earlier PPE measures were recommended for suspected Ebola infection (Table 21.1) [120\u2013122].Protecting Staff Against Serious InfectionDuring the pandemic flu in 2009, Norwegian health authorities did not allow the staff at hospitals to use respirator masks (P3 masks) when taking care of the flu patients; they should use surgical masks [138].", [["head", "ANATOMY", 29, 33], ["neck", "ANATOMY", 37, 41], ["Ebola infection", "DISEASE", 224, 239], ["Ebola infection", "DISEASE", 303, 318], ["flu", "DISEASE", 404, 407], ["head", "ORGANISM_SUBDIVISION", 29, 33], ["neck", "ORGAN", 37, 41], ["Ebola", "ORGANISM", 224, 229], ["Ebola", "ORGANISM", 303, 308], ["patients", "ORGANISM", 546, 554], ["patients", "SPECIES", 546, 554], ["Ebola", "SPECIES", 224, 229], ["covering of the head or neck", "PROBLEM", 13, 41], ["the PPE measures", "TREATMENT", 167, 183], ["strict isolation measures", "TREATMENT", 187, 212], ["Ebola infection", "PROBLEM", 224, 239], ["the earlier PPE measures", "TREATMENT", 247, 271], ["Ebola infection", "PROBLEM", 303, 318], ["respirator masks (P3 masks", "TREATMENT", 490, 516], ["surgical masks", "TREATMENT", 572, 586], ["head", "ANATOMY", 29, 33], ["neck", "ANATOMY", 37, 41], ["Ebola", "OBSERVATION_MODIFIER", 224, 229], ["infection", "OBSERVATION", 230, 239]]], ["Exceptions were for aerosol-generating procedures.", [["aerosol-generating procedures", "TREATMENT", 20, 49]]], ["The same health authorities went public and said that surgical masks did not have any protective effect! [138]Protecting Staff Against Serious InfectionRecurrent problems are that the health authorities are not able to see the importance in protecting health professionals who are\u2014and will always be\u2014the front-line workers, even at the most serious infectious diseases [137].", [["surgical masks", "TREATMENT", 54, 68], ["Serious InfectionRecurrent problems", "PROBLEM", 135, 170]]], ["If the disease is not as dangerous as SARS and Ebola, a highly contagious pandemic influenza or a large norovirus outbreak could paralyse the healthcare system when a high number of the staff get sick at the same time.", [["SARS", "DISEASE", 38, 42], ["Ebola", "DISEASE", 47, 52], ["influenza", "DISEASE", 83, 92], ["norovirus", "DISEASE", 104, 113], ["the disease", "PROBLEM", 3, 14], ["SARS", "PROBLEM", 38, 42], ["Ebola", "PROBLEM", 47, 52], ["a highly contagious pandemic influenza", "PROBLEM", 54, 92], ["a large norovirus outbreak", "PROBLEM", 96, 122], ["disease", "OBSERVATION", 7, 14], ["large", "OBSERVATION_MODIFIER", 98, 103], ["norovirus", "OBSERVATION", 104, 113]]], ["By preventing disease transmission to health professionals, the hospital can be operatively enough to handle properly other serious diseases such as traffic accidents, myocardial infarction, stroke, etc., even at large-scale epidemics.Protecting Staff Against Serious InfectionIn spite of problems concerning isolation and prevention of spread of emerging and new serious infections, new guidelines are now appearing, which works with reduction of infection control in severely affected countries with endemic infections [139, 140].CDC Isolation Guidelines - Overview - Selected by the Author", [["myocardial", "ANATOMY", 168, 178], ["traffic accidents", "DISEASE", 149, 166], ["myocardial infarction", "DISEASE", 168, 189], ["stroke", "DISEASE", 191, 197], ["infections", "DISEASE", 372, 382], ["infection", "DISEASE", 448, 457], ["infections", "DISEASE", 510, 520], ["myocardial", "MULTI-TISSUE_STRUCTURE", 168, 178], ["properly other serious diseases", "PROBLEM", 109, 140], ["myocardial infarction", "PROBLEM", 168, 189], ["stroke", "PROBLEM", 191, 197], ["new serious infections", "PROBLEM", 360, 382], ["infection control", "TREATMENT", 448, 465], ["endemic infections", "PROBLEM", 502, 520], ["myocardial", "ANATOMY", 168, 178], ["infarction", "OBSERVATION", 179, 189], ["stroke", "OBSERVATION", 191, 197], ["new", "OBSERVATION_MODIFIER", 360, 363], ["serious", "OBSERVATION_MODIFIER", 364, 371], ["infections", "OBSERVATION", 372, 382], ["infection", "OBSERVATION", 448, 457]]]], "816034c362e494e9f9737a0b8c3090909beabf7e": [["The SARS-CoV-2 (COVID- 19) virus causes a wide spectrum of disease in healthy individuals as well as those with common comorbidities (1) .", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["COVID- 19) virus", "ORGANISM", 16, 32], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["COVID", "TEST", 16, 21], ["virus", "PROBLEM", 27, 32], ["a wide spectrum of disease in healthy individuals", "PROBLEM", 40, 89], ["wide spectrum", "OBSERVATION_MODIFIER", 42, 55], ["disease", "OBSERVATION", 59, 66]]], ["Severe COVID-19 is characterised acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) (2) .", [["respiratory", "ANATOMY", 39, 50], ["extracorporeal membrane", "ANATOMY", 165, 188], ["acute respiratory distress syndrome", "DISEASE", 33, 68], ["ARDS", "DISEASE", 70, 74], ["pneumonitis", "DISEASE", 95, 106], ["Severe COVID", "PROBLEM", 0, 12], ["acute respiratory distress syndrome", "PROBLEM", 33, 68], ["ARDS)", "PROBLEM", 70, 75], ["viral pneumonitis", "PROBLEM", 89, 106], ["treatment", "TREATMENT", 108, 117], ["mechanical ventilation", "TREATMENT", 139, 161], ["extracorporeal membrane oxygenation", "TREATMENT", 165, 200], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory distress syndrome", "OBSERVATION", 39, 68], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["pneumonitis", "OBSERVATION", 95, 106], ["may require", "UNCERTAINTY", 127, 138], ["mechanical ventilation", "OBSERVATION", 139, 161]]], ["Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example a recent review found that 72% of patients with COVID-19 received antimicrobial therapy (3) .", [["lower respiratory tract", "ANATOMY", 87, 110], ["bacterial co-infection", "DISEASE", 43, 65], ["respiratory tract viral infection", "DISEASE", 93, 126], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 87, 110], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["bacterial co-infection", "PROBLEM", 43, 65], ["lower respiratory tract viral infection", "PROBLEM", 87, 126], ["COVID", "TEST", 188, 193], ["antimicrobial therapy", "TREATMENT", 206, 227], ["co-infection", "OBSERVATION", 53, 65], ["lower", "ANATOMY_MODIFIER", 87, 92], ["respiratory tract", "ANATOMY", 93, 110], ["viral infection", "OBSERVATION", 111, 126]]], ["However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.", [["pulmonary", "ANATOMY", 76, 85], ["fungal co-infection", "DISEASE", 21, 40], ["COVID-19", "CHEMICAL", 56, 64], ["pulmonary aspergillosis", "DISEASE", 76, 99], ["CAPA", "DISEASE", 101, 105], ["COVID-19", "GENE_OR_GENE_PRODUCT", 56, 64], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 76, 99], ["fungal co-infection", "PROBLEM", 21, 40], ["pulmonary aspergillosis", "PROBLEM", 76, 99], ["fungal co-infection", "OBSERVATION", 21, 40], ["pulmonary", "ANATOMY", 76, 85], ["aspergillosis", "OBSERVATION", 86, 99]]]], "5bcfcf89e794c73c8d079ddacc6eb7849501b927": [["IntroductionAs an essential interface between the environment and the internal milieu, the lungs are continuously exposed to dust, pollen, chemicals, and microbial pathogens.", [["lungs", "ANATOMY", 91, 96], ["lungs", "ORGAN", 91, 96], ["pollen", "PROBLEM", 131, 137], ["microbial pathogens", "PROBLEM", 154, 173], ["essential", "OBSERVATION_MODIFIER", 18, 27], ["interface", "OBSERVATION", 28, 37], ["internal milieu", "ANATOMY", 70, 85], ["lungs", "ANATOMY", 91, 96], ["microbial pathogens", "OBSERVATION", 154, 173]]], ["Pneumonia and related patterns of lower respiratory tract infection are a frequent consequence of this interaction and account for a significant proportion of human morbidity and mortality throughout the world [1, 2] .", [["lower respiratory tract", "ANATOMY", 34, 57], ["Pneumonia", "DISEASE", 0, 9], ["lower respiratory tract infection", "DISEASE", 34, 67], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 34, 57], ["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["Pneumonia", "PROBLEM", 0, 9], ["lower respiratory tract infection", "PROBLEM", 34, 67], ["human morbidity", "PROBLEM", 159, 174], ["lower", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57], ["infection", "OBSERVATION", 58, 67]]], ["To contain potential environmental threats, the lungs are equipped with complex and multifaceted host defences.", [["lungs", "ANATOMY", 48, 53], ["lungs", "ORGAN", 48, 53], ["lungs", "ANATOMY", 48, 53], ["host defences", "OBSERVATION", 97, 110]]], ["During tidal ventilation, the complex geometry of the nasal passages and branching pattern of the central airways impede the penetration of relatively large or heavy infectious particles while tight intercellular junctions ensure the structural integrity of the lung epithelium.", [["nasal", "ANATOMY", 54, 59], ["central airways", "ANATOMY", 98, 113], ["intercellular junctions", "ANATOMY", 199, 222], ["lung epithelium", "ANATOMY", 262, 277], ["central airways", "MULTI-TISSUE_STRUCTURE", 98, 113], ["intercellular junctions", "CELLULAR_COMPONENT", 199, 222], ["lung epithelium", "TISSUE", 262, 277], ["tidal ventilation", "TREATMENT", 7, 24], ["the nasal passages", "TREATMENT", 50, 68], ["relatively large or heavy infectious particles", "PROBLEM", 140, 186], ["tidal ventilation", "OBSERVATION", 7, 24], ["complex", "OBSERVATION_MODIFIER", 30, 37], ["geometry", "OBSERVATION_MODIFIER", 38, 46], ["nasal passages", "OBSERVATION", 54, 68], ["branching", "OBSERVATION_MODIFIER", 73, 82], ["pattern", "OBSERVATION_MODIFIER", 83, 90], ["central", "ANATOMY_MODIFIER", 98, 105], ["airways", "ANATOMY", 106, 113], ["penetration", "OBSERVATION_MODIFIER", 125, 136], ["relatively", "OBSERVATION_MODIFIER", 140, 150], ["large", "OBSERVATION_MODIFIER", 151, 156], ["heavy", "OBSERVATION_MODIFIER", 160, 165], ["infectious", "OBSERVATION", 166, 176], ["intercellular junctions", "OBSERVATION", 199, 222], ["structural integrity", "OBSERVATION", 234, 254], ["lung", "ANATOMY", 262, 266], ["epithelium", "ANATOMY_MODIFIER", 267, 277]]], ["This barrier is enhanced by airway goblet cells that secrete mucus and ciliated epithelial cells that constantly transport this viscous layer towards the bronchi and away from the alveoli to facilitate expulsion of trapped particles [3] .", [["airway goblet cells", "ANATOMY", 28, 47], ["mucus", "ANATOMY", 61, 66], ["epithelial cells", "ANATOMY", 80, 96], ["bronchi", "ANATOMY", 154, 161], ["alveoli", "ANATOMY", 180, 187], ["airway goblet cells", "CELL", 28, 47], ["mucus", "ORGANISM_SUBSTANCE", 61, 66], ["ciliated epithelial cells", "CELL", 71, 96], ["bronchi", "MULTI-TISSUE_STRUCTURE", 154, 161], ["alveoli", "MULTI-TISSUE_STRUCTURE", 180, 187], ["airway goblet cells", "CELL_TYPE", 28, 47], ["ciliated epithelial cells", "CELL_TYPE", 71, 96], ["airway goblet cells", "TEST", 28, 47], ["secrete mucus and ciliated epithelial cells", "PROBLEM", 53, 96], ["expulsion of trapped particles", "PROBLEM", 202, 232], ["airway", "ANATOMY", 28, 34], ["goblet cells", "OBSERVATION", 35, 47], ["ciliated epithelial cells", "OBSERVATION", 71, 96], ["bronchi", "ANATOMY", 154, 161], ["alveoli", "ANATOMY", 180, 187], ["trapped particles", "OBSERVATION", 215, 232]]], ["A variety of soluble host defence mediators such as secretory IgA, antimicrobial peptides, surfactant proteins, lactoferrin, and lysozyme also bolster the mucosal defences of the lower respiratory tract.", [["mucosal", "ANATOMY", 155, 162], ["lower respiratory tract", "ANATOMY", 179, 202], ["IgA", "GENE_OR_GENE_PRODUCT", 62, 65], ["surfactant proteins", "GENE_OR_GENE_PRODUCT", 91, 110], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 112, 123], ["lysozyme", "GENE_OR_GENE_PRODUCT", 129, 137], ["mucosal", "PATHOLOGICAL_FORMATION", 155, 162], ["lower respiratory", "ORGANISM_SUBDIVISION", 179, 196], ["tract", "ORGANISM_SUBDIVISION", 197, 202], ["soluble host defence mediators", "PROTEIN", 13, 43], ["secretory IgA", "PROTEIN", 52, 65], ["surfactant proteins", "PROTEIN", 91, 110], ["lactoferrin", "PROTEIN", 112, 123], ["lysozyme", "PROTEIN", 129, 137], ["soluble host defence mediators", "TREATMENT", 13, 43], ["secretory IgA", "TREATMENT", 52, 65], ["antimicrobial peptides", "TREATMENT", 67, 89], ["surfactant proteins", "TREATMENT", 91, 110], ["lactoferrin", "TREATMENT", 112, 123], ["lysozyme", "TREATMENT", 129, 137], ["mucosal defences", "OBSERVATION", 155, 171], ["lower", "ANATOMY_MODIFIER", 179, 184], ["respiratory tract", "ANATOMY", 185, 202]]], ["Finally, resident alveolar macrophages (AMs) and airway mucosal dendritic cells (DCs) provide constant surveillance for potentially pathogenic factors while inhibiting T cell responses to myriad non-pathogenic antigens [4] .", [["alveolar macrophages", "ANATOMY", 18, 38], ["AMs", "ANATOMY", 40, 43], ["airway mucosal dendritic cells", "ANATOMY", 49, 79], ["DCs", "ANATOMY", 81, 84], ["T cell", "ANATOMY", 168, 174], ["alveolar macrophages", "CELL", 18, 38], ["AMs", "CELL", 40, 43], ["airway mucosal dendritic cells", "CELL", 49, 79], ["DCs", "CELL", 81, 84], ["T cell", "CELL", 168, 174], ["resident alveolar macrophages", "CELL_TYPE", 9, 38], ["AMs", "CELL_TYPE", 40, 43], ["airway mucosal dendritic cells", "CELL_TYPE", 49, 79], ["DCs", "CELL_TYPE", 81, 84], ["airway mucosal dendritic cells", "PROBLEM", 49, 79], ["constant surveillance", "TEST", 94, 115], ["potentially pathogenic factors", "PROBLEM", 120, 150], ["myriad non-pathogenic antigens", "PROBLEM", 188, 218], ["alveolar macrophages", "OBSERVATION", 18, 38], ["airway mucosal", "ANATOMY", 49, 63], ["dendritic cells", "OBSERVATION", 64, 79]]], ["These normal host defences ensure that most encounters between the respiratory tract and pathogens are inconsequential; nevertheless, in response to prolonged, intense, or highly virulent microbial exposure, an inflammatory response or productive infection is likely to occur.", [["respiratory tract", "ANATOMY", 67, 84], ["infection", "DISEASE", 247, 256], ["respiratory tract", "ORGANISM_SUBDIVISION", 67, 84], ["the respiratory tract", "PROBLEM", 63, 84], ["pathogens", "PROBLEM", 89, 98], ["highly virulent microbial exposure", "PROBLEM", 172, 206], ["an inflammatory response", "PROBLEM", 208, 232], ["productive infection", "PROBLEM", 236, 256], ["normal", "OBSERVATION", 6, 12], ["host defences", "OBSERVATION", 13, 26], ["respiratory tract", "ANATOMY", 67, 84], ["pathogens", "OBSERVATION", 89, 98], ["virulent", "OBSERVATION_MODIFIER", 179, 187], ["inflammatory", "OBSERVATION_MODIFIER", 211, 223], ["productive", "OBSERVATION_MODIFIER", 236, 246], ["infection", "OBSERVATION", 247, 256]]], ["To rapidly initiate an acute inflammatory response in these circumstances, the lung epithelium, myeloid cells, and associated lymphoid tissue are all equipped with a series of highly conserved pattern recognition receptor (PRRs) including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I like receptors (RLRs).", [["lung epithelium", "ANATOMY", 79, 94], ["myeloid cells", "ANATOMY", 96, 109], ["lymphoid tissue", "ANATOMY", 126, 141], ["lung epithelium", "TISSUE", 79, 94], ["myeloid cells", "CELL", 96, 109], ["lymphoid tissue", "TISSUE", 126, 141], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 193, 221], ["PRRs", "GENE_OR_GENE_PRODUCT", 223, 227], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 239, 258], ["TLRs", "GENE_OR_GENE_PRODUCT", 260, 264], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 267, 285], ["NLRs", "GENE_OR_GENE_PRODUCT", 287, 291], ["RIG-I like receptors", "GENE_OR_GENE_PRODUCT", 298, 318], ["RLRs", "GENE_OR_GENE_PRODUCT", 320, 324], ["myeloid cells", "CELL_TYPE", 96, 109], ["pattern recognition receptor", "PROTEIN", 193, 221], ["PRRs", "PROTEIN", 223, 227], ["Toll-like receptors", "PROTEIN", 239, 258], ["TLRs", "PROTEIN", 260, 264], ["NOD-like receptors", "PROTEIN", 267, 285], ["NLRs", "PROTEIN", 287, 291], ["RIG-I like receptors", "PROTEIN", 298, 318], ["RLRs", "PROTEIN", 320, 324], ["an acute inflammatory response", "PROBLEM", 20, 50], ["the lung epithelium, myeloid cells", "PROBLEM", 75, 109], ["associated lymphoid tissue", "PROBLEM", 115, 141], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["inflammatory", "OBSERVATION", 29, 41], ["lung", "ANATOMY", 79, 83], ["epithelium", "ANATOMY_MODIFIER", 84, 94], ["myeloid cells", "OBSERVATION", 96, 109], ["lymphoid tissue", "OBSERVATION", 126, 141]]], ["PRR activation leads to the release of cytokines and chemokines that attract leukocytes to the site of infection and trigger the maturation and trafficking of antigen presenting cells for induction of adaptive immunity (figure 1).", [["leukocytes", "ANATOMY", 77, 87], ["site", "ANATOMY", 95, 99], ["cells", "ANATOMY", 178, 183], ["infection", "DISEASE", 103, 112], ["leukocytes", "CELL", 77, 87], ["cells", "CELL", 178, 183], ["PRR", "PROTEIN", 0, 3], ["cytokines", "PROTEIN", 39, 48], ["chemokines", "PROTEIN", 53, 63], ["leukocytes", "CELL_TYPE", 77, 87], ["antigen presenting cells", "CELL_TYPE", 159, 183], ["PRR activation", "PROBLEM", 0, 14], ["cytokines", "TREATMENT", 39, 48], ["chemokines", "TREATMENT", 53, 63], ["leukocytes", "PROBLEM", 77, 87], ["infection", "PROBLEM", 103, 112], ["the maturation", "PROBLEM", 125, 139], ["antigen presenting cells", "PROBLEM", 159, 183], ["induction of adaptive immunity", "TREATMENT", 188, 218], ["infection", "OBSERVATION", 103, 112]]], ["The purpose of this article is to review the role of TLRs in the pathogenesis or consequences of acute lung injury (ALI) and chronic inflammatory lung diseases including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF).Microbial ligandsConstant interactions between the respiratory tract and the environment pose a major challenge to host immunity and necessitate robust surveillance mechanisms to distinguish innocuous from pathogenic exposures.", [["lung", "ANATOMY", 103, 107], ["lung", "ANATOMY", 146, 150], ["pulmonary", "ANATOMY", 198, 207], ["cystic", "ANATOMY", 228, 234], ["respiratory tract", "ANATOMY", 300, 317], ["acute lung injury", "DISEASE", 97, 114], ["ALI", "DISEASE", 116, 119], ["lung diseases", "DISEASE", 146, 159], ["asthma", "DISEASE", 170, 176], ["chronic obstructive pulmonary disease", "DISEASE", 178, 215], ["COPD", "DISEASE", 217, 221], ["cystic fibrosis", "DISEASE", 228, 243], ["CF", "DISEASE", 245, 247], ["TLRs", "GENE_OR_GENE_PRODUCT", 53, 57], ["lung", "ORGAN", 103, 107], ["lung", "ORGAN", 146, 150], ["pulmonary", "ORGAN", 198, 207], ["respiratory tract", "ORGANISM_SUBDIVISION", 300, 317], ["TLRs", "PROTEIN", 53, 57], ["acute lung injury", "PROBLEM", 97, 114], ["ALI", "PROBLEM", 116, 119], ["chronic inflammatory lung diseases", "PROBLEM", 125, 159], ["asthma", "PROBLEM", 170, 176], ["chronic obstructive pulmonary disease", "PROBLEM", 178, 215], ["COPD)", "PROBLEM", 217, 222], ["cystic fibrosis", "PROBLEM", 228, 243], ["Microbial ligands", "TEST", 249, 266], ["Constant interactions between the respiratory tract", "PROBLEM", 266, 317], ["robust surveillance mechanisms", "TREATMENT", 394, 424], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["ALI", "ANATOMY", 116, 119], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145], ["lung", "ANATOMY", 146, 150], ["diseases", "OBSERVATION", 151, 159], ["asthma", "OBSERVATION", 170, 176], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["obstructive", "OBSERVATION_MODIFIER", 186, 197], ["pulmonary", "ANATOMY", 198, 207], ["disease", "OBSERVATION", 208, 215], ["COPD", "OBSERVATION", 217, 221], ["cystic", "OBSERVATION_MODIFIER", 228, 234], ["fibrosis", "OBSERVATION", 235, 243], ["ligands", "OBSERVATION", 259, 266], ["respiratory tract", "ANATOMY", 300, 317]]], ["One strategy that is used by TLRs for selective induction of a host response is recognition of unique microbial structures termed pathogen-associated molecular patterns (PAMPs) [5] [6] [7] [8] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 29, 33], ["[5] [6] [7] [8]", "SIMPLE_CHEMICAL", 177, 192], ["TLRs", "PROTEIN", 29, 33], ["unique microbial structures termed pathogen", "PROBLEM", 95, 138]]], ["Eleven functional TLR genes that play diverse roles in host defense, inflammation, autoimmunity, and neoplasia have been discovered in mouse and man (mouse TLR10 is a pseudogene and human TLR11 encodes a truncated protein) [5] .", [["neoplasia", "ANATOMY", 101, 110], ["inflammation", "DISEASE", 69, 81], ["autoimmunity", "DISEASE", 83, 95], ["neoplasia", "DISEASE", 101, 110], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["neoplasia", "CANCER", 101, 110], ["mouse", "ORGANISM", 135, 140], ["man", "ORGANISM", 145, 148], ["mouse", "ORGANISM", 150, 155], ["TLR10", "GENE_OR_GENE_PRODUCT", 156, 161], ["human", "ORGANISM", 182, 187], ["TLR11", "GENE_OR_GENE_PRODUCT", 188, 193], ["TLR genes", "DNA", 18, 27], ["mouse TLR10", "DNA", 150, 161], ["human TLR11", "DNA", 182, 193], ["truncated protein", "PROTEIN", 204, 221], ["mouse", "SPECIES", 135, 140], ["man", "SPECIES", 145, 148], ["mouse", "SPECIES", 150, 155], ["human", "SPECIES", 182, 187], ["mouse", "SPECIES", 135, 140], ["mouse", "SPECIES", 150, 155], ["human", "SPECIES", 182, 187], ["inflammation", "PROBLEM", 69, 81], ["autoimmunity", "PROBLEM", 83, 95], ["neoplasia", "PROBLEM", 101, 110], ["TLR genes", "OBSERVATION", 18, 27], ["host defense", "OBSERVATION_MODIFIER", 55, 67], ["inflammation", "OBSERVATION", 69, 81], ["neoplasia", "OBSERVATION", 101, 110]]], ["Prototypic examples of PAMPs include lipopolysaccharide (LPS), a outer membrane component of Gram-negative bacteria that stimulates TLR4 [8, 9] , bacterial lipoproteins that stimulate TLR2 in conjunction with either TLR1 or TLR6 [10] , and flagellin, the protein monomer of bacterial flagella that activates TLR5 [11] .", [["outer membrane", "ANATOMY", 65, 79], ["flagella", "ANATOMY", 284, 292], ["lipopolysaccharide", "CHEMICAL", 37, 55], ["LPS", "CHEMICAL", 57, 60], ["PAMPs", "GENE_OR_GENE_PRODUCT", 23, 28], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 37, 55], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["outer membrane", "CELLULAR_COMPONENT", 65, 79], ["Gram-", "GENE_OR_GENE_PRODUCT", 93, 98], ["TLR4", "GENE_OR_GENE_PRODUCT", 132, 136], ["TLR2", "GENE_OR_GENE_PRODUCT", 184, 188], ["TLR1", "GENE_OR_GENE_PRODUCT", 216, 220], ["TLR6", "GENE_OR_GENE_PRODUCT", 224, 228], ["10", "GENE_OR_GENE_PRODUCT", 230, 232], ["flagellin", "GENE_OR_GENE_PRODUCT", 240, 249], ["TLR5", "GENE_OR_GENE_PRODUCT", 308, 312], ["PAMPs", "PROTEIN", 23, 28], ["TLR4", "PROTEIN", 132, 136], ["bacterial lipoproteins", "PROTEIN", 146, 168], ["TLR2", "PROTEIN", 184, 188], ["TLR1", "PROTEIN", 216, 220], ["TLR6", "PROTEIN", 224, 228], ["flagellin", "PROTEIN", 240, 249], ["TLR5", "PROTEIN", 308, 312], ["PAMPs", "PROBLEM", 23, 28], ["lipopolysaccharide (LPS", "TEST", 37, 60], ["a outer membrane component", "TEST", 63, 89], ["Gram-negative bacteria", "PROBLEM", 93, 115], ["bacterial lipoproteins", "TREATMENT", 146, 168], ["TLR1 or TLR6", "TREATMENT", 216, 228], ["flagellin", "TREATMENT", 240, 249], ["bacterial flagella", "PROBLEM", 274, 292], ["negative bacteria", "OBSERVATION", 98, 115]]], ["Nucleic acids are recognized by endosomal TLRs; double-stranded DNA with unmethylated CpG motifs activates TLR9 in a host species-specific manner while TLR3 and TLR7/8 are activated by dsRNA including synthetic poly (I:C) [12] and ssRNA, respectively [13, 14] .Host-derived ligandsFollowing the discovery that TLRs discriminate self from non-self through their intracellular localization or recognition of distinct ligand signatures, evidence was gathered in support of the hypothesis that endogenous host molecules termed danger associated molecular patterns (DAMPs) also stimulate TLRs.", [["endosomal", "ANATOMY", 32, 41], ["intracellular", "ANATOMY", 361, 374], ["CpG", "CHEMICAL", 86, 89], ["poly (I:C)", "CHEMICAL", 211, 221], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["endosomal", "CELLULAR_COMPONENT", 32, 41], ["TLRs", "GENE_OR_GENE_PRODUCT", 42, 46], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["TLR9", "GENE_OR_GENE_PRODUCT", 107, 111], ["TLR3", "GENE_OR_GENE_PRODUCT", 152, 156], ["TLR7", "GENE_OR_GENE_PRODUCT", 161, 165], ["8", "GENE_OR_GENE_PRODUCT", 166, 167], ["TLRs", "GENE_OR_GENE_PRODUCT", 310, 314], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 361, 374], ["danger associated molecular patterns", "GENE_OR_GENE_PRODUCT", 523, 559], ["DAMPs", "GENE_OR_GENE_PRODUCT", 561, 566], ["TLRs", "GENE_OR_GENE_PRODUCT", 583, 587], ["endosomal TLRs", "PROTEIN", 32, 46], ["double-stranded DNA", "DNA", 48, 67], ["unmethylated CpG motifs", "DNA", 73, 96], ["TLR9", "PROTEIN", 107, 111], ["TLR3", "PROTEIN", 152, 156], ["TLR7/8", "PROTEIN", 161, 167], ["synthetic poly (I:C) [12]", "DNA", 201, 226], ["TLRs", "PROTEIN", 310, 314], ["endogenous host molecules", "PROTEIN", 490, 515], ["danger associated molecular patterns", "PROTEIN", 523, 559], ["DAMPs", "PROTEIN", 561, 566], ["TLRs", "PROTEIN", 583, 587], ["Nucleic acids", "TEST", 0, 13], ["double-stranded DNA", "TREATMENT", 48, 67], ["unmethylated CpG motifs", "TREATMENT", 73, 96], ["TLR3 and TLR7/8", "TREATMENT", 152, 167], ["synthetic poly (I:C)", "TREATMENT", 201, 221]]], ["The first suggestion of this process came from studies of heat shock protein (hsp) [15] ; subsequently, a number of other endogenous ligands including the extra domain A of fibronectin and hyaluronic acid were also shown to activate TLRs [16, 17] .", [["hyaluronic acid", "CHEMICAL", 189, 204], ["heat shock protein (hsp) [15]", "GENE_OR_GENE_PRODUCT", 58, 87], ["fibronectin", "GENE_OR_GENE_PRODUCT", 173, 184], ["hyaluronic acid", "SIMPLE_CHEMICAL", 189, 204], ["TLRs", "GENE_OR_GENE_PRODUCT", 233, 237], ["heat shock protein", "PROTEIN", 58, 76], ["hsp", "PROTEIN", 78, 81], ["extra domain A", "PROTEIN", 155, 169], ["fibronectin", "PROTEIN", 173, 184], ["TLRs", "PROTEIN", 233, 237], ["this process", "PROBLEM", 24, 36], ["heat shock protein", "TEST", 58, 76], ["other endogenous ligands", "PROBLEM", 116, 140], ["the extra domain A of fibronectin", "TREATMENT", 151, 184], ["hyaluronic acid", "TREATMENT", 189, 204], ["endogenous ligands", "OBSERVATION", 122, 140]]], ["Recognition of endogenous ligands by TLRs may also contribute to the onset and initiation of autoimmune responses.", [["TLRs", "GENE_OR_GENE_PRODUCT", 37, 41], ["TLRs", "PROTEIN", 37, 41], ["autoimmune responses", "PROBLEM", 93, 113], ["endogenous ligands", "OBSERVATION", 15, 33]]], ["For example, the high mobility group box protein 1 (HMGB1) protein that normally resides in the cell nucleus can activate TLR2 and induce hallmarks of lupus-like disease when released from apoptotic cells as a complex with nucleosomes [18] .TLR signalingThe activation of TLRs results in acute inflammation and controls the adaptive immune response at various levels.", [["cell nucleus", "ANATOMY", 96, 108], ["cells", "ANATOMY", 199, 204], ["lupus-like disease", "DISEASE", 151, 169], ["inflammation", "DISEASE", 294, 306], ["high mobility group box protein 1", "GENE_OR_GENE_PRODUCT", 17, 50], ["HMGB1", "GENE_OR_GENE_PRODUCT", 52, 57], ["cell nucleus", "CELLULAR_COMPONENT", 96, 108], ["TLR2", "GENE_OR_GENE_PRODUCT", 122, 126], ["cells", "CELL", 199, 204], ["TLR", "GENE_OR_GENE_PRODUCT", 241, 244], ["TLRs", "GENE_OR_GENE_PRODUCT", 272, 276], ["high mobility group box protein 1 (HMGB1) protein", "PROTEIN", 17, 66], ["TLR2", "PROTEIN", 122, 126], ["apoptotic cells", "CELL_TYPE", 189, 204], ["TLR", "PROTEIN", 241, 244], ["TLRs", "PROTEIN", 272, 276], ["the high mobility group box protein", "TEST", 13, 48], ["HMGB1) protein", "TEST", 52, 66], ["lupus", "PROBLEM", 151, 156], ["disease", "PROBLEM", 162, 169], ["apoptotic cells", "PROBLEM", 189, 204], ["acute inflammation", "PROBLEM", 288, 306], ["high", "OBSERVATION_MODIFIER", 17, 21], ["cell nucleus", "OBSERVATION", 96, 108], ["lupus", "OBSERVATION", 151, 156], ["acute", "OBSERVATION_MODIFIER", 288, 293], ["inflammation", "OBSERVATION", 294, 306]]], ["Partially overlapping intracellular signaling pathways downstream of each TLR activate specific transcription factors that regulate the expression of genes responsible for inflammatory and immune responses.", [["intracellular", "ANATOMY", 22, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["TLR", "GENE_OR_GENE_PRODUCT", 74, 77], ["TLR", "PROTEIN", 74, 77], ["transcription factors", "PROTEIN", 96, 117], ["Partially overlapping intracellular signaling pathways", "PROBLEM", 0, 54], ["inflammatory and immune responses", "PROBLEM", 172, 205], ["intracellular signaling", "OBSERVATION", 22, 45]]], ["Four adaptors that harbour a Toll-Interleukin-1 Receptor (TIR) domain, including MyD88, TIRAP (MAL), TRIF (TICAM1), and TRAM, connect the TLRs to the cytoplasmic signaling machinery [5] .", [["cytoplasmic", "ANATOMY", 150, 161], ["Toll-Interleukin-1 Receptor", "GENE_OR_GENE_PRODUCT", 29, 56], ["TIR", "GENE_OR_GENE_PRODUCT", 58, 61], ["MyD88", "GENE_OR_GENE_PRODUCT", 81, 86], ["TIRAP", "GENE_OR_GENE_PRODUCT", 88, 93], ["MAL", "GENE_OR_GENE_PRODUCT", 95, 98], ["TRIF", "GENE_OR_GENE_PRODUCT", 101, 105], ["TICAM1", "GENE_OR_GENE_PRODUCT", 107, 113], ["TRAM", "GENE_OR_GENE_PRODUCT", 120, 124], ["TLRs", "GENE_OR_GENE_PRODUCT", 138, 142], ["cytoplasmic", "ORGANISM_SUBSTANCE", 150, 161], ["Toll-Interleukin-1 Receptor (TIR) domain", "PROTEIN", 29, 69], ["MyD88", "PROTEIN", 81, 86], ["TIRAP", "PROTEIN", 88, 93], ["MAL", "PROTEIN", 95, 98], ["TRIF", "PROTEIN", 101, 105], ["TICAM1", "PROTEIN", 107, 113], ["TRAM", "PROTEIN", 120, 124], ["TLRs", "PROTEIN", 138, 142], ["Interleukin-1 Receptor (TIR) domain", "TREATMENT", 34, 69], ["MyD88, TIRAP (MAL)", "TREATMENT", 81, 99], ["TRIF (TICAM1)", "TREATMENT", 101, 114], ["TRAM", "TREATMENT", 120, 124]]], ["MyD88 was initially identified as part of the interleukin (IL) -1R and IL-18R signalling pathways and was subsequently implicated in signalling by almost all TLRs to trigger NF-B, Interferon Regulatory Factor (IRF) 5, and Mitogen Activated Protein (MAP) kinase activation.", [["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["interleukin (IL) -1R", "GENE_OR_GENE_PRODUCT", 46, 66], ["IL-18R", "GENE_OR_GENE_PRODUCT", 71, 77], ["TLRs", "GENE_OR_GENE_PRODUCT", 158, 162], ["NF-B", "GENE_OR_GENE_PRODUCT", 174, 178], ["Interferon Regulatory Factor (IRF) 5", "GENE_OR_GENE_PRODUCT", 180, 216], ["Mitogen Activated Protein (MAP) kinase", "GENE_OR_GENE_PRODUCT", 222, 260], ["MyD88", "PROTEIN", 0, 5], ["18R", "PROTEIN", 74, 77], ["TLRs", "PROTEIN", 158, 162], ["NF-B", "PROTEIN", 174, 178], ["Interferon Regulatory Factor (IRF) 5", "PROTEIN", 180, 216], ["Mitogen Activated Protein (MAP) kinase", "PROTEIN", 222, 260], ["the interleukin (IL)", "TREATMENT", 42, 62], ["IL", "TREATMENT", 71, 73], ["NF", "TEST", 174, 176], ["Interferon Regulatory Factor (IRF)", "TREATMENT", 180, 214], ["Mitogen Activated Protein (MAP) kinase activation", "TREATMENT", 222, 271]]], ["A notable exception is TLR3 that mediates the activation of IRFs exclusively through the adaptor molecule TRIF [19] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 23, 27], ["IRFs", "GENE_OR_GENE_PRODUCT", 60, 64], ["TRIF", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR3", "PROTEIN", 23, 27], ["IRFs", "PROTEIN", 60, 64], ["adaptor molecule TRIF [19]", "PROTEIN", 89, 115], ["notable", "OBSERVATION_MODIFIER", 2, 9], ["TLR3", "OBSERVATION", 23, 27]]], ["The function of TIRAP is to recruit MyD88 to TLR2 and TLR4 at the plasma membrane, while TRAM recruits TRIF to TLR4 for activation of IRF3.", [["plasma membrane", "ANATOMY", 66, 81], ["TIRAP", "GENE_OR_GENE_PRODUCT", 16, 21], ["MyD88", "GENE_OR_GENE_PRODUCT", 36, 41], ["TLR2", "GENE_OR_GENE_PRODUCT", 45, 49], ["TLR4", "GENE_OR_GENE_PRODUCT", 54, 58], ["plasma membrane", "CELLULAR_COMPONENT", 66, 81], ["TRAM", "GENE_OR_GENE_PRODUCT", 89, 93], ["TRIF", "GENE_OR_GENE_PRODUCT", 103, 107], ["TLR4", "GENE_OR_GENE_PRODUCT", 111, 115], ["IRF3", "GENE_OR_GENE_PRODUCT", 134, 138], ["TIRAP", "PROTEIN", 16, 21], ["MyD88", "PROTEIN", 36, 41], ["TLR2", "PROTEIN", 45, 49], ["TLR4", "PROTEIN", 54, 58], ["TRAM", "PROTEIN", 89, 93], ["TRIF", "PROTEIN", 103, 107], ["TLR4", "PROTEIN", 111, 115], ["IRF3", "PROTEIN", 134, 138], ["TLR4 at the plasma membrane", "TREATMENT", 54, 81], ["IRF3", "PROBLEM", 134, 138], ["plasma membrane", "ANATOMY", 66, 81]]], ["A fifth adaptor protein, SARM, negatively regulates TRIF-dependent signaling [20, 21] .", [["SARM", "GENE_OR_GENE_PRODUCT", 25, 29], ["TRIF", "GENE_OR_GENE_PRODUCT", 52, 56], ["fifth adaptor protein", "PROTEIN", 2, 23], ["SARM", "PROTEIN", 25, 29], ["TRIF", "PROTEIN", 52, 56], ["A fifth adaptor protein", "TEST", 0, 23], ["SARM", "TEST", 25, 29]]], ["Activation of different intracellular signaling mechanisms through TLRs results in the induction of distinct gene programs and cytokine expression patterns that control the recruitment of downstream molecules and regulate the identity, strength, and kinetics of gene and protein expression.", [["intracellular", "ANATOMY", 24, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 37], ["TLRs", "GENE_OR_GENE_PRODUCT", 67, 71], ["TLRs", "PROTEIN", 67, 71], ["cytokine", "PROTEIN", 127, 135], ["downstream molecules", "PROTEIN", 188, 208], ["different intracellular signaling mechanisms", "PROBLEM", 14, 58], ["distinct gene programs", "TREATMENT", 100, 122], ["cytokine expression patterns", "TREATMENT", 127, 155], ["intracellular signaling", "OBSERVATION", 24, 47]]], ["More detailed reviews of the TLR signalling pathways have been published elsewhere [22] [23] [24] .TLR signalingThe potent stimulatory responses mediated by TLR signaling must be tightly regulated at numerous levels in order to prevent the deleterious consequences of excessive innate immune activation [25] .", [["TLR", "GENE_OR_GENE_PRODUCT", 29, 32], ["[22] [23", "SIMPLE_CHEMICAL", 83, 91], ["TLR", "GENE_OR_GENE_PRODUCT", 99, 102], ["TLR", "GENE_OR_GENE_PRODUCT", 157, 160], ["TLR", "PROTEIN", 29, 32], ["TLR", "PROTEIN", 99, 102], ["TLR", "PROTEIN", 157, 160], ["The potent stimulatory responses", "TREATMENT", 112, 144], ["excessive innate immune activation", "PROBLEM", 268, 302]]], ["For example, soluble forms of TLR4 and TLR2 may function as decoy receptors to terminate ligand interactions with membrane bound TLRs [26] .", [["membrane", "ANATOMY", 114, 122], ["TLR4", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR2", "GENE_OR_GENE_PRODUCT", 39, 43], ["membrane", "CELLULAR_COMPONENT", 114, 122], ["TLRs", "GENE_OR_GENE_PRODUCT", 129, 133], ["TLR4", "PROTEIN", 30, 34], ["TLR2", "PROTEIN", 39, 43], ["decoy receptors", "PROTEIN", 60, 75], ["membrane bound TLRs", "PROTEIN", 114, 133], ["TLR4 and TLR2", "TREATMENT", 30, 43], ["decoy receptors", "TREATMENT", 60, 75]]], ["Furthermore, IRAK-M has 30-40% homology to the other IRAK-family members and stabilizes the TLR-MyD88-IRAK4 complex, leading to a unique negative regulatory influence on TLR signaling [27, 28] .", [["IRAK-M", "GENE_OR_GENE_PRODUCT", 13, 19], ["IRAK", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR", "GENE_OR_GENE_PRODUCT", 92, 95], ["MyD88", "GENE_OR_GENE_PRODUCT", 96, 101], ["IRAK4", "GENE_OR_GENE_PRODUCT", 102, 107], ["TLR", "GENE_OR_GENE_PRODUCT", 170, 173], ["IRAK", "PROTEIN", 13, 17], ["IRAK-family members", "PROTEIN", 53, 72], ["TLR", "PROTEIN", 92, 95], ["MyD88", "PROTEIN", 96, 101], ["IRAK4 complex", "PROTEIN", 102, 115], ["TLR", "PROTEIN", 170, 173], ["IRAK", "TEST", 13, 17], ["TLR signaling", "TEST", 170, 183]]], ["TLR signaling is also inhibited by transmembrane receptors like ST2, SIGIRR, and TRAILR while proteins such as Tollip [29] , SARM [21] , an inducible splice variant of MyD88 (MyD88s) [30] , and the suppressor of cytokine signaling 1 (SOCS1) [31] are responsible for modulation of intracellular TLR signaling.TLR signalingIn addition to TLRs, a variety of other PRRs including the cytoplasmic NLRs and RLRs play important roles in the induction of lung inflammation.", [["transmembrane", "ANATOMY", 35, 48], ["intracellular", "ANATOMY", 280, 293], ["cytoplasmic", "ANATOMY", 380, 391], ["lung", "ANATOMY", 447, 451], ["lung inflammation", "DISEASE", 447, 464], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["ST2", "GENE_OR_GENE_PRODUCT", 64, 67], ["SIGIRR", "GENE_OR_GENE_PRODUCT", 69, 75], ["TRAILR", "GENE_OR_GENE_PRODUCT", 81, 87], ["Tollip [29]", "GENE_OR_GENE_PRODUCT", 111, 122], ["SARM [21]", "GENE_OR_GENE_PRODUCT", 125, 134], ["MyD88", "GENE_OR_GENE_PRODUCT", 168, 173], ["MyD88s) [30", "GENE_OR_GENE_PRODUCT", 175, 186], ["suppressor of cytokine signaling 1", "GENE_OR_GENE_PRODUCT", 198, 232], ["SOCS1", "GENE_OR_GENE_PRODUCT", 234, 239], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 280, 293], ["TLR", "GENE_OR_GENE_PRODUCT", 294, 297], ["TLR", "GENE_OR_GENE_PRODUCT", 308, 311], ["TLRs", "GENE_OR_GENE_PRODUCT", 336, 340], ["PRRs", "GENE_OR_GENE_PRODUCT", 361, 365], ["cytoplasmic", "ORGANISM_SUBSTANCE", 380, 391], ["NLRs", "GENE_OR_GENE_PRODUCT", 392, 396], ["RLRs", "GENE_OR_GENE_PRODUCT", 401, 405], ["lung", "ORGAN", 447, 451], ["TLR", "PROTEIN", 0, 3], ["transmembrane receptors", "PROTEIN", 35, 58], ["ST2", "PROTEIN", 64, 67], ["SIGIRR", "PROTEIN", 69, 75], ["TRAILR", "PROTEIN", 81, 87], ["Tollip [29]", "PROTEIN", 111, 122], ["MyD88", "PROTEIN", 168, 173], ["MyD88s", "PROTEIN", 175, 181], ["SOCS1", "PROTEIN", 234, 239], ["TLR", "PROTEIN", 294, 297], ["TLR", "PROTEIN", 308, 311], ["TLRs", "PROTEIN", 336, 340], ["PRRs", "PROTEIN", 361, 365], ["cytoplasmic NLRs", "PROTEIN", 380, 396], ["RLRs", "PROTEIN", 401, 405], ["transmembrane receptors", "TEST", 35, 58], ["ST2", "TEST", 64, 67], ["SIGIRR", "TEST", 69, 75], ["Tollip", "TEST", 111, 117], ["SARM", "TEST", 125, 129], ["cytokine signaling", "TEST", 212, 230], ["intracellular TLR signaling", "PROBLEM", 280, 307], ["TLRs", "TREATMENT", 336, 340], ["the cytoplasmic NLRs and RLRs", "TREATMENT", 376, 405], ["lung inflammation", "PROBLEM", 447, 464], ["intracellular TLR", "OBSERVATION", 280, 297], ["lung", "ANATOMY", 447, 451], ["inflammation", "OBSERVATION", 452, 464]]], ["For example, the cytoplasmic NALP3 protein, a member of the NLR family that triggers assembly of the caspase-1 inflammasome and production of mature IL-1\u03b2, was recently implicated in the development of asbestos or silica-induced pulmonary fibrosis [32] .", [["cytoplasmic", "ANATOMY", 17, 28], ["pulmonary", "ANATOMY", 229, 238], ["asbestos", "DISEASE", 202, 210], ["silica", "CHEMICAL", 214, 220], ["pulmonary fibrosis", "DISEASE", 229, 247], ["silica", "CHEMICAL", 214, 220], ["cytoplasmic", "ORGANISM_SUBSTANCE", 17, 28], ["NALP3", "GENE_OR_GENE_PRODUCT", 29, 34], ["NLR", "GENE_OR_GENE_PRODUCT", 60, 63], ["caspase-1", "GENE_OR_GENE_PRODUCT", 101, 110], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 149, 154], ["asbestos", "SIMPLE_CHEMICAL", 202, 210], ["silica", "SIMPLE_CHEMICAL", 214, 220], ["pulmonary", "ORGAN", 229, 238], ["cytoplasmic NALP3 protein", "PROTEIN", 17, 42], ["NLR family", "PROTEIN", 60, 70], ["caspase-1 inflammasome", "PROTEIN", 101, 123], ["mature IL-1\u03b2", "PROTEIN", 142, 154], ["the cytoplasmic NALP3 protein", "TEST", 13, 42], ["the caspase", "TEST", 97, 108], ["inflammasome", "PROBLEM", 111, 123], ["asbestos", "PROBLEM", 202, 210], ["silica-induced pulmonary fibrosis", "PROBLEM", 214, 247], ["cytoplasmic", "OBSERVATION_MODIFIER", 17, 28], ["NALP3", "OBSERVATION", 29, 34], ["asbestos", "OBSERVATION", 202, 210], ["pulmonary", "ANATOMY", 229, 238], ["fibrosis", "OBSERVATION", 239, 247]]], ["RLRs on immune and non-immune cells recognize viral RNA species and induce host responses through the adaptor IPS-1.", [["non-immune cells", "ANATOMY", 19, 35], ["RLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["immune", "CELL", 8, 14], ["non-immune cells", "CELL", 19, 35], ["IPS-1", "GENE_OR_GENE_PRODUCT", 110, 115], ["RLRs", "PROTEIN", 0, 4], ["immune and non-immune cells", "CELL_TYPE", 8, 35], ["viral RNA species", "RNA", 46, 63], ["adaptor IPS-1", "PROTEIN", 102, 115], ["immune and non-immune cells", "TREATMENT", 8, 35], ["viral RNA species", "PROBLEM", 46, 63], ["the adaptor IPS", "TREATMENT", 98, 113], ["non-immune cells", "OBSERVATION", 19, 35], ["viral RNA species", "OBSERVATION", 46, 63]]], ["Several putative cytosolic detectors of double-stranded DNA including DAI (ZBP1-DLM1) and AIM2 have also been identified; however their roles in lung diseases have not been established.", [["cytosolic", "ANATOMY", 17, 26], ["lung", "ANATOMY", 145, 149], ["lung diseases", "DISEASE", 145, 158], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["DAI", "GENE_OR_GENE_PRODUCT", 70, 73], ["ZBP1-DLM1", "GENE_OR_GENE_PRODUCT", 75, 84], ["AIM2", "GENE_OR_GENE_PRODUCT", 90, 94], ["lung", "ORGAN", 145, 149], ["double-stranded DNA", "DNA", 40, 59], ["DAI", "PROTEIN", 70, 73], ["ZBP1", "PROTEIN", 75, 79], ["DLM1", "PROTEIN", 80, 84], ["AIM2", "PROTEIN", 90, 94], ["double-stranded DNA", "TREATMENT", 40, 59], ["DAI (ZBP1", "TREATMENT", 70, 79], ["AIM2", "PROBLEM", 90, 94], ["lung diseases", "PROBLEM", 145, 158], ["cytosolic detectors", "OBSERVATION", 17, 36], ["double-stranded DNA", "OBSERVATION_MODIFIER", 40, 59], ["lung", "ANATOMY", 145, 149], ["diseases", "OBSERVATION", 150, 158]]], ["A detailed discussion of these important non-TLR innate immune receptors is beyond the scope of this article; however, interested readers may consult other sources [33] .Expression and function of TLRs in lung cells or tissueTLRs are widely expressed on both resident lung cells as well as infiltrating cells of myeloid and lymphoid origin.", [["lung cells", "ANATOMY", 205, 215], ["tissueTLRs", "ANATOMY", 219, 229], ["lung cells", "ANATOMY", 268, 278], ["infiltrating cells", "ANATOMY", 290, 308], ["myeloid", "ANATOMY", 312, 319], ["lymphoid", "ANATOMY", 324, 332], ["non-TLR", "GENE_OR_GENE_PRODUCT", 41, 48], ["TLRs", "GENE_OR_GENE_PRODUCT", 197, 201], ["lung cells", "CELL", 205, 215], ["tissueTLRs", "GENE_OR_GENE_PRODUCT", 219, 229], ["lung cells", "CELL", 268, 278], ["infiltrating cells", "CELL", 290, 308], ["myeloid", "CELL", 312, 319], ["lymphoid", "CELL", 324, 332], ["non-TLR innate immune receptors", "PROTEIN", 41, 72], ["TLRs", "PROTEIN", 197, 201], ["lung cells", "CELL_TYPE", 205, 215], ["tissueTLRs", "PROTEIN", 219, 229], ["resident lung cells", "CELL_TYPE", 259, 278], ["infiltrating cells", "CELL_TYPE", 290, 308], ["myeloid and lymphoid origin", "CELL_TYPE", 312, 339], ["these important non-TLR innate immune receptors", "TREATMENT", 25, 72], ["TLRs in lung cells", "PROBLEM", 197, 215], ["infiltrating cells of myeloid and lymphoid origin", "PROBLEM", 290, 339], ["lung", "ANATOMY", 205, 209], ["lung", "ANATOMY", 268, 272], ["cells", "OBSERVATION", 273, 278], ["infiltrating cells", "OBSERVATION", 290, 308], ["myeloid", "ANATOMY", 312, 319], ["lymphoid origin", "OBSERVATION", 324, 339]]], ["Primary bronchial epithelial cells express mRNA for TLR1-10 and secrete the chemokine CXCL8 (IL-8) in response to various TLR ligands [34] .", [["Primary bronchial epithelial cells", "ANATOMY", 0, 34], ["bronchial epithelial cells", "CELL", 8, 34], ["TLR1-10", "GENE_OR_GENE_PRODUCT", 52, 59], ["CXCL8", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL-8", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR", "GENE_OR_GENE_PRODUCT", 122, 125], ["bronchial epithelial cells", "CELL_TYPE", 8, 34], ["mRNA", "RNA", 43, 47], ["TLR1", "PROTEIN", 52, 56], ["chemokine", "PROTEIN", 76, 85], ["CXCL8", "PROTEIN", 86, 91], ["IL-8", "PROTEIN", 93, 97], ["TLR", "PROTEIN", 122, 125], ["Primary bronchial epithelial cells", "PROBLEM", 0, 34], ["mRNA", "TEST", 43, 47], ["TLR1", "TEST", 52, 56], ["secrete the chemokine CXCL8", "TEST", 64, 91], ["IL", "TEST", 93, 95], ["bronchial", "ANATOMY", 8, 17], ["epithelial cells", "OBSERVATION", 18, 34]]], ["Human AMs have been shown to express low levels of TLR3, TLR5, and TLR9 and higher levels of TLR1, TLR2, TLR4, TLR7, and TLR8 [35, 36] .", [["AMs", "ANATOMY", 6, 9], ["Human", "ORGANISM", 0, 5], ["AMs", "CELL", 6, 9], ["TLR3", "GENE_OR_GENE_PRODUCT", 51, 55], ["TLR5", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR9", "GENE_OR_GENE_PRODUCT", 67, 71], ["TLR1", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR2", "GENE_OR_GENE_PRODUCT", 99, 103], ["TLR4", "GENE_OR_GENE_PRODUCT", 105, 109], ["TLR7", "GENE_OR_GENE_PRODUCT", 111, 115], ["TLR8", "GENE_OR_GENE_PRODUCT", 121, 125], ["Human AMs", "CELL_TYPE", 0, 9], ["TLR3", "PROTEIN", 51, 55], ["TLR5", "PROTEIN", 57, 61], ["TLR9", "PROTEIN", 67, 71], ["TLR1", "PROTEIN", 93, 97], ["TLR2", "PROTEIN", 99, 103], ["TLR4", "PROTEIN", 105, 109], ["TLR7", "PROTEIN", 111, 115], ["TLR8", "PROTEIN", 121, 125], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human AMs", "TEST", 0, 9], ["TLR5", "TEST", 57, 61], ["TLR9", "TEST", 67, 71], ["TLR1", "TEST", 93, 97], ["TLR2", "TEST", 99, 103], ["TLR7", "TEST", 111, 115], ["TLR1", "ANATOMY", 93, 97], ["TLR2", "ANATOMY", 99, 103]]], ["Lung endothelial cells express TLR4 that is crucial for neutrophil recruitment and capillary sequestration following systemic LPS administration [37] .", [["Lung endothelial cells", "ANATOMY", 0, 22], ["neutrophil", "ANATOMY", 56, 66], ["capillary", "ANATOMY", 83, 92], ["LPS", "CHEMICAL", 126, 129], ["Lung endothelial cells", "CELL", 0, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 31, 35], ["neutrophil", "CELL", 56, 66], ["capillary", "TISSUE", 83, 92], ["LPS", "SIMPLE_CHEMICAL", 126, 129], ["Lung endothelial cells", "CELL_TYPE", 0, 22], ["TLR4", "PROTEIN", 31, 35], ["Lung endothelial cells", "PROBLEM", 0, 22], ["TLR4", "PROBLEM", 31, 35], ["neutrophil recruitment", "TREATMENT", 56, 78], ["capillary sequestration", "TREATMENT", 83, 106], ["systemic LPS administration", "TREATMENT", 117, 144], ["endothelial cells", "OBSERVATION", 5, 22], ["TLR4", "OBSERVATION_MODIFIER", 31, 35], ["crucial for", "UNCERTAINTY", 44, 55], ["neutrophil recruitment", "OBSERVATION", 56, 78], ["capillary sequestration", "OBSERVATION", 83, 106]]], ["Neutrophils that localize to the lung vasculature in response to LPS express TLR1, TLR2, TLR4, TLR5, and TLR9 [38] .", [["Neutrophils", "ANATOMY", 0, 11], ["lung vasculature", "ANATOMY", 33, 49], ["LPS", "CHEMICAL", 65, 68], ["Neutrophils", "CELL", 0, 11], ["lung vasculature", "MULTI-TISSUE_STRUCTURE", 33, 49], ["LPS", "GENE_OR_GENE_PRODUCT", 65, 68], ["TLR1", "GENE_OR_GENE_PRODUCT", 77, 81], ["TLR2", "GENE_OR_GENE_PRODUCT", 83, 87], ["TLR4", "GENE_OR_GENE_PRODUCT", 89, 93], ["TLR5", "GENE_OR_GENE_PRODUCT", 95, 99], ["TLR9", "GENE_OR_GENE_PRODUCT", 105, 109], ["Neutrophils", "CELL_TYPE", 0, 11], ["TLR1", "PROTEIN", 77, 81], ["TLR2", "PROTEIN", 83, 87], ["TLR4", "PROTEIN", 89, 93], ["TLR5", "PROTEIN", 95, 99], ["TLR9", "PROTEIN", 105, 109], ["Neutrophils", "TEST", 0, 11], ["LPS", "TEST", 65, 68], ["TLR1", "TEST", 77, 81], ["TLR2", "TEST", 83, 87], ["TLR4", "TEST", 89, 93], ["TLR5", "TEST", 95, 99], ["TLR9", "TEST", 105, 109], ["lung", "ANATOMY", 33, 37], ["vasculature", "ANATOMY_MODIFIER", 38, 49], ["TLR1", "ANATOMY_MODIFIER", 77, 81], ["TLR2", "ANATOMY", 83, 87], ["TLR4", "ANATOMY", 89, 93]]], ["Several DC subsets have been identified in the mouse and human lung and can be distinguished according to their surface marker expression and anatomical location [39, 40] .", [["DC", "ANATOMY", 8, 10], ["lung", "ANATOMY", 63, 67], ["surface", "ANATOMY", 112, 119], ["mouse", "ORGANISM", 47, 52], ["human", "ORGANISM", 57, 62], ["lung", "ORGAN", 63, 67], ["DC subsets", "CELL_TYPE", 8, 18], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 57, 62], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 57, 62], ["Several DC subsets", "TREATMENT", 0, 18], ["lung", "ANATOMY", 63, 67]]], ["Lung DCs act as sentinels that are activated by TLR ligation in order to bridge innate and adaptive immunity.", [["Lung DCs", "ANATOMY", 0, 8], ["Lung DCs", "CELL", 0, 8], ["TLR", "GENE_OR_GENE_PRODUCT", 48, 51], ["Lung DCs", "CELL_TYPE", 0, 8], ["TLR", "PROTEIN", 48, 51], ["TLR ligation", "TREATMENT", 48, 60], ["innate and adaptive immunity", "TREATMENT", 80, 108]]], ["Lung plasmacytoid DCs (pDCs) express uniquely high levels of TLR7 and TLR9 that suppress the allergic response and regulatory lung DCs give rise to regulatory T cells [41] .", [["Lung plasmacytoid DCs", "ANATOMY", 0, 21], ["pDCs", "ANATOMY", 23, 27], ["lung DCs", "ANATOMY", 126, 134], ["regulatory T cells", "ANATOMY", 148, 166], ["allergic", "DISEASE", 93, 101], ["Lung plasmacytoid DCs", "CELL", 0, 21], ["pDCs", "CELL", 23, 27], ["TLR7", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR9", "GENE_OR_GENE_PRODUCT", 70, 74], ["lung DCs", "CELL", 126, 134], ["T cells", "CELL", 159, 166], ["Lung plasmacytoid DCs", "CELL_TYPE", 0, 21], ["pDCs", "CELL_TYPE", 23, 27], ["TLR7", "PROTEIN", 61, 65], ["TLR9", "PROTEIN", 70, 74], ["regulatory lung DCs", "CELL_TYPE", 115, 134], ["regulatory T cells", "CELL_TYPE", 148, 166], ["Lung plasmacytoid DCs", "PROBLEM", 0, 21], ["TLR7 and TLR9", "TREATMENT", 61, 74], ["the allergic response", "PROBLEM", 89, 110], ["regulatory lung DCs", "TEST", 115, 134], ["plasmacytoid DCs", "OBSERVATION", 5, 21], ["lung", "ANATOMY", 126, 130]]], ["Notably, in some cases the level of TLR transcription in cells does not correlate with functional responses [35, 36] .", [["cells", "ANATOMY", 57, 62], ["TLR", "GENE_OR_GENE_PRODUCT", 36, 39], ["cells", "CELL", 57, 62], ["TLR", "PROTEIN", 36, 39], ["TLR transcription", "TREATMENT", 36, 53]]], ["For example, following stimulation with LPS or mycobacterial DNA, human AMs produced higher levels of the inflammatory cytokine TNF-\u03b1 while interstitial macrophages produced higher levels of the immunoregulatory cytokines IL-6 and IL-10 despite similar levels of TLR mRNA [35] .", [["AMs", "ANATOMY", 72, 75], ["interstitial macrophages", "ANATOMY", 140, 164], ["LPS", "CHEMICAL", 40, 43], ["LPS", "SIMPLE_CHEMICAL", 40, 43], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["human", "ORGANISM", 66, 71], ["AMs", "CELL", 72, 75], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 128, 133], ["interstitial macrophages", "CELL", 140, 164], ["IL-6", "GENE_OR_GENE_PRODUCT", 222, 226], ["IL-10", "GENE_OR_GENE_PRODUCT", 231, 236], ["TLR", "GENE_OR_GENE_PRODUCT", 263, 266], ["human AMs", "CELL_TYPE", 66, 75], ["inflammatory cytokine", "PROTEIN", 106, 127], ["TNF", "PROTEIN", 128, 131], ["interstitial macrophages", "CELL_TYPE", 140, 164], ["immunoregulatory cytokines", "PROTEIN", 195, 221], ["IL-6", "PROTEIN", 222, 226], ["IL", "PROTEIN", 231, 233], ["TLR mRNA", "RNA", 263, 271], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["LPS", "TREATMENT", 40, 43], ["mycobacterial DNA", "PROBLEM", 47, 64], ["human AMs", "TEST", 66, 75], ["the inflammatory cytokine TNF", "TEST", 102, 131], ["interstitial macrophages", "PROBLEM", 140, 164], ["the immunoregulatory cytokines IL", "TEST", 191, 224], ["IL", "TEST", 231, 233], ["inflammatory", "OBSERVATION_MODIFIER", 106, 118], ["interstitial", "ANATOMY_MODIFIER", 140, 152], ["macrophages", "ANATOMY", 153, 164]]], ["Finally, lung tissue cells may also be activated through cooperative interactions with TLR responsive lymphoid cells, as exemplified by airway smooth muscle cell activation via IL-1\u03b2 release from LPS-stimulated monocytes [42] .", [["lung tissue cells", "ANATOMY", 9, 26], ["lymphoid cells", "ANATOMY", 102, 116], ["airway smooth muscle cell", "ANATOMY", 136, 161], ["monocytes", "ANATOMY", 211, 220], ["LPS", "CHEMICAL", 196, 199], ["lung tissue cells", "CELL", 9, 26], ["TLR", "GENE_OR_GENE_PRODUCT", 87, 90], ["lymphoid cells", "CELL", 102, 116], ["airway smooth muscle cell", "CELL", 136, 161], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 177, 182], ["LPS", "SIMPLE_CHEMICAL", 196, 199], ["monocytes", "CELL", 211, 220], ["lung tissue cells", "CELL_TYPE", 9, 26], ["TLR responsive lymphoid cells", "CELL_TYPE", 87, 116], ["IL-1\u03b2", "PROTEIN", 177, 182], ["LPS-stimulated monocytes", "CELL_LINE", 196, 220], ["lung tissue cells", "PROBLEM", 9, 26], ["TLR responsive lymphoid cells", "TREATMENT", 87, 116], ["IL", "TEST", 177, 179], ["LPS", "TEST", 196, 199], ["lung", "ANATOMY", 9, 13], ["tissue cells", "OBSERVATION", 14, 26], ["lymphoid cells", "OBSERVATION", 102, 116], ["airway", "ANATOMY", 136, 142]]], ["Thus, responsiveness to TLR ligands in the lung is shaped by cell intrinsic mechanisms as well as cooperative actions of both resident and recruited cell populations.Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS)ALI or ARDS is a life-threatening condition that is characterized by increased inflammatory cytokine expression and cell infiltration into the lungs, non-cardiogenic pulmonary edema, and diffuse alveolar damage that culminates in respiratory failure [43, 44] .", [["lung", "ANATOMY", 43, 47], ["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 149, 153], ["Lung", "ANATOMY", 172, 176], ["cell", "ANATOMY", 348, 352], ["lungs", "ANATOMY", 375, 380], ["pulmonary", "ANATOMY", 398, 407], ["alveolar", "ANATOMY", 427, 435], ["respiratory", "ANATOMY", 462, 473], ["Lung Injury", "DISEASE", 172, 183], ["ALI", "DISEASE", 185, 188], ["Respiratory Distress Syndrome", "DISEASE", 196, 225], ["ARDS", "DISEASE", 227, 231], ["ALI", "DISEASE", 232, 235], ["ARDS", "DISEASE", 239, 243], ["pulmonary edema", "DISEASE", 398, 413], ["alveolar damage", "DISEASE", 427, 442], ["respiratory failure", "DISEASE", 462, 481], ["TLR", "GENE_OR_GENE_PRODUCT", 24, 27], ["lung", "ORGAN", 43, 47], ["cell", "CELL", 61, 65], ["cell populations", "CELL", 149, 165], ["Lung", "ORGAN", 172, 176], ["cell", "CELL", 348, 352], ["lungs", "ORGAN", 375, 380], ["pulmonary", "ORGAN", 398, 407], ["alveolar", "MULTI-TISSUE_STRUCTURE", 427, 435], ["TLR", "PROTEIN", 24, 27], ["resident and recruited cell populations", "CELL_TYPE", 126, 165], ["inflammatory cytokine", "PROTEIN", 311, 332], ["Acute Lung Injury (ALI)", "PROBLEM", 166, 189], ["Acute Respiratory Distress Syndrome", "PROBLEM", 190, 225], ["ARDS)", "PROBLEM", 227, 232], ["ALI", "PROBLEM", 232, 235], ["ARDS", "PROBLEM", 239, 243], ["a life-threatening condition", "PROBLEM", 247, 275], ["increased inflammatory cytokine expression", "PROBLEM", 301, 343], ["cell infiltration into the lungs", "PROBLEM", 348, 380], ["non-cardiogenic pulmonary edema", "PROBLEM", 382, 413], ["diffuse alveolar damage", "PROBLEM", 419, 442], ["respiratory failure", "PROBLEM", 462, 481], ["lung", "ANATOMY", 43, 47], ["shaped", "OBSERVATION_MODIFIER", 51, 57], ["cell populations", "OBSERVATION", 149, 165], ["Lung", "ANATOMY", 172, 176], ["Injury", "OBSERVATION", 177, 183], ["ALI", "ANATOMY", 185, 188], ["Acute", "OBSERVATION_MODIFIER", 190, 195], ["Respiratory Distress", "OBSERVATION", 196, 216], ["ARDS", "OBSERVATION", 239, 243], ["increased", "OBSERVATION_MODIFIER", 301, 310], ["inflammatory", "OBSERVATION_MODIFIER", 311, 323], ["cytokine expression", "OBSERVATION", 324, 343], ["cell infiltration", "OBSERVATION", 348, 365], ["lungs", "ANATOMY", 375, 380], ["non-cardiogenic", "OBSERVATION_MODIFIER", 382, 397], ["pulmonary", "ANATOMY", 398, 407], ["edema", "OBSERVATION", 408, 413], ["diffuse", "OBSERVATION_MODIFIER", 419, 426], ["alveolar", "ANATOMY_MODIFIER", 427, 435], ["damage", "OBSERVATION", 436, 442], ["respiratory failure", "OBSERVATION", 462, 481]]], ["ALI can be a consequence of bacterial or viral infection or may be triggered by non-infectious insults including environmental toxin exposure (ozone, heavy metals), trauma, or hyperoxia.", [["ALI", "DISEASE", 0, 3], ["infection", "DISEASE", 47, 56], ["ozone", "CHEMICAL", 143, 148], ["trauma", "DISEASE", 165, 171], ["hyperoxia", "DISEASE", 176, 185], ["ozone", "CHEMICAL", 143, 148], ["ozone", "SIMPLE_CHEMICAL", 143, 148], ["ALI", "PROBLEM", 0, 3], ["bacterial or viral infection", "PROBLEM", 28, 56], ["non-infectious insults", "PROBLEM", 80, 102], ["environmental toxin exposure", "PROBLEM", 113, 141], ["trauma", "PROBLEM", 165, 171], ["hyperoxia", "PROBLEM", 176, 185], ["bacterial", "OBSERVATION_MODIFIER", 28, 37], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["non-infectious", "OBSERVATION_MODIFIER", 80, 94], ["hyperoxia", "OBSERVATION", 176, 185]]], ["TLRs mediate ALI through recognition of microbial PAMPs or through detection of endogenous DAMPs (hsp, hyaluronan, fibrinogen, HMGB1 [16, [45] [46] [47] [48] [49] [50] , both of which trigger inflammation [51] [52] [53] [54] [55] [56] [57] .", [["ALI", "DISEASE", 13, 16], ["16, [45] [46] [47] [48] [49] [50", "CHEMICAL", 134, 166], ["inflammation", "DISEASE", 192, 204], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PAMPs", "GENE_OR_GENE_PRODUCT", 50, 55], ["DAMPs", "GENE_OR_GENE_PRODUCT", 91, 96], ["hsp", "GENE_OR_GENE_PRODUCT", 98, 101], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 103, 113], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 115, 125], ["HMGB1", "GENE_OR_GENE_PRODUCT", 127, 132], ["16, [45] [46] [47] [48] [49] [50]", "SIMPLE_CHEMICAL", 134, 167], ["[51] [52] [53] [54] [55] [56] [57]", "SIMPLE_CHEMICAL", 205, 239], ["TLRs", "PROTEIN", 0, 4], ["microbial PAMPs", "PROTEIN", 40, 55], ["endogenous DAMPs", "PROTEIN", 80, 96], ["hsp", "PROTEIN", 98, 101], ["hyaluronan", "PROTEIN", 103, 113], ["fibrinogen", "PROTEIN", 115, 125], ["HMGB1", "PROTEIN", 127, 132], ["microbial PAMPs", "TEST", 40, 55], ["endogenous DAMPs", "PROBLEM", 80, 96], ["hsp", "TEST", 98, 101], ["hyaluronan", "TEST", 103, 113], ["fibrinogen", "TEST", 115, 125], ["HMGB1", "TEST", 127, 132], ["inflammation", "TEST", 192, 204], ["endogenous DAMPs", "OBSERVATION", 80, 96]]], ["Depending on the specific nature and intensity of the inciting stimulus, this response can be beneficial (maintenance of tissue integrity and repair) or detrimental (increased fibrosis and fluid in the lungs) for host recovery (figure 1) [43, 57, 58] .", [["tissue", "ANATOMY", 121, 127], ["fluid", "ANATOMY", 189, 194], ["lungs", "ANATOMY", 202, 207], ["fibrosis", "DISEASE", 176, 184], ["tissue", "TISSUE", 121, 127], ["lungs", "ORGAN", 202, 207], ["the inciting stimulus", "PROBLEM", 50, 71], ["tissue integrity", "TREATMENT", 121, 137], ["repair", "TREATMENT", 142, 148], ["detrimental (increased fibrosis and fluid in the lungs", "PROBLEM", 153, 207], ["increased", "OBSERVATION_MODIFIER", 166, 175], ["fibrosis", "OBSERVATION", 176, 184], ["fluid", "OBSERVATION", 189, 194], ["lungs", "ANATOMY", 202, 207]]], ["In this review we will focus on the contribution of TLR signaling to a subset of clinically relevant causes of ALI.Non-infectious causes of ALI/ARDSHemorrhagic shock (HS) is common in trauma patients and can prime the host immune response to elicit excessive inflammation, neutrophil influx and tissue injury in response to a secondary stimulus, causing ALI through the so-called 'two-hit hypothesis' [59] [60] [61] .", [["neutrophil", "ANATOMY", 273, 283], ["tissue", "ANATOMY", 295, 301], ["ALI", "DISEASE", 111, 114], ["ALI", "DISEASE", 140, 143], ["ARDSHemorrhagic shock", "DISEASE", 144, 165], ["HS", "DISEASE", 167, 169], ["trauma", "DISEASE", 184, 190], ["inflammation", "DISEASE", 259, 271], ["ALI", "DISEASE", 354, 357], ["TLR", "GENE_OR_GENE_PRODUCT", 52, 55], ["patients", "ORGANISM", 191, 199], ["neutrophil", "CELL", 273, 283], ["tissue", "TISSUE", 295, 301], ["TLR", "PROTEIN", 52, 55], ["patients", "SPECIES", 191, 199], ["TLR signaling", "PROBLEM", 52, 65], ["ALI", "PROBLEM", 111, 114], ["ALI", "PROBLEM", 140, 143], ["ARDSHemorrhagic shock", "PROBLEM", 144, 165], ["excessive inflammation", "PROBLEM", 249, 271], ["neutrophil influx", "PROBLEM", 273, 290], ["tissue injury", "PROBLEM", 295, 308], ["a secondary stimulus", "PROBLEM", 324, 344], ["ALI", "PROBLEM", 354, 357], ["ALI", "OBSERVATION", 111, 114], ["ALI", "OBSERVATION", 140, 143], ["ARDSHemorrhagic shock", "OBSERVATION", 144, 165], ["neutrophil influx", "OBSERVATION", 273, 290]]], ["Well characterized mouse models of HS-induced ALI using LPS as the secondary stimulus have determined that cross talk between TLR2 and TLR4 elicits heightened inflammatory mediator expression, such as CXCL1, leading to increased neutrophil influx and pulmonary edema [55, 60, [62] [63] [64] .", [["neutrophil", "ANATOMY", 229, 239], ["pulmonary", "ANATOMY", 251, 260], ["ALI", "DISEASE", 46, 49], ["LPS", "CHEMICAL", 56, 59], ["pulmonary edema", "DISEASE", 251, 266], ["mouse", "ORGANISM", 19, 24], ["LPS", "SIMPLE_CHEMICAL", 56, 59], ["TLR2", "GENE_OR_GENE_PRODUCT", 126, 130], ["TLR4", "GENE_OR_GENE_PRODUCT", 135, 139], ["CXCL1", "GENE_OR_GENE_PRODUCT", 201, 206], ["neutrophil", "CELL", 229, 239], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 251, 266], ["TLR2", "PROTEIN", 126, 130], ["TLR4", "PROTEIN", 135, 139], ["CXCL1", "PROTEIN", 201, 206], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["LPS", "TREATMENT", 56, 59], ["heightened inflammatory mediator expression", "PROBLEM", 148, 191], ["CXCL1", "TEST", 201, 206], ["increased neutrophil influx", "PROBLEM", 219, 246], ["pulmonary edema", "PROBLEM", 251, 266], ["inflammatory", "OBSERVATION_MODIFIER", 159, 171], ["increased", "OBSERVATION_MODIFIER", 219, 228], ["neutrophil influx", "OBSERVATION", 229, 246], ["pulmonary", "ANATOMY", 251, 260], ["edema", "OBSERVATION", 261, 266]]], ["Early inflammation in HS-induced ALI is dependent on upregulation of TLR4 by LPS, while later inflammation is mediated by heightened TLR2 expression on AMs and endothelial cells [64] .", [["AMs", "ANATOMY", 152, 155], ["endothelial cells", "ANATOMY", 160, 177], ["inflammation", "DISEASE", 6, 18], ["ALI", "DISEASE", 33, 36], ["LPS", "CHEMICAL", 77, 80], ["inflammation", "DISEASE", 94, 106], ["TLR4", "GENE_OR_GENE_PRODUCT", 69, 73], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["TLR2", "GENE_OR_GENE_PRODUCT", 133, 137], ["AMs", "CELL", 152, 155], ["endothelial cells", "CELL", 160, 177], ["TLR4", "PROTEIN", 69, 73], ["TLR2", "PROTEIN", 133, 137], ["AMs", "CELL_TYPE", 152, 155], ["endothelial cells", "CELL_TYPE", 160, 177], ["Early inflammation", "PROBLEM", 0, 18], ["ALI", "PROBLEM", 33, 36], ["endothelial cells", "TEST", 160, 177], ["inflammation", "OBSERVATION", 6, 18], ["HS-induced", "OBSERVATION_MODIFIER", 22, 32], ["ALI", "OBSERVATION", 33, 36], ["dependent", "OBSERVATION_MODIFIER", 40, 49]]], ["Deletion of either TLR2 or TLR4 in mice conferred protection from ALI and confirmed the presence of cross talk between these two receptors [63, 65] .Non-infectious causes of ALI/ARDSHyperoxia (high concentrations of inspired oxygen) is a common therapy in critically ill patients; however, this treatment can also cause severe ALI by upregulating the production of reactive oxygen species [44, [66] [67] [68] [69] .", [["ALI", "DISEASE", 66, 69], ["ALI", "DISEASE", 174, 177], ["ARDSHyperoxia", "CHEMICAL", 178, 191], ["oxygen", "CHEMICAL", 225, 231], ["critically ill", "DISEASE", 256, 270], ["ALI", "DISEASE", 327, 330], ["oxygen", "CHEMICAL", 374, 380], ["oxygen", "CHEMICAL", 225, 231], ["oxygen", "CHEMICAL", 374, 380], ["TLR2", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["mice", "ORGANISM", 35, 39], ["oxygen", "SIMPLE_CHEMICAL", 225, 231], ["patients", "ORGANISM", 271, 279], ["reactive oxygen species", "SIMPLE_CHEMICAL", 365, 388], ["TLR2", "PROTEIN", 19, 23], ["TLR4", "PROTEIN", 27, 31], ["mice", "SPECIES", 35, 39], ["patients", "SPECIES", 271, 279], ["mice", "SPECIES", 35, 39], ["ALI", "PROBLEM", 174, 177], ["ARDSHyperoxia", "PROBLEM", 178, 191], ["inspired oxygen", "TREATMENT", 216, 231], ["a common therapy", "TREATMENT", 236, 252], ["severe ALI", "PROBLEM", 320, 330], ["reactive oxygen species", "TEST", 365, 388], ["TLR2", "ANATOMY", 19, 23], ["ALI", "OBSERVATION", 174, 177], ["reactive", "OBSERVATION_MODIFIER", 365, 373]]], ["TLR4 protects the host from hyperoxia-induced ALI by maintaining lung integrity and inducing the expression of protective anti-apoptotic factors such as Bcl2 and Phospho-Akt [70, 71] .", [["lung", "ANATOMY", 65, 69], ["hyperoxia", "CHEMICAL", 28, 37], ["ALI", "DISEASE", 46, 49], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung", "ORGAN", 65, 69], ["Bcl2", "GENE_OR_GENE_PRODUCT", 153, 157], ["Phospho-Akt", "GENE_OR_GENE_PRODUCT", 162, 173], ["TLR4", "PROTEIN", 0, 4], ["anti-apoptotic factors", "PROTEIN", 122, 144], ["Bcl2", "PROTEIN", 153, 157], ["Phospho", "PROTEIN", 162, 169], ["Akt", "PROTEIN", 170, 173], ["hyperoxia", "PROBLEM", 28, 37], ["ALI", "PROBLEM", 46, 49], ["protective anti-apoptotic factors", "TREATMENT", 111, 144], ["Bcl2", "TEST", 153, 157], ["Phospho", "TEST", 162, 169], ["ALI", "OBSERVATION", 46, 49], ["lung", "ANATOMY", 65, 69], ["integrity", "OBSERVATION", 70, 79]]], ["TLR4 or TLR2/TLR4 double knockout mice exposed to hyperoxia have significantly greater lung inflammation and permeability and are more susceptible to lethal ALI compared to wild type mice [71, 72] .", [["lung", "ANATOMY", 87, 91], ["hyperoxia", "CHEMICAL", 50, 59], ["inflammation", "DISEASE", 92, 104], ["ALI", "DISEASE", 157, 160], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "GENE_OR_GENE_PRODUCT", 8, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 13, 17], ["lung", "ORGAN", 87, 91], ["mice", "ORGANISM", 183, 187], ["TLR4", "PROTEIN", 0, 4], ["TLR2", "PROTEIN", 8, 12], ["TLR4", "PROTEIN", 13, 17], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 183, 187], ["TLR2/TLR4 double knockout mice", "TREATMENT", 8, 38], ["significantly greater lung inflammation", "PROBLEM", 65, 104], ["lethal ALI", "PROBLEM", 150, 160], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["greater", "OBSERVATION_MODIFIER", 79, 86], ["lung", "ANATOMY", 87, 91], ["inflammation", "OBSERVATION", 92, 104]]], ["Conversely, TLR3-deficient mice are protected from ALI due to decreased neutrophil recruitment, induction of pro-apoptotic factors, and increased surfactant protein expression that clears injury-induced cellular debris [73] [74] [75] .Non-infectious causes of ALI/ARDSBleomycin is a potent anticancer agent that ultimately leads to cell death through generation of oxygen radicals and DNA breaks [76] .", [["neutrophil", "ANATOMY", 72, 82], ["cellular", "ANATOMY", 203, 211], ["anticancer", "ANATOMY", 290, 300], ["cell", "ANATOMY", 332, 336], ["ALI", "DISEASE", 51, 54], ["ALI", "DISEASE", 260, 263], ["ARDSBleomycin", "CHEMICAL", 264, 277], ["death", "DISEASE", 337, 342], ["oxygen", "CHEMICAL", 365, 371], ["ARDSBleomycin", "CHEMICAL", 264, 277], ["oxygen", "CHEMICAL", 365, 371], ["TLR3", "GENE_OR_GENE_PRODUCT", 12, 16], ["mice", "ORGANISM", 27, 31], ["neutrophil", "CELL", 72, 82], ["cellular", "CELL", 203, 211], ["ARDSBleomycin", "SIMPLE_CHEMICAL", 264, 277], ["anticancer", "CANCER", 290, 300], ["cell", "CELL", 332, 336], ["oxygen radicals", "SIMPLE_CHEMICAL", 365, 380], ["DNA", "CELLULAR_COMPONENT", 385, 388], ["TLR3", "PROTEIN", 12, 16], ["pro-apoptotic factors", "PROTEIN", 109, 130], ["surfactant protein", "PROTEIN", 146, 164], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["ALI", "PROBLEM", 51, 54], ["decreased neutrophil recruitment", "TREATMENT", 62, 94], ["pro-apoptotic factors", "TREATMENT", 109, 130], ["increased surfactant protein expression", "TREATMENT", 136, 175], ["induced cellular debris", "PROBLEM", 195, 218], ["ALI", "PROBLEM", 260, 263], ["ARDSBleomycin", "TREATMENT", 264, 277], ["a potent anticancer agent", "TREATMENT", 281, 306], ["cell death", "PROBLEM", 332, 342], ["oxygen radicals", "TREATMENT", 365, 380], ["DNA breaks", "PROBLEM", 385, 395], ["decreased", "OBSERVATION_MODIFIER", 62, 71], ["neutrophil recruitment", "OBSERVATION", 72, 94], ["ALI", "OBSERVATION", 260, 263]]], ["Bleomycin toxicity is usually associated with diffuse pulmonary fibrosis but may also cause ALI by triggering the degradation of high molecular weight hyaluronan (HA) in the extracellular matrix [77] [78] [79] .", [["pulmonary", "ANATOMY", 54, 63], ["extracellular matrix", "ANATOMY", 174, 194], ["Bleomycin", "CHEMICAL", 0, 9], ["toxicity", "DISEASE", 10, 18], ["fibrosis", "DISEASE", 64, 72], ["ALI", "DISEASE", 92, 95], ["Bleomycin", "CHEMICAL", 0, 9], ["Bleomycin", "SIMPLE_CHEMICAL", 0, 9], ["pulmonary", "ORGAN", 54, 63], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 151, 161], ["extracellular matrix", "CELLULAR_COMPONENT", 174, 194], ["Bleomycin toxicity", "PROBLEM", 0, 18], ["diffuse pulmonary fibrosis", "PROBLEM", 46, 72], ["ALI", "PROBLEM", 92, 95], ["usually associated with", "UNCERTAINTY", 22, 45], ["diffuse", "OBSERVATION_MODIFIER", 46, 53], ["pulmonary", "ANATOMY", 54, 63], ["fibrosis", "OBSERVATION", 64, 72], ["may also cause", "UNCERTAINTY", 77, 91], ["ALI", "OBSERVATION", 92, 95]]], ["In contrast to intact HA that mediates homeostasis, accumulation of low molecular weight HA fragments is detrimental because it induces relentless pulmonary inflammation in AMs [72, 78] .", [["pulmonary", "ANATOMY", 147, 156], ["AMs", "ANATOMY", 173, 176], ["pulmonary inflammation", "DISEASE", 147, 169], ["HA", "GENE_OR_GENE_PRODUCT", 22, 24], ["pulmonary", "ORGAN", 147, 156], ["AMs", "CELL", 173, 176], ["AMs", "CELL_TYPE", 173, 176], ["low molecular weight HA fragments", "PROBLEM", 68, 101], ["relentless pulmonary inflammation", "PROBLEM", 136, 169], ["accumulation", "OBSERVATION_MODIFIER", 52, 64], ["low molecular", "OBSERVATION_MODIFIER", 68, 81], ["fragments", "OBSERVATION", 92, 101], ["relentless", "OBSERVATION_MODIFIER", 136, 146], ["pulmonary", "ANATOMY", 147, 156], ["inflammation", "OBSERVATION", 157, 169]]], ["Loss of TLR2 and TLR4 or the adaptor molecule MyD88 leads to increased tissue injury, epithelial cell apoptosis and decreased survival following bleomycin exposure as well as decreased chemokine expression and defective neutrophil recruitment to the lungs [72] .", [["tissue", "ANATOMY", 71, 77], ["epithelial cell", "ANATOMY", 86, 101], ["neutrophil", "ANATOMY", 220, 230], ["lungs", "ANATOMY", 250, 255], ["bleomycin", "CHEMICAL", 145, 154], ["bleomycin", "CHEMICAL", 145, 154], ["TLR2", "GENE_OR_GENE_PRODUCT", 8, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 17, 21], ["MyD88", "GENE_OR_GENE_PRODUCT", 46, 51], ["tissue", "TISSUE", 71, 77], ["epithelial cell", "CELL", 86, 101], ["bleomycin", "SIMPLE_CHEMICAL", 145, 154], ["neutrophil", "CELL", 220, 230], ["lungs", "ORGAN", 250, 255], ["TLR2", "PROTEIN", 8, 12], ["TLR4", "PROTEIN", 17, 21], ["adaptor molecule", "PROTEIN", 29, 45], ["MyD88", "PROTEIN", 46, 51], ["chemokine", "PROTEIN", 185, 194], ["Loss of TLR2", "PROBLEM", 0, 12], ["the adaptor molecule MyD88", "TREATMENT", 25, 51], ["increased tissue injury", "PROBLEM", 61, 84], ["epithelial cell apoptosis", "PROBLEM", 86, 111], ["decreased survival", "PROBLEM", 116, 134], ["bleomycin exposure", "TREATMENT", 145, 163], ["decreased chemokine expression", "TREATMENT", 175, 205], ["defective neutrophil recruitment", "TREATMENT", 210, 242], ["TLR2", "ANATOMY_MODIFIER", 8, 12], ["increased tissue", "OBSERVATION_MODIFIER", 61, 77], ["injury", "OBSERVATION", 78, 84], ["epithelial cell apoptosis", "OBSERVATION", 86, 111], ["decreased", "OBSERVATION_MODIFIER", 116, 125], ["survival", "OBSERVATION_MODIFIER", 126, 134], ["decreased", "OBSERVATION_MODIFIER", 175, 184], ["chemokine expression", "OBSERVATION", 185, 205], ["defective", "OBSERVATION_MODIFIER", 210, 219], ["neutrophil recruitment", "OBSERVATION", 220, 242], ["lungs", "ANATOMY", 250, 255]]], ["Further mechanistic studies showed that TLR2 and TLR4 not only trigger basal NF-B activation at the lung epithelium through interactions with intact HA in order to maintain cell integrity and decrease lung injury, but also mediate macrophage inflammatory responses to HA fragments following chemically induced tissue injury [72, 80] .Infectious causes of ALI/ARDSPneumonia is the most common cause of ALI or ARDS [81] .", [["lung epithelium", "ANATOMY", 100, 115], ["cell", "ANATOMY", 173, 177], ["lung", "ANATOMY", 201, 205], ["macrophage", "ANATOMY", 231, 241], ["fragments", "ANATOMY", 271, 280], ["tissue", "ANATOMY", 310, 316], ["lung injury", "DISEASE", 201, 212], ["tissue injury", "DISEASE", 310, 323], ["ALI", "DISEASE", 355, 358], ["ARDSPneumonia", "DISEASE", 359, 372], ["ALI", "DISEASE", 401, 404], ["ARDS", "DISEASE", 408, 412], ["TLR2", "GENE_OR_GENE_PRODUCT", 40, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 49, 53], ["NF-B", "GENE_OR_GENE_PRODUCT", 77, 81], ["lung epithelium", "TISSUE", 100, 115], ["cell", "CELL", 173, 177], ["lung", "ORGAN", 201, 205], ["macrophage", "CELL", 231, 241], ["tissue", "TISSUE", 310, 316], ["TLR2", "PROTEIN", 40, 44], ["TLR4", "PROTEIN", 49, 53], ["NF-B", "PROTEIN", 77, 81], ["Further mechanistic studies", "TEST", 0, 27], ["basal NF", "PROBLEM", 71, 79], ["intact HA", "PROBLEM", 142, 151], ["decrease lung injury", "PROBLEM", 192, 212], ["mediate macrophage inflammatory responses", "PROBLEM", 223, 264], ["HA fragments", "PROBLEM", 268, 280], ["chemically induced tissue injury", "PROBLEM", 291, 323], ["ALI", "PROBLEM", 355, 358], ["ARDSPneumonia", "PROBLEM", 359, 372], ["ALI", "PROBLEM", 401, 404], ["ARDS", "PROBLEM", 408, 412], ["lung", "ANATOMY", 100, 104], ["epithelium", "ANATOMY_MODIFIER", 105, 115], ["decrease", "OBSERVATION_MODIFIER", 192, 200], ["lung", "ANATOMY", 201, 205], ["injury", "OBSERVATION", 206, 212], ["macrophage", "OBSERVATION_MODIFIER", 231, 241], ["inflammatory", "OBSERVATION_MODIFIER", 242, 254], ["chemically induced", "OBSERVATION_MODIFIER", 291, 309], ["tissue", "OBSERVATION_MODIFIER", 310, 316], ["injury", "OBSERVATION", 317, 323], ["ALI", "OBSERVATION", 355, 358], ["ARDSPneumonia", "OBSERVATION", 359, 372], ["most common", "OBSERVATION_MODIFIER", 380, 391], ["ALI", "OBSERVATION", 401, 404], ["ARDS", "OBSERVATION", 408, 412]]], ["During the past decade, novel and highly virulent respiratory viruses, such as the Severe Acute Respiratory Syndrome Coronavirus (SARS CoV), have emerged as important causes of excessive lung damage in infected humans [82] .", [["lung", "ANATOMY", 187, 191], ["respiratory viruses", "DISEASE", 50, 69], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 90, 128], ["SARS", "DISEASE", 130, 134], ["lung damage", "DISEASE", 187, 198], ["Severe Acute Respiratory Syndrome Coronavirus", "ORGANISM", 83, 128], ["SARS CoV", "ORGANISM", 130, 138], ["lung", "ORGAN", 187, 191], ["humans", "ORGANISM", 211, 217], ["humans", "SPECIES", 211, 217], ["Severe Acute Respiratory Syndrome Coronavirus (SARS CoV", "SPECIES", 83, 138], ["humans", "SPECIES", 211, 217], ["highly virulent respiratory viruses", "PROBLEM", 34, 69], ["the Severe Acute Respiratory Syndrome Coronavirus (SARS CoV", "PROBLEM", 79, 138], ["excessive lung damage in infected humans", "PROBLEM", 177, 217], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["virulent", "OBSERVATION_MODIFIER", 41, 49], ["respiratory viruses", "OBSERVATION", 50, 69], ["Severe", "OBSERVATION_MODIFIER", 83, 89], ["Acute", "OBSERVATION_MODIFIER", 90, 95], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 96, 128], ["excessive", "OBSERVATION_MODIFIER", 177, 186], ["lung", "ANATOMY", 187, 191], ["damage", "OBSERVATION", 192, 198], ["infected", "OBSERVATION", 202, 210]]], ["The 2003 global SARS epidemic had a 50% mortality rate with 16% of all infected individuals developing ALI [83, 84] .", [["SARS", "DISEASE", 16, 20], ["ALI", "DISEASE", 103, 106], ["mortality rate", "TEST", 40, 54], ["all infected individuals developing ALI", "PROBLEM", 67, 106]]], ["The lung pathology in these patients mirrored ALI caused by other factors, consisting primarily of diffuse alveolar damage caused by virusalveolar cell interaction [85] .", [["lung", "ANATOMY", 4, 8], ["alveolar", "ANATOMY", 107, 115], ["cell", "ANATOMY", 147, 151], ["ALI", "DISEASE", 46, 49], ["alveolar damage", "DISEASE", 107, 122], ["lung", "ORGAN", 4, 8], ["patients", "ORGANISM", 28, 36], ["alveolar", "TISSUE", 107, 115], ["virusalveolar cell", "CELL", 133, 151], ["patients", "SPECIES", 28, 36], ["The lung pathology", "TEST", 0, 18], ["diffuse alveolar damage", "PROBLEM", 99, 122], ["virusalveolar cell interaction", "PROBLEM", 133, 163], ["lung", "ANATOMY", 4, 8], ["pathology", "OBSERVATION", 9, 18], ["ALI", "OBSERVATION", 46, 49], ["diffuse", "OBSERVATION_MODIFIER", 99, 106], ["alveolar damage", "OBSERVATION", 107, 122], ["virusalveolar cell", "OBSERVATION", 133, 151]]], ["The contribution of TLRs to SARS pathogenesis is not well understood [86] ; however, using different mouse models of related CoV infection, a protective role for TLR4 [87] and MyD88 [88] has been suggested while TLR7 may be important for viral clearance through production of type I IFN [89] .Infectious causes of ALI/ARDSHighly pathogenic strains of influenza virus are another important cause of ALI/ARDS in humans.", [["SARS", "DISEASE", 28, 32], ["CoV infection", "DISEASE", 125, 138], ["ALI", "DISEASE", 314, 317], ["influenza virus", "DISEASE", 351, 366], ["ALI", "DISEASE", 398, 401], ["ARDS", "DISEASE", 402, 406], ["TLRs", "GENE_OR_GENE_PRODUCT", 20, 24], ["mouse", "ORGANISM", 101, 106], ["CoV", "ORGANISM", 125, 128], ["TLR4 [87]", "GENE_OR_GENE_PRODUCT", 162, 171], ["MyD88", "GENE_OR_GENE_PRODUCT", 176, 181], ["88", "GENE_OR_GENE_PRODUCT", 183, 185], ["TLR7", "GENE_OR_GENE_PRODUCT", 212, 216], ["type I IFN", "GENE_OR_GENE_PRODUCT", 276, 286], ["influenza virus", "ORGANISM", 351, 366], ["humans", "ORGANISM", 410, 416], ["TLRs", "PROTEIN", 20, 24], ["TLR4", "PROTEIN", 162, 166], ["MyD88", "PROTEIN", 176, 181], ["TLR7", "PROTEIN", 212, 216], ["type I IFN", "PROTEIN", 276, 286], ["mouse", "SPECIES", 101, 106], ["influenza virus", "SPECIES", 351, 366], ["humans", "SPECIES", 410, 416], ["mouse", "SPECIES", 101, 106], ["CoV", "SPECIES", 125, 128], ["influenza virus", "SPECIES", 351, 366], ["humans", "SPECIES", 410, 416], ["SARS pathogenesis", "PROBLEM", 28, 45], ["related CoV infection", "PROBLEM", 117, 138], ["viral clearance", "PROBLEM", 238, 253], ["ALI", "PROBLEM", 314, 317], ["ARDSHighly pathogenic strains", "PROBLEM", 318, 347], ["influenza virus", "PROBLEM", 351, 366], ["ALI", "PROBLEM", 398, 401], ["ARDS in humans", "PROBLEM", 402, 416], ["CoV infection", "OBSERVATION", 125, 138], ["ALI", "ANATOMY", 314, 317], ["influenza virus", "OBSERVATION", 351, 366], ["ALI", "OBSERVATION", 398, 401], ["ARDS", "OBSERVATION", 402, 406]]], ["Compared to seasonal influenza strains that bind cells of the upper respiratory tract, highly pathogenic H5N1 influenza virus infects alveolar type II cells, macrophages, and nonciliated cuboidal epithelium of the terminal bronchi leading to a lower respiratory tract infection and ALI/ARDS [90, 91] .", [["cells", "ANATOMY", 49, 54], ["upper respiratory tract", "ANATOMY", 62, 85], ["alveolar type II cells", "ANATOMY", 134, 156], ["macrophages", "ANATOMY", 158, 169], ["cuboidal epithelium", "ANATOMY", 187, 206], ["terminal bronchi", "ANATOMY", 214, 230], ["lower respiratory tract", "ANATOMY", 244, 267], ["influenza", "DISEASE", 110, 119], ["respiratory tract infection", "DISEASE", 250, 277], ["ALI", "DISEASE", 282, 285], ["ARDS", "DISEASE", 286, 290], ["cells", "CELL", 49, 54], ["upper respiratory", "ORGANISM_SUBDIVISION", 62, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["H5N1 influenza virus", "ORGANISM", 105, 125], ["alveolar type II cells", "CELL", 134, 156], ["macrophages", "CELL", 158, 169], ["nonciliated cuboidal epithelium", "TISSUE", 175, 206], ["bronchi", "MULTI-TISSUE_STRUCTURE", 223, 230], ["tract", "ORGANISM_SUBDIVISION", 262, 267], ["alveolar type II cells", "CELL_TYPE", 134, 156], ["macrophages", "CELL_TYPE", 158, 169], ["H5N1 influenza virus", "SPECIES", 105, 125], ["H5N1 influenza virus", "SPECIES", 105, 125], ["seasonal influenza strains", "PROBLEM", 12, 38], ["bind cells of the upper respiratory tract", "PROBLEM", 44, 85], ["highly pathogenic H5N1 influenza virus infects alveolar type II cells", "PROBLEM", 87, 156], ["macrophages", "PROBLEM", 158, 169], ["nonciliated cuboidal epithelium of the terminal bronchi", "PROBLEM", 175, 230], ["a lower respiratory tract infection", "PROBLEM", 242, 277], ["ALI", "PROBLEM", 282, 285], ["ARDS", "PROBLEM", 286, 290], ["bind cells", "OBSERVATION", 44, 54], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["pathogenic", "OBSERVATION_MODIFIER", 94, 104], ["H5N1", "OBSERVATION", 105, 109], ["alveolar type II cells", "OBSERVATION", 134, 156], ["macrophages", "OBSERVATION_MODIFIER", 158, 169], ["nonciliated", "ANATOMY_MODIFIER", 175, 186], ["cuboidal", "ANATOMY_MODIFIER", 187, 195], ["epithelium", "ANATOMY_MODIFIER", 196, 206], ["terminal", "ANATOMY_MODIFIER", 214, 222], ["bronchi", "ANATOMY", 223, 230], ["lower", "ANATOMY_MODIFIER", 244, 249], ["respiratory tract", "ANATOMY", 250, 267], ["infection", "OBSERVATION", 268, 277], ["ARDS", "OBSERVATION", 286, 290]]], ["Modeling of H5N1 infection in mice reproduced the pattern of damage seen in humans including increased neutrophilia, alveolar and interstitial edema, lung hemorrhage, and elevated TNF-\u03b1 and IL-6 expression in the airway lining fluid [92, 93] .", [["alveolar", "ANATOMY", 117, 125], ["interstitial edema", "ANATOMY", 130, 148], ["lung", "ANATOMY", 150, 154], ["airway lining fluid", "ANATOMY", 213, 232], ["H5N1 infection", "DISEASE", 12, 26], ["neutrophilia", "DISEASE", 103, 115], ["interstitial edema", "DISEASE", 130, 148], ["lung hemorrhage", "DISEASE", 150, 165], ["H5N1", "ORGANISM", 12, 16], ["mice", "ORGANISM", 30, 34], ["humans", "ORGANISM", 76, 82], ["alveolar", "TISSUE", 117, 125], ["interstitial edema", "PATHOLOGICAL_FORMATION", 130, 148], ["lung", "ORGAN", 150, 154], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 180, 185], ["IL-6", "GENE_OR_GENE_PRODUCT", 190, 194], ["airway lining", "TISSUE", 213, 226], ["fluid", "ORGANISM_SUBSTANCE", 227, 232], ["TNF", "PROTEIN", 180, 183], ["IL-6", "PROTEIN", 190, 194], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 76, 82], ["H5N1", "SPECIES", 12, 16], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 76, 82], ["H5N1 infection", "PROBLEM", 12, 26], ["damage", "PROBLEM", 61, 67], ["increased neutrophilia", "PROBLEM", 93, 115], ["alveolar and interstitial edema", "PROBLEM", 117, 148], ["lung hemorrhage", "PROBLEM", 150, 165], ["elevated TNF", "PROBLEM", 171, 183], ["IL", "TEST", 190, 192], ["the airway lining fluid", "TEST", 209, 232], ["H5N1", "OBSERVATION_MODIFIER", 12, 16], ["infection", "OBSERVATION", 17, 26], ["damage", "OBSERVATION", 61, 67], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["neutrophilia", "OBSERVATION", 103, 115], ["alveolar", "ANATOMY_MODIFIER", 117, 125], ["interstitial", "ANATOMY_MODIFIER", 130, 142], ["edema", "OBSERVATION", 143, 148], ["lung", "ANATOMY", 150, 154], ["hemorrhage", "OBSERVATION", 155, 165], ["elevated", "OBSERVATION_MODIFIER", 171, 179], ["TNF", "OBSERVATION_MODIFIER", 180, 183], ["airway", "ANATOMY", 213, 219], ["lining", "ANATOMY_MODIFIER", 220, 226], ["fluid", "OBSERVATION", 227, 232]]], ["Mice that survived beyond the acute phase of infection had large regions of lung interstitial and intra-alveolar fibrosis and ALI [93] .Infectious causes of ALI/ARDSThe role of TLRs has been intensively studied in influenza infection.", [["lung interstitial", "ANATOMY", 76, 93], ["intra-alveolar", "ANATOMY", 98, 112], ["infection", "DISEASE", 45, 54], ["fibrosis", "DISEASE", 113, 121], ["ALI", "DISEASE", 126, 129], ["ALI", "DISEASE", 157, 160], ["influenza infection", "DISEASE", 214, 233], ["Mice", "ORGANISM", 0, 4], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 76, 93], ["intra-alveolar", "TISSUE", 98, 112], ["TLRs", "GENE_OR_GENE_PRODUCT", 177, 181], ["TLRs", "PROTEIN", 177, 181], ["Mice", "SPECIES", 0, 4], ["infection", "PROBLEM", 45, 54], ["lung interstitial and intra-alveolar fibrosis", "PROBLEM", 76, 121], ["ALI", "PROBLEM", 126, 129], ["ALI", "PROBLEM", 157, 160], ["TLRs", "TREATMENT", 177, 181], ["influenza infection", "PROBLEM", 214, 233], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["phase", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 45, 54], ["large", "OBSERVATION_MODIFIER", 59, 64], ["lung", "ANATOMY", 76, 80], ["interstitial", "ANATOMY_MODIFIER", 81, 93], ["intra-alveolar", "ANATOMY_MODIFIER", 98, 112], ["fibrosis", "OBSERVATION", 113, 121], ["ALI", "OBSERVATION_MODIFIER", 126, 129], ["ALI", "OBSERVATION", 157, 160], ["influenza", "OBSERVATION_MODIFIER", 214, 223], ["infection", "OBSERVATION", 224, 233]]], ["TLR7 expression on pDCs plays a cell-specific role against influenza through MyD88dependent IFN-\u03b1 induction [13, 94] .", [["pDCs", "ANATOMY", 19, 23], ["cell", "ANATOMY", 32, 36], ["influenza", "DISEASE", 59, 68], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["pDCs", "CELL", 19, 23], ["cell", "CELL", 32, 36], ["influenza", "ORGANISM", 59, 68], ["MyD88dependent IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 77, 97], ["TLR7", "PROTEIN", 0, 4], ["pDCs", "CELL_TYPE", 19, 23], ["IFN", "PROTEIN", 92, 95], ["\u03b1", "PROTEIN", 96, 97], ["influenza", "PROBLEM", 59, 68]]], ["Despite the importance of TLR7/MyD88 signaling, MyD88-deficient mice can still produce type I IFN, control viral replication, and recover from the infection [95] .", [["infection", "DISEASE", 147, 156], ["TLR7", "GENE_OR_GENE_PRODUCT", 26, 30], ["MyD88", "GENE_OR_GENE_PRODUCT", 31, 36], ["MyD88", "GENE_OR_GENE_PRODUCT", 48, 53], ["mice", "ORGANISM", 64, 68], ["type I IFN", "GENE_OR_GENE_PRODUCT", 87, 97], ["TLR7", "PROTEIN", 26, 30], ["MyD88", "PROTEIN", 31, 36], ["MyD88", "PROTEIN", 48, 53], ["type I IFN", "PROTEIN", 87, 97], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["TLR7/MyD88 signaling", "TREATMENT", 26, 46], ["MyD88-deficient mice", "TREATMENT", 48, 68], ["type I IFN", "PROBLEM", 87, 97], ["viral replication", "TREATMENT", 107, 124], ["the infection", "PROBLEM", 143, 156], ["viral replication", "OBSERVATION", 107, 124], ["infection", "OBSERVATION", 147, 156]]], ["An increased lung viral load was seen only when MyD88 and IPS-1 (the adaptor molecule for the cytosolic RIG-I pathway) were both absent, suggesting that these pathways can compensate for one another during influenza infection [95] .", [["lung", "ANATOMY", 13, 17], ["cytosolic", "ANATOMY", 94, 103], ["influenza infection", "DISEASE", 206, 225], ["lung", "ORGAN", 13, 17], ["MyD88", "GENE_OR_GENE_PRODUCT", 48, 53], ["IPS-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["RIG-I", "GENE_OR_GENE_PRODUCT", 104, 109], ["MyD88", "PROTEIN", 48, 53], ["IPS-1", "PROTEIN", 58, 63], ["adaptor molecule", "PROTEIN", 69, 85], ["cytosolic RIG-I", "PROTEIN", 94, 109], ["An increased lung viral load", "PROBLEM", 0, 28], ["MyD88", "TEST", 48, 53], ["IPS", "TEST", 58, 61], ["the adaptor molecule", "TREATMENT", 65, 85], ["the cytosolic RIG", "TEST", 90, 107], ["influenza infection", "PROBLEM", 206, 225], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["lung", "ANATOMY", 13, 17], ["viral load", "OBSERVATION", 18, 28]]], ["Though not essential for survival, MyD88 does play a distinct role in the adaptive immune response to influenza through regulation of B-cell isotype switching [95, 96] .Infectious causes of ALI/ARDSThe role of TLR3 in the immune response to influenza has been debated in the literature.", [["B-cell", "ANATOMY", 134, 140], ["influenza", "DISEASE", 102, 111], ["ALI", "DISEASE", 190, 193], ["ARDS", "DISEASE", 194, 198], ["influenza", "DISEASE", 241, 250], ["MyD88", "GENE_OR_GENE_PRODUCT", 35, 40], ["B-cell", "CELL", 134, 140], ["TLR3", "GENE_OR_GENE_PRODUCT", 210, 214], ["MyD88", "PROTEIN", 35, 40], ["TLR3", "PROTEIN", 210, 214], ["influenza", "PROBLEM", 102, 111], ["B-cell isotype switching", "TREATMENT", 134, 158], ["ALI", "PROBLEM", 190, 193], ["ARDS", "PROBLEM", 194, 198], ["TLR3", "TREATMENT", 210, 214], ["influenza", "PROBLEM", 241, 250], ["ALI", "OBSERVATION", 190, 193], ["ARDS", "OBSERVATION", 194, 198]]], ["Although several studies have shown that dsRNA is not produced during influenza replication [97, 98] , very low and potentially undetectable levels of this viral intermediate could still elicit a substantial immune response through TLR3 [99, 100] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 232, 236], ["TLR3", "PROTEIN", 232, 236], ["several studies", "TEST", 9, 24], ["dsRNA", "PROBLEM", 41, 46], ["influenza replication", "PROBLEM", 70, 91], ["this viral intermediate", "PROBLEM", 151, 174], ["TLR3", "TEST", 232, 236], ["dsRNA", "OBSERVATION", 41, 46]]], ["The finding that TLR3 is upregulated in human bronchial and alveolar epithelial cells during influenza infection suggests that it may play an important role in immune signaling [101] .", [["bronchial", "ANATOMY", 46, 55], ["alveolar epithelial cells", "ANATOMY", 60, 85], ["influenza infection", "DISEASE", 93, 112], ["TLR3", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 40, 45], ["bronchial", "CELL", 46, 55], ["alveolar epithelial cells", "CELL", 60, 85], ["TLR3", "PROTEIN", 17, 21], ["human bronchial and alveolar epithelial cells", "CELL_TYPE", 40, 85], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["alveolar epithelial cells", "PROBLEM", 60, 85], ["influenza infection", "PROBLEM", 93, 112], ["bronchial", "ANATOMY", 46, 55], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["epithelial cells", "OBSERVATION", 69, 85]]], ["Deletion of TLR3 leads to downregulation of inflammatory cytokine and chemokine production and an elevated viral load during the late phase of influenza infection.", [["influenza infection", "DISEASE", 143, 162], ["TLR3", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR3", "PROTEIN", 12, 16], ["inflammatory cytokine", "PROTEIN", 44, 65], ["chemokine", "PROTEIN", 70, 79], ["Deletion of TLR3", "PROBLEM", 0, 16], ["inflammatory cytokine", "PROBLEM", 44, 65], ["chemokine production", "PROBLEM", 70, 90], ["an elevated viral load", "PROBLEM", 95, 117], ["influenza infection", "PROBLEM", 143, 162], ["inflammatory", "OBSERVATION_MODIFIER", 44, 56], ["chemokine production", "OBSERVATION", 70, 90], ["elevated", "OBSERVATION_MODIFIER", 98, 106], ["viral load", "OBSERVATION", 107, 117], ["late phase", "OBSERVATION_MODIFIER", 129, 139], ["influenza", "OBSERVATION_MODIFIER", 143, 152], ["infection", "OBSERVATION", 153, 162]]], ["Surprisingly, TLR3 mutant mice have an increased survival rate compared to wild type mice suggesting that TLR3 signaling is detrimental to the host, despite its role in reducing viral replication [102, 103] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 14, 18], ["mice", "ORGANISM", 26, 30], ["wild type mice", "ORGANISM", 75, 89], ["TLR3", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR3", "PROTEIN", 14, 18], ["TLR3", "PROTEIN", 106, 110], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 85, 89], ["an increased survival rate", "PROBLEM", 36, 62], ["TLR3 signaling", "PROBLEM", 106, 120], ["reducing viral replication", "TREATMENT", 169, 195], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["survival", "OBSERVATION", 49, 57]]], ["In addition to the TLRs, RIG-I, NLRP3, and NOD2 have also been implicated in the immune response to influenza [104] [105] [106] [107] [108] ; however, the relative contribution of these PRRs to influenza-specific host defense requires additional study.Cystic Fibrosis (CF)CF is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene [109] .", [["influenza", "DISEASE", 100, 109], ["Cystic Fibrosis (CF)CF", "DISEASE", 252, 274], ["autosomal recessive disorder", "DISEASE", 281, 309], ["fibrosis", "DISEASE", 344, 352], ["TLRs", "GENE_OR_GENE_PRODUCT", 19, 23], ["RIG-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["NLRP3", "GENE_OR_GENE_PRODUCT", 32, 37], ["NOD2", "GENE_OR_GENE_PRODUCT", 43, 47], ["PRRs", "GENE_OR_GENE_PRODUCT", 186, 190], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 337, 388], ["CFTR", "GENE_OR_GENE_PRODUCT", 390, 394], ["TLRs", "PROTEIN", 19, 23], ["RIG", "PROTEIN", 25, 28], ["NLRP3", "PROTEIN", 32, 37], ["NOD2", "PROTEIN", 43, 47], ["PRRs", "PROTEIN", 186, 190], ["cystic fibrosis transmembrane conductance regulator (CFTR) gene", "DNA", 337, 400], ["influenza", "PROBLEM", 100, 109], ["additional study", "TEST", 235, 251], ["Cystic Fibrosis (CF)CF", "PROBLEM", 252, 274], ["an autosomal recessive disorder", "PROBLEM", 278, 309], ["mutations in the cystic fibrosis transmembrane conductance regulator", "PROBLEM", 320, 388], ["Fibrosis", "OBSERVATION", 259, 267], ["autosomal", "OBSERVATION_MODIFIER", 281, 290], ["recessive disorder", "OBSERVATION", 291, 309], ["cystic", "OBSERVATION_MODIFIER", 337, 343], ["fibrosis", "OBSERVATION", 344, 352]]], ["The airways of CF patients are characterized by chronic bacterial colonization and associated neutrophilic inflammation.", [["airways", "ANATOMY", 4, 11], ["neutrophilic", "ANATOMY", 94, 106], ["CF", "DISEASE", 15, 17], ["inflammation", "DISEASE", 107, 119], ["airways", "MULTI-TISSUE_STRUCTURE", 4, 11], ["patients", "ORGANISM", 18, 26], ["neutrophilic inflammation", "PATHOLOGICAL_FORMATION", 94, 119], ["patients", "SPECIES", 18, 26], ["chronic bacterial colonization", "PROBLEM", 48, 78], ["associated neutrophilic inflammation", "PROBLEM", 83, 119], ["airways", "ANATOMY", 4, 11], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["bacterial colonization", "OBSERVATION", 56, 78], ["neutrophilic", "OBSERVATION_MODIFIER", 94, 106], ["inflammation", "OBSERVATION", 107, 119]]], ["P. aeruginosa infection is the major cause of morbidity and mortality among CF-affected individuals, producing acute pneumonia or chronic lung disease with periodic acute exacerbations [3, 110, 111] .", [["lung", "ANATOMY", 138, 142], ["P. aeruginosa infection", "DISEASE", 0, 23], ["pneumonia", "DISEASE", 117, 126], ["chronic lung disease", "DISEASE", 130, 150], ["P. aeruginosa", "ORGANISM", 0, 13], ["individuals", "ORGANISM", 88, 99], ["lung", "ORGAN", 138, 142], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa infection", "PROBLEM", 0, 23], ["morbidity", "PROBLEM", 46, 55], ["affected individuals", "PROBLEM", 79, 99], ["acute pneumonia", "PROBLEM", 111, 126], ["chronic lung disease", "PROBLEM", 130, 150], ["periodic acute exacerbations", "PROBLEM", 156, 184], ["aeruginosa", "OBSERVATION_MODIFIER", 3, 13], ["infection", "OBSERVATION", 14, 23], ["morbidity", "OBSERVATION", 46, 55], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["pneumonia", "OBSERVATION", 117, 126], ["chronic", "OBSERVATION_MODIFIER", 130, 137], ["lung", "ANATOMY", 138, 142], ["disease", "OBSERVATION", 143, 150], ["periodic", "OBSERVATION_MODIFIER", 156, 164], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["exacerbations", "OBSERVATION", 171, 184]]], ["A predisposition to chronic and progressive P. aeruginosa infection occurs despite the finding that both CF and non-CF lung epithelial cells express functional TLRs that can mediate inflammatory responses to microbes.", [["CF", "ANATOMY", 105, 107], ["non-CF lung epithelial cells", "ANATOMY", 112, 140], ["P. aeruginosa infection", "DISEASE", 44, 67], ["P. aeruginosa", "ORGANISM", 44, 57], ["non-CF lung epithelial cells", "CELL", 112, 140], ["TLRs", "GENE_OR_GENE_PRODUCT", 160, 164], ["non-CF lung epithelial cells", "CELL_TYPE", 112, 140], ["TLRs", "PROTEIN", 160, 164], ["P. aeruginosa", "SPECIES", 44, 57], ["P. aeruginosa", "SPECIES", 44, 57], ["chronic and progressive P. aeruginosa infection", "PROBLEM", 20, 67], ["non-CF lung epithelial cells", "PROBLEM", 112, 140], ["functional TLRs", "PROBLEM", 149, 164], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["progressive", "OBSERVATION_MODIFIER", 32, 43], ["P.", "OBSERVATION_MODIFIER", 44, 46], ["aeruginosa", "OBSERVATION_MODIFIER", 47, 57], ["infection", "OBSERVATION", 58, 67], ["lung", "ANATOMY", 119, 123], ["epithelial cells", "OBSERVATION", 124, 140], ["inflammatory", "OBSERVATION_MODIFIER", 182, 194]]], ["For example, in one study comparing human CFTE29o (trachea; homozygous for the delta F508 CFTR mutation) and 16HBE14o (bronchial non-CF) cells, comparable mRNA and surface protein expression of TLR1-5 and TLR9 was observed [112] .", [["trachea", "ANATOMY", 51, 58], ["16HBE14o (bronchial non-CF) cells", "ANATOMY", 109, 142], ["surface", "ANATOMY", 164, 171], ["human", "ORGANISM", 36, 41], ["CFTE29o", "GENE_OR_GENE_PRODUCT", 42, 49], ["trachea", "MULTI-TISSUE_STRUCTURE", 51, 58], ["CFTR", "GENE_OR_GENE_PRODUCT", 90, 94], ["surface", "CELLULAR_COMPONENT", 164, 171], ["TLR1-5", "GENE_OR_GENE_PRODUCT", 194, 200], ["TLR9", "GENE_OR_GENE_PRODUCT", 205, 209], ["human CFTE29o", "PROTEIN", 36, 49], ["delta F508 CFTR", "PROTEIN", 79, 94], ["16HBE14o (bronchial non-CF) cells", "CELL_LINE", 109, 142], ["mRNA", "RNA", 155, 159], ["TLR1", "PROTEIN", 194, 198], ["TLR9", "PROTEIN", 205, 209], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["one study", "TEST", 16, 25], ["the delta F508 CFTR mutation", "TEST", 75, 103], ["16HBE14o (bronchial non-CF) cells", "PROBLEM", 109, 142], ["mRNA", "TEST", 155, 159], ["surface protein expression", "TEST", 164, 190], ["TLR1", "TEST", 194, 198], ["TLR9", "TEST", 205, 209], ["trachea", "ANATOMY", 51, 58], ["bronchial", "ANATOMY", 119, 128]]], ["TLR6 mRNA, but not protein, expression was observed in both cell lines; however, for unclear reasons only the CF line responded to TLR2/TLR6 agonist MALP-2 [112] .", [["cell lines", "ANATOMY", 60, 70], ["CF line", "ANATOMY", 110, 117], ["MALP-2 [112", "CHEMICAL", 149, 160], ["TLR6", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell lines", "CELL", 60, 70], ["CF line", "CELL", 110, 117], ["TLR2", "GENE_OR_GENE_PRODUCT", 131, 135], ["TLR6", "GENE_OR_GENE_PRODUCT", 136, 140], ["MALP-2", "GENE_OR_GENE_PRODUCT", 149, 155], ["TLR6 mRNA", "RNA", 0, 9], ["cell lines", "CELL_LINE", 60, 70], ["CF line", "CELL_LINE", 110, 117], ["TLR2", "PROTEIN", 131, 135], ["TLR6", "PROTEIN", 136, 140], ["TLR6 mRNA", "TEST", 0, 9], ["the CF line", "TREATMENT", 106, 117], ["TLR2/TLR6 agonist", "TREATMENT", 131, 148], ["MALP", "TEST", 149, 153], ["cell lines", "OBSERVATION", 60, 70]]], ["Despite this similar TLR expression pattern, a more recent study showed increased inflammatory responses following stimulation with clinical Pseudomonas isolates in a CF airway epithelial cell line (IB3-1) compared to a \"CF-corrected\" line stably expressing wild type CFTR [113] .", [["CF airway epithelial cell line", "ANATOMY", 167, 197], ["IB3-1", "ANATOMY", 199, 204], ["TLR", "GENE_OR_GENE_PRODUCT", 21, 24], ["CF airway epithelial cell line", "CELL", 167, 197], ["IB3-1", "CELL", 199, 204], ["CFTR", "GENE_OR_GENE_PRODUCT", 268, 272], ["TLR", "PROTEIN", 21, 24], ["CF airway epithelial cell line", "CELL_LINE", 167, 197], ["IB3-1", "CELL_LINE", 199, 204], ["CF-corrected\" line", "CELL_LINE", 221, 239], ["CFTR", "PROTEIN", 268, 272], ["a more recent study", "TEST", 45, 64], ["increased inflammatory responses", "PROBLEM", 72, 104], ["clinical Pseudomonas isolates", "PROBLEM", 132, 161], ["a CF airway epithelial cell line", "TREATMENT", 165, 197], ["IB3", "TEST", 199, 202], ["a \"CF-corrected\" line", "TREATMENT", 218, 239], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["inflammatory", "OBSERVATION", 82, 94], ["airway", "ANATOMY", 170, 176], ["epithelial cell line", "OBSERVATION", 177, 197]]], ["A detailed analysis showed that these responses were dependent on bacterial flagellin and TLR5 expression.", [["flagellin", "GENE_OR_GENE_PRODUCT", 76, 85], ["TLR5", "GENE_OR_GENE_PRODUCT", 90, 94], ["flagellin", "PROTEIN", 76, 85], ["TLR5", "PROTEIN", 90, 94], ["A detailed analysis", "TEST", 0, 19], ["bacterial flagellin", "TREATMENT", 66, 85], ["bacterial flagellin", "OBSERVATION", 66, 85], ["TLR5 expression", "OBSERVATION", 90, 105]]], ["Peripheral blood mononuclear cells from CF patients also responded more vigorously to stimulation with P. aeruginosa and TLR ligands compared to healthy controls and expressed higher levels of TLR5 mRNA, suggesting that CFTR mutations modulate the host inflammatory response through undetermined mechanisms [113] .", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["patients", "ORGANISM", 43, 51], ["P. aeruginosa", "ORGANISM", 103, 116], ["TLR", "GENE_OR_GENE_PRODUCT", 121, 124], ["TLR5", "GENE_OR_GENE_PRODUCT", 193, 197], ["CFTR", "GENE_OR_GENE_PRODUCT", 220, 224], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["TLR", "PROTEIN", 121, 124], ["TLR5 mRNA", "RNA", 193, 202], ["CFTR", "PROTEIN", 220, 224], ["patients", "SPECIES", 43, 51], ["P. aeruginosa", "SPECIES", 103, 116], ["P. aeruginosa", "SPECIES", 103, 116], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["P. aeruginosa and TLR ligands", "PROBLEM", 103, 132], ["TLR5 mRNA", "PROBLEM", 193, 202], ["CFTR mutations", "PROBLEM", 220, 234], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["TLR5 mRNA", "OBSERVATION", 193, 202]]], ["In another study, a selective increase in TLR5 expression was found on airway, but not circulating, neutrophils from CF patients compared to patients with bronchiectasis and healthy control subjects [38] .", [["airway", "ANATOMY", 71, 77], ["neutrophils", "ANATOMY", 100, 111], ["bronchiectasis", "DISEASE", 155, 169], ["TLR5", "GENE_OR_GENE_PRODUCT", 42, 46], ["airway", "MULTI-TISSUE_STRUCTURE", 71, 77], ["neutrophils", "CELL", 100, 111], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 141, 149], ["TLR5", "PROTEIN", 42, 46], ["neutrophils", "CELL_TYPE", 100, 111], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 141, 149], ["another study", "TEST", 3, 16], ["a selective increase in TLR5 expression", "TREATMENT", 18, 57], ["airway", "TEST", 71, 77], ["bronchiectasis", "PROBLEM", 155, 169], ["selective", "OBSERVATION_MODIFIER", 20, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["TLR5 expression", "OBSERVATION", 42, 57], ["airway", "ANATOMY", 71, 77], ["bronchiectasis", "OBSERVATION", 155, 169]]], ["The functional relevance of neutrophil TLR5 expression was reflected by its correlation with lung function values in P. aeruginosa-infected CF patients.", [["neutrophil", "ANATOMY", 28, 38], ["lung", "ANATOMY", 93, 97], ["P. aeruginosa-infected CF", "DISEASE", 117, 142], ["neutrophil", "CELL", 28, 38], ["TLR5", "GENE_OR_GENE_PRODUCT", 39, 43], ["lung", "ORGAN", 93, 97], ["P. aeruginosa", "ORGANISM", 117, 130], ["CF", "ORGANISM", 140, 142], ["patients", "ORGANISM", 143, 151], ["neutrophil", "CELL_TYPE", 28, 38], ["TLR5", "PROTEIN", 39, 43], ["P. aeruginosa", "SPECIES", 117, 130], ["patients", "SPECIES", 143, 151], ["P. aeruginosa", "SPECIES", 117, 130], ["neutrophil TLR5 expression", "TREATMENT", 28, 54], ["lung function values", "TEST", 93, 113], ["P. aeruginosa", "PROBLEM", 117, 130], ["neutrophil TLR5", "OBSERVATION", 28, 43], ["lung", "ANATOMY", 93, 97]]], ["Neutrophils also had increased flagellin dependent IL-8 secretion, phagocytosis, and respiratory burst activity that were attributed to chronic infection rather than as a primary consequence of mutant CFTR [38] .", [["Neutrophils", "ANATOMY", 0, 11], ["infection", "DISEASE", 144, 153], ["Neutrophils", "CELL", 0, 11], ["flagellin", "GENE_OR_GENE_PRODUCT", 31, 40], ["IL-8", "GENE_OR_GENE_PRODUCT", 51, 55], ["CFTR", "GENE_OR_GENE_PRODUCT", 201, 205], ["Neutrophils", "CELL_TYPE", 0, 11], ["flagellin", "PROTEIN", 31, 40], ["IL-8", "PROTEIN", 51, 55], ["mutant CFTR", "PROTEIN", 194, 205], ["Neutrophils", "TEST", 0, 11], ["increased flagellin dependent IL", "PROBLEM", 21, 53], ["phagocytosis", "PROBLEM", 67, 79], ["respiratory burst activity", "PROBLEM", 85, 111], ["chronic infection", "PROBLEM", 136, 153], ["mutant CFTR", "PROBLEM", 194, 205], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["flagellin dependent", "OBSERVATION_MODIFIER", 31, 50], ["respiratory burst activity", "OBSERVATION", 85, 111], ["attributed to", "UNCERTAINTY", 122, 135], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["infection", "OBSERVATION", 144, 153]]], ["TLR5-deficient mice showed impaired bacterial clearance, reduced airway neutrophil recruitment and MCP-1 production after low dose challenge with flagellated P. aeruginosa that was not observed after challenge with an isotypic non-flagellated strain, confirming a specific contribution of TLR5-dependent pathways to the host inflammatory response [114] .Cystic Fibrosis (CF)In addition to TLR5-dependent recognition of flagellin, P. aeruginosa LPS is detected by TLR4 and the P. aeruginosa ExoS toxin is recognized by both TLR2 and TLR4 [11, [115] [116] [117] .", [["airway neutrophil", "ANATOMY", 65, 82], ["Cystic Fibrosis", "DISEASE", 354, 369], ["CF", "DISEASE", 371, 373], ["LPS", "CHEMICAL", 444, 447], ["TLR5", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 15, 19], ["airway neutrophil", "CELL", 65, 82], ["MCP-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["P. aeruginosa", "ORGANISM", 158, 171], ["TLR5", "GENE_OR_GENE_PRODUCT", 289, 293], ["TLR5", "GENE_OR_GENE_PRODUCT", 389, 393], ["flagellin", "GENE_OR_GENE_PRODUCT", 419, 428], ["P. aeruginosa", "ORGANISM", 430, 443], ["LPS", "GENE_OR_GENE_PRODUCT", 444, 447], ["TLR4", "GENE_OR_GENE_PRODUCT", 463, 467], ["P. aeruginosa", "ORGANISM", 476, 489], ["ExoS", "GENE_OR_GENE_PRODUCT", 490, 494], ["TLR2", "GENE_OR_GENE_PRODUCT", 523, 527], ["TLR4", "GENE_OR_GENE_PRODUCT", 532, 536], ["TLR5", "PROTEIN", 0, 4], ["MCP", "PROTEIN", 99, 102], ["TLR5", "PROTEIN", 289, 293], ["TLR5", "PROTEIN", 389, 393], ["flagellin", "PROTEIN", 419, 428], ["TLR4", "PROTEIN", 463, 467], ["P. aeruginosa ExoS toxin", "PROTEIN", 476, 500], ["TLR2", "PROTEIN", 523, 527], ["TLR4", "PROTEIN", 532, 536], ["mice", "SPECIES", 15, 19], ["P. aeruginosa", "SPECIES", 158, 171], ["P. aeruginosa", "SPECIES", 430, 443], ["P. aeruginosa", "SPECIES", 476, 489], ["mice", "SPECIES", 15, 19], ["P. aeruginosa", "SPECIES", 158, 171], ["P. aeruginosa", "SPECIES", 430, 443], ["P. aeruginosa", "SPECIES", 476, 489], ["TLR5", "TEST", 0, 4], ["impaired bacterial clearance", "PROBLEM", 27, 55], ["reduced airway neutrophil recruitment", "PROBLEM", 57, 94], ["MCP", "TEST", 99, 102], ["low dose challenge", "TREATMENT", 122, 140], ["flagellated P. aeruginosa", "PROBLEM", 146, 171], ["an isotypic non-flagellated strain", "PROBLEM", 215, 249], ["Cystic Fibrosis (CF", "PROBLEM", 354, 373], ["TLR5-dependent recognition of flagellin", "TREATMENT", 389, 428], ["P. aeruginosa LPS", "TEST", 430, 447], ["TLR4", "TEST", 463, 467], ["the P. aeruginosa ExoS toxin", "TEST", 472, 500], ["TLR4", "TEST", 532, 536], ["impaired", "OBSERVATION_MODIFIER", 27, 35], ["bacterial clearance", "OBSERVATION", 36, 55], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["airway neutrophil recruitment", "OBSERVATION", 65, 94], ["Fibrosis", "OBSERVATION", 361, 369]]], ["Loss of a single TLR does not confer susceptibility to P. aeruginosa infection while deletion of the adaptor molecule MyD88 does confer hypersusceptibility, increased lung bacterial load, and deficient neutrophil recruitment [114, [117] [118] [119] [120] [121] [122] [123] .", [["lung", "ANATOMY", 167, 171], ["neutrophil", "ANATOMY", 202, 212], ["P. aeruginosa infection", "DISEASE", 55, 78], ["TLR", "GENE_OR_GENE_PRODUCT", 17, 20], ["P. aeruginosa", "ORGANISM", 55, 68], ["MyD88", "GENE_OR_GENE_PRODUCT", 118, 123], ["lung", "ORGAN", 167, 171], ["neutrophil", "CELL", 202, 212], ["TLR", "PROTEIN", 17, 20], ["adaptor molecule", "PROTEIN", 101, 117], ["MyD88", "PROTEIN", 118, 123], ["neutrophil", "CELL_TYPE", 202, 212], ["P. aeruginosa", "SPECIES", 55, 68], ["P. aeruginosa", "SPECIES", 55, 68], ["P. aeruginosa infection", "PROBLEM", 55, 78], ["hypersusceptibility", "PROBLEM", 136, 155], ["increased lung bacterial load", "PROBLEM", 157, 186], ["neutrophil recruitment", "TEST", 202, 224], ["increased", "OBSERVATION_MODIFIER", 157, 166], ["lung", "ANATOMY", 167, 171], ["bacterial load", "OBSERVATION", 172, 186]]], ["Interestingly, MyD88 may play an essential role only during the early phase of infection (4-8 hours) as inflammation and control of bacterial load 48 hours after low dose infection occurred through an undetermined MyD88-independent mechanism [119] .", [["infection", "DISEASE", 79, 88], ["inflammation", "DISEASE", 104, 116], ["infection", "DISEASE", 171, 180], ["MyD88", "GENE_OR_GENE_PRODUCT", 15, 20], ["MyD88", "GENE_OR_GENE_PRODUCT", 214, 219], ["MyD88", "PROTEIN", 15, 20], ["MyD88", "PROTEIN", 214, 219], ["infection", "PROBLEM", 79, 88], ["inflammation", "PROBLEM", 104, 116], ["bacterial load", "PROBLEM", 132, 146], ["low dose infection", "PROBLEM", 162, 180], ["infection", "OBSERVATION", 79, 88]]], ["Both TLR2 and TLR4 signal through MyD88-dependent and -independent pathways while TLR5 signals exclusively through MyD88.", [["TLR2", "GENE_OR_GENE_PRODUCT", 5, 9], ["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["MyD88", "GENE_OR_GENE_PRODUCT", 34, 39], ["TLR5", "GENE_OR_GENE_PRODUCT", 82, 86], ["MyD88", "GENE_OR_GENE_PRODUCT", 115, 120], ["TLR2", "PROTEIN", 5, 9], ["TLR4", "PROTEIN", 14, 18], ["MyD88", "PROTEIN", 34, 39], ["TLR5", "PROTEIN", 82, 86], ["MyD88", "PROTEIN", 115, 120], ["MyD88", "TEST", 34, 39], ["TLR2", "ANATOMY_MODIFIER", 5, 9], ["TLR4", "ANATOMY_MODIFIER", 14, 18]]], ["Studies to determine the relative contribution of TLR2, TLR4, and TLR5 have had conflicting results, possibly due to the complex pathogenesis of pseudomonal infection [123] [124] [125] .Cystic Fibrosis (CF)Staphylococcus aureus and Burkholderia cenocepacia have been associated with early and advanced CF lung disease, respectively [3] .", [["CF lung", "ANATOMY", 302, 309], ["pseudomonal infection", "DISEASE", 145, 166], ["Cystic Fibrosis (CF)Staphylococcus aureus", "DISEASE", 186, 227], ["CF lung disease", "DISEASE", 302, 317], ["TLR2", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLR4", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR5", "GENE_OR_GENE_PRODUCT", 66, 70], ["Staphylococcus aureus", "ORGANISM", 206, 227], ["Burkholderia cenocepacia", "ORGANISM", 232, 256], ["lung", "ORGAN", 305, 309], ["TLR2", "PROTEIN", 50, 54], ["TLR4", "PROTEIN", 56, 60], ["TLR5", "PROTEIN", 66, 70], ["Staphylococcus aureus", "SPECIES", 206, 227], ["Burkholderia cenocepacia", "SPECIES", 232, 256], ["Staphylococcus aureus", "SPECIES", 206, 227], ["Burkholderia cenocepacia", "SPECIES", 232, 256], ["Studies", "TEST", 0, 7], ["pseudomonal infection", "PROBLEM", 145, 166], ["Cystic Fibrosis", "PROBLEM", 186, 201], ["Staphylococcus aureus", "PROBLEM", 206, 227], ["Burkholderia cenocepacia", "PROBLEM", 232, 256], ["advanced CF lung disease", "PROBLEM", 293, 317], ["TLR2", "ANATOMY", 50, 54], ["pseudomonal", "OBSERVATION_MODIFIER", 145, 156], ["infection", "OBSERVATION", 157, 166], ["Fibrosis", "OBSERVATION", 193, 201], ["Staphylococcus aureus", "OBSERVATION", 206, 227], ["Burkholderia", "OBSERVATION_MODIFIER", 232, 244], ["cenocepacia", "OBSERVATION", 245, 256], ["advanced", "OBSERVATION_MODIFIER", 293, 301], ["lung", "ANATOMY", 305, 309], ["disease", "OBSERVATION", 310, 317]]], ["B. cenocepacia provokes lung epithelial damage and TNF-\u03b1 secretion that leads to severe pneumonia and sepsis in CF patients [126, 127] .", [["lung epithelial", "ANATOMY", 24, 39], ["pneumonia", "DISEASE", 88, 97], ["sepsis", "DISEASE", 102, 108], ["CF", "DISEASE", 112, 114], ["B. cenocepacia", "ORGANISM", 0, 14], ["lung epithelial", "TISSUE", 24, 39], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["patients", "ORGANISM", 115, 123], ["TNF", "PROTEIN", 51, 54], ["B. cenocepacia", "SPECIES", 0, 14], ["patients", "SPECIES", 115, 123], ["B. cenocepacia", "SPECIES", 0, 14], ["B. cenocepacia", "PROBLEM", 0, 14], ["lung epithelial damage", "PROBLEM", 24, 46], ["TNF", "PROBLEM", 51, 54], ["\u03b1 secretion", "PROBLEM", 55, 66], ["severe pneumonia", "PROBLEM", 81, 97], ["sepsis", "PROBLEM", 102, 108], ["cenocepacia", "OBSERVATION", 3, 14], ["lung", "ANATOMY", 24, 28], ["epithelial", "ANATOMY_MODIFIER", 29, 39], ["damage", "OBSERVATION", 40, 46], ["TNF", "OBSERVATION_MODIFIER", 51, 54], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["pneumonia", "OBSERVATION", 88, 97], ["sepsis", "OBSERVATION", 102, 108]]], ["Excess inflammation and mortality in B. cenocepacia infection occurred through flagellin-dependent activation of TLR5 and MyD88 [128, 129] .", [["inflammation", "DISEASE", 7, 19], ["infection", "DISEASE", 52, 61], ["B. cenocepacia", "ORGANISM", 37, 51], ["flagellin", "GENE_OR_GENE_PRODUCT", 79, 88], ["TLR5", "GENE_OR_GENE_PRODUCT", 113, 117], ["MyD88", "GENE_OR_GENE_PRODUCT", 122, 127], ["flagellin", "PROTEIN", 79, 88], ["TLR5", "PROTEIN", 113, 117], ["MyD88", "PROTEIN", 122, 127], ["B. cenocepacia", "SPECIES", 37, 51], ["B. cenocepacia", "SPECIES", 37, 51], ["Excess inflammation", "PROBLEM", 0, 19], ["mortality in B. cenocepacia infection", "PROBLEM", 24, 61], ["inflammation", "OBSERVATION", 7, 19], ["cenocepacia", "OBSERVATION_MODIFIER", 40, 51], ["infection", "OBSERVATION", 52, 61]]], ["Another study showed that, despite higher bacterial load, MyD88-deficient mice had less inflammation and decreased mortality compared to wild type mice infected with B. cenocepacia [130] .Chronic Obstructive Pulmonary Disease (COPD)COPD includes disorders of the respiratory system that are characterized by abnormal inflammation as well as expiratory airflow limitation that is not fully reversible.", [["Pulmonary", "ANATOMY", 208, 217], ["respiratory system", "ANATOMY", 263, 281], ["inflammation", "DISEASE", 88, 100], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 188, 225], ["COPD", "DISEASE", 227, 231], ["COPD", "DISEASE", 232, 236], ["disorders of the respiratory system", "DISEASE", 246, 281], ["abnormal inflammation", "DISEASE", 308, 329], ["MyD88", "GENE_OR_GENE_PRODUCT", 58, 63], ["mice", "ORGANISM", 74, 78], ["mice", "ORGANISM", 147, 151], ["B. cenocepacia", "ORGANISM", 166, 180], ["Pulmonary", "ORGAN", 208, 217], ["MyD88", "PROTEIN", 58, 63], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 147, 151], ["B. cenocepacia", "SPECIES", 166, 180], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 147, 151], ["B. cenocepacia", "SPECIES", 166, 180], ["Another study", "TEST", 0, 13], ["higher bacterial load", "PROBLEM", 35, 56], ["MyD88", "TEST", 58, 63], ["less inflammation", "PROBLEM", 83, 100], ["decreased mortality", "PROBLEM", 105, 124], ["B. cenocepacia", "PROBLEM", 166, 180], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 188, 232], ["COPD", "PROBLEM", 232, 236], ["disorders of the respiratory system", "PROBLEM", 246, 281], ["abnormal inflammation", "PROBLEM", 308, 329], ["expiratory airflow limitation", "PROBLEM", 341, 370], ["bacterial load", "OBSERVATION", 42, 56], ["less", "OBSERVATION_MODIFIER", 83, 87], ["inflammation", "OBSERVATION", 88, 100], ["decreased", "OBSERVATION_MODIFIER", 105, 114], ["Obstructive", "OBSERVATION_MODIFIER", 196, 207], ["Pulmonary", "ANATOMY", 208, 217], ["Disease", "OBSERVATION", 218, 225], ["COPD", "OBSERVATION", 227, 231], ["COPD", "OBSERVATION", 232, 236], ["respiratory system", "ANATOMY", 263, 281], ["abnormal", "OBSERVATION_MODIFIER", 308, 316], ["inflammation", "OBSERVATION", 317, 329], ["expiratory airflow limitation", "OBSERVATION", 341, 370], ["not", "UNCERTAINTY", 379, 382], ["fully reversible", "OBSERVATION_MODIFIER", 383, 399]]], ["In humans, the main risk factor for COPD is smoking and the disease prevalence rises with age [131] .", [["COPD", "DISEASE", 36, 40], ["smoking", "CHEMICAL", 44, 51], ["humans", "ORGANISM", 3, 9], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["COPD", "PROBLEM", 36, 40], ["the disease prevalence rises", "PROBLEM", 56, 84], ["COPD", "OBSERVATION", 36, 40]]], ["Although the pathogenesis of COPD is not well understood, various aspects of lung innate immunity are impaired including mucociliary clearance, AM function, and expression of airway antimicrobial polypeptides [132] .", [["lung", "ANATOMY", 77, 81], ["mucociliary", "ANATOMY", 121, 132], ["airway", "ANATOMY", 175, 181], ["COPD", "DISEASE", 29, 33], ["lung", "ORGAN", 77, 81], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 121, 132], ["AM", "GENE_OR_GENE_PRODUCT", 144, 146], ["airway antimicrobial polypeptides", "GENE_OR_GENE_PRODUCT", 175, 208], ["COPD", "PROBLEM", 29, 33], ["mucociliary clearance", "TEST", 121, 142], ["airway antimicrobial polypeptides", "PROBLEM", 175, 208], ["COPD", "OBSERVATION", 29, 33], ["lung", "ANATOMY", 77, 81], ["airway", "ANATOMY", 175, 181]]], ["As a result, microbial pathogens frequently establish residence in the lower respiratory tract and induce a vicious circle of inflammation and infection that may contribute to progressive loss of lung function [133] (figure 1).Chronic Obstructive Pulmonary Disease (COPD)There is accumulating evidence that impaired innate immunity is likely to contribute to the pathogenesis of COPD [134] .", [["lower respiratory tract", "ANATOMY", 71, 94], ["lung", "ANATOMY", 196, 200], ["Pulmonary", "ANATOMY", 247, 256], ["inflammation", "DISEASE", 126, 138], ["infection", "DISEASE", 143, 152], ["loss of lung function", "DISEASE", 188, 209], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 227, 264], ["COPD", "DISEASE", 266, 270], ["COPD", "DISEASE", 379, 383], ["lower", "ORGANISM_SUBDIVISION", 71, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["lung", "ORGAN", 196, 200], ["Pulmonary", "ORGAN", 247, 256], ["microbial pathogens", "PROBLEM", 13, 32], ["the lower respiratory tract", "PROBLEM", 67, 94], ["inflammation", "PROBLEM", 126, 138], ["infection", "PROBLEM", 143, 152], ["progressive loss of lung function", "PROBLEM", 176, 209], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 227, 271], ["impaired innate immunity", "PROBLEM", 307, 331], ["COPD", "PROBLEM", 379, 383], ["lower", "ANATOMY_MODIFIER", 71, 76], ["respiratory tract", "ANATOMY", 77, 94], ["inflammation", "OBSERVATION", 126, 138], ["infection", "OBSERVATION", 143, 152], ["progressive", "OBSERVATION_MODIFIER", 176, 187], ["loss", "OBSERVATION_MODIFIER", 188, 192], ["lung", "ANATOMY", 196, 200], ["Obstructive", "OBSERVATION_MODIFIER", 235, 246], ["Pulmonary", "ANATOMY", 247, 256], ["Disease", "OBSERVATION", 257, 264], ["COPD", "OBSERVATION", 266, 270], ["impaired", "OBSERVATION_MODIFIER", 307, 315], ["innate immunity", "OBSERVATION", 316, 331], ["COPD", "OBSERVATION", 379, 383]]], ["An essential role for TLRs in the maintenance of lung structural homeostasis under ambient conditions was recently described [135] .", [["lung", "ANATOMY", 49, 53], ["TLRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["lung", "ORGAN", 49, 53], ["TLRs", "PROTEIN", 22, 26], ["TLRs", "TREATMENT", 22, 26], ["lung", "ANATOMY", 49, 53], ["structural homeostasis", "OBSERVATION", 54, 76]]], ["In this study, TLR4-and MyD88-deficient mice developed spontaneous age-related emphysema that was associated with increased oxidant stress, cell death, and elastolytic activity.", [["cell", "ANATOMY", 140, 144], ["emphysema", "DISEASE", 79, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 15, 19], ["MyD88", "GENE_OR_GENE_PRODUCT", 24, 29], ["mice", "ORGANISM", 40, 44], ["emphysema", "PATHOLOGICAL_FORMATION", 79, 88], ["cell", "CELL", 140, 144], ["TLR4", "PROTEIN", 15, 19], ["MyD88", "PROTEIN", 24, 29], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["this study", "TEST", 3, 13], ["TLR4", "TEST", 15, 19], ["related emphysema", "PROBLEM", 71, 88], ["increased oxidant stress", "PROBLEM", 114, 138], ["cell death", "PROBLEM", 140, 150], ["elastolytic activity", "PROBLEM", 156, 176], ["emphysema", "OBSERVATION", 79, 88], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["oxidant stress", "OBSERVATION", 124, 138], ["cell death", "OBSERVATION", 140, 150], ["elastolytic", "OBSERVATION_MODIFIER", 156, 167], ["activity", "OBSERVATION_MODIFIER", 168, 176]]], ["A detailed mechanistic analysis showed that TLR4 maintains a critical oxidant/antioxidant balance in the lung by modulating the expression and activity of NADPH oxidase 3 in structural cells.", [["lung", "ANATOMY", 105, 109], ["cells", "ANATOMY", 185, 190], ["NADPH", "CHEMICAL", 155, 160], ["NADPH", "CHEMICAL", 155, 160], ["TLR4", "GENE_OR_GENE_PRODUCT", 44, 48], ["lung", "ORGAN", 105, 109], ["NADPH oxidase 3", "GENE_OR_GENE_PRODUCT", 155, 170], ["cells", "CELL", 185, 190], ["TLR4", "PROTEIN", 44, 48], ["NADPH oxidase 3", "PROTEIN", 155, 170], ["structural cells", "CELL_TYPE", 174, 190], ["A detailed mechanistic analysis", "TEST", 0, 31], ["TLR4", "PROBLEM", 44, 48], ["NADPH oxidase", "TREATMENT", 155, 168], ["antioxidant balance", "OBSERVATION", 78, 97], ["lung", "ANATOMY", 105, 109], ["structural cells", "OBSERVATION", 174, 190]]], ["In light of this finding, the free radicals and oxidant properties of tobacco smoke have been hypothesized to subvert innate immunity and cause lung cell necrosis and tissue damage [136, 137] .", [["lung cell", "ANATOMY", 144, 153], ["tissue", "ANATOMY", 167, 173], ["lung cell necrosis", "DISEASE", 144, 162], ["tissue damage", "DISEASE", 167, 180], ["tobacco", "ORGANISM", 70, 77], ["lung cell", "CELL", 144, 153], ["tissue", "TISSUE", 167, 173], ["tobacco", "SPECIES", 70, 77], ["tobacco", "SPECIES", 70, 77], ["lung cell necrosis", "PROBLEM", 144, 162], ["tissue damage", "PROBLEM", 167, 180], ["lung", "ANATOMY", 144, 148], ["cell necrosis", "OBSERVATION", 149, 162]]], ["Indeed, mice with short-term cigarette smoke exposure develop neutrophilic airway inflammation that is dependent on TLR4, MyD88, and IL-1R1 signaling [138] .", [["airway", "ANATOMY", 75, 81], ["smoke", "CHEMICAL", 39, 44], ["airway inflammation", "DISEASE", 75, 94], ["mice", "ORGANISM", 8, 12], ["cigarette", "ORGANISM", 29, 38], ["neutrophilic airway", "PATHOLOGICAL_FORMATION", 62, 81], ["TLR4", "GENE_OR_GENE_PRODUCT", 116, 120], ["MyD88", "GENE_OR_GENE_PRODUCT", 122, 127], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 133, 139], ["TLR4", "PROTEIN", 116, 120], ["MyD88", "PROTEIN", 122, 127], ["1R1", "PROTEIN", 136, 139], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["neutrophilic airway inflammation", "PROBLEM", 62, 94], ["TLR4", "TEST", 116, 120], ["MyD88", "TEST", 122, 127], ["IL", "TEST", 133, 135], ["neutrophilic airway inflammation", "OBSERVATION", 62, 94], ["dependent", "OBSERVATION_MODIFIER", 103, 112]]], ["Consistent with these findings, C3H/HeJ mice that have naturally defective TLR4 signaling develop less chronic inflammation after 5 weeks of cigarette smoke exposure [139] .", [["inflammation", "DISEASE", 111, 123], ["smoke", "CHEMICAL", 151, 156], ["C3H/HeJ mice", "ORGANISM", 32, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 75, 79], ["TLR4", "PROTEIN", 75, 79], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["C3H/HeJ mice", "TREATMENT", 32, 44], ["naturally defective TLR4 signaling", "PROBLEM", 55, 89], ["less chronic inflammation", "PROBLEM", 98, 123], ["less", "OBSERVATION_MODIFIER", 98, 102], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["inflammation", "OBSERVATION", 111, 123]]], ["Finally, long-term cigarette smoke exposure induced strain-dependent emphysema in mice in one study, although no specific association to TLRs was described [140] .Chronic Obstructive Pulmonary Disease (COPD)Several studies have evaluated TLR expression and function in AMs from COPD patients, smokers, and non-smokers.", [["Pulmonary", "ANATOMY", 183, 192], ["AMs", "ANATOMY", 269, 272], ["smoke", "CHEMICAL", 29, 34], ["emphysema", "DISEASE", 69, 78], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 163, 200], ["COPD", "DISEASE", 202, 206], ["COPD", "DISEASE", 278, 282], ["cigarette", "ORGANISM", 19, 28], ["emphysema", "PATHOLOGICAL_FORMATION", 69, 78], ["mice", "ORGANISM", 82, 86], ["TLRs", "GENE_OR_GENE_PRODUCT", 137, 141], ["Pulmonary", "ORGAN", 183, 192], ["TLR", "GENE_OR_GENE_PRODUCT", 238, 241], ["AMs", "CELL", 269, 272], ["patients", "ORGANISM", 283, 291], ["TLRs", "PROTEIN", 137, 141], ["TLR", "PROTEIN", 238, 241], ["AMs", "CELL_TYPE", 269, 272], ["mice", "SPECIES", 82, 86], ["patients", "SPECIES", 283, 291], ["mice", "SPECIES", 82, 86], ["dependent emphysema", "PROBLEM", 59, 78], ["one study", "TEST", 90, 99], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 163, 207], ["Several studies", "TEST", 207, 222], ["COPD", "PROBLEM", 278, 282], ["long-term", "OBSERVATION_MODIFIER", 9, 18], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["emphysema", "OBSERVATION", 69, 78], ["Obstructive", "OBSERVATION_MODIFIER", 171, 182], ["Pulmonary", "ANATOMY", 183, 192], ["Disease", "OBSERVATION", 193, 200], ["COPD", "OBSERVATION", 202, 206]]], ["Using flow cytometry, one group showed reduced TLR2 expression on AMs of COPD patients and smokers compared to non-smokers following ex vivo ligand stimulation.", [["AMs", "ANATOMY", 66, 69], ["COPD", "DISEASE", 73, 77], ["TLR2", "GENE_OR_GENE_PRODUCT", 47, 51], ["AMs", "CELL", 66, 69], ["patients", "ORGANISM", 78, 86], ["TLR2", "PROTEIN", 47, 51], ["AMs", "CELL_TYPE", 66, 69], ["patients", "SPECIES", 78, 86], ["flow cytometry", "TEST", 6, 20], ["reduced TLR2 expression", "PROBLEM", 39, 62], ["COPD", "PROBLEM", 73, 77], ["ex vivo ligand stimulation", "TREATMENT", 133, 159], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["TLR2 expression", "OBSERVATION", 47, 62], ["COPD", "OBSERVATION", 73, 77]]], ["Upregulation of TLR2 mRNA and protein expression was observed only in AMs from nonsmokers while no significant differences in TLR4 expression were demonstrated among these three groups [141] .", [["AMs", "ANATOMY", 70, 73], ["TLR2", "GENE_OR_GENE_PRODUCT", 16, 20], ["AMs", "CELL", 70, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 126, 130], ["TLR2 mRNA", "RNA", 16, 25], ["AMs", "CELL_TYPE", 70, 73], ["TLR4", "PROTEIN", 126, 130], ["TLR2 mRNA", "PROBLEM", 16, 25], ["protein expression", "PROBLEM", 30, 48], ["significant differences in TLR4 expression", "PROBLEM", 99, 141], ["TLR2 mRNA", "OBSERVATION", 16, 25], ["no", "UNCERTAINTY", 96, 98], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["TLR4 expression", "OBSERVATION", 126, 141]]], ["Another report showed comparable AM expression of TLR2, TLR4 or the co-receptors MD-2 or CD14 between smokers and non-smokers [142] , yet AM stimulation with TLR2 or TLR4 ligands elicited lower mRNA and protein expression of inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6) or chemokines (IL-8, RANTES) in smokers that was associated with suppressed IRAK-1 and p38 phosphorylation and impaired NF-B activation [142] .", [["AM", "GENE_OR_GENE_PRODUCT", 33, 35], ["TLR2", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLR4", "GENE_OR_GENE_PRODUCT", 56, 60], ["MD-2", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD14", "GENE_OR_GENE_PRODUCT", 89, 93], ["AM", "CELL", 138, 140], ["TLR2", "GENE_OR_GENE_PRODUCT", 158, 162], ["TLR4", "GENE_OR_GENE_PRODUCT", 166, 170], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 249, 254], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 256, 261], ["IL-6", "GENE_OR_GENE_PRODUCT", 263, 267], ["IL-8", "GENE_OR_GENE_PRODUCT", 284, 288], ["RANTES", "GENE_OR_GENE_PRODUCT", 290, 296], ["smokers", "ORGANISM", 301, 308], ["IRAK-1", "GENE_OR_GENE_PRODUCT", 345, 351], ["p38", "GENE_OR_GENE_PRODUCT", 356, 359], ["NF-B", "GENE_OR_GENE_PRODUCT", 389, 393], ["TLR2", "PROTEIN", 50, 54], ["TLR4", "PROTEIN", 56, 60], ["MD", "PROTEIN", 81, 83], ["CD14", "PROTEIN", 89, 93], ["TLR2", "PROTEIN", 158, 162], ["TLR4", "PROTEIN", 166, 170], ["inflammatory cytokines", "PROTEIN", 225, 247], ["TNF", "PROTEIN", 249, 252], ["IL-1\u03b2, IL-6", "PROTEIN", 256, 267], ["chemokines", "PROTEIN", 272, 282], ["IL-8", "PROTEIN", 284, 288], ["RANTES", "PROTEIN", 290, 296], ["IRAK", "PROTEIN", 345, 349], ["p38", "PROTEIN", 356, 359], ["NF-B", "PROTEIN", 389, 393], ["TLR2 or TLR4 ligands", "TREATMENT", 158, 178], ["lower mRNA", "PROBLEM", 188, 198], ["inflammatory cytokines", "PROBLEM", 225, 247], ["TNF", "TEST", 249, 252], ["IL", "TEST", 256, 258], ["IL", "TEST", 263, 265], ["chemokines (IL", "TREATMENT", 272, 286], ["IRAK", "TEST", 345, 349], ["p38 phosphorylation", "TEST", 356, 375], ["inflammatory", "OBSERVATION_MODIFIER", 225, 237]]], ["From this data, the authors concluded that chronic LPS exposure via cigarette smoking selectively reprograms AMs and alters the inflammatory response to TLR2 and TLR4 ligands [142] .", [["AMs", "ANATOMY", 109, 112], ["LPS", "CHEMICAL", 51, 54], ["smoking", "CHEMICAL", 78, 85], ["LPS", "SIMPLE_CHEMICAL", 51, 54], ["cigarette", "ORGANISM", 68, 77], ["AMs", "CELL", 109, 112], ["TLR2", "GENE_OR_GENE_PRODUCT", 153, 157], ["TLR4", "GENE_OR_GENE_PRODUCT", 162, 166], ["AMs", "CELL_TYPE", 109, 112], ["TLR2", "PROTEIN", 153, 157], ["TLR4", "PROTEIN", 162, 166], ["chronic LPS exposure", "PROBLEM", 43, 63], ["the inflammatory response", "PROBLEM", 124, 149], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["inflammatory", "OBSERVATION_MODIFIER", 128, 140]]], ["Finally, another study showed reduced TLR4 mRNA expression in nasal and tracheal epithelial cells of smokers compared to healthy nonsmoking control subjects with no differences in TLR2 expression [143] .", [["nasal", "ANATOMY", 62, 67], ["tracheal epithelial cells", "ANATOMY", 72, 97], ["TLR4", "GENE_OR_GENE_PRODUCT", 38, 42], ["nasal", "CELL", 62, 67], ["tracheal epithelial cells", "CELL", 72, 97], ["TLR2", "GENE_OR_GENE_PRODUCT", 180, 184], ["TLR4 mRNA", "RNA", 38, 47], ["nasal and tracheal epithelial cells", "CELL_TYPE", 62, 97], ["TLR2", "PROTEIN", 180, 184], ["another study", "TEST", 9, 22], ["reduced TLR4 mRNA expression in nasal and tracheal epithelial cells", "PROBLEM", 30, 97], ["reduced", "OBSERVATION_MODIFIER", 30, 37], ["TLR4 mRNA expression", "OBSERVATION", 38, 58], ["nasal", "ANATOMY", 62, 67], ["tracheal", "ANATOMY", 72, 80], ["epithelial cells", "OBSERVATION", 81, 97]]], ["Relative to non-smokers, patients with mild or moderate COPD showed increased expression of TLR4 and HBD-2, a TLR4 inducible antimicrobial peptide, while those with advanced COPD had a reduction in TLR4 and HBD-2 expression [143] .", [["COPD", "DISEASE", 56, 60], ["COPD", "DISEASE", 174, 178], ["patients", "ORGANISM", 25, 33], ["TLR4", "GENE_OR_GENE_PRODUCT", 92, 96], ["HBD-2", "GENE_OR_GENE_PRODUCT", 101, 106], ["TLR4", "GENE_OR_GENE_PRODUCT", 110, 114], ["TLR4", "GENE_OR_GENE_PRODUCT", 198, 202], ["HBD-2", "GENE_OR_GENE_PRODUCT", 207, 212], ["TLR4", "PROTEIN", 92, 96], ["HBD", "PROTEIN", 101, 104], ["TLR4", "PROTEIN", 110, 114], ["TLR4", "PROTEIN", 198, 202], ["HBD", "PROTEIN", 207, 210], ["patients", "SPECIES", 25, 33], ["mild or moderate COPD", "PROBLEM", 39, 60], ["increased expression of TLR4", "PROBLEM", 68, 96], ["HBD", "TEST", 101, 104], ["a TLR4 inducible antimicrobial peptide", "TREATMENT", 108, 146], ["advanced COPD", "PROBLEM", 165, 178], ["a reduction in TLR4", "PROBLEM", 183, 202], ["HBD", "TEST", 207, 210], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["moderate", "OBSERVATION_MODIFIER", 47, 55], ["COPD", "OBSERVATION", 56, 60], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["TLR4", "ANATOMY", 92, 96], ["COPD", "OBSERVATION", 174, 178], ["reduction", "OBSERVATION_MODIFIER", 185, 194]]], ["Modulation of TLR4 expression by cigarette smoke extract was studied in vitro and revealed a dose-dependent reduction in TLR4 mRNA and protein expression as well as reduced IL-8 secretion in the A549 alveolar epithelial cells [143] .", [["A549 alveolar epithelial cells", "ANATOMY", 195, 225], ["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["cigarette", "ORGANISM", 33, 42], ["TLR4", "GENE_OR_GENE_PRODUCT", 121, 125], ["IL-8", "GENE_OR_GENE_PRODUCT", 173, 177], ["A549 alveolar epithelial cells", "CELL", 195, 225], ["TLR4", "PROTEIN", 14, 18], ["TLR4 mRNA", "RNA", 121, 130], ["IL-8", "PROTEIN", 173, 177], ["A549 alveolar epithelial cells", "CELL_LINE", 195, 225], ["a dose-dependent reduction in TLR4 mRNA", "TREATMENT", 91, 130], ["protein expression", "TEST", 135, 153], ["reduced IL", "TEST", 165, 175], ["TLR4 expression", "OBSERVATION", 14, 29], ["TLR4 mRNA", "OBSERVATION", 121, 130], ["A549", "ANATOMY", 195, 199], ["alveolar", "ANATOMY_MODIFIER", 200, 208], ["epithelial cells", "OBSERVATION", 209, 225]]], ["Taken together, these findings point to dynamic regulation of airway epithelial and AM TLRs in response to diverse environmental stimuli.", [["airway epithelial", "ANATOMY", 62, 79], ["airway epithelial", "CELL", 62, 79], ["AM TLRs", "GENE_OR_GENE_PRODUCT", 84, 91], ["airway epithelial", "CELL_TYPE", 62, 79], ["AM TLRs", "PROTEIN", 84, 91], ["diverse environmental stimuli", "TEST", 107, 136], ["airway epithelial", "ANATOMY", 62, 79], ["diverse", "OBSERVATION_MODIFIER", 107, 114], ["environmental stimuli", "OBSERVATION", 115, 136]]], ["The differences in TLR expression across studies could be related to variable LPS content in tobacco smoke, bacterial colonization, or a persistent inflammatory state.", [["LPS", "CHEMICAL", 78, 81], ["TLR", "GENE_OR_GENE_PRODUCT", 19, 22], ["LPS", "SIMPLE_CHEMICAL", 78, 81], ["tobacco", "ORGANISM", 93, 100], ["TLR", "PROTEIN", 19, 22], ["tobacco", "SPECIES", 93, 100], ["variable LPS content", "PROBLEM", 69, 89], ["bacterial colonization", "PROBLEM", 108, 130], ["a persistent inflammatory state", "PROBLEM", 135, 166], ["could be related to", "UNCERTAINTY", 49, 68], ["variable", "OBSERVATION_MODIFIER", 69, 77], ["LPS content", "OBSERVATION", 78, 89], ["tobacco smoke", "OBSERVATION", 93, 106], ["bacterial colonization", "OBSERVATION", 108, 130], ["persistent", "OBSERVATION_MODIFIER", 137, 147], ["inflammatory", "OBSERVATION", 148, 160]]], ["Increased TLR4 expression in mild or moderate COPD may reflect a robust host response, while the decreased TLR4 expression level in association with severe COPD may reflect a loss of innate immunity or an adaptive regulatory response.Chronic Obstructive Pulmonary Disease (COPD)The interaction of cigarette smoke and PRR activation has been studied using mouse models.", [["Pulmonary", "ANATOMY", 254, 263], ["COPD", "DISEASE", 46, 50], ["COPD", "DISEASE", 156, 160], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 234, 271], ["COPD", "DISEASE", 273, 277], ["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["TLR4", "GENE_OR_GENE_PRODUCT", 107, 111], ["Pulmonary", "ORGAN", 254, 263], ["cigarette", "ORGANISM", 297, 306], ["PRR", "GENE_OR_GENE_PRODUCT", 317, 320], ["mouse", "ORGANISM", 355, 360], ["TLR4", "PROTEIN", 10, 14], ["TLR4", "PROTEIN", 107, 111], ["PRR", "PROTEIN", 317, 320], ["mouse", "SPECIES", 355, 360], ["mouse", "SPECIES", 355, 360], ["Increased TLR4 expression", "PROBLEM", 0, 25], ["mild or moderate COPD", "PROBLEM", 29, 50], ["the decreased TLR4 expression level", "PROBLEM", 93, 128], ["severe COPD", "PROBLEM", 149, 160], ["a loss of innate immunity", "PROBLEM", 173, 198], ["Chronic Obstructive Pulmonary Disease (COPD", "PROBLEM", 234, 277], ["PRR activation", "PROBLEM", 317, 331], ["TLR4 expression", "OBSERVATION", 10, 25], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["moderate", "OBSERVATION_MODIFIER", 37, 45], ["COPD", "OBSERVATION", 46, 50], ["robust", "OBSERVATION_MODIFIER", 65, 71], ["host response", "OBSERVATION", 72, 85], ["decreased", "OBSERVATION_MODIFIER", 97, 106], ["TLR4 expression", "OBSERVATION", 107, 122], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["COPD", "OBSERVATION", 156, 160], ["may reflect", "UNCERTAINTY", 161, 172], ["loss", "OBSERVATION_MODIFIER", 175, 179], ["Obstructive", "OBSERVATION_MODIFIER", 242, 253], ["Pulmonary", "ANATOMY", 254, 263], ["Disease", "OBSERVATION", 264, 271], ["COPD", "OBSERVATION", 273, 277]]], ["In one study, AMs from mice that had been exposed to cigarette smoke for eight weeks showed decreased cytokine (TNF-\u03b1, IL-6) and chemokine (RANTES) production following in vitro stimulation with double-stranded RNA, LPS, or NLR agonists [144] .", [["AMs", "ANATOMY", 14, 17], ["LPS", "CHEMICAL", 216, 219], ["AMs", "CELL", 14, 17], ["mice", "ORGANISM", 23, 27], ["cigarette", "ORGANISM", 53, 62], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["RANTES", "GENE_OR_GENE_PRODUCT", 140, 146], ["LPS", "SIMPLE_CHEMICAL", 216, 219], ["NLR", "GENE_OR_GENE_PRODUCT", 224, 227], ["AMs", "CELL_TYPE", 14, 17], ["cytokine", "PROTEIN", 102, 110], ["TNF", "PROTEIN", 112, 115], ["chemokine", "PROTEIN", 129, 138], ["RANTES", "PROTEIN", 140, 146], ["double-stranded RNA", "RNA", 195, 214], ["NLR", "PROTEIN", 224, 227], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["one study", "TEST", 3, 12], ["decreased cytokine", "PROBLEM", 92, 110], ["TNF", "TEST", 112, 115], ["IL", "TEST", 119, 121], ["chemokine (RANTES) production", "TREATMENT", 129, 158], ["vitro stimulation", "TREATMENT", 172, 189], ["double-stranded RNA", "TREATMENT", 195, 214], ["NLR agonists", "TEST", 224, 236]]], ["No alteration of TLR3 or TLR4 expression was observed; however, there was decreased nuclear translocation of the transcription factor NF-B.", [["nuclear", "ANATOMY", 84, 91], ["TLR3", "GENE_OR_GENE_PRODUCT", 17, 21], ["TLR4", "GENE_OR_GENE_PRODUCT", 25, 29], ["nuclear", "CELLULAR_COMPONENT", 84, 91], ["NF-B.", "GENE_OR_GENE_PRODUCT", 134, 139], ["TLR3", "PROTEIN", 17, 21], ["TLR4", "PROTEIN", 25, 29], ["transcription factor NF-B.", "PROTEIN", 113, 139], ["alteration of TLR3 or TLR4 expression", "PROBLEM", 3, 40], ["alteration", "OBSERVATION_MODIFIER", 3, 13], ["TLR3", "OBSERVATION_MODIFIER", 17, 21], ["TLR4 expression", "OBSERVATION", 25, 40], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["nuclear translocation", "OBSERVATION", 84, 105]]], ["The functional impairment of cytokine release was specific to AMs and reversible after cessation of smoke exposure [144] .", [["AMs", "ANATOMY", 62, 65], ["smoke", "CHEMICAL", 100, 105], ["AMs", "CELL", 62, 65], ["cytokine", "PROTEIN", 29, 37], ["AMs", "CELL_TYPE", 62, 65], ["The functional impairment of cytokine release", "PROBLEM", 0, 45]]], ["A subsequent report found a synergistic interaction of cigarette smoke and dsRNA or influenza virus that leads to emphysema in mice through epithelial and endothelial cell apoptosis as well as proteolysis [145] .", [["epithelial", "ANATOMY", 140, 150], ["endothelial cell", "ANATOMY", 155, 171], ["smoke", "CHEMICAL", 65, 70], ["influenza virus", "DISEASE", 84, 99], ["emphysema", "DISEASE", 114, 123], ["cigarette", "ORGANISM", 55, 64], ["influenza virus", "ORGANISM", 84, 99], ["emphysema", "PATHOLOGICAL_FORMATION", 114, 123], ["mice", "ORGANISM", 127, 131], ["epithelial", "CELL", 140, 150], ["endothelial cell", "CELL", 155, 171], ["mice", "SPECIES", 127, 131], ["influenza virus", "SPECIES", 84, 99], ["mice", "SPECIES", 127, 131], ["dsRNA", "PROBLEM", 75, 80], ["influenza virus", "PROBLEM", 84, 99], ["emphysema", "PROBLEM", 114, 123], ["epithelial and endothelial cell apoptosis", "PROBLEM", 140, 181], ["cigarette smoke", "OBSERVATION", 55, 70], ["influenza virus", "OBSERVATION", 84, 99], ["emphysema", "OBSERVATION", 114, 123], ["epithelial", "ANATOMY", 140, 150], ["endothelial cell apoptosis", "OBSERVATION", 155, 181]]], ["This process was mediated by IL-12, IL-18, and IFN-\u03b3 as well as activation of antiviral response pathways including the intracellular signaling adaptor protein IPS-1 and the kinase PKR.Chronic Obstructive Pulmonary Disease (COPD)Defective innate immunity may predispose to acute exacerbations of COPD that are characterized by acutely worsening dyspnea, cough, sputum production, and accelerated airflow obstruction [146] .", [["intracellular", "ANATOMY", 120, 133], ["Pulmonary", "ANATOMY", 205, 214], ["sputum", "ANATOMY", 361, 367], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 185, 222], ["COPD", "DISEASE", 224, 228], ["COPD", "DISEASE", 296, 300], ["dyspnea", "DISEASE", 345, 352], ["cough", "DISEASE", 354, 359], ["airflow obstruction", "DISEASE", 396, 415], ["IL-12", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-18", "GENE_OR_GENE_PRODUCT", 36, 41], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 47, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 133], ["IPS-1", "GENE_OR_GENE_PRODUCT", 160, 165], ["PKR", "GENE_OR_GENE_PRODUCT", 181, 184], ["Pulmonary", "ORGAN", 205, 214], ["IL-18", "PROTEIN", 36, 41], ["IFN", "PROTEIN", 47, 50], ["\u03b3", "PROTEIN", 51, 52], ["intracellular signaling adaptor protein IPS-1", "PROTEIN", 120, 165], ["kinase PKR", "PROTEIN", 174, 184], ["IL", "TEST", 29, 31], ["IL", "TEST", 36, 38], ["IFN", "TREATMENT", 47, 50], ["antiviral response pathways", "TREATMENT", 78, 105], ["the intracellular signaling adaptor protein IPS", "TEST", 116, 163], ["the kinase PKR", "TEST", 170, 184], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 185, 229], ["Defective innate immunity", "PROBLEM", 229, 254], ["acute exacerbations", "PROBLEM", 273, 292], ["COPD", "PROBLEM", 296, 300], ["acutely worsening dyspnea", "PROBLEM", 327, 352], ["cough", "PROBLEM", 354, 359], ["sputum production", "PROBLEM", 361, 378], ["accelerated airflow obstruction", "PROBLEM", 384, 415], ["Obstructive", "OBSERVATION_MODIFIER", 193, 204], ["Pulmonary", "ANATOMY", 205, 214], ["Disease", "OBSERVATION", 215, 222], ["COPD", "OBSERVATION", 224, 228], ["acute", "OBSERVATION_MODIFIER", 273, 278], ["exacerbations", "OBSERVATION", 279, 292], ["COPD", "OBSERVATION", 296, 300], ["acutely", "OBSERVATION_MODIFIER", 327, 334], ["worsening", "OBSERVATION_MODIFIER", 335, 344], ["dyspnea", "OBSERVATION", 345, 352], ["cough", "OBSERVATION", 354, 359], ["airflow obstruction", "OBSERVATION", 396, 415]]], ["Bacterial colonization (Streptococcus pneumoniae, Haemophilus influenzae) or viral infection (Influenza A and B, Respiratory Syncytial Virus) of the lower respiratory tract are primary causes of acute COPD exacerbations [146] [147] [148] [149] [150] [151] [152] .", [["lower respiratory tract", "ANATOMY", 149, 172], ["Streptococcus pneumoniae", "DISEASE", 24, 48], ["Haemophilus influenzae", "DISEASE", 50, 72], ["viral infection", "DISEASE", 77, 92], ["Influenza A and B", "DISEASE", 94, 111], ["Respiratory Syncytial Virus) of the lower respiratory tract", "DISEASE", 113, 172], ["COPD", "DISEASE", 201, 205], ["Streptococcus pneumoniae", "ORGANISM", 24, 48], ["Haemophilus influenzae", "ORGANISM", 50, 72], ["Influenza A and B", "ORGANISM", 94, 111], ["Respiratory Syncytial Virus", "ORGANISM", 113, 140], ["lower", "ORGANISM_SUBDIVISION", 149, 154], ["respiratory tract", "ORGANISM_SUBDIVISION", 155, 172], ["Streptococcus pneumoniae", "SPECIES", 24, 48], ["Haemophilus influenzae", "SPECIES", 50, 72], ["Streptococcus pneumoniae", "SPECIES", 24, 48], ["Haemophilus influenzae", "SPECIES", 50, 72], ["Influenza A", "SPECIES", 94, 105], ["Bacterial colonization", "PROBLEM", 0, 22], ["Streptococcus pneumoniae", "PROBLEM", 24, 48], ["Haemophilus influenzae", "PROBLEM", 50, 72], ["viral infection", "PROBLEM", 77, 92], ["Influenza A and B, Respiratory Syncytial Virus", "PROBLEM", 94, 140], ["the lower respiratory tract", "PROBLEM", 145, 172], ["acute COPD exacerbations", "PROBLEM", 195, 219], ["colonization", "OBSERVATION", 10, 22], ["Streptococcus pneumoniae", "OBSERVATION", 24, 48], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["Syncytial Virus", "OBSERVATION", 125, 140], ["lower", "ANATOMY_MODIFIER", 149, 154], ["respiratory tract", "ANATOMY", 155, 172], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["COPD", "OBSERVATION", 201, 205]]], ["Virulent pneumococci express the toxin pneumolysin that is able to physically interact with TLR4 [153] [154] [155] [156] [157] [158] [159] .", [["pneumolysin", "GENE_OR_GENE_PRODUCT", 39, 50], ["TLR4", "GENE_OR_GENE_PRODUCT", 92, 96], ["toxin pneumolysin", "PROTEIN", 33, 50], ["TLR4", "PROTEIN", 92, 96], ["Virulent pneumococci", "PROBLEM", 0, 20], ["the toxin pneumolysin", "PROBLEM", 29, 50], ["pneumococci", "OBSERVATION", 9, 20]]], ["Consistent with this finding, nasopharyngeal infection of TLR4-deficient mice with S. pneumoniae causes enhanced bacterial load, dissemination, and death compared to wild type mice [158] .", [["nasopharyngeal", "ANATOMY", 30, 44], ["nasopharyngeal infection", "DISEASE", 30, 54], ["death", "DISEASE", 148, 153], ["nasopharyngeal", "ORGAN", 30, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 58, 62], ["mice", "ORGANISM", 73, 77], ["S. pneumoniae", "ORGANISM", 83, 96], ["mice", "ORGANISM", 176, 180], ["TLR4", "PROTEIN", 58, 62], ["mice", "SPECIES", 73, 77], ["S. pneumoniae", "SPECIES", 83, 96], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 73, 77], ["S. pneumoniae", "SPECIES", 83, 96], ["mice", "SPECIES", 176, 180], ["nasopharyngeal infection of TLR4", "PROBLEM", 30, 62], ["S. pneumoniae", "PROBLEM", 83, 96], ["enhanced bacterial load", "PROBLEM", 104, 127], ["death", "PROBLEM", 148, 153], ["nasopharyngeal", "ANATOMY", 30, 44], ["infection", "OBSERVATION", 45, 54], ["pneumoniae", "OBSERVATION", 86, 96], ["enhanced", "OBSERVATION_MODIFIER", 104, 112], ["bacterial load", "OBSERVATION", 113, 127]]], ["Interestingly, the role of TLR4 seems to be specific to the nasopharynx as TLR4deficient mice exhibit only a modest impairment of host defense following direct pneumococcal infection of the lower respiratory tract [160] .", [["nasopharynx", "ANATOMY", 60, 71], ["lower respiratory tract", "ANATOMY", 190, 213], ["infection", "DISEASE", 173, 182], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["nasopharynx", "ORGAN", 60, 71], ["TLR4deficient mice", "ORGANISM", 75, 93], ["pneumococcal", "ORGANISM", 160, 172], ["TLR4", "PROTEIN", 27, 31], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["pneumococcal", "SPECIES", 160, 172], ["a modest impairment of host defense", "PROBLEM", 107, 142], ["direct pneumococcal infection of the lower respiratory tract", "PROBLEM", 153, 213], ["nasopharynx", "ANATOMY", 60, 71], ["modest", "OBSERVATION_MODIFIER", 109, 115], ["host defense", "OBSERVATION", 130, 142], ["pneumococcal", "OBSERVATION_MODIFIER", 160, 172], ["infection", "OBSERVATION", 173, 182], ["lower", "ANATOMY_MODIFIER", 190, 195], ["respiratory tract", "ANATOMY", 196, 213]]], ["TLR2 is also upregulated following pneumococcal infection and enhances host inflammatory responses [161, 162] .", [["pneumococcal infection", "DISEASE", 35, 57], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "PROTEIN", 0, 4], ["pneumococcal", "SPECIES", 35, 47], ["TLR2", "TREATMENT", 0, 4], ["pneumococcal infection", "PROBLEM", 35, 57], ["upregulated", "OBSERVATION_MODIFIER", 13, 24], ["pneumococcal", "OBSERVATION_MODIFIER", 35, 47], ["infection", "OBSERVATION", 48, 57], ["host", "OBSERVATION_MODIFIER", 71, 75], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["Despite a modest reduction of inflammatory mediator production, TLR2deficient mice can still clear high and low infectious doses of S. pneumoniae, suggesting that another PRR compensates for the loss of TLR2 in this model [160, 163] .", [["mice", "ORGANISM", 78, 82], ["S. pneumoniae", "ORGANISM", 132, 145], ["PRR", "GENE_OR_GENE_PRODUCT", 171, 174], ["TLR2", "GENE_OR_GENE_PRODUCT", 203, 207], ["PRR", "PROTEIN", 171, 174], ["TLR2", "PROTEIN", 203, 207], ["mice", "SPECIES", 78, 82], ["S. pneumoniae", "SPECIES", 132, 145], ["mice", "SPECIES", 78, 82], ["S. pneumoniae", "SPECIES", 132, 145], ["inflammatory mediator production", "PROBLEM", 30, 62], ["S. pneumoniae", "PROBLEM", 132, 145], ["another PRR compensates", "PROBLEM", 163, 186], ["the loss of TLR2", "PROBLEM", 191, 207], ["modest", "OBSERVATION_MODIFIER", 10, 16], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["inflammatory", "OBSERVATION_MODIFIER", 30, 42], ["low infectious", "OBSERVATION_MODIFIER", 108, 122], ["pneumoniae", "OBSERVATION", 135, 145]]], ["TLR9-deficient mice are slightly more susceptible to pneumococcal infection compared to wild type animals [164] .", [["pneumococcal infection", "DISEASE", 53, 75], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 15, 19], ["pneumococcal", "ORGANISM", 53, 65], ["TLR9", "PROTEIN", 0, 4], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["pneumococcal", "SPECIES", 53, 65], ["pneumococcal infection", "PROBLEM", 53, 75], ["slightly", "OBSERVATION_MODIFIER", 24, 32], ["more susceptible", "OBSERVATION_MODIFIER", 33, 49], ["pneumococcal", "OBSERVATION_MODIFIER", 53, 65], ["infection", "OBSERVATION", 66, 75]]], ["Conversely, abrogation of MyD88 signaling leads to uncontrolled airway pneumococcal growth, systemic bacterial dissemination and decreased immune mediator (TNF-\u03b1 and IL-6) expression [158, 165, 166] .", [["airway", "ANATOMY", 64, 70], ["MyD88", "GENE_OR_GENE_PRODUCT", 26, 31], ["airway", "MULTI-TISSUE_STRUCTURE", 64, 70], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["MyD88", "PROTEIN", 26, 31], ["TNF", "PROTEIN", 156, 159], ["pneumococcal", "SPECIES", 71, 83], ["uncontrolled airway pneumococcal growth", "PROBLEM", 51, 90], ["systemic bacterial dissemination", "PROBLEM", 92, 124], ["decreased immune mediator", "PROBLEM", 129, 154], ["TNF", "TEST", 156, 159], ["IL", "TEST", 166, 168], ["uncontrolled", "OBSERVATION_MODIFIER", 51, 63], ["airway", "ANATOMY", 64, 70], ["pneumococcal", "OBSERVATION_MODIFIER", 71, 83], ["growth", "OBSERVATION_MODIFIER", 84, 90], ["systemic", "OBSERVATION_MODIFIER", 92, 100], ["bacterial dissemination", "OBSERVATION", 101, 124], ["decreased", "OBSERVATION_MODIFIER", 129, 138]]], ["The severe susceptibility phenotype of MyD88-deficient mice compared to mice with a single deletion of TLR9 or combined deletion of TLR2 and TLR4 highlights the crucial role of this downstream adaptor in host defense against S. pneumoniae [158, 160, 163, 164, 167] .Chronic Obstructive Pulmonary Disease (COPD)Non-typeable H. influenzae (NTHi) is another bacterium that commonly colonizes the respiratory epithelium and causes COPD exacerbations [168] [169] [170] [171] .", [["Pulmonary", "ANATOMY", 286, 295], ["respiratory epithelium", "ANATOMY", 393, 415], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 266, 303], ["COPD", "DISEASE", 305, 309], ["COPD", "DISEASE", 427, 431], ["MyD88", "GENE_OR_GENE_PRODUCT", 39, 44], ["mice", "ORGANISM", 55, 59], ["mice", "ORGANISM", 72, 76], ["TLR9", "GENE_OR_GENE_PRODUCT", 103, 107], ["TLR2", "GENE_OR_GENE_PRODUCT", 132, 136], ["TLR4", "GENE_OR_GENE_PRODUCT", 141, 145], ["S. pneumoniae", "ORGANISM", 225, 238], ["Pulmonary", "ORGAN", 286, 295], ["H. influenzae", "ORGANISM", 323, 336], ["NTHi", "ORGANISM", 338, 342], ["respiratory epithelium", "TISSUE", 393, 415], ["MyD88", "PROTEIN", 39, 44], ["TLR9", "PROTEIN", 103, 107], ["TLR2", "PROTEIN", 132, 136], ["TLR4", "PROTEIN", 141, 145], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 72, 76], ["S. pneumoniae", "SPECIES", 225, 238], ["H. influenzae", "SPECIES", 323, 336], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 72, 76], ["S. pneumoniae", "SPECIES", 225, 238], ["H. influenzae", "SPECIES", 323, 336], ["The severe susceptibility phenotype of MyD88", "PROBLEM", 0, 44], ["a single deletion of TLR9", "TREATMENT", 82, 107], ["combined deletion of TLR2 and TLR4", "TREATMENT", 111, 145], ["S. pneumoniae", "PROBLEM", 225, 238], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 266, 310], ["Non-typeable H. influenzae (NTHi", "PROBLEM", 310, 342], ["another bacterium", "PROBLEM", 347, 364], ["the respiratory epithelium", "PROBLEM", 389, 415], ["COPD exacerbations", "PROBLEM", 427, 445], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["susceptibility", "OBSERVATION_MODIFIER", 11, 25], ["pneumoniae", "OBSERVATION", 228, 238], ["Obstructive", "OBSERVATION_MODIFIER", 274, 285], ["Pulmonary", "ANATOMY", 286, 295], ["Disease", "OBSERVATION", 296, 303], ["COPD", "OBSERVATION", 305, 309], ["respiratory epithelium", "OBSERVATION", 393, 415]]], ["While NTHi produces both TLR4 and TLR2 ligands, TLR4/MyD88 is the dominant immune signaling pathway in vitro and mediates bacterial clearance in vivo [172] .", [["NTHi", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR4", "GENE_OR_GENE_PRODUCT", 25, 29], ["TLR2", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLR4", "GENE_OR_GENE_PRODUCT", 48, 52], ["MyD88", "GENE_OR_GENE_PRODUCT", 53, 58], ["TLR4", "PROTEIN", 25, 29], ["TLR2", "PROTEIN", 34, 38], ["TLR4", "PROTEIN", 48, 52], ["MyD88", "PROTEIN", 53, 58], ["NTHi", "PROBLEM", 6, 10], ["TLR4/MyD88", "TREATMENT", 48, 58], ["bacterial clearance", "TEST", 122, 141], ["both", "ANATOMY_MODIFIER", 20, 24], ["TLR4", "ANATOMY_MODIFIER", 25, 29]]], ["TLR4 signaling in response to NTHi is entirely MyD88 dependent as TRIF KO mice had an identical bacterial load compared to wild type mice [172] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["NTHi", "GENE_OR_GENE_PRODUCT", 30, 34], ["MyD88", "GENE_OR_GENE_PRODUCT", 47, 52], ["TRIF", "GENE_OR_GENE_PRODUCT", 66, 70], ["mice", "ORGANISM", 74, 78], ["mice", "ORGANISM", 133, 137], ["TLR4", "PROTEIN", 0, 4], ["MyD88", "PROTEIN", 47, 52], ["TRIF", "PROTEIN", 66, 70], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 74, 78], ["TLR4 signaling", "PROBLEM", 0, 14], ["NTHi", "PROBLEM", 30, 34], ["MyD88 dependent", "PROBLEM", 47, 62], ["an identical bacterial load", "PROBLEM", 83, 110], ["bacterial load", "OBSERVATION", 96, 110]]], ["TLR3 may also play a role in inflammatory mediator production in the immune response to NTHi although its relative contribution to bacterial clearance is not clear [173] .AsthmaAsthma is a potentially life-threatening chronic inflammatory airway disease that is characterized by episodic bronchoconstriction, mucus hypersecretion, goblet cell hyperplasia and tissue remodelling that may begin in childhood.", [["airway", "ANATOMY", 239, 245], ["mucus", "ANATOMY", 309, 314], ["goblet cell", "ANATOMY", 331, 342], ["tissue", "ANATOMY", 359, 365], ["AsthmaAsthma", "DISEASE", 171, 183], ["airway disease", "DISEASE", 239, 253], ["mucus hypersecretion", "DISEASE", 309, 329], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["NTHi", "GENE_OR_GENE_PRODUCT", 88, 92], ["airway", "ORGAN", 239, 245], ["mucus", "ORGANISM_SUBSTANCE", 309, 314], ["goblet cell", "CELL", 331, 342], ["tissue", "TISSUE", 359, 365], ["TLR3", "PROTEIN", 0, 4], ["TLR3", "TREATMENT", 0, 4], ["inflammatory mediator production", "PROBLEM", 29, 61], ["NTHi", "PROBLEM", 88, 92], ["bacterial clearance", "PROBLEM", 131, 150], ["threatening chronic inflammatory airway disease", "PROBLEM", 206, 253], ["episodic bronchoconstriction", "PROBLEM", 279, 307], ["mucus hypersecretion", "PROBLEM", 309, 329], ["goblet cell hyperplasia", "PROBLEM", 331, 354], ["tissue remodelling", "PROBLEM", 359, 377], ["inflammatory", "OBSERVATION_MODIFIER", 29, 41], ["threatening", "OBSERVATION_MODIFIER", 206, 217], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["inflammatory airway disease", "OBSERVATION", 226, 253], ["episodic", "OBSERVATION_MODIFIER", 279, 287], ["bronchoconstriction", "OBSERVATION", 288, 307], ["mucus hypersecretion", "OBSERVATION", 309, 329], ["goblet cell hyperplasia", "OBSERVATION", 331, 354], ["tissue remodelling", "OBSERVATION", 359, 377]]], ["The underlying immune response in asthma is targeted against environmental antigens including pollen or dust particles and is characterized by the presence of antigen-specific Th2 cells in the lung that facilitate production of antigen specific IgE [174, 175] .", [["pollen", "ANATOMY", 94, 100], ["Th2 cells", "ANATOMY", 176, 185], ["lung", "ANATOMY", 193, 197], ["asthma", "DISEASE", 34, 40], ["pollen", "ORGANISM_SUBSTANCE", 94, 100], ["antigen", "GENE_OR_GENE_PRODUCT", 159, 166], ["Th2 cells", "CELL", 176, 185], ["lung", "ORGAN", 193, 197], ["IgE", "GENE_OR_GENE_PRODUCT", 245, 248], ["Th2 cells", "CELL_TYPE", 176, 185], ["IgE", "PROTEIN", 245, 248], ["asthma", "PROBLEM", 34, 40], ["environmental antigens", "PROBLEM", 61, 83], ["pollen or dust particles", "PROBLEM", 94, 118], ["antigen-specific Th2 cells in the lung", "PROBLEM", 159, 197], ["immune response", "OBSERVATION", 15, 30], ["asthma", "OBSERVATION", 34, 40], ["dust particles", "OBSERVATION", 104, 118], ["Th2 cells", "OBSERVATION", 176, 185], ["lung", "ANATOMY", 193, 197]]], ["Viral and bacterial infections have been associated with induction or protection against asthma, suggesting that innate immunity plays an important role in disease pathogenesis [176] .", [["Viral and bacterial infections", "DISEASE", 0, 30], ["asthma", "DISEASE", 89, 95], ["Viral", "ORGANISM", 0, 5], ["Viral and bacterial infections", "PROBLEM", 0, 30], ["protection", "TREATMENT", 70, 80], ["asthma", "PROBLEM", 89, 95], ["disease pathogenesis", "PROBLEM", 156, 176], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30]]], ["On the basis of several epidemiologic, human, and animal studies, the timing and extent of LPS exposure, and presumably TLR4 activation, appears to determine whether a protective Th1 response or a permissive Th2 response develops in the lung [177] .", [["lung", "ANATOMY", 237, 241], ["LPS", "CHEMICAL", 91, 94], ["human", "ORGANISM", 39, 44], ["LPS", "SIMPLE_CHEMICAL", 91, 94], ["TLR4", "GENE_OR_GENE_PRODUCT", 120, 124], ["lung", "ORGAN", 237, 241], ["TLR4", "PROTEIN", 120, 124], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["animal studies", "TEST", 50, 64], ["LPS exposure", "PROBLEM", 91, 103], ["TLR4 activation", "PROBLEM", 120, 135], ["a permissive Th2 response", "PROBLEM", 195, 220], ["LPS exposure", "OBSERVATION", 91, 103], ["TLR4 activation", "OBSERVATION", 120, 135], ["permissive", "OBSERVATION_MODIFIER", 197, 207], ["Th2 response", "OBSERVATION", 208, 220], ["lung", "ANATOMY", 237, 241]]], ["For example, it was demonstrated that low dose administration of intranasal LPS induces a Th2 biased immune response in the lung whereas elsewhere in the body LPS is a strong inducer of a Th1 immune response [178] .", [["lung", "ANATOMY", 124, 128], ["body", "ANATOMY", 154, 158], ["LPS", "CHEMICAL", 76, 79], ["LPS", "CHEMICAL", 159, 162], ["LPS", "SIMPLE_CHEMICAL", 76, 79], ["lung", "ORGAN", 124, 128], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["LPS", "SIMPLE_CHEMICAL", 159, 162], ["low dose administration", "TREATMENT", 38, 61], ["intranasal LPS", "TREATMENT", 65, 79], ["the body LPS", "TEST", 150, 162], ["low dose", "OBSERVATION_MODIFIER", 38, 46], ["lung", "ANATOMY", 124, 128], ["body LPS", "ANATOMY", 154, 162]]], ["Nevertheless, experimental treatment of mice with microbes [179] or TLR agonists [180, 181] inhibits allergic sensitization, eosinophilic inflammation, and airways hyperresponsiveness.", [["eosinophilic", "ANATOMY", 125, 137], ["airways", "ANATOMY", 156, 163], ["[180, 181]", "CHEMICAL", 81, 91], ["allergic sensitization", "DISEASE", 101, 123], ["eosinophilic inflammation", "DISEASE", 125, 150], ["airways hyperresponsiveness", "DISEASE", 156, 183], ["mice", "ORGANISM", 40, 44], ["TLR", "GENE_OR_GENE_PRODUCT", 68, 71], ["airways", "MULTI-TISSUE_STRUCTURE", 156, 163], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["TLR agonists", "TEST", 68, 80], ["allergic sensitization", "PROBLEM", 101, 123], ["eosinophilic inflammation", "PROBLEM", 125, 150], ["airways hyperresponsiveness", "PROBLEM", 156, 183], ["eosinophilic inflammation", "OBSERVATION", 125, 150], ["airways", "ANATOMY", 156, 163], ["hyperresponsiveness", "OBSERVATION", 164, 183]]], ["Recently, experimental intranasal infection of pregnant mice with Acinetobacter lwoffii F78 was shown to confer protection against ovalbumin-induced asthma in the progeny.", [["infection", "DISEASE", 34, 43], ["Acinetobacter lwoffii F78", "CHEMICAL", 66, 91], ["ovalbumin", "CHEMICAL", 131, 140], ["asthma", "DISEASE", 149, 155], ["mice", "ORGANISM", 56, 60], ["Acinetobacter lwoffii F78", "ORGANISM", 66, 91], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 131, 140], ["mice", "SPECIES", 56, 60], ["Acinetobacter lwoffii", "SPECIES", 66, 87], ["mice", "SPECIES", 56, 60], ["Acinetobacter lwoffii", "SPECIES", 66, 87], ["experimental intranasal infection", "PROBLEM", 10, 43], ["Acinetobacter lwoffii F78", "TREATMENT", 66, 91], ["ovalbumin", "PROBLEM", 131, 140], ["asthma", "PROBLEM", 149, 155], ["infection", "OBSERVATION", 34, 43], ["asthma", "OBSERVATION", 149, 155]]], ["Using knockout mice, the protective effect was shown to be dependent on maternal TLR expression and suggests that microbial recognition during pregnancy somehow primes the fetal lung environment for a Th1 response later in life [182] .AsthmaLung resident cells that express TLR4 also play an important role in the induction of allergen specific Th2 cells via recognition of house dust mite (a ubiquitous indoor allergen) that leads to the production of thymic stromal lymphopoietin, granulocyte-macrophage colonystimulating factor, IL-25 and IL-33.", [["fetal lung", "ANATOMY", 172, 182], ["cells", "ANATOMY", 255, 260], ["Th2 cells", "ANATOMY", 345, 354], ["thymic stromal lymphopoietin", "ANATOMY", 453, 481], ["mice", "ORGANISM", 15, 19], ["TLR", "GENE_OR_GENE_PRODUCT", 81, 84], ["fetal", "MULTI-TISSUE_STRUCTURE", 172, 177], ["lung", "ORGAN", 178, 182], ["AsthmaLung resident cells", "CELL", 235, 260], ["TLR4", "GENE_OR_GENE_PRODUCT", 274, 278], ["Th2 cells", "CELL", 345, 354], ["house dust mite", "ORGANISM", 374, 389], ["thymic stromal lymphopoietin", "CANCER", 453, 481], ["granulocyte-macrophage colonystimulating factor", "GENE_OR_GENE_PRODUCT", 483, 530], ["IL-25", "GENE_OR_GENE_PRODUCT", 532, 537], ["IL-33", "GENE_OR_GENE_PRODUCT", 542, 547], ["TLR", "PROTEIN", 81, 84], ["AsthmaLung resident cells", "CELL_TYPE", 235, 260], ["TLR4", "PROTEIN", 274, 278], ["allergen specific Th2 cells", "CELL_TYPE", 327, 354], ["thymic stromal lymphopoietin", "CELL_TYPE", 453, 481], ["granulocyte-macrophage colonystimulating factor", "PROTEIN", 483, 530], ["IL-25 and IL-33", "PROTEIN", 532, 547], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["house dust mite", "SPECIES", 374, 389], ["knockout mice", "TREATMENT", 6, 19], ["microbial recognition during pregnancy", "PROBLEM", 114, 152], ["the fetal lung environment", "PROBLEM", 168, 194], ["thymic stromal lymphopoietin", "TREATMENT", 453, 481], ["granulocyte", "TEST", 483, 494], ["IL", "TEST", 532, 534], ["IL", "TEST", 542, 544], ["lung", "ANATOMY", 178, 182], ["thymic", "ANATOMY", 453, 459], ["stromal lymphopoietin", "OBSERVATION", 460, 481]]], ["This cytokine milieu can bias lung DCs towards a Th2 activating phenotype that drives the polarization of na\u00efve lymphocytes [183] .", [["lung DCs", "ANATOMY", 30, 38], ["lymphocytes", "ANATOMY", 112, 123], ["lung DCs", "CELL", 30, 38], ["na\u00efve lymphocytes", "CELL", 106, 123], ["cytokine", "PROTEIN", 5, 13], ["lung DCs", "CELL_TYPE", 30, 38], ["na\u00efve lymphocytes", "CELL_TYPE", 106, 123], ["bias lung DCs", "PROBLEM", 25, 38], ["a Th2 activating phenotype", "PROBLEM", 47, 73], ["lung", "ANATOMY", 30, 34]]], ["In addition, eosinophil derived neurotoxin can induce TLR2-dependent DC maturation, leading to Th2 polarization by secretion of high amounts of IL-6 and IL-10 [184] while basophils may also instruct T cells to become Th2 cells [185] .AsthmaTLRs have been shown via genetic association studies as well as single and multiple gene knockout studies to play a role in the development of allergic asthma.", [["eosinophil", "ANATOMY", 13, 23], ["DC", "ANATOMY", 69, 71], ["basophils", "ANATOMY", 171, 180], ["T cells", "ANATOMY", 199, 206], ["Th2 cells", "ANATOMY", 217, 226], ["allergic asthma", "DISEASE", 383, 398], ["eosinophil", "CELL", 13, 23], ["TLR2", "GENE_OR_GENE_PRODUCT", 54, 58], ["DC", "CELL", 69, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["IL-10", "GENE_OR_GENE_PRODUCT", 153, 158], ["basophils", "CELL", 171, 180], ["T cells", "CELL", 199, 206], ["Th2 cells", "CELL", 217, 226], ["AsthmaTLRs", "GENE_OR_GENE_PRODUCT", 234, 244], ["eosinophil", "CELL_TYPE", 13, 23], ["TLR2", "PROTEIN", 54, 58], ["DC", "CELL_TYPE", 69, 71], ["basophils", "CELL_TYPE", 171, 180], ["T cells", "CELL_TYPE", 199, 206], ["Th2 cells", "CELL_TYPE", 217, 226], ["AsthmaTLRs", "PROTEIN", 234, 244], ["eosinophil derived neurotoxin", "TREATMENT", 13, 42], ["TLR2-dependent DC maturation", "TREATMENT", 54, 82], ["IL", "TEST", 144, 146], ["Th2 cells", "PROBLEM", 217, 226], ["multiple gene knockout studies", "TREATMENT", 315, 345], ["allergic asthma", "PROBLEM", 383, 398], ["allergic asthma", "OBSERVATION", 383, 398]]], ["For example TLR7 and TLR8 are associated with human asthma [186] while ligands of TLR7 and TLR8 can prevent airway remodeling caused by experimentally induced asthma [187, 188] .", [["airway", "ANATOMY", 108, 114], ["asthma", "DISEASE", 52, 58], ["asthma", "DISEASE", 159, 165], ["TLR7", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR8", "GENE_OR_GENE_PRODUCT", 21, 25], ["human", "ORGANISM", 46, 51], ["TLR7", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR8", "GENE_OR_GENE_PRODUCT", 91, 95], ["airway", "MULTI-TISSUE_STRUCTURE", 108, 114], ["TLR7", "PROTEIN", 12, 16], ["TLR8", "PROTEIN", 21, 25], ["TLR7", "PROTEIN", 82, 86], ["TLR8", "PROTEIN", 91, 95], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["human asthma", "PROBLEM", 46, 58], ["TLR7", "TREATMENT", 82, 86], ["TLR8", "TREATMENT", 91, 95], ["airway remodeling", "PROBLEM", 108, 125], ["experimentally induced asthma", "PROBLEM", 136, 165], ["asthma", "OBSERVATION", 52, 58], ["airway", "ANATOMY", 108, 114], ["remodeling", "OBSERVATION", 115, 125]]], ["TLR10 single nucleotide polymorphisms have also been associated with asthma in two independent samples [189] although the ligand for TLR10 has not been defined.", [["asthma", "DISEASE", 69, 75], ["TLR10", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLR10", "GENE_OR_GENE_PRODUCT", 133, 138], ["TLR10", "PROTEIN", 0, 5], ["TLR10", "PROTEIN", 133, 138], ["TLR10 single nucleotide polymorphisms", "TREATMENT", 0, 37], ["asthma", "PROBLEM", 69, 75], ["asthma", "OBSERVATION", 69, 75]]], ["Finally, in a multicentre asthma study, TLR4 and TLR9 were both associated with wheezing and TLR4 was also associated with allergen specific IgE secretion [190] .", [["asthma", "DISEASE", 26, 32], ["wheezing", "DISEASE", 80, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 40, 44], ["TLR9", "GENE_OR_GENE_PRODUCT", 49, 53], ["TLR4", "GENE_OR_GENE_PRODUCT", 93, 97], ["IgE", "GENE_OR_GENE_PRODUCT", 141, 144], ["TLR4", "PROTEIN", 40, 44], ["TLR9", "PROTEIN", 49, 53], ["TLR4", "PROTEIN", 93, 97], ["IgE", "PROTEIN", 141, 144], ["a multicentre asthma study", "TEST", 12, 38], ["TLR4 and TLR9", "TREATMENT", 40, 53], ["wheezing", "PROBLEM", 80, 88], ["TLR4", "PROBLEM", 93, 97], ["allergen specific IgE secretion", "PROBLEM", 123, 154], ["wheezing", "OBSERVATION", 80, 88]]], ["Based on this observation, TLR9 ligands are currently in clinical trials for the treatment or prevention of asthma [191] .AsthmaAsthma can be further exacerbated by bacterial respiratory tract infection including Mycoplasma pneumoniae or Chlamydophila pneumoniae [192] .", [["respiratory tract", "ANATOMY", 175, 192], ["asthma", "DISEASE", 108, 114], ["AsthmaAsthma", "DISEASE", 122, 134], ["respiratory tract infection", "DISEASE", 175, 202], ["Mycoplasma pneumoniae", "DISEASE", 213, 234], ["TLR9", "GENE_OR_GENE_PRODUCT", 27, 31], ["bacterial respiratory tract", "ORGANISM", 165, 192], ["Mycoplasma pneumoniae", "ORGANISM", 213, 234], ["Chlamydophila pneumoniae", "ORGANISM", 238, 262], ["TLR9", "PROTEIN", 27, 31], ["Mycoplasma pneumoniae", "SPECIES", 213, 234], ["Chlamydophila pneumoniae", "SPECIES", 238, 262], ["Mycoplasma pneumoniae", "SPECIES", 213, 234], ["Chlamydophila pneumoniae", "SPECIES", 238, 262], ["this observation", "TEST", 9, 25], ["TLR9 ligands", "TREATMENT", 27, 39], ["the treatment", "TREATMENT", 77, 90], ["asthma", "PROBLEM", 108, 114], ["AsthmaAsthma", "PROBLEM", 122, 134], ["bacterial respiratory tract infection", "PROBLEM", 165, 202], ["Mycoplasma pneumoniae", "PROBLEM", 213, 234], ["Chlamydophila pneumoniae", "PROBLEM", 238, 262], ["asthma", "OBSERVATION", 108, 114], ["bacterial", "OBSERVATION_MODIFIER", 165, 174], ["respiratory tract", "ANATOMY", 175, 192], ["Mycoplasma pneumoniae", "OBSERVATION", 213, 234], ["Chlamydophila", "OBSERVATION_MODIFIER", 238, 251], ["pneumoniae", "OBSERVATION", 252, 262]]], ["In one study, 50% of patients suffering from their first asthmatic episode were infected with M. pneumoniae while 10% were serologically positive for acute C. pneumoniae infection [193, 194] .", [["asthmatic episode", "DISEASE", 57, 74], ["M. pneumoniae", "DISEASE", 94, 107], ["C. pneumoniae infection", "DISEASE", 156, 179], ["patients", "ORGANISM", 21, 29], ["M. pneumoniae", "ORGANISM", 94, 107], ["C. pneumoniae", "ORGANISM", 156, 169], ["patients", "SPECIES", 21, 29], ["M. pneumoniae", "SPECIES", 94, 107], ["C. pneumoniae", "SPECIES", 156, 169], ["M. pneumoniae", "SPECIES", 94, 107], ["C. pneumoniae", "SPECIES", 156, 169], ["one study", "TEST", 3, 12], ["their first asthmatic episode", "PROBLEM", 45, 74], ["M. pneumoniae", "PROBLEM", 94, 107], ["acute C. pneumoniae infection", "PROBLEM", 150, 179], ["pneumoniae", "OBSERVATION_MODIFIER", 159, 169], ["infection", "OBSERVATION", 170, 179]]], ["MyD88-deficient mice infected with C. pneumoniae failed to upregulate cytokine and chemokine expression, had delayed CD8 + and CD4 + T cell recruitment, and could not clear the bacterium from the lungs leading to severe chronic infection and significantly increased mortality [195] .", [["CD8 +", "ANATOMY", 117, 122], ["CD4 + T cell", "ANATOMY", 127, 139], ["lungs", "ANATOMY", 196, 201], ["chronic infection", "DISEASE", 220, 237], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 16, 20], ["C. pneumoniae", "ORGANISM", 35, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["lungs", "ORGAN", 196, 201], ["MyD88", "PROTEIN", 0, 5], ["cytokine", "PROTEIN", 70, 78], ["chemokine", "PROTEIN", 83, 92], ["CD8", "PROTEIN", 117, 120], ["CD4", "PROTEIN", 127, 130], ["mice", "SPECIES", 16, 20], ["C. pneumoniae", "SPECIES", 35, 48], ["mice", "SPECIES", 16, 20], ["C. pneumoniae", "SPECIES", 35, 48], ["MyD88", "TEST", 0, 5], ["C. pneumoniae", "PROBLEM", 35, 48], ["chemokine expression", "TEST", 83, 103], ["CD4 + T cell recruitment", "PROBLEM", 127, 151], ["the bacterium", "PROBLEM", 173, 186], ["severe chronic infection", "PROBLEM", 213, 237], ["significantly increased mortality", "PROBLEM", 242, 275], ["pneumoniae", "OBSERVATION", 38, 48], ["cell recruitment", "OBSERVATION", 135, 151], ["bacterium", "OBSERVATION", 177, 186], ["lungs", "ANATOMY", 196, 201], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["chronic", "OBSERVATION_MODIFIER", 220, 227], ["infection", "OBSERVATION", 228, 237], ["significantly", "OBSERVATION_MODIFIER", 242, 255], ["increased", "OBSERVATION_MODIFIER", 256, 265]]], ["At a later stage of infection, IL-1\u03b2, IFN-\u03b3 and other inflammatory mediators may be upregulated via a MyD88-independent pathway but are not sufficient to prevent mortality from C. pneumoniae [195] .", [["infection", "DISEASE", 20, 29], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 38, 43], ["MyD88", "GENE_OR_GENE_PRODUCT", 102, 107], ["C. pneumoniae", "ORGANISM", 177, 190], ["IL-1\u03b2", "PROTEIN", 31, 36], ["IFN-\u03b3", "PROTEIN", 38, 43], ["inflammatory mediators", "PROTEIN", 54, 76], ["MyD88", "PROTEIN", 102, 107], ["C. pneumoniae", "SPECIES", 177, 190], ["C. pneumoniae", "SPECIES", 177, 190], ["infection", "PROBLEM", 20, 29], ["IL", "TEST", 31, 33], ["IFN", "TREATMENT", 38, 41], ["other inflammatory mediators", "PROBLEM", 48, 76], ["a MyD88-independent pathway", "TREATMENT", 100, 127], ["C. pneumoniae", "PROBLEM", 177, 190], ["infection", "OBSERVATION", 20, 29], ["pneumoniae", "OBSERVATION", 180, 190]]], ["TLR2 and TLR4-deficient mice can recover from C. pneumoniae infection with no impairment of bacterial clearance suggesting that other PRRs are also involved in host defense or that TLR2/ TLR4 act in concert during C. pneumoniae infection [195, 196] .AsthmaTLR2 is also upregulated in response to M. pneumoniae infection, leading to increased expression of airway mucin [197, 198] .", [["airway", "ANATOMY", 356, 362], ["C. pneumoniae infection", "DISEASE", 46, 69], ["C. pneumoniae infection", "DISEASE", 214, 237], ["infection", "DISEASE", 310, 319], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 9, 13], ["mice", "ORGANISM", 24, 28], ["C. pneumoniae", "ORGANISM", 46, 59], ["PRRs", "GENE_OR_GENE_PRODUCT", 134, 138], ["TLR2", "GENE_OR_GENE_PRODUCT", 181, 185], ["TLR4", "GENE_OR_GENE_PRODUCT", 187, 191], ["C. pneumoniae", "ORGANISM", 214, 227], ["AsthmaTLR2", "GENE_OR_GENE_PRODUCT", 250, 260], ["M. pneumoniae", "ORGANISM", 296, 309], ["airway mucin", "GENE_OR_GENE_PRODUCT", 356, 368], ["TLR2", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 9, 13], ["PRRs", "PROTEIN", 134, 138], ["TLR2", "PROTEIN", 181, 185], ["TLR4", "PROTEIN", 187, 191], ["AsthmaTLR2", "PROTEIN", 250, 260], ["mice", "SPECIES", 24, 28], ["C. pneumoniae", "SPECIES", 46, 59], ["C. pneumoniae", "SPECIES", 214, 227], ["M. pneumoniae", "SPECIES", 296, 309], ["mice", "SPECIES", 24, 28], ["C. pneumoniae", "SPECIES", 46, 59], ["C. pneumoniae", "SPECIES", 214, 227], ["M. pneumoniae", "SPECIES", 296, 309], ["TLR2", "TREATMENT", 0, 4], ["TLR4-deficient mice", "TREATMENT", 9, 28], ["C. pneumoniae infection", "PROBLEM", 46, 69], ["bacterial clearance", "PROBLEM", 92, 111], ["TLR2/ TLR4 act", "TREATMENT", 181, 195], ["C. pneumoniae infection", "PROBLEM", 214, 237], ["AsthmaTLR2", "TREATMENT", 250, 260], ["M. pneumoniae infection", "PROBLEM", 296, 319], ["increased expression of airway mucin", "PROBLEM", 332, 368], ["pneumoniae", "OBSERVATION_MODIFIER", 49, 59], ["infection", "OBSERVATION", 60, 69], ["pneumoniae", "OBSERVATION_MODIFIER", 299, 309], ["infection", "OBSERVATION", 310, 319], ["increased", "OBSERVATION_MODIFIER", 332, 341], ["airway", "ANATOMY", 356, 362]]], ["Allergic inflammation along with the induction of Th2 cytokines (IL-4, IL-13) leads to TLR2 inhibition during M. pneumoniae infection, thereby decreasing the production of IL-6 and other Th1 proinflammatory mediators that are required for bacterial clearance [199] .", [["Allergic inflammation", "DISEASE", 0, 21], ["M. pneumoniae infection", "DISEASE", 110, 133], ["IL-4", "GENE_OR_GENE_PRODUCT", 65, 69], ["IL-13", "GENE_OR_GENE_PRODUCT", 71, 76], ["TLR2", "GENE_OR_GENE_PRODUCT", 87, 91], ["M. pneumoniae", "ORGANISM", 110, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 172, 176], ["Th2 cytokines", "PROTEIN", 50, 63], ["IL-4, IL-13", "PROTEIN", 65, 76], ["TLR2", "PROTEIN", 87, 91], ["IL-6", "PROTEIN", 172, 176], ["Th1 proinflammatory mediators", "PROTEIN", 187, 216], ["M. pneumoniae", "SPECIES", 110, 123], ["M. pneumoniae", "SPECIES", 110, 123], ["Allergic inflammation", "PROBLEM", 0, 21], ["Th2 cytokines (IL", "TREATMENT", 50, 67], ["IL", "TREATMENT", 71, 73], ["TLR2 inhibition", "TREATMENT", 87, 102], ["M. pneumoniae infection", "PROBLEM", 110, 133], ["IL", "TEST", 172, 174], ["other Th1 proinflammatory mediators", "TREATMENT", 181, 216], ["bacterial clearance", "PROBLEM", 239, 258], ["inflammation", "OBSERVATION", 9, 21], ["pneumoniae", "OBSERVATION_MODIFIER", 113, 123], ["infection", "OBSERVATION", 124, 133], ["decreasing", "OBSERVATION_MODIFIER", 143, 153]]], ["Antibiotic treatment of asthmatic patients infected with M. pneumoniae improves their pulmonary function and highlights the increasingly important role that bacterial colonization and interactions with the host innate immune response play in asthma exacerbations and mortality [200, 201] .AsthmaViral infection of the lower respiratory tract can also contribute to asthma development and exacerbations.", [["pulmonary", "ANATOMY", 86, 95], ["lower respiratory tract", "ANATOMY", 318, 341], ["asthmatic", "DISEASE", 24, 33], ["asthma", "DISEASE", 242, 248], ["infection of the lower respiratory tract", "DISEASE", 301, 341], ["asthma", "DISEASE", 365, 371], ["patients", "ORGANISM", 34, 42], ["M. pneumoniae", "ORGANISM", 57, 70], ["pulmonary", "ORGAN", 86, 95], ["lower", "ORGANISM_SUBDIVISION", 318, 323], ["respiratory tract", "ORGANISM_SUBDIVISION", 324, 341], ["patients", "SPECIES", 34, 42], ["M. pneumoniae", "SPECIES", 57, 70], ["M. pneumoniae", "SPECIES", 57, 70], ["Antibiotic treatment", "TREATMENT", 0, 20], ["asthmatic patients infected", "PROBLEM", 24, 51], ["M. pneumoniae", "PROBLEM", 57, 70], ["bacterial colonization", "PROBLEM", 157, 179], ["asthma exacerbations", "PROBLEM", 242, 262], ["AsthmaViral infection of the lower respiratory tract", "PROBLEM", 289, 341], ["asthma development", "PROBLEM", 365, 383], ["exacerbations", "PROBLEM", 388, 401], ["asthmatic", "OBSERVATION_MODIFIER", 24, 33], ["pulmonary", "ANATOMY", 86, 95], ["bacterial colonization", "OBSERVATION", 157, 179], ["infection", "OBSERVATION", 301, 310], ["lower", "ANATOMY_MODIFIER", 318, 323], ["respiratory tract", "ANATOMY", 324, 341], ["asthma", "OBSERVATION", 365, 371]]], ["Respiratory Syncytial Virus (RSV) is a particularly important cause of acute bronchiolitis and wheezing in children that may lead to the subsequent development of asthma [202] [203] [204] [205] [206] .", [["Respiratory Syncytial Virus (RSV)", "DISEASE", 0, 33], ["bronchiolitis", "DISEASE", 77, 90], ["wheezing", "DISEASE", 95, 103], ["asthma", "DISEASE", 163, 169], ["Respiratory Syncytial Virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["Respiratory Syncytial Virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory Syncytial Virus (RSV", "PROBLEM", 0, 32], ["acute bronchiolitis", "PROBLEM", 71, 90], ["wheezing", "PROBLEM", 95, 103], ["asthma", "PROBLEM", 163, 169], ["Syncytial Virus", "OBSERVATION", 12, 27], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["bronchiolitis", "OBSERVATION", 77, 90], ["wheezing", "OBSERVATION", 95, 103], ["asthma", "OBSERVATION", 163, 169]]], ["Wheezing after the acquisition of severe RSV infection early in life has been associated with elevated Th2 responses, eosinophilia, and IL-10 production [207] [208] [209] [210] [211] .", [["Wheezing", "DISEASE", 0, 8], ["RSV infection", "DISEASE", 41, 54], ["eosinophilia", "DISEASE", 118, 130], ["RSV", "ORGANISM", 41, 44], ["IL-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["RSV", "SPECIES", 41, 44], ["Wheezing", "PROBLEM", 0, 8], ["severe RSV infection", "PROBLEM", 34, 54], ["elevated Th2 responses", "PROBLEM", 94, 116], ["eosinophilia", "PROBLEM", 118, 130], ["IL", "TEST", 136, 138], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["RSV", "OBSERVATION_MODIFIER", 41, 44], ["infection", "OBSERVATION", 45, 54], ["elevated", "OBSERVATION_MODIFIER", 94, 102], ["Th2 responses", "OBSERVATION", 103, 116]]], ["During RSV infection, the viral G protein mediates attachment to lung epithelial cells and the F protein leads to the fusion of the viral envelope with the host cell plasma membrane [212] .", [["lung epithelial cells", "ANATOMY", 65, 86], ["cell plasma membrane", "ANATOMY", 161, 181], ["RSV infection", "DISEASE", 7, 20], ["RSV", "ORGANISM", 7, 10], ["viral G protein", "GENE_OR_GENE_PRODUCT", 26, 41], ["lung epithelial cells", "CELL", 65, 86], ["F protein", "GENE_OR_GENE_PRODUCT", 95, 104], ["cell", "CELLULAR_COMPONENT", 161, 165], ["plasma membrane", "CELLULAR_COMPONENT", 166, 181], ["viral G protein", "PROTEIN", 26, 41], ["lung epithelial cells", "CELL_TYPE", 65, 86], ["F protein", "PROTEIN", 95, 104], ["RSV", "SPECIES", 7, 10], ["RSV infection", "PROBLEM", 7, 20], ["the viral G protein mediates attachment to lung epithelial cells", "PROBLEM", 22, 86], ["the fusion", "TREATMENT", 114, 124], ["RSV", "ANATOMY", 7, 10], ["infection", "OBSERVATION", 11, 20], ["lung", "ANATOMY", 65, 69], ["epithelial cells", "OBSERVATION", 70, 86], ["fusion", "OBSERVATION", 118, 124], ["viral envelope", "OBSERVATION", 132, 146], ["host cell plasma membrane", "OBSERVATION", 156, 181]]], ["In response to RSV infection, TLRs are broadly upregulated in the human tracheal epithelial cell line 9HTEo [213] .", [["tracheal epithelial cell line 9HTEo", "ANATOMY", 72, 107], ["RSV infection", "DISEASE", 15, 28], ["RSV", "ORGANISM", 15, 18], ["TLRs", "GENE_OR_GENE_PRODUCT", 30, 34], ["human", "ORGANISM", 66, 71], ["tracheal epithelial cell line 9HTEo [213]", "CELL", 72, 113], ["TLRs", "PROTEIN", 30, 34], ["human tracheal epithelial cell line", "CELL_LINE", 66, 101], ["human", "SPECIES", 66, 71], ["RSV", "SPECIES", 15, 18], ["human", "SPECIES", 66, 71], ["RSV infection", "PROBLEM", 15, 28], ["TLRs", "TREATMENT", 30, 34], ["RSV infection", "OBSERVATION", 15, 28], ["tracheal", "ANATOMY", 72, 80], ["epithelial cell line", "OBSERVATION", 81, 101]]], ["In mice, TLR4 has been shown to recognize the F protein and activate NF-B during RSV infection [203, 214] .", [["RSV infection", "DISEASE", 81, 94], ["mice", "ORGANISM", 3, 7], ["TLR4", "GENE_OR_GENE_PRODUCT", 9, 13], ["F", "GENE_OR_GENE_PRODUCT", 46, 47], ["NF-B", "GENE_OR_GENE_PRODUCT", 69, 73], ["RSV", "ORGANISM", 81, 84], ["TLR4", "PROTEIN", 9, 13], ["F protein", "PROTEIN", 46, 55], ["NF-B", "PROTEIN", 69, 73], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["RSV", "SPECIES", 81, 84], ["RSV infection", "PROBLEM", 81, 94], ["RSV", "ANATOMY", 81, 84], ["infection", "OBSERVATION", 85, 94]]], ["Accordingly, TLR4-deficient animals exhibit impaired NK cell function and increased viral load [205, 215] .", [["NK cell", "ANATOMY", 53, 60], ["TLR4", "GENE_OR_GENE_PRODUCT", 13, 17], ["NK cell", "CELL", 53, 60], ["TLR4", "PROTEIN", 13, 17], ["TLR4", "TEST", 13, 17], ["impaired NK cell function", "PROBLEM", 44, 69], ["increased viral load", "PROBLEM", 74, 94], ["impaired NK cell function", "OBSERVATION", 44, 69], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["viral load", "OBSERVATION", 84, 94]]], ["Defective TLR4 signalling has also been linked to increased pathology in a study of pre-term infants [216] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["infants", "ORGANISM", 93, 100], ["TLR4", "PROTEIN", 10, 14], ["infants", "SPECIES", 93, 100], ["Defective TLR4 signalling", "PROBLEM", 0, 25], ["increased pathology", "PROBLEM", 50, 69], ["a study", "TEST", 73, 80], ["TLR4", "OBSERVATION", 10, 14], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["pathology", "OBSERVATION", 60, 69]]], ["An essential role for IL-12, rather than TLR4, in susceptibility to RSV has also been proposed [214] ; however, significant differences in experimental design limit the comparison of these apparently discordant studies [217] .AsthmaIn human lung fibroblasts and epithelial cells, the formation of dsRNA during RSV replication can activate TLR3-mediated immune signaling, leading to the upregulation of the chemokines RANTES and IP-10 [218] .", [["lung fibroblasts", "ANATOMY", 241, 257], ["epithelial cells", "ANATOMY", 262, 278], ["RSV", "DISEASE", 68, 71], ["IL-12", "GENE_OR_GENE_PRODUCT", 22, 27], ["TLR4", "GENE_OR_GENE_PRODUCT", 41, 45], ["RSV", "ORGANISM", 68, 71], ["human", "ORGANISM", 235, 240], ["lung fibroblasts", "CELL", 241, 257], ["epithelial cells", "CELL", 262, 278], ["RSV", "ORGANISM", 310, 313], ["TLR3", "GENE_OR_GENE_PRODUCT", 339, 343], ["RANTES", "GENE_OR_GENE_PRODUCT", 417, 423], ["IP-10", "GENE_OR_GENE_PRODUCT", 428, 433], ["IL-12", "PROTEIN", 22, 27], ["TLR4", "PROTEIN", 41, 45], ["AsthmaIn human lung fibroblasts", "CELL_TYPE", 226, 257], ["epithelial cells", "CELL_TYPE", 262, 278], ["TLR3", "PROTEIN", 339, 343], ["chemokines", "PROTEIN", 406, 416], ["RANTES", "PROTEIN", 417, 423], ["human", "SPECIES", 235, 240], ["RSV", "SPECIES", 68, 71], ["human", "SPECIES", 235, 240], ["RSV", "SPECIES", 310, 313], ["AsthmaIn human lung fibroblasts", "PROBLEM", 226, 257], ["epithelial cells", "PROBLEM", 262, 278], ["dsRNA", "PROBLEM", 297, 302], ["RSV replication", "TREATMENT", 310, 325], ["the chemokines RANTES", "TREATMENT", 402, 423], ["IP", "TEST", 428, 430], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["differences", "OBSERVATION_MODIFIER", 124, 135], ["lung", "ANATOMY", 241, 245], ["fibroblasts", "OBSERVATION", 246, 257], ["epithelial cells", "OBSERVATION", 262, 278], ["dsRNA", "OBSERVATION_MODIFIER", 297, 302]]], ["TLR3-deficient mice have a predominantly Th2 response to RSV characterized by increased airway eosinophilia, mucus hypersecretion and expression of IL-5 and IL-13 [219] .", [["airway", "ANATOMY", 88, 94], ["mucus", "ANATOMY", 109, 114], ["RSV", "DISEASE", 57, 60], ["eosinophilia", "DISEASE", 95, 107], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 15, 19], ["RSV", "ORGANISM", 57, 60], ["airway eosinophilia", "PATHOLOGICAL_FORMATION", 88, 107], ["mucus", "ORGANISM_SUBSTANCE", 109, 114], ["IL-5", "GENE_OR_GENE_PRODUCT", 148, 152], ["IL-13", "GENE_OR_GENE_PRODUCT", 157, 162], ["TLR3", "PROTEIN", 0, 4], ["IL", "PROTEIN", 148, 150], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["RSV", "SPECIES", 57, 60], ["RSV", "PROBLEM", 57, 60], ["increased airway eosinophilia", "PROBLEM", 78, 107], ["mucus hypersecretion", "PROBLEM", 109, 129], ["IL", "TEST", 148, 150], ["IL", "TEST", 157, 159], ["predominantly", "OBSERVATION_MODIFIER", 27, 40], ["Th2 response", "OBSERVATION", 41, 53], ["RSV", "OBSERVATION", 57, 60], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["airway", "ANATOMY", 88, 94], ["eosinophilia", "OBSERVATION", 95, 107], ["mucus hypersecretion", "OBSERVATION", 109, 129]]], ["RIG-I-induced IFN-\u03b2 expression during RSV infection was recently shown to trigger TLR3 activation, suggesting that TLR3 mediates a secondary immune signaling pathway [220] .", [["RSV infection", "DISEASE", 38, 51], ["RIG-I-induced IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 19], ["RSV", "ORGANISM", 38, 41], ["TLR3", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR3", "GENE_OR_GENE_PRODUCT", 115, 119], ["RIG", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 14, 17], ["\u03b2", "PROTEIN", 18, 19], ["TLR3", "PROTEIN", 82, 86], ["TLR3", "PROTEIN", 115, 119], ["RSV", "SPECIES", 38, 41], ["RIG-I-induced IFN", "TREATMENT", 0, 17], ["RSV infection", "PROBLEM", 38, 51], ["a secondary immune signaling pathway", "PROBLEM", 129, 165], ["RSV", "ANATOMY", 38, 41], ["infection", "OBSERVATION", 42, 51]]], ["Interestingly, while TLR3 is involved in chemokine expression it has no role in RSV viral clearance, which is primarily mediated by the TLR2/TLR6 heterodimer [218, 219] .AsthmaIn summary, the emerging picture of allergic asthma suggests that the disease can be mediated or exacerbated in genetically predisposed individuals by infection.", [["allergic asthma", "DISEASE", 212, 227], ["infection", "DISEASE", 327, 336], ["TLR3", "GENE_OR_GENE_PRODUCT", 21, 25], ["RSV", "ORGANISM", 80, 83], ["TLR2", "GENE_OR_GENE_PRODUCT", 136, 140], ["TLR6", "GENE_OR_GENE_PRODUCT", 141, 145], ["individuals", "ORGANISM", 312, 323], ["TLR3", "PROTEIN", 21, 25], ["chemokine", "PROTEIN", 41, 50], ["TLR2", "PROTEIN", 136, 140], ["TLR6 heterodimer", "PROTEIN", 141, 157], ["RSV", "SPECIES", 80, 83], ["RSV viral clearance", "PROBLEM", 80, 99], ["allergic asthma", "PROBLEM", 212, 227], ["the disease", "PROBLEM", 242, 253], ["infection", "PROBLEM", 327, 336], ["no role", "UNCERTAINTY", 69, 76], ["allergic asthma", "OBSERVATION", 212, 227], ["infection", "OBSERVATION", 327, 336]]], ["In some cases these infections may induce an inflammatory state that protects against asthma, while in others the infection may elicit an acute allergic response or bias the host towards a subsequent Th2 response (figure 1).ConclusionInnate immunity is a principal mechanism for the maintenance of lung tissue homeostasis despite continuous exposure to environmental irritants and potentially pathogenic microorganisms.", [["lung tissue", "ANATOMY", 298, 309], ["infections", "DISEASE", 20, 30], ["asthma", "DISEASE", 86, 92], ["infection", "DISEASE", 114, 123], ["allergic", "DISEASE", 144, 152], ["lung tissue", "TISSUE", 298, 309], ["these infections", "PROBLEM", 14, 30], ["an inflammatory state", "PROBLEM", 42, 63], ["asthma", "PROBLEM", 86, 92], ["the infection", "PROBLEM", 110, 123], ["an acute allergic response", "PROBLEM", 135, 161], ["bias the host", "PROBLEM", 165, 178], ["lung tissue homeostasis", "PROBLEM", 298, 321], ["environmental irritants", "PROBLEM", 353, 376], ["potentially pathogenic microorganisms", "PROBLEM", 381, 418], ["infections", "OBSERVATION", 20, 30], ["inflammatory", "OBSERVATION", 45, 57], ["infection", "OBSERVATION", 114, 123], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["allergic", "OBSERVATION", 144, 152], ["lung", "ANATOMY", 298, 302], ["tissue", "OBSERVATION", 303, 309]]], ["In recent years tremendous progress has been made with regard to how the TLRs contribute to host defence and tissue repair.", [["tissue", "ANATOMY", 109, 115], ["TLRs", "GENE_OR_GENE_PRODUCT", 73, 77], ["tissue", "TISSUE", 109, 115], ["TLRs", "PROTEIN", 73, 77], ["tissue repair", "TREATMENT", 109, 122], ["tissue repair", "OBSERVATION", 109, 122]]], ["The insights that have arisen from this work allow one to postulate a few general principles with regard to lung innate immunity.", [["lung", "ANATOMY", 108, 112], ["lung", "ORGAN", 108, 112], ["lung innate immunity", "TREATMENT", 108, 128], ["lung", "ANATOMY", 108, 112]]], ["First, acute pulmonary diseases such as ALI and bronchiolitis frequently develop into chronic inflammatory states (fibroproliferative ARDS) or exhibit a relapsing and remitting pattern (asthma).", [["pulmonary", "ANATOMY", 13, 22], ["acute pulmonary diseases", "DISEASE", 7, 31], ["ALI", "DISEASE", 40, 43], ["bronchiolitis", "DISEASE", 48, 61], ["ARDS", "DISEASE", 134, 138], ["asthma", "DISEASE", 186, 192], ["pulmonary", "ORGAN", 13, 22], ["acute pulmonary diseases", "PROBLEM", 7, 31], ["ALI", "PROBLEM", 40, 43], ["bronchiolitis", "PROBLEM", 48, 61], ["chronic inflammatory states", "PROBLEM", 86, 113], ["fibroproliferative ARDS", "PROBLEM", 115, 138], ["a relapsing and remitting pattern (asthma)", "PROBLEM", 151, 193], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["pulmonary", "ANATOMY", 13, 22], ["diseases", "OBSERVATION", 23, 31], ["ALI", "OBSERVATION", 40, 43], ["bronchiolitis", "OBSERVATION", 48, 61], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["inflammatory", "OBSERVATION", 94, 106], ["fibroproliferative", "OBSERVATION_MODIFIER", 115, 133], ["ARDS", "OBSERVATION", 134, 138], ["relapsing", "OBSERVATION_MODIFIER", 153, 162], ["remitting", "OBSERVATION_MODIFIER", 167, 176], ["asthma", "OBSERVATION", 186, 192]]], ["Second, infectious diseases are principal causes of sustained lung inflammation, as exemplified by severe influenza pneumonia that progresses to ARDS or severe RSV infection that precedes the development of asthma.", [["lung", "ANATOMY", 62, 66], ["infectious diseases", "DISEASE", 8, 27], ["lung inflammation", "DISEASE", 62, 79], ["influenza pneumonia", "DISEASE", 106, 125], ["ARDS", "DISEASE", 145, 149], ["RSV infection", "DISEASE", 160, 173], ["asthma", "DISEASE", 207, 213], ["lung", "ORGAN", 62, 66], ["RSV", "ORGANISM", 160, 163], ["RSV", "SPECIES", 160, 163], ["infectious diseases", "PROBLEM", 8, 27], ["sustained lung inflammation", "PROBLEM", 52, 79], ["severe influenza pneumonia", "PROBLEM", 99, 125], ["ARDS", "PROBLEM", 145, 149], ["severe RSV infection", "PROBLEM", 153, 173], ["asthma", "PROBLEM", 207, 213], ["infectious", "OBSERVATION", 8, 18], ["sustained", "OBSERVATION_MODIFIER", 52, 61], ["lung", "ANATOMY", 62, 66], ["inflammation", "OBSERVATION", 67, 79], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["influenza", "OBSERVATION_MODIFIER", 106, 115], ["pneumonia", "OBSERVATION", 116, 125], ["ARDS", "OBSERVATION", 145, 149], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["RSV", "OBSERVATION_MODIFIER", 160, 163], ["infection", "OBSERVATION", 164, 173], ["asthma", "OBSERVATION", 207, 213]]], ["Third, defective innate immunity contributes to the development of chronic obstructive lung diseases while directly or indirectly predisposing the host to infection, as observed in CF patients with chronic P. aeruginosa infection or acute exacerbations of COPD caused by S. pneumoniae.", [["lung", "ANATOMY", 87, 91], ["obstructive lung diseases", "DISEASE", 75, 100], ["infection", "DISEASE", 155, 164], ["CF", "DISEASE", 181, 183], ["chronic P. aeruginosa infection", "DISEASE", 198, 229], ["COPD", "DISEASE", 256, 260], ["lung", "ORGAN", 87, 91], ["patients", "ORGANISM", 184, 192], ["P. aeruginosa", "ORGANISM", 206, 219], ["S. pneumoniae", "ORGANISM", 271, 284], ["patients", "SPECIES", 184, 192], ["P. aeruginosa", "SPECIES", 206, 219], ["S. pneumoniae", "SPECIES", 271, 284], ["P. aeruginosa", "SPECIES", 206, 219], ["S. pneumoniae", "SPECIES", 271, 284], ["chronic obstructive lung diseases", "PROBLEM", 67, 100], ["infection", "PROBLEM", 155, 164], ["chronic P. aeruginosa infection", "PROBLEM", 198, 229], ["acute exacerbations", "PROBLEM", 233, 252], ["COPD", "PROBLEM", 256, 260], ["S. pneumoniae", "PROBLEM", 271, 284], ["defective", "OBSERVATION_MODIFIER", 7, 16], ["innate immunity", "OBSERVATION", 17, 32], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["obstructive", "OBSERVATION_MODIFIER", 75, 86], ["lung", "ANATOMY", 87, 91], ["diseases", "OBSERVATION", 92, 100], ["infection", "OBSERVATION", 155, 164], ["chronic", "OBSERVATION_MODIFIER", 198, 205], ["aeruginosa", "OBSERVATION_MODIFIER", 209, 219], ["infection", "OBSERVATION", 220, 229], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["exacerbations", "OBSERVATION", 239, 252], ["COPD", "OBSERVATION", 256, 260], ["pneumoniae", "OBSERVATION", 274, 284]]], ["Finally, tissue repair and remodelling are crucial to the pathogenesis of lung inflammation as well as to host defense, and based on current data it appears that TLRdependent mechanisms mediate the development of both processes.ConclusionDespite extensive research, many questions remain unanswered, including the relative contributions of TLR and non-TLR PRRs to lung inflammation and protective immunity, the precise nature of gene-environment interactions in asthma pathogenesis, the molecular mechanisms that negatively regulate the innate immune response during ALI, the failure of innate immunity to sterilize the lower respiratory tract in CF, and the role of innate immunity in tissue remodelling in asthma and COPD.", [["tissue", "ANATOMY", 9, 15], ["lung", "ANATOMY", 74, 78], ["lung", "ANATOMY", 364, 368], ["lower respiratory tract", "ANATOMY", 620, 643], ["tissue", "ANATOMY", 686, 692], ["lung inflammation", "DISEASE", 74, 91], ["lung inflammation", "DISEASE", 364, 381], ["asthma", "DISEASE", 462, 468], ["ALI", "DISEASE", 567, 570], ["asthma", "DISEASE", 708, 714], ["COPD", "DISEASE", 719, 723], ["tissue", "TISSUE", 9, 15], ["lung", "ORGAN", 74, 78], ["TLR", "GENE_OR_GENE_PRODUCT", 340, 343], ["non-TLR PRRs", "GENE_OR_GENE_PRODUCT", 348, 360], ["lung", "ORGAN", 364, 368], ["lower", "ORGANISM_SUBDIVISION", 620, 625], ["respiratory tract", "ORGANISM_SUBDIVISION", 626, 643], ["tissue", "TISSUE", 686, 692], ["TLR", "PROTEIN", 340, 343], ["non-TLR PRRs", "PROTEIN", 348, 360], ["tissue repair", "TREATMENT", 9, 22], ["remodelling", "TREATMENT", 27, 38], ["lung inflammation", "PROBLEM", 74, 91], ["TLR", "TREATMENT", 340, 343], ["lung inflammation", "PROBLEM", 364, 381], ["protective immunity", "TREATMENT", 386, 405], ["asthma pathogenesis", "PROBLEM", 462, 481], ["innate immunity", "TREATMENT", 587, 602], ["the lower respiratory tract in CF", "PROBLEM", 616, 649], ["asthma", "PROBLEM", 708, 714], ["COPD", "PROBLEM", 719, 723], ["tissue", "OBSERVATION_MODIFIER", 9, 15], ["repair", "OBSERVATION", 16, 22], ["lung", "ANATOMY", 74, 78], ["inflammation", "OBSERVATION", 79, 91], ["both", "OBSERVATION_MODIFIER", 213, 217], ["processes", "OBSERVATION", 218, 227], ["lung", "ANATOMY", 364, 368], ["inflammation", "OBSERVATION", 369, 381], ["lower", "ANATOMY_MODIFIER", 620, 625], ["respiratory tract", "ANATOMY", 626, 643], ["asthma", "OBSERVATION", 708, 714], ["COPD", "OBSERVATION", 719, 723]]], ["A deeper understanding of the basic biology of TLRs will provide additional opportunities to elucidate the links between innate immunity and the development of acute and chronic inflammatory or infectious lung diseases.", [["lung", "ANATOMY", 205, 209], ["infectious lung diseases", "DISEASE", 194, 218], ["TLRs", "GENE_OR_GENE_PRODUCT", 47, 51], ["lung", "ORGAN", 205, 209], ["TLRs", "PROTEIN", 47, 51], ["acute and chronic inflammatory or infectious lung diseases", "PROBLEM", 160, 218], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["inflammatory", "OBSERVATION", 178, 190], ["infectious", "OBSERVATION_MODIFIER", 194, 204], ["lung", "ANATOMY", 205, 209], ["diseases", "OBSERVATION", 210, 218]]], ["Ultimately, it is our hope that such knowledge will provide new strategies to limit the burden of human suffering and death due to respiratory disease.", [["respiratory", "ANATOMY", 131, 142], ["death", "DISEASE", 118, 123], ["respiratory disease", "DISEASE", 131, 150], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["new strategies", "TREATMENT", 60, 74], ["death", "PROBLEM", 118, 123], ["respiratory disease", "PROBLEM", 131, 150], ["respiratory disease", "OBSERVATION", 131, 150]]]], "PMC7502009": [["IntroductionMedialization thyroplasty (MT) is the most widely used laryngeal framework surgery technique available to treat unilateral vocal fold paralysis (UVFP), enabling improvement in voice and swallowing function, and preventing life-threatening aspiration events.1 While other surgical techniques such as injection laryngoplasty, arytenoid adduction (AA), and laryngeal innervation are used to treat UVFP, MT has the unique advantage of intra-operative manipulation to optimize vocal quality.2,3", [["laryngeal", "ANATOMY", 67, 76], ["vocal fold", "ANATOMY", 135, 145], ["arytenoid", "ANATOMY", 336, 345], ["laryngeal innervation", "ANATOMY", 366, 387], ["vocal", "ANATOMY", 484, 489], ["vocal fold paralysis", "DISEASE", 135, 155], ["UVFP", "DISEASE", 157, 161], ["arytenoid adduction", "DISEASE", 336, 355], ["UVFP", "DISEASE", 406, 410], ["2,3", "CHEMICAL", 498, 501], ["laryngeal", "ORGAN", 67, 76], ["arytenoid", "ORGAN", 336, 345], ["laryngeal innervation", "MULTI-TISSUE_STRUCTURE", 366, 387], ["vocal", "ORGAN", 484, 489], ["2,3", "SIMPLE_CHEMICAL", 498, 501], ["IntroductionMedialization thyroplasty (MT)", "TREATMENT", 0, 42], ["laryngeal framework surgery technique", "TREATMENT", 67, 104], ["unilateral vocal fold paralysis", "PROBLEM", 124, 155], ["swallowing function", "TEST", 198, 217], ["life-threatening aspiration events", "PROBLEM", 234, 268], ["other surgical techniques", "TREATMENT", 277, 302], ["injection laryngoplasty", "TREATMENT", 311, 334], ["arytenoid adduction (AA)", "TREATMENT", 336, 360], ["laryngeal innervation", "TREATMENT", 366, 387], ["UVFP", "TREATMENT", 406, 410], ["intra-operative manipulation", "TREATMENT", 443, 471], ["Medialization thyroplasty", "OBSERVATION", 12, 37], ["laryngeal", "ANATOMY", 67, 76], ["vocal fold", "ANATOMY", 135, 145], ["paralysis", "OBSERVATION", 146, 155], ["aspiration", "OBSERVATION", 251, 261], ["arytenoid adduction", "OBSERVATION", 336, 355], ["laryngeal", "ANATOMY", 366, 375]]]], "efc9fd7e58f62478268198b730e0c9f41fe29d44": [["InTRoduCTIonSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes covid-19, was first reported to WHO as a pneumonia of unknown cause in Wuhan, China, on 31 December 2019.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["pneumonia", "DISEASE", 128, 137], ["InTRoduCTIonSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["InTRoduCTIonSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["covid", "TEST", 87, 92], ["a pneumonia", "PROBLEM", 126, 137], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["pneumonia", "OBSERVATION", 128, 137]]], ["1 While the initial outbreak was mostly confined to the epicentre in China, SARS-CoV-2 quickly spreads internationally causing a global pandemic.", [["SARS", "DISEASE", 76, 80], ["SARS-CoV-2", "ORGANISM", 76, 86], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "PROBLEM", 76, 80], ["a global pandemic", "PROBLEM", 127, 144], ["China", "ANATOMY", 69, 74], ["global", "OBSERVATION_MODIFIER", 129, 135], ["pandemic", "OBSERVATION", 136, 144]]], ["By 15 March, the number of cases outside of China surpassed those in China, and as of 12 April 2020, over 1.8 million cases and 110 000 deaths were reported worldwide, affecting 185 countries.", [["deaths", "DISEASE", 136, 142]]], ["2 The most common symptoms of covid-19 include fever, dry cough, myalgia or fatigue, as is the case in many other viral infections.", [["fever", "DISEASE", 47, 52], ["dry cough", "DISEASE", 54, 63], ["myalgia", "DISEASE", 65, 72], ["fatigue", "DISEASE", 76, 83], ["viral infections", "DISEASE", 114, 130], ["covid", "TEST", 30, 35], ["fever", "PROBLEM", 47, 52], ["dry cough", "PROBLEM", 54, 63], ["myalgia", "PROBLEM", 65, 72], ["fatigue", "PROBLEM", 76, 83], ["many other viral infections", "PROBLEM", 103, 130], ["cough", "OBSERVATION", 58, 63], ["myalgia", "OBSERVATION", 65, 72], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infections", "OBSERVATION", 120, 130]]], ["3 4 According to a study by the Chinese Center for Disease Control and Prevention of 44 672 laboratory confirmed, 10 567 clinically diagnosed and 16 186 suspected cases of covid-19, 81.4% exhibited mild illness (with no or mild symptoms of pneumonia), 13.9% had severe symptoms (dyspnoea with respiratory rate \u226530/ min, SpO 2 \u226493%, PaO 2 /FiO 2 <300 and/or infiltration of lung field >50% within 24-48 hours), and 4.7% were critically ill (respiratory failure, septic shock and/or multiorgan failure).", [["respiratory", "ANATOMY", 293, 304], ["lung", "ANATOMY", 373, 377], ["respiratory", "ANATOMY", 440, 451], ["multiorgan", "ANATOMY", 481, 491], ["illness", "DISEASE", 203, 210], ["pneumonia", "DISEASE", 240, 249], ["dyspnoea", "DISEASE", 279, 287], ["critically ill", "DISEASE", 424, 438], ["respiratory failure", "DISEASE", 440, 459], ["septic shock", "DISEASE", 461, 473], ["multiorgan failure", "DISEASE", 481, 499], ["lung", "ORGAN", 373, 377], ["multiorgan", "ORGAN", 481, 491], ["a study", "TEST", 17, 24], ["Disease Control", "TREATMENT", 51, 66], ["covid", "TEST", 172, 177], ["mild illness", "PROBLEM", 198, 210], ["mild symptoms", "PROBLEM", 223, 236], ["pneumonia", "PROBLEM", 240, 249], ["severe symptoms", "PROBLEM", 262, 277], ["dyspnoea", "PROBLEM", 279, 287], ["respiratory rate", "TEST", 293, 309], ["SpO", "TEST", 320, 323], ["PaO", "TEST", 332, 335], ["FiO", "TEST", 339, 342], ["infiltration of lung field", "PROBLEM", 357, 383], ["critically ill", "PROBLEM", 424, 438], ["respiratory failure", "PROBLEM", 440, 459], ["septic shock", "PROBLEM", 461, 473], ["multiorgan failure", "PROBLEM", 481, 499], ["mild", "OBSERVATION_MODIFIER", 198, 202], ["illness", "OBSERVATION", 203, 210], ["pneumonia", "OBSERVATION", 240, 249], ["infiltration", "OBSERVATION", 357, 369], ["lung", "ANATOMY", 373, 377], ["respiratory failure", "OBSERVATION", 440, 459], ["septic shock", "OBSERVATION", 461, 473], ["multiorgan failure", "OBSERVATION", 481, 499]]], ["5 In patients with severe or critical disease, viral pneumonia can progress to acute respiratory distress syndrome (ARDS), and multisystem failure accompanied by a cytokine storm.", [["respiratory", "ANATOMY", 85, 96], ["viral pneumonia", "DISEASE", 47, 62], ["acute respiratory distress syndrome", "DISEASE", 79, 114], ["ARDS", "DISEASE", 116, 120], ["multisystem failure", "DISEASE", 127, 146], ["patients", "ORGANISM", 5, 13], ["cytokine", "PROTEIN", 164, 172], ["patients", "SPECIES", 5, 13], ["severe or critical disease", "PROBLEM", 19, 45], ["viral pneumonia", "PROBLEM", 47, 62], ["acute respiratory distress syndrome", "PROBLEM", 79, 114], ["ARDS", "PROBLEM", 116, 120], ["multisystem failure", "PROBLEM", 127, 146], ["a cytokine storm", "PROBLEM", 162, 178], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["critical", "OBSERVATION_MODIFIER", 29, 37], ["disease", "OBSERVATION", 38, 45], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["pneumonia", "OBSERVATION", 53, 62], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory distress", "OBSERVATION", 85, 105], ["ARDS", "OBSERVATION", 116, 120], ["multisystem", "OBSERVATION_MODIFIER", 127, 138], ["failure", "OBSERVATION", 139, 146], ["cytokine storm", "OBSERVATION", 164, 178]]], ["5 Since patients with covid-19 with cardiovascular comorbidities have higher mortality, 5 and the severity of covid-19 disease correlates with cardiovascular manifestations, 6 it is important to understand the interaction of covid-19 and cardiovascular disease (CVD).", [["cardiovascular", "ANATOMY", 36, 50], ["cardiovascular", "ANATOMY", 143, 157], ["cardiovascular", "ANATOMY", 238, 252], ["cardiovascular comorbidities", "DISEASE", 36, 64], ["cardiovascular disease", "DISEASE", 238, 260], ["CVD", "DISEASE", 262, 265], ["patients", "ORGANISM", 8, 16], ["cardiovascular", "ANATOMICAL_SYSTEM", 36, 50], ["cardiovascular", "ANATOMICAL_SYSTEM", 143, 157], ["covid-19", "GENE_OR_GENE_PRODUCT", 225, 233], ["cardiovascular", "ANATOMICAL_SYSTEM", 238, 252], ["patients", "SPECIES", 8, 16], ["covid", "TEST", 22, 27], ["cardiovascular comorbidities", "PROBLEM", 36, 64], ["covid-19 disease", "PROBLEM", 110, 126], ["cardiovascular manifestations", "PROBLEM", 143, 172], ["cardiovascular disease (CVD", "PROBLEM", 238, 265], ["cardiovascular", "ANATOMY", 238, 252], ["disease", "OBSERVATION", 253, 260]]], ["This review will summarise our current understanding of the cardiovascular manifestations of covid-19, as compared with SARS (caused by SARS-CoV), the Middle East respiratory syndrome (MERS) (caused by MERS-CoV) and influenza.", [["cardiovascular", "ANATOMY", 60, 74], ["SARS", "DISEASE", 120, 124], ["SARS-CoV)", "DISEASE", 136, 145], ["Middle East respiratory syndrome", "DISEASE", 151, 183], ["MERS", "DISEASE", 185, 189], ["influenza", "DISEASE", 216, 225], ["cardiovascular", "ANATOMICAL_SYSTEM", 60, 74], ["SARS-CoV", "ORGANISM", 136, 144], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 202, 210], ["SARS-CoV", "SPECIES", 136, 144], ["Middle East respiratory syndrome (MERS)", "SPECIES", 151, 190], ["MERS-CoV", "SPECIES", 202, 210], ["covid", "TEST", 93, 98], ["SARS", "PROBLEM", 120, 124], ["SARS", "PROBLEM", 136, 140], ["the Middle East respiratory syndrome", "PROBLEM", 147, 183], ["influenza", "PROBLEM", 216, 225], ["Middle", "ANATOMY_MODIFIER", 151, 157], ["respiratory syndrome", "OBSERVATION", 163, 183]]], ["We will also discuss cardiovascular considerations regarding treatment strategies.CARdIovAsCulAR ComoRbIdITIesThe prevalence of diabetes mellitus (DM) and obesity in patients with covid-19 in the USA appear to be higher than in the general population, but the prevalence of CVD appears to be similar (table 1) .", [["cardiovascular", "ANATOMY", 21, 35], ["diabetes mellitus", "DISEASE", 128, 145], ["DM", "DISEASE", 147, 149], ["obesity", "DISEASE", 155, 162], ["CVD", "DISEASE", 274, 277], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["treatment strategies", "TREATMENT", 61, 81], ["diabetes mellitus", "PROBLEM", 128, 145], ["DM)", "PROBLEM", 147, 150], ["obesity", "PROBLEM", 155, 162], ["covid", "TEST", 180, 185], ["CVD", "PROBLEM", 274, 277], ["ComoRbIdITIes", "OBSERVATION", 97, 110], ["diabetes mellitus", "OBSERVATION", 128, 145], ["obesity", "OBSERVATION", 155, 162], ["higher", "OBSERVATION_MODIFIER", 213, 219]]], ["However, in hospitalised patients with covid-19 with more severe disease, DM, hypertension and CVD seem to be more prevalent in both the USA and China, similar to MERS and influenza (table 2) .", [["DM", "DISEASE", 74, 76], ["hypertension", "DISEASE", 78, 90], ["CVD", "DISEASE", 95, 98], ["MERS", "DISEASE", 163, 167], ["influenza", "DISEASE", 172, 181], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["covid", "TEST", 39, 44], ["more severe disease", "PROBLEM", 53, 72], ["DM", "PROBLEM", 74, 76], ["hypertension", "PROBLEM", 78, 90], ["CVD", "PROBLEM", 95, 98], ["influenza", "PROBLEM", 172, 181], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 65, 72], ["DM", "OBSERVATION", 74, 76], ["hypertension", "OBSERVATION", 78, 90]]], ["A retrospective, single-centre case series of 187 patients with covid-19 found that patients with underlying CVD were more likely to have cardiac injury (troponin (Tn) elevation) compared with patients without CVD (54.5% vs 13.2%).", [["cardiac", "ANATOMY", 138, 145], ["CVD", "DISEASE", 109, 112], ["cardiac injury", "DISEASE", 138, 152], ["CVD", "DISEASE", 210, 213], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 84, 92], ["cardiac", "ORGAN", 138, 145], ["troponin (Tn)", "GENE_OR_GENE_PRODUCT", 154, 167], ["patients", "ORGANISM", 193, 201], ["Tn", "PROTEIN", 164, 166], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 193, 201], ["covid", "TEST", 64, 69], ["underlying CVD", "PROBLEM", 98, 112], ["cardiac injury", "PROBLEM", 138, 152], ["troponin (Tn) elevation", "PROBLEM", 154, 177], ["CVD", "TEST", 210, 213], ["cardiac", "ANATOMY", 138, 145], ["injury", "OBSERVATION", 146, 152]]], ["6 In-hospital mortality was 7.6% for patients without underlying CVD and normal Tn, 13.3% for those with CVD and normal Tn, 37.5% for those without CVD but elevated Tn and 69.4% for those with CVD and elevated Tn.", [["CVD", "DISEASE", 65, 68], ["CVD", "DISEASE", 105, 108], ["CVD", "DISEASE", 148, 151], ["CVD", "DISEASE", 193, 196], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["underlying CVD", "PROBLEM", 54, 68], ["CVD", "TEST", 105, 108], ["CVD", "PROBLEM", 148, 151], ["elevated Tn", "PROBLEM", 156, 167], ["CVD", "PROBLEM", 193, 196], ["elevated Tn.", "PROBLEM", 201, 213], ["normal", "OBSERVATION", 73, 79], ["normal", "OBSERVATION", 113, 119], ["elevated", "OBSERVATION", 156, 164], ["elevated", "OBSERVATION", 201, 209]]], ["6 These observations suggest that although patients with pre-existing CVD may not be more susceptible to contracting SARS-CoV-2, they are prone to more severe complications of covid-19 with increased mortality.", [["CVD", "DISEASE", 70, 73], ["SARS", "DISEASE", 117, 121], ["patients", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 117, 127], ["patients", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 117, 125], ["pre-existing CVD", "PROBLEM", 57, 73], ["CoV", "TEST", 122, 125], ["covid", "TEST", 176, 181], ["increased mortality", "PROBLEM", 190, 209], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["increased", "OBSERVATION_MODIFIER", 190, 199], ["mortality", "OBSERVATION", 200, 209]]], ["7 The association of cardiovascular and other comorbidities with case fatality rate is summarised in figure 1.CARdIovAsCulAR ComoRbIdITIesThe higher mortality in patients with cardiovascular comorbidities may be directly attributable to underlying CVD or merely coincident with CVD.", [["cardiovascular", "ANATOMY", 21, 35], ["cardiovascular", "ANATOMY", 176, 190], ["cardiovascular and other comorbidities", "DISEASE", 21, 59], ["cardiovascular comorbidities", "DISEASE", 176, 204], ["CVD", "DISEASE", 248, 251], ["CVD", "DISEASE", 278, 281], ["cardiovascular", "ANATOMICAL_SYSTEM", 21, 35], ["patients", "ORGANISM", 162, 170], ["cardiovascular", "ANATOMICAL_SYSTEM", 176, 190], ["patients", "SPECIES", 162, 170], ["cardiovascular and other comorbidities", "PROBLEM", 21, 59], ["case fatality rate", "PROBLEM", 65, 83], ["CARdIovAsCulAR ComoRbIdITIes", "PROBLEM", 110, 138], ["cardiovascular comorbidities", "PROBLEM", 176, 204], ["underlying CVD", "PROBLEM", 237, 251], ["CVD", "PROBLEM", 278, 281], ["ComoRbIdITIes", "OBSERVATION", 125, 138], ["higher", "OBSERVATION_MODIFIER", 142, 148], ["mortality", "OBSERVATION_MODIFIER", 149, 158]]], ["CVD may also be a marker of accelerated ageing, immune system dysregulation, or other mechanisms that affect covid-19 prognosis.", [["immune system", "ANATOMY", 48, 61], ["CVD", "DISEASE", 0, 3], ["CVD", "PROBLEM", 0, 3], ["accelerated ageing", "PROBLEM", 28, 46], ["immune system dysregulation", "PROBLEM", 48, 75], ["may also be", "UNCERTAINTY", 4, 15]]], ["Age is both a risk factor for CVD and an important determinant of covid-19 fatality, which has been found to be 14.8% in patients older than 80 years of age but <4% in patients younger than 70 years of age.", [["CVD", "DISEASE", 30, 33], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 168, 176], ["CVD", "PROBLEM", 30, 33], ["covid", "TEST", 66, 71]]], ["5 Patients with elevated Tn levels were older than patients with normal Tn (71.4\u00b19.4 vs 53.5\u00b113.2 years).", [["Patients", "ORGANISM", 2, 10], ["Tn", "GENE_OR_GENE_PRODUCT", 25, 27], ["patients", "ORGANISM", 51, 59], ["Tn", "GENE_OR_GENE_PRODUCT", 72, 74], ["Tn", "PROTEIN", 25, 27], ["Patients", "SPECIES", 2, 10], ["patients", "SPECIES", 51, 59], ["elevated Tn levels", "PROBLEM", 16, 34], ["Tn", "TEST", 72, 74]]], ["6 In addition, ageing weakens the immune system, as demonstrated by the lower protective titres after influenza vaccination in 50% of adults older than 65 years of age.", [["immune system", "ANATOMY", 34, 47], ["the lower protective titres", "TREATMENT", 68, 95], ["influenza vaccination", "TREATMENT", 102, 123]]], ["8PAThoPhysIology of CARdIAC InjuRySARS-CoV-2 is an enveloped, positive-sense singlestranded RNA virus.", [["InjuRySARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 44], ["CARdIAC InjuRySARS-CoV-2", "DNA", 20, 44], ["CARdIAC InjuRySARS", "TEST", 20, 38], ["CoV", "TEST", 39, 42], ["sense singlestranded RNA virus", "PROBLEM", 71, 101], ["CARdIAC", "ANATOMY", 20, 27], ["InjuRySARS", "OBSERVATION", 28, 38], ["RNA virus", "OBSERVATION", 92, 101]]], ["9 SARS-CoV-2 and other similar coronaviruses use the ACE 2 (ACE2) protein for ligand binding before entering the cell via receptor-mediated endocytosis.", [["cell", "ANATOMY", 113, 117], ["CoV-2", "ORGANISM", 7, 12], ["coronaviruses", "ORGANISM", 31, 44], ["ACE 2", "GENE_OR_GENE_PRODUCT", 53, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["cell", "CELL", 113, 117], ["ACE 2 (ACE2) protein", "PROTEIN", 53, 73], ["CoV", "TEST", 7, 10], ["other similar coronaviruses", "PROBLEM", 17, 44], ["the ACE 2 (ACE2) protein", "TREATMENT", 49, 73], ["ligand binding", "PROBLEM", 78, 92]]], ["10 Recent data on viral structure reveal that SARS-CoV-2 has tighter interaction with the human ACE2 receptor binding domain as compared with SARS-CoV, which may explain in part the greater transmissibility of the current virus among humans.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["human", "ORGANISM", 90, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS-CoV", "ORGANISM", 142, 150], ["humans", "ORGANISM", 234, 240], ["human ACE2 receptor binding domain", "PROTEIN", 90, 124], ["human", "SPECIES", 90, 95], ["humans", "SPECIES", 234, 240], ["SARS-CoV", "SPECIES", 46, 54], ["human", "SPECIES", 90, 95], ["SARS-CoV", "SPECIES", 142, 150], ["humans", "SPECIES", 234, 240], ["viral structure", "TEST", 18, 33], ["SARS", "PROBLEM", 46, 50], ["the human ACE2 receptor binding domain", "TREATMENT", 86, 124], ["SARS-CoV", "PROBLEM", 142, 150], ["virus", "OBSERVATION", 222, 227]]], ["11 ACE2 is a membrane protein that serves many physiological functions in the lungs, heart, kidneys and other organs.", [["membrane", "ANATOMY", 13, 21], ["lungs", "ANATOMY", 78, 83], ["heart", "ANATOMY", 85, 90], ["kidneys", "ANATOMY", 92, 99], ["organs", "ANATOMY", 110, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["lungs", "ORGAN", 78, 83], ["heart", "ORGAN", 85, 90], ["kidneys", "ORGAN", 92, 99], ["organs", "ORGAN", 110, 116], ["ACE2", "PROTEIN", 3, 7], ["membrane protein", "PROTEIN", 13, 29], ["a membrane protein", "TREATMENT", 11, 29], ["lungs", "ANATOMY", 78, 83], ["heart", "ANATOMY", 85, 90], ["kidneys", "ANATOMY", 92, 99], ["organs", "ANATOMY", 110, 116]]], ["12 It is highly expressed in type 2 lung alveolar cells, which provides an explanation for the respiratory symptoms experienced by patients with covid-19.", [["type 2 lung alveolar cells", "ANATOMY", 29, 55], ["respiratory", "ANATOMY", 95, 106], ["respiratory symptoms", "DISEASE", 95, 115], ["type 2 lung alveolar cells", "CELL", 29, 55], ["patients", "ORGANISM", 131, 139], ["type 2 lung alveolar cells", "CELL_TYPE", 29, 55], ["patients", "SPECIES", 131, 139], ["type 2 lung alveolar cells", "PROBLEM", 29, 55], ["the respiratory symptoms", "PROBLEM", 91, 115], ["covid", "TEST", 145, 150], ["lung", "ANATOMY", 36, 40], ["alveolar cells", "OBSERVATION", 41, 55]]], ["13 More than 7.5% of myocardial cells have positive ACE2 expression, based on single-cell RNA sequencing, 14 which could mediate SARS-CoV-2 entry into cardiomyocytes and cause direct cardiotoxicity.", [["myocardial cells", "ANATOMY", 21, 37], ["cardiomyocytes", "ANATOMY", 151, 165], ["cardiotoxicity", "DISEASE", 183, 197], ["myocardial cells", "CELL", 21, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 129, 139], ["cardiomyocytes", "CELL", 151, 165], ["myocardial cells", "CELL_TYPE", 21, 37], ["ACE2", "PROTEIN", 52, 56], ["cardiomyocytes", "CELL_TYPE", 151, 165], ["myocardial cells", "TEST", 21, 37], ["positive ACE2 expression", "PROBLEM", 43, 67], ["single-cell RNA sequencing", "TEST", 78, 104], ["CoV", "TEST", 134, 137], ["direct cardiotoxicity", "PROBLEM", 176, 197], ["myocardial", "ANATOMY", 21, 31], ["ACE2 expression", "OBSERVATION", 52, 67], ["cardiomyocytes", "ANATOMY", 151, 165]]], ["The mechanisms of cardiovascular injury from covid-19 have not been fully elucidated and are likely multifactorial.", [["cardiovascular", "ANATOMY", 18, 32], ["cardiovascular injury", "DISEASE", 18, 39], ["covid-19", "CHEMICAL", 45, 53], ["cardiovascular", "ANATOMICAL_SYSTEM", 18, 32], ["cardiovascular injury", "PROBLEM", 18, 39], ["covid", "TEST", 45, 50], ["cardiovascular", "ANATOMY", 18, 32], ["injury", "OBSERVATION", 33, 39], ["likely", "UNCERTAINTY", 93, 99], ["multifactorial", "OBSERVATION_MODIFIER", 100, 114]]], ["SARS-CoV-2 viral particles have been identified by RT-PCR in cardiac tissue in some cases, 15 supporting that direct cardiotoxicity may occur.", [["cardiac tissue", "ANATOMY", 61, 75], ["SARS", "DISEASE", 0, 4], ["cardiotoxicity", "DISEASE", 117, 131], ["SARS-CoV-2", "ORGANISM", 0, 10], ["cardiac tissue", "TISSUE", 61, 75], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["2 viral particles", "PROBLEM", 9, 26], ["PCR", "TEST", 54, 57], ["direct cardiotoxicity", "PROBLEM", 110, 131], ["cardiac tissue", "ANATOMY", 61, 75]]], ["Virally driven hyperinflammation with cytokine release may lead to vascular inflammation, plaque instability, myocardial inflammation, a hypercoagulable state, and direct myocardial suppression.", [["vascular", "ANATOMY", 67, 75], ["plaque", "ANATOMY", 90, 96], ["myocardial", "ANATOMY", 110, 120], ["myocardial", "ANATOMY", 171, 181], ["hyperinflammation", "DISEASE", 15, 32], ["inflammation", "DISEASE", 76, 88], ["plaque instability", "DISEASE", 90, 108], ["myocardial inflammation", "DISEASE", 110, 133], ["myocardial suppression", "DISEASE", 171, 193], ["vascular", "MULTI-TISSUE_STRUCTURE", 67, 75], ["plaque", "PATHOLOGICAL_FORMATION", 90, 96], ["myocardial", "MULTI-TISSUE_STRUCTURE", 110, 120], ["myocardial", "MULTI-TISSUE_STRUCTURE", 171, 181], ["cytokine", "PROTEIN", 38, 46], ["Virally driven hyperinflammation", "PROBLEM", 0, 32], ["cytokine release", "TREATMENT", 38, 54], ["vascular inflammation", "PROBLEM", 67, 88], ["plaque instability", "PROBLEM", 90, 108], ["myocardial inflammation", "PROBLEM", 110, 133], ["a hypercoagulable state", "PROBLEM", 135, 158], ["direct myocardial suppression", "PROBLEM", 164, 193], ["may lead to", "UNCERTAINTY", 55, 66], ["vascular", "ANATOMY", 67, 75], ["inflammation", "OBSERVATION", 76, 88], ["plaque", "OBSERVATION_MODIFIER", 90, 96], ["instability", "OBSERVATION", 97, 108], ["myocardial", "ANATOMY", 110, 120], ["inflammation", "OBSERVATION", 121, 133], ["hypercoagulable state", "OBSERVATION", 137, 158], ["myocardial", "ANATOMY", 171, 181], ["suppression", "OBSERVATION", 182, 193]]], ["16 17 Other systemic consequences of covid-19 infection, including sepsis and disseminated intravascular coagulation (DIC), may also mediate cardiac injury.", [["intravascular", "ANATOMY", 91, 104], ["cardiac", "ANATOMY", 141, 148], ["infection", "DISEASE", 46, 55], ["sepsis", "DISEASE", 67, 73], ["disseminated intravascular coagulation", "DISEASE", 78, 116], ["DIC", "DISEASE", 118, 121], ["cardiac injury", "DISEASE", 141, 155], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["cardiac", "ORGAN", 141, 148], ["covid-19", "SPECIES", 37, 45], ["covid", "TEST", 37, 42], ["19 infection", "PROBLEM", 43, 55], ["sepsis", "PROBLEM", 67, 73], ["disseminated intravascular coagulation", "PROBLEM", 78, 116], ["cardiac injury", "PROBLEM", 141, 155], ["infection", "OBSERVATION", 46, 55], ["sepsis", "OBSERVATION", 67, 73], ["disseminated", "OBSERVATION_MODIFIER", 78, 90], ["intravascular coagulation", "OBSERVATION", 91, 116], ["cardiac", "ANATOMY", 141, 148], ["injury", "OBSERVATION", 149, 155]]], ["Based on postmortem biopsies, the pathological features of covid-19 in multiple organs greatly resemble those seen in SARS 18 19 and MERS.", [["organs", "ANATOMY", 80, 86], ["SARS", "DISEASE", 118, 122], ["postmortem biopsies", "MULTI-TISSUE_STRUCTURE", 9, 28], ["organs", "ORGAN", 80, 86], ["postmortem biopsies", "TEST", 9, 28], ["the pathological features", "TEST", 30, 55], ["covid", "TEST", 59, 64], ["SARS", "TEST", 118, 122]]], ["20 21 In cardiac tissue, pathological findings vary from minimal change to interstitial inflammatory infiltration and myocyte necrosis (table 3).", [["cardiac tissue", "ANATOMY", 9, 23], ["interstitial", "ANATOMY", 75, 87], ["myocyte", "ANATOMY", 118, 125], ["necrosis", "DISEASE", 126, 134], ["cardiac tissue", "TISSUE", 9, 23], ["interstitial inflammatory infiltration", "PROBLEM", 75, 113], ["myocyte necrosis", "PROBLEM", 118, 134], ["cardiac tissue", "ANATOMY", 9, 23], ["pathological", "OBSERVATION", 25, 37], ["minimal", "OBSERVATION_MODIFIER", 57, 64], ["change", "OBSERVATION_MODIFIER", 65, 71], ["interstitial", "ANATOMY_MODIFIER", 75, 87], ["inflammatory infiltration", "OBSERVATION", 88, 113], ["myocyte", "ANATOMY", 118, 125], ["necrosis", "OBSERVATION", 126, 134]]], ["In the vasculature, microthrombosis and vascular inflammation could be found (table 3) .CARdIovAsCulAR mAnIfesTATIonsThe clinical cardiovascular manifestations of covid-19 include elevation of cardiac biomarkers (ischaemic or non-ischaemic aetiology), cardiac arrhythmia, arterial and venous thromboembolism (VTE), and cardiogenic shock and arrest.", [["vasculature", "ANATOMY", 7, 18], ["vascular", "ANATOMY", 40, 48], ["cardiovascular", "ANATOMY", 130, 144], ["cardiac", "ANATOMY", 193, 200], ["cardiac", "ANATOMY", 252, 259], ["arterial", "ANATOMY", 272, 280], ["venous", "ANATOMY", 285, 291], ["microthrombosis", "DISEASE", 20, 35], ["vascular inflammation", "DISEASE", 40, 61], ["ischaemic or non-ischaemic aetiology", "DISEASE", 213, 249], ["cardiac arrhythmia", "DISEASE", 252, 270], ["arterial and venous thromboembolism", "DISEASE", 272, 307], ["VTE", "DISEASE", 309, 312], ["cardiogenic shock", "DISEASE", 319, 336], ["vasculature", "MULTI-TISSUE_STRUCTURE", 7, 18], ["vascular", "MULTI-TISSUE_STRUCTURE", 40, 48], ["cardiac", "ORGAN", 193, 200], ["cardiac", "ORGAN", 252, 259], ["arterial", "MULTI-TISSUE_STRUCTURE", 272, 280], ["venous", "MULTI-TISSUE_STRUCTURE", 285, 291], ["microthrombosis", "PROBLEM", 20, 35], ["vascular inflammation", "PROBLEM", 40, 61], ["CARdIovAsCulAR mAnIfesTATIons", "PROBLEM", 88, 117], ["covid", "TEST", 163, 168], ["elevation of cardiac biomarkers", "PROBLEM", 180, 211], ["ischaemic or non-ischaemic aetiology", "PROBLEM", 213, 249], ["cardiac arrhythmia", "PROBLEM", 252, 270], ["arterial and venous thromboembolism", "PROBLEM", 272, 307], ["VTE", "PROBLEM", 309, 312], ["cardiogenic shock", "PROBLEM", 319, 336], ["arrest", "PROBLEM", 341, 347], ["vasculature", "ANATOMY", 7, 18], ["microthrombosis", "OBSERVATION", 20, 35], ["vascular", "ANATOMY", 40, 48], ["inflammation", "OBSERVATION", 49, 61], ["elevation", "OBSERVATION", 180, 189], ["cardiac", "ANATOMY", 193, 200], ["ischaemic", "OBSERVATION_MODIFIER", 213, 222], ["non-ischaemic", "OBSERVATION", 226, 239], ["cardiac", "ANATOMY", 252, 259], ["arrhythmia", "OBSERVATION", 260, 270], ["arterial", "ANATOMY", 272, 280], ["venous", "ANATOMY", 285, 291], ["thromboembolism", "OBSERVATION", 292, 307], ["cardiogenic shock", "OBSERVATION", 319, 336], ["arrest", "OBSERVATION_MODIFIER", 341, 347]]], ["The possible mechanisms and cardiovascular manifestations are shown in figure 2 .elevation of cardiac biomarkersMyocardial injury is common among patients with covid-19 infection and correlates with disease severity.", [["cardiovascular", "ANATOMY", 28, 42], ["cardiac", "ANATOMY", 94, 101], ["Myocardial", "ANATOMY", 112, 122], ["Myocardial injury", "DISEASE", 112, 129], ["infection", "DISEASE", 169, 178], ["cardiac", "ORGAN", 94, 101], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 112, 122], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["cardiovascular manifestations", "PROBLEM", 28, 57], ["cardiac biomarkers", "TEST", 94, 112], ["Myocardial injury", "PROBLEM", 112, 129], ["covid-19 infection", "PROBLEM", 160, 178], ["disease severity", "PROBLEM", 199, 215], ["possible", "UNCERTAINTY", 4, 12], ["cardiac", "ANATOMY", 94, 101], ["injury", "OBSERVATION", 123, 129], ["infection", "OBSERVATION", 169, 178]]], ["Although somewhat variable, studies on patients with covid-19 have generally defined myocardial injury as the elevation of high-sensitivity cardiac troponin (hs-cTn) above the 99th percentile of its upper limit of normal or evidence of new electrocardiographic or echocardiographic abnormalities.", [["myocardial", "ANATOMY", 85, 95], ["myocardial injury", "DISEASE", 85, 102], ["patients", "ORGANISM", 39, 47], ["myocardial", "MULTI-TISSUE_STRUCTURE", 85, 95], ["cardiac troponin", "GENE_OR_GENE_PRODUCT", 140, 156], ["hs-cTn", "GENE_OR_GENE_PRODUCT", 158, 164], ["high-sensitivity cardiac troponin", "PROTEIN", 123, 156], ["hs", "PROTEIN", 158, 160], ["cTn", "PROTEIN", 161, 164], ["patients", "SPECIES", 39, 47], ["studies", "TEST", 28, 35], ["covid", "TEST", 53, 58], ["generally defined myocardial injury", "PROBLEM", 67, 102], ["the elevation", "PROBLEM", 106, 119], ["new electrocardiographic or echocardiographic abnormalities", "PROBLEM", 236, 295], ["myocardial", "ANATOMY", 85, 95], ["injury", "OBSERVATION", 96, 102], ["elevation", "OBSERVATION_MODIFIER", 110, 119], ["high", "OBSERVATION_MODIFIER", 123, 127], ["upper limit", "OBSERVATION_MODIFIER", 199, 210], ["normal", "OBSERVATION", 214, 220], ["evidence of", "UNCERTAINTY", 224, 235], ["new", "OBSERVATION_MODIFIER", 236, 239], ["abnormalities", "OBSERVATION", 282, 295]]], ["3 22 Increased levels of hs-cTn correlate with disease severity and mortality rate in covid-19, even after controlling for other comorbidities.", [["hs-cTn", "GENE_OR_GENE_PRODUCT", 25, 31], ["cTn", "PROTEIN", 28, 31], ["hs", "TEST", 25, 27], ["disease severity", "PROBLEM", 47, 63], ["mortality rate", "TEST", 68, 82], ["covid", "TEST", 86, 91], ["other comorbidities", "PROBLEM", 123, 142]]], ["23 A summary of studies with prevalence of myocardial injury and risk of severe disease or mortality is shown in table 4.elevation of cardiac biomarkersThe pattern in the rise of cTn levels is also significant from a prognostic standpoint.", [["myocardial", "ANATOMY", 43, 53], ["cardiac", "ANATOMY", 134, 141], ["myocardial injury", "DISEASE", 43, 60], ["myocardial", "MULTI-TISSUE_STRUCTURE", 43, 53], ["cardiac", "ORGAN", 134, 141], ["cTn", "GENE_OR_GENE_PRODUCT", 179, 182], ["cTn", "PROTEIN", 179, 182], ["studies", "TEST", 16, 23], ["myocardial injury", "PROBLEM", 43, 60], ["severe disease", "PROBLEM", 73, 87], ["mortality", "PROBLEM", 91, 100], ["cardiac biomarkers", "TEST", 134, 152], ["cTn levels", "TEST", 179, 189], ["myocardial", "ANATOMY", 43, 53], ["injury", "OBSERVATION", 54, 60], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87], ["cardiac", "ANATOMY", 134, 141], ["pattern", "OBSERVATION_MODIFIER", 156, 163], ["rise", "OBSERVATION_MODIFIER", 171, 175], ["significant", "OBSERVATION_MODIFIER", 198, 209]]], ["Non-survivors had a higher level of Tn elevation which continued to rise until death (mean time from symptom onset to death was 18.5 days (IQR 15-20 days)), while Tn levels for survivors remained unchanged.", [["death", "DISEASE", 79, 84], ["death", "DISEASE", 118, 123], ["Tn", "GENE_OR_GENE_PRODUCT", 36, 38], ["Tn", "GENE_OR_GENE_PRODUCT", 163, 165], ["Tn", "PROTEIN", 36, 38], ["Tn", "PROTEIN", 163, 165], ["Tn elevation", "PROBLEM", 36, 48], ["death", "PROBLEM", 79, 84], ["Tn levels", "TEST", 163, 172], ["unchanged", "OBSERVATION_MODIFIER", 196, 205]]], ["22 This finding may support the monitoring of cTn levels every few days in hospitalised patients.elevation of cardiac biomarkersIt is a challenging task to differentiate potential aetiologies of cardiac injury: acute coronary syndrome (ACS) due to plaque rupture or thrombosis (type I myocardial infarction (MI)) or supply-demand mismatch (type II MI), myocardial injury due to DIC, and non-ischaemic injury (myocarditis, stress-induced cardiomyopathy, or cytokine release syndrome).Ischaemic myocardial injury Myocardial infarctionSevere viral infections can cause a systemic inflammatory response syndrome that increases the risk of plaque rupture and thrombus formation, resulting in either an ST-elevation MI or non-ST-elevation MI.", [["cardiac", "ANATOMY", 110, 117], ["cardiac", "ANATOMY", 195, 202], ["coronary", "ANATOMY", 217, 225], ["plaque", "ANATOMY", 248, 254], ["myocardial", "ANATOMY", 285, 295], ["myocardial", "ANATOMY", 353, 363], ["myocardial", "ANATOMY", 493, 503], ["Myocardial", "ANATOMY", 511, 521], ["plaque", "ANATOMY", 635, 641], ["thrombus", "ANATOMY", 654, 662], ["cardiac injury", "DISEASE", 195, 209], ["acute coronary syndrome", "DISEASE", 211, 234], ["ACS", "DISEASE", 236, 239], ["plaque rupture", "DISEASE", 248, 262], ["thrombosis", "DISEASE", 266, 276], ["type I myocardial infarction", "DISEASE", 278, 306], ["MI", "DISEASE", 308, 310], ["MI", "DISEASE", 348, 350], ["myocardial injury", "DISEASE", 353, 370], ["DIC", "DISEASE", 378, 381], ["non-ischaemic injury", "DISEASE", 387, 407], ["myocarditis", "DISEASE", 409, 420], ["cardiomyopathy", "DISEASE", 437, 451], ["Ischaemic myocardial injury", "DISEASE", 483, 510], ["Myocardial infarction", "DISEASE", 511, 532], ["viral infections", "DISEASE", 539, 555], ["plaque rupture", "DISEASE", 635, 649], ["thrombus", "DISEASE", 654, 662], ["MI", "DISEASE", 710, 712], ["non-ST", "DISEASE", 716, 722], ["MI", "DISEASE", 733, 735], ["cTn", "GENE_OR_GENE_PRODUCT", 46, 49], ["patients", "ORGANISM", 88, 96], ["cardiac", "ORGAN", 110, 117], ["cardiac", "ORGAN", 195, 202], ["coronary", "MULTI-TISSUE_STRUCTURE", 217, 225], ["plaque", "PATHOLOGICAL_FORMATION", 248, 254], ["myocardial", "MULTI-TISSUE_STRUCTURE", 285, 295], ["myocardial", "MULTI-TISSUE_STRUCTURE", 353, 363], ["myocardial", "MULTI-TISSUE_STRUCTURE", 493, 503], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 511, 521], ["plaque rupture", "PATHOLOGICAL_FORMATION", 635, 649], ["thrombus", "PATHOLOGICAL_FORMATION", 654, 662], ["cTn", "PROTEIN", 46, 49], ["cytokine", "PROTEIN", 456, 464], ["patients", "SPECIES", 88, 96], ["the monitoring of cTn levels", "TEST", 28, 56], ["cardiac biomarkers", "TEST", 110, 128], ["cardiac injury", "PROBLEM", 195, 209], ["acute coronary syndrome", "PROBLEM", 211, 234], ["ACS)", "PROBLEM", 236, 240], ["plaque rupture", "PROBLEM", 248, 262], ["thrombosis", "PROBLEM", 266, 276], ["type I myocardial infarction", "PROBLEM", 278, 306], ["MI", "PROBLEM", 308, 310], ["demand mismatch", "PROBLEM", 323, 338], ["type II MI", "PROBLEM", 340, 350], ["myocardial injury", "PROBLEM", 353, 370], ["DIC", "PROBLEM", 378, 381], ["non-ischaemic injury", "PROBLEM", 387, 407], ["myocarditis", "PROBLEM", 409, 420], ["stress-induced cardiomyopathy", "PROBLEM", 422, 451], ["cytokine release syndrome", "PROBLEM", 456, 481], ["Ischaemic myocardial injury", "PROBLEM", 483, 510], ["Myocardial infarction", "PROBLEM", 511, 532], ["Severe viral infections", "PROBLEM", 532, 555], ["a systemic inflammatory response syndrome", "PROBLEM", 566, 607], ["plaque rupture", "PROBLEM", 635, 649], ["thrombus formation", "PROBLEM", 654, 672], ["an ST-elevation MI", "PROBLEM", 694, 712], ["non-ST-elevation MI", "PROBLEM", 716, 735], ["cardiac", "ANATOMY", 110, 117], ["cardiac", "ANATOMY", 195, 202], ["injury", "OBSERVATION", 203, 209], ["acute", "OBSERVATION_MODIFIER", 211, 216], ["coronary", "ANATOMY", 217, 225], ["syndrome", "OBSERVATION", 226, 234], ["plaque", "OBSERVATION_MODIFIER", 248, 254], ["rupture", "OBSERVATION", 255, 262], ["thrombosis", "OBSERVATION", 266, 276], ["myocardial", "ANATOMY", 285, 295], ["infarction", "OBSERVATION", 296, 306], ["myocardial", "ANATOMY", 353, 363], ["injury", "OBSERVATION", 364, 370], ["non-ischaemic", "OBSERVATION_MODIFIER", 387, 400], ["injury", "OBSERVATION", 401, 407], ["myocarditis", "OBSERVATION", 409, 420], ["myocardial", "ANATOMY", 493, 503], ["injury", "OBSERVATION", 504, 510], ["Myocardial", "ANATOMY", 511, 521], ["infarction", "OBSERVATION", 522, 532], ["viral", "OBSERVATION_MODIFIER", 539, 544], ["infections", "OBSERVATION", 545, 555], ["systemic", "OBSERVATION_MODIFIER", 568, 576], ["inflammatory response syndrome", "OBSERVATION", 577, 607], ["plaque", "OBSERVATION_MODIFIER", 635, 641], ["rupture", "OBSERVATION", 642, 649], ["thrombus", "OBSERVATION", 654, 662], ["elevation", "OBSERVATION_MODIFIER", 700, 709], ["elevation MI", "OBSERVATION", 723, 735]]], ["24 In a study of 75 patients hospitalised with SARS, acute MI was the cause of death in two of five fatal cases.", [["SARS", "DISEASE", 47, 51], ["MI", "DISEASE", 59, 61], ["death", "DISEASE", 79, 84], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["a study", "TEST", 6, 13], ["SARS", "PROBLEM", 47, 51], ["acute MI", "PROBLEM", 53, 61], ["death", "PROBLEM", 79, 84], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["MI", "OBSERVATION", 59, 61]]], ["25 There is also a significant association between acute MI and influenza.", [["MI", "DISEASE", 57, 59], ["influenza", "DISEASE", 64, 73], ["acute MI", "PROBLEM", 51, 59], ["influenza", "PROBLEM", 64, 73], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["MI", "OBSERVATION", 57, 59], ["influenza", "OBSERVATION", 64, 73]]], ["As compared with the prevalence of acute MI Review figure 1 Influence of cardiovascular and other comorbidities on CFR from respiratory viral infections.", [["cardiovascular", "ANATOMY", 73, 87], ["MI", "DISEASE", 41, 43], ["respiratory viral infections", "DISEASE", 124, 152], ["cardiovascular", "ANATOMICAL_SYSTEM", 73, 87], ["acute MI", "PROBLEM", 35, 43], ["other comorbidities", "PROBLEM", 92, 111], ["CFR", "TEST", 115, 118], ["respiratory viral infections", "PROBLEM", 124, 152], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory", "ANATOMY", 124, 135], ["viral infections", "OBSERVATION", 136, 152]]], ["CDC, Center for Disease Control and Prevention; CFR, case fatality rate; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.", [["Middle East respiratory syndrome", "DISEASE", 79, 111], ["SARS", "DISEASE", 113, 117], ["acute respiratory syndrome", "DISEASE", 126, 152], ["Disease Control", "TREATMENT", 16, 31], ["MERS", "PROBLEM", 73, 77], ["Middle East respiratory syndrome", "PROBLEM", 79, 111], ["SARS", "PROBLEM", 113, 117], ["severe acute respiratory syndrome", "PROBLEM", 119, 152], ["respiratory syndrome", "OBSERVATION", 91, 111], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["respiratory syndrome", "OBSERVATION", 132, 152]]], ["Data are from Chinese CDC, 5 Mertz et al, 71 Chan et al 72 and Badawi et al. 73 occurred 1 year before or 7 days to 1 year after influenza, the incidence ratio of acute MI within 7 days of influenza infection was 6.1 (95% CI: 3.9 to 9.5).", [["influenza", "DISEASE", 129, 138], ["MI", "DISEASE", 169, 171], ["influenza infection", "DISEASE", 189, 208], ["influenza", "PROBLEM", 129, 138], ["acute MI", "PROBLEM", 163, 171], ["influenza infection", "PROBLEM", 189, 208], ["CI", "TEST", 222, 224], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["MI", "OBSERVATION", 169, 171]]], ["26 Although reports of type I MI in patients with covid- 19 have not yet been published, anecdotal report was presented.", [["type I MI", "DISEASE", 23, 32], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["type I MI", "PROBLEM", 23, 32], ["covid", "TEST", 50, 55]]], ["27 Treatment of ACS in covid-19 should be according to the updated Society for Cardiovascular Angiography and Interventions guidelines.", [["Cardiovascular", "ANATOMY", 79, 93], ["ACS", "DISEASE", 16, 19], ["ACS", "PROBLEM", 16, 19], ["Cardiovascular Angiography", "TEST", 79, 105], ["Interventions guidelines", "TREATMENT", 110, 134]]], ["28 Severe respiratory viral infections can also lead to decreased oxygen delivery to the myocardium via hypoxaemia and vasoconstriction, as well as the haemodynamic effects of sepsis with increased myocardial oxygen demand.", [["respiratory", "ANATOMY", 10, 21], ["myocardium", "ANATOMY", 89, 99], ["myocardial", "ANATOMY", 198, 208], ["respiratory viral infections", "DISEASE", 10, 38], ["oxygen", "CHEMICAL", 66, 72], ["hypoxaemia", "DISEASE", 104, 114], ["sepsis", "DISEASE", 176, 182], ["oxygen", "CHEMICAL", 209, 215], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "CHEMICAL", 209, 215], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["myocardium", "ORGAN", 89, 99], ["myocardial", "MULTI-TISSUE_STRUCTURE", 198, 208], ["oxygen", "SIMPLE_CHEMICAL", 209, 215], ["Severe respiratory viral infections", "PROBLEM", 3, 38], ["decreased oxygen delivery", "TREATMENT", 56, 81], ["hypoxaemia", "PROBLEM", 104, 114], ["vasoconstriction", "PROBLEM", 119, 135], ["sepsis", "PROBLEM", 176, 182], ["increased myocardial oxygen demand", "PROBLEM", 188, 222], ["respiratory", "ANATOMY", 10, 21], ["viral infections", "OBSERVATION", 22, 38], ["decreased", "OBSERVATION_MODIFIER", 56, 65], ["oxygen delivery", "OBSERVATION", 66, 81], ["myocardium", "ANATOMY", 89, 99], ["hypoxaemia", "OBSERVATION", 104, 114], ["vasoconstriction", "OBSERVATION", 119, 135], ["sepsis", "OBSERVATION", 176, 182], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["myocardial", "ANATOMY", 198, 208], ["oxygen demand", "OBSERVATION", 209, 222]]], ["This supply and demand mismatch may lead to sustained myocardial ischaemia in patients with underlying coronary artery disease.", [["myocardial", "ANATOMY", 54, 64], ["coronary artery", "ANATOMY", 103, 118], ["myocardial ischaemia", "DISEASE", 54, 74], ["coronary artery disease", "DISEASE", 103, 126], ["myocardial", "MULTI-TISSUE_STRUCTURE", 54, 64], ["patients", "ORGANISM", 78, 86], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 103, 118], ["patients", "SPECIES", 78, 86], ["demand mismatch", "PROBLEM", 16, 31], ["sustained myocardial ischaemia", "PROBLEM", 44, 74], ["underlying coronary artery disease", "PROBLEM", 92, 126], ["demand mismatch", "OBSERVATION", 16, 31], ["may lead to", "UNCERTAINTY", 32, 43], ["sustained", "OBSERVATION_MODIFIER", 44, 53], ["myocardial", "ANATOMY", 54, 64], ["ischaemia", "OBSERVATION", 65, 74], ["coronary artery", "ANATOMY", 103, 118], ["disease", "OBSERVATION", 119, 126]]], ["However, a rise and/ or fall of hs-cTn is not sufficient to secure the diagnosis of acute MI as seen in MI with non-obstructive coronaries, even in the absence of covid-19.", [["coronaries", "ANATOMY", 128, 138], ["MI", "DISEASE", 90, 92], ["MI", "DISEASE", 104, 106], ["non-obstructive coronaries", "DISEASE", 112, 138], ["hs-cTn", "GENE_OR_GENE_PRODUCT", 32, 38], ["coronaries", "MULTI-TISSUE_STRUCTURE", 128, 138], ["cTn", "PROTEIN", 35, 38], ["fall of hs", "PROBLEM", 24, 34], ["acute MI", "PROBLEM", 84, 92], ["MI", "PROBLEM", 104, 106], ["non-obstructive coronaries", "PROBLEM", 112, 138], ["covid", "TEST", 163, 168], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["MI", "OBSERVATION", 90, 92], ["non-obstructive", "OBSERVATION", 112, 127], ["coronaries", "ANATOMY", 128, 138]]], ["Therefore, the diagnosis of acute MI should also be based on clinical judgement, symptom/signs, ECG changes, and imaging studies.Myocardial injury with DICDIC is a life-threatening condition present in 71.4% (15/21) of non-survivors with covid-19 and 0.6% (1/162) of survivors.", [["Myocardial", "ANATOMY", 129, 139], ["MI", "DISEASE", 34, 36], ["Myocardial injury", "DISEASE", 129, 146], ["DICDIC", "DISEASE", 152, 158], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 129, 139], ["acute MI", "PROBLEM", 28, 36], ["clinical judgement", "TEST", 61, 79], ["symptom", "PROBLEM", 81, 88], ["signs", "PROBLEM", 89, 94], ["ECG changes", "PROBLEM", 96, 107], ["imaging studies", "TEST", 113, 128], ["Myocardial injury", "PROBLEM", 129, 146], ["covid", "TEST", 238, 243], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["MI", "OBSERVATION", 34, 36], ["injury", "OBSERVATION", 140, 146]]], ["29 A marker of severe sepsis, DIC further perpetuates multiorgan damage through thrombosis, reduced perfusion, and bleeding, DIC has been implicated in the thrombosis of coronary arteries (epicardial vessels and microvasculature), focal necrosis of the myocardium, and severe cardiac dysfunction.", [["multiorgan", "ANATOMY", 54, 64], ["coronary arteries", "ANATOMY", 170, 187], ["epicardial vessels", "ANATOMY", 189, 207], ["microvasculature", "ANATOMY", 212, 228], ["myocardium", "ANATOMY", 253, 263], ["cardiac", "ANATOMY", 276, 283], ["sepsis", "DISEASE", 22, 28], ["DIC", "DISEASE", 30, 33], ["multiorgan damage", "DISEASE", 54, 71], ["thrombosis", "DISEASE", 80, 90], ["bleeding", "DISEASE", 115, 123], ["DIC", "DISEASE", 125, 128], ["thrombosis", "DISEASE", 156, 166], ["necrosis of the myocardium", "DISEASE", 237, 263], ["cardiac dysfunction", "DISEASE", 276, 295], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 170, 187], ["epicardial vessels", "MULTI-TISSUE_STRUCTURE", 189, 207], ["microvasculature", "TISSUE", 212, 228], ["myocardium", "MULTI-TISSUE_STRUCTURE", 253, 263], ["cardiac", "ORGAN", 276, 283], ["severe sepsis", "PROBLEM", 15, 28], ["DIC", "PROBLEM", 30, 33], ["multiorgan damage through thrombosis", "PROBLEM", 54, 90], ["reduced perfusion", "PROBLEM", 92, 109], ["bleeding", "PROBLEM", 115, 123], ["DIC", "PROBLEM", 125, 128], ["the thrombosis of coronary arteries", "PROBLEM", 152, 187], ["focal necrosis of the myocardium", "PROBLEM", 231, 263], ["severe cardiac dysfunction", "PROBLEM", 269, 295], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["sepsis", "OBSERVATION", 22, 28], ["thrombosis", "OBSERVATION", 80, 90], ["reduced", "OBSERVATION_MODIFIER", 92, 99], ["perfusion", "OBSERVATION_MODIFIER", 100, 109], ["bleeding", "OBSERVATION", 115, 123], ["thrombosis", "OBSERVATION", 156, 166], ["coronary arteries", "ANATOMY", 170, 187], ["epicardial", "ANATOMY_MODIFIER", 189, 199], ["vessels", "ANATOMY", 200, 207], ["microvasculature", "ANATOMY", 212, 228], ["focal", "OBSERVATION_MODIFIER", 231, 236], ["necrosis", "OBSERVATION", 237, 245], ["myocardium", "ANATOMY", 253, 263], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["cardiac", "ANATOMY", 276, 283], ["dysfunction", "OBSERVATION", 284, 295]]], ["30 Myocardial injury with DIC has been recently reported in two critically ill patients with covid-19.", [["Myocardial", "ANATOMY", 3, 13], ["Myocardial injury", "DISEASE", 3, 20], ["DIC", "DISEASE", 26, 29], ["critically ill", "DISEASE", 64, 78], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 3, 13], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Myocardial injury", "PROBLEM", 3, 20], ["DIC", "PROBLEM", 26, 29], ["covid", "TEST", 93, 98], ["Myocardial", "ANATOMY", 3, 13], ["injury", "OBSERVATION", 14, 20]]], ["31 Both patients had significantly elevated Tn and brain natriuretic peptide, which normalised after treatment with heparin, mechanical ventilation, and antiviral agents.Non-ischaemic myocardial injury Myocarditis and stress-induced cardiomyopathyMyocardial injury from SARS-CoV-2 infection may also be mediated by non-ischaemic mechanisms, such as acute and fulminant myocarditis and stress-induced cardiomyopathy.", [["brain", "ANATOMY", 51, 56], ["myocardial", "ANATOMY", 184, 194], ["Myocardial", "ANATOMY", 247, 257], ["heparin", "CHEMICAL", 116, 123], ["myocardial injury", "DISEASE", 184, 201], ["Myocarditis", "DISEASE", 202, 213], ["cardiomyopathy", "DISEASE", 233, 247], ["Myocardial injury", "DISEASE", 247, 264], ["SARS", "DISEASE", 270, 274], ["infection", "DISEASE", 281, 290], ["myocarditis", "DISEASE", 369, 380], ["cardiomyopathy", "DISEASE", 400, 414], ["patients", "ORGANISM", 8, 16], ["Tn", "GENE_OR_GENE_PRODUCT", 44, 46], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 51, 76], ["heparin", "SIMPLE_CHEMICAL", 116, 123], ["myocardial", "MULTI-TISSUE_STRUCTURE", 184, 194], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 247, 257], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 270, 280], ["Tn", "PROTEIN", 44, 46], ["patients", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 270, 278], ["significantly elevated Tn", "PROBLEM", 21, 46], ["brain natriuretic peptide", "PROBLEM", 51, 76], ["heparin", "TREATMENT", 116, 123], ["mechanical ventilation", "TREATMENT", 125, 147], ["antiviral agents", "TREATMENT", 153, 169], ["Non-ischaemic myocardial injury Myocarditis", "PROBLEM", 170, 213], ["stress-induced cardiomyopathy", "PROBLEM", 218, 247], ["Myocardial injury", "PROBLEM", 247, 264], ["SARS", "PROBLEM", 270, 274], ["CoV-2 infection", "PROBLEM", 275, 290], ["non-ischaemic mechanisms", "PROBLEM", 315, 339], ["acute and fulminant myocarditis", "PROBLEM", 349, 380], ["stress-induced cardiomyopathy", "PROBLEM", 385, 414], ["elevated", "OBSERVATION_MODIFIER", 35, 43], ["Tn", "OBSERVATION", 44, 46], ["brain natriuretic", "ANATOMY", 51, 68], ["mechanical ventilation", "OBSERVATION", 125, 147], ["myocardial", "ANATOMY", 184, 194], ["injury", "OBSERVATION", 195, 201], ["Myocardial", "ANATOMY", 247, 257], ["injury", "OBSERVATION", 258, 264], ["infection", "OBSERVATION", 281, 290], ["may also be mediated", "UNCERTAINTY", 291, 311], ["non-ischaemic", "OBSERVATION", 315, 328], ["acute", "OBSERVATION_MODIFIER", 349, 354], ["fulminant", "OBSERVATION_MODIFIER", 359, 368], ["myocarditis", "OBSERVATION", 369, 380], ["cardiomyopathy", "OBSERVATION", 400, 414]]], ["Reports of various presentations of non-ischaemic myocardial injury in covid-19 are summarised in table 5.", [["myocardial", "ANATOMY", 50, 60], ["non-ischaemic myocardial injury", "DISEASE", 36, 67], ["myocardial", "MULTI-TISSUE_STRUCTURE", 50, 60], ["non-ischaemic myocardial injury", "PROBLEM", 36, 67], ["non-ischaemic", "OBSERVATION_MODIFIER", 36, 49], ["myocardial", "ANATOMY", 50, 60], ["injury", "OBSERVATION", 61, 67]]], ["The distinction between myocarditis and stress-induced cardiomyopathy can be challenging, since cardiovascular magnetic resonance (CMR) and/or biopsy are not available in most cases.", [["cardiovascular", "ANATOMY", 96, 110], ["myocarditis", "DISEASE", 24, 35], ["cardiomyopathy", "DISEASE", 55, 69], ["myocarditis", "PROBLEM", 24, 35], ["stress-induced cardiomyopathy", "PROBLEM", 40, 69], ["cardiovascular magnetic resonance", "TEST", 96, 129], ["CMR", "TEST", 131, 134], ["biopsy", "TEST", 143, 149], ["myocarditis", "OBSERVATION", 24, 35], ["cardiomyopathy", "OBSERVATION", 55, 69]]], ["Fried et al and Sala et al each reported a patient with covid-19 with mid-left ventricular (LV) or basal-to-mid LV hypokinesis, a pattern of mid-ventricular, or reverse Takotsubo stress cardiomyopathy, respectively.", [["mid-left ventricular", "ANATOMY", 70, 90], ["LV", "ANATOMY", 92, 94], ["LV", "ANATOMY", 112, 114], ["mid-ventricular", "ANATOMY", 141, 156], ["LV hypokinesis", "DISEASE", 112, 126], ["Takotsubo stress cardiomyopathy", "DISEASE", 169, 200], ["patient", "ORGANISM", 43, 50], ["ventricular", "MULTI-TISSUE_STRUCTURE", 79, 90], ["LV", "MULTI-TISSUE_STRUCTURE", 92, 94], ["LV", "MULTI-TISSUE_STRUCTURE", 112, 114], ["patient", "SPECIES", 43, 50], ["covid", "TEST", 56, 61], ["basal-to-mid LV hypokinesis", "PROBLEM", 99, 126], ["mid-ventricular", "PROBLEM", 141, 156], ["reverse Takotsubo stress cardiomyopathy", "PROBLEM", 161, 200], ["mid-left ventricular", "ANATOMY", 70, 90], ["LV", "ANATOMY", 92, 94], ["basal", "ANATOMY_MODIFIER", 99, 104], ["mid LV", "ANATOMY", 108, 114], ["hypokinesis", "OBSERVATION", 115, 126], ["reverse Takotsubo", "OBSERVATION", 161, 178], ["stress cardiomyopathy", "OBSERVATION", 179, 200]]], ["32 33 The incidence of acute heart failure was 33% (7/21) in critically ill patients with covid-19 without a past history of LV systolic dysfunction in Washington state.", [["heart", "ANATOMY", 29, 34], ["LV", "ANATOMY", 125, 127], ["heart failure", "DISEASE", 29, 42], ["critically ill", "DISEASE", 61, 75], ["LV systolic dysfunction", "DISEASE", 125, 148], ["heart", "ORGAN", 29, 34], ["patients", "ORGANISM", 76, 84], ["LV systolic", "MULTI-TISSUE_STRUCTURE", 125, 136], ["patients", "SPECIES", 76, 84], ["acute heart failure", "PROBLEM", 23, 42], ["covid", "TEST", 90, 95], ["LV systolic dysfunction", "PROBLEM", 125, 148], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["heart", "ANATOMY", 29, 34], ["failure", "OBSERVATION", 35, 42], ["LV systolic", "ANATOMY", 125, 136], ["dysfunction", "OBSERVATION", 137, 148]]], ["34 Importantly, cardiomyopathy can develop in covid-19 with mild or absent respiratory symptoms.", [["respiratory", "ANATOMY", 75, 86], ["cardiomyopathy", "DISEASE", 16, 30], ["respiratory symptoms", "DISEASE", 75, 95], ["cardiomyopathy", "PROBLEM", 16, 30], ["covid", "TEST", 46, 51], ["mild or absent respiratory symptoms", "PROBLEM", 60, 95], ["cardiomyopathy", "OBSERVATION", 16, 30], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["absent", "OBSERVATION_MODIFIER", 68, 74], ["respiratory symptoms", "OBSERVATION", 75, 95]]], ["35 Myocardial injury with cytokine release syndrome Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 can elicit the intense release of multiple cytokines and chemokines by the immune system.", [["Myocardial", "ANATOMY", 3, 13], ["immune system", "ANATOMY", 172, 185], ["Myocardial injury", "DISEASE", 3, 20], ["SARS-CoV", "DISEASE", 63, 71], ["SARS", "DISEASE", 86, 90], ["MERS-CoV", "ORGANISM", 76, 84], ["SARS-CoV-2", "ORGANISM", 86, 96], ["cytokine", "PROTEIN", 26, 34], ["cytokines", "PROTEIN", 140, 149], ["chemokines", "PROTEIN", 154, 164], ["SARS-CoV", "SPECIES", 63, 71], ["MERS-CoV", "SPECIES", 76, 84], ["Myocardial injury", "PROBLEM", 3, 20], ["cytokine release syndrome", "PROBLEM", 26, 51], ["SARS", "PROBLEM", 63, 67], ["CoV", "PROBLEM", 68, 71], ["MERS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["SARS", "PROBLEM", 86, 90], ["multiple cytokines", "TREATMENT", 131, 149], ["chemokines", "TREATMENT", 154, 164], ["Myocardial", "ANATOMY", 3, 13], ["injury", "OBSERVATION", 14, 20], ["multiple", "OBSERVATION_MODIFIER", 131, 139], ["cytokines", "OBSERVATION", 140, 149]]], ["3 36 Cytokine release syndrome (aka 'cytokine storm'), a poorly understood immunopathological process caused by hyperinduction of proinflammatory cytokines such as interleukin (IL)-1, IL-6, T helper 1 cytokine interferon-gamma, and tumour necrosis factor-alpha (TNF-\u03b1), has been reported in the setting of SARS, MERS, and influenza.", [["necrosis", "DISEASE", 239, 247], ["SARS", "DISEASE", 306, 310], ["influenza", "DISEASE", 322, 331], ["Cytokine", "GENE_OR_GENE_PRODUCT", 5, 13], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 164, 182], ["IL-6", "GENE_OR_GENE_PRODUCT", 184, 188], ["T helper 1", "GENE_OR_GENE_PRODUCT", 190, 200], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 210, 226], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 232, 260], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 262, 267], ["Cytokine", "PROTEIN", 5, 13], ["cytokine", "PROTEIN", 37, 45], ["proinflammatory cytokines", "PROTEIN", 130, 155], ["interleukin (IL)-1, IL-6", "PROTEIN", 164, 188], ["T helper 1 cytokine interferon-gamma", "PROTEIN", 190, 226], ["tumour necrosis factor-alpha", "PROTEIN", 232, 260], ["TNF-\u03b1", "PROTEIN", 262, 267], ["Cytokine release syndrome", "PROBLEM", 5, 30], ["aka 'cytokine storm'", "TREATMENT", 32, 52], ["a poorly understood immunopathological process", "PROBLEM", 55, 101], ["proinflammatory cytokines", "PROBLEM", 130, 155], ["interleukin (IL)", "TREATMENT", 164, 180], ["IL", "TEST", 184, 186], ["cytokine interferon", "TREATMENT", 201, 220], ["tumour necrosis factor", "PROBLEM", 232, 254], ["alpha (TNF", "TEST", 255, 265], ["SARS", "PROBLEM", 306, 310], ["MERS", "PROBLEM", 312, 316], ["influenza", "PROBLEM", 322, 331], ["proinflammatory cytokines", "OBSERVATION", 130, 155], ["gamma", "ANATOMY", 221, 226], ["tumour", "ANATOMY", 232, 238], ["necrosis", "OBSERVATION", 239, 247], ["alpha", "ANATOMY", 255, 260], ["SARS", "OBSERVATION", 306, 310], ["influenza", "OBSERVATION", 322, 331]]], ["[37] [38] [39] It is postulated that proinflammatory cytokines depress myocardial function immediately through activation of the neural sphingomyelinase pathway and subacutely (hours to days) via nitric oxide-mediated blunting of beta-adrenergic signalling.", [["myocardial", "ANATOMY", 71, 81], ["neural", "ANATOMY", 129, 135], ["nitric oxide", "CHEMICAL", 196, 208], ["nitric oxide", "CHEMICAL", 196, 208], ["myocardial", "MULTI-TISSUE_STRUCTURE", 71, 81], ["sphingomyelinase", "GENE_OR_GENE_PRODUCT", 136, 152], ["nitric oxide", "SIMPLE_CHEMICAL", 196, 208], ["beta-adrenergic", "SIMPLE_CHEMICAL", 230, 245], ["proinflammatory cytokines", "PROTEIN", 37, 62], ["proinflammatory cytokines depress myocardial function", "PROBLEM", 37, 90], ["the neural sphingomyelinase pathway", "TEST", 125, 160], ["nitric oxide", "TREATMENT", 196, 208], ["blunting of beta-adrenergic signalling", "PROBLEM", 218, 256], ["neural sphingomyelinase", "ANATOMY", 129, 152], ["blunting", "OBSERVATION", 218, 226], ["beta-adrenergic signalling", "OBSERVATION", 230, 256]]], ["40 Accumulating evidence suggest that a subgroup of patients with severe covid-19 can develop cytokine storm.", [["patients", "ORGANISM", 52, 60], ["cytokine", "PROTEIN", 94, 102], ["patients", "SPECIES", 52, 60], ["severe covid", "PROBLEM", 66, 78], ["cytokine storm", "PROBLEM", 94, 108], ["cytokine storm", "OBSERVATION", 94, 108]]], ["36 Plasma levels of IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1 have been found to be significantly higher in patients with covid-19.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 20, 25], ["IL-6", "GENE_OR_GENE_PRODUCT", 27, 31], ["IL-8", "GENE_OR_GENE_PRODUCT", 33, 37], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 42, 47], ["patients", "ORGANISM", 94, 102], ["IL", "PROTEIN", 20, 22], ["IL-6, IL-8", "PROTEIN", 27, 37], ["TNF", "PROTEIN", 42, 45], ["patients", "SPECIES", 94, 102], ["Plasma levels", "TEST", 3, 16], ["IL", "TEST", 20, 22], ["IL", "TEST", 27, 29], ["IL", "TEST", 33, 35], ["TNF", "TEST", 42, 45], ["covid", "TEST", 108, 113], ["significantly", "OBSERVATION_MODIFIER", 70, 83], ["higher", "OBSERVATION_MODIFIER", 84, 90]]], ["3 The clinical and biochemical profiles of non-survivors in patients with covid-19 with highly elevated ferritin and IL-6 also suggest that cytokine release contribute to mortality.", [["patients", "ORGANISM", 60, 68], ["ferritin", "GENE_OR_GENE_PRODUCT", 104, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["ferritin", "PROTEIN", 104, 112], ["IL-6", "PROTEIN", 117, 121], ["cytokine", "PROTEIN", 140, 148], ["patients", "SPECIES", 60, 68], ["covid", "TEST", 74, 79], ["highly elevated ferritin", "PROBLEM", 88, 112], ["cytokine release", "PROBLEM", 140, 156]]], ["41ArrhythmiaArrhythmia could be the first presentation of covid-19, and new-onset and/or progressive arrhythmia could indicate cardiac involvement.", [["cardiac", "ANATOMY", 127, 134], ["41ArrhythmiaArrhythmia", "DISEASE", 0, 22], ["arrhythmia", "DISEASE", 101, 111], ["cardiac", "ORGAN", 127, 134], ["covid", "TEST", 58, 63], ["progressive arrhythmia", "PROBLEM", 89, 111], ["cardiac involvement", "PROBLEM", 127, 146], ["progressive", "OBSERVATION_MODIFIER", 89, 100], ["arrhythmia", "OBSERVATION", 101, 111], ["cardiac", "ANATOMY", 127, 134], ["involvement", "OBSERVATION", 135, 146]]], ["A study of 137 patients in Wuhan showed that 7.3% had experienced palpitations as one of their presenting symptoms for covid-19.", [["palpitations", "DISEASE", 66, 78], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["A study", "TEST", 0, 7], ["palpitations", "PROBLEM", 66, 78], ["their presenting symptoms", "PROBLEM", 89, 114], ["covid", "TEST", 119, 124]]], ["42 The prevalence of unspecified arrhythmia in two additional studies is listed in table 4.", [["arrhythmia", "DISEASE", 33, 43], ["unspecified arrhythmia", "PROBLEM", 21, 43], ["additional studies", "TEST", 51, 69], ["unspecified", "OBSERVATION_MODIFIER", 21, 32], ["arrhythmia", "OBSERVATION", 33, 43]]], ["Arrhythmias were found to be more common in intensive care unit (ICU) patients with covid-19 (44.4%) than non-ICU patients (6.9%).", [["Arrhythmias", "DISEASE", 0, 11], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 114, 122], ["Arrhythmias", "PROBLEM", 0, 11], ["covid", "TEST", 84, 89]]], ["4 Patients with elevated Tn also had a higher incidence of malignant arrhythmia (haemodynamically unstable ventricular tachycardia or ventricular fibrillation) than those with normal Tn levels (11.5% vs 5.2%, p<0.001).", [["ventricular", "ANATOMY", 107, 118], ["ventricular", "ANATOMY", 134, 145], ["malignant arrhythmia", "DISEASE", 59, 79], ["ventricular tachycardia", "DISEASE", 107, 130], ["ventricular fibrillation", "DISEASE", 134, 158], ["Patients", "ORGANISM", 2, 10], ["Tn", "GENE_OR_GENE_PRODUCT", 25, 27], ["ventricular", "ORGAN", 107, 118], ["ventricular", "ORGAN", 134, 145], ["Tn", "GENE_OR_GENE_PRODUCT", 183, 185], ["Tn", "PROTEIN", 25, 27], ["Tn", "PROTEIN", 183, 185], ["Patients", "SPECIES", 2, 10], ["elevated Tn", "PROBLEM", 16, 27], ["malignant arrhythmia", "PROBLEM", 59, 79], ["haemodynamically unstable ventricular tachycardia", "PROBLEM", 81, 130], ["ventricular fibrillation", "PROBLEM", 134, 158], ["malignant", "OBSERVATION_MODIFIER", 59, 68], ["arrhythmia", "OBSERVATION", 69, 79], ["ventricular", "ANATOMY", 134, 145], ["fibrillation", "OBSERVATION", 146, 158]]], ["6venous thromboembolismDue to prolonged immobilisation, hypercoagulable status, active inflammation, and propensity for DIC, patients with covid-19 are at increased risk of VTE.", [["6venous", "ANATOMY", 0, 7], ["inflammation", "DISEASE", 87, 99], ["DIC", "DISEASE", 120, 123], ["VTE", "DISEASE", 173, 176], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["6venous thromboembolismDue", "PROBLEM", 0, 26], ["prolonged immobilisation", "PROBLEM", 30, 54], ["hypercoagulable status", "PROBLEM", 56, 78], ["active inflammation", "PROBLEM", 80, 99], ["DIC", "PROBLEM", 120, 123], ["covid", "TEST", 139, 144], ["VTE", "PROBLEM", 173, 176], ["prolonged", "OBSERVATION_MODIFIER", 30, 39], ["immobilisation", "OBSERVATION", 40, 54], ["active", "OBSERVATION_MODIFIER", 80, 86], ["inflammation", "OBSERVATION", 87, 99], ["VTE", "OBSERVATION", 173, 176]]], ["The prevalence of ultrasoundconfirmed deep venous thrombosis in patients with covid-19 is 22.7% 43 and 27% in ICU patients.", [["venous", "ANATOMY", 43, 49], ["venous thrombosis", "DISEASE", 43, 60], ["deep venous", "MULTI-TISSUE_STRUCTURE", 38, 49], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 114, 122], ["ultrasoundconfirmed deep venous thrombosis", "PROBLEM", 18, 60], ["covid", "TEST", 78, 83], ["deep", "ANATOMY_MODIFIER", 38, 42], ["venous", "ANATOMY", 43, 49], ["thrombosis", "OBSERVATION", 50, 60]]], ["44 Patients with covid-19 have been shown to have significant higher level of D-dimer, fibrin degradation products (FDP), and fibrinogen, compared with healthy controls.", [["Patients", "ORGANISM", 3, 11], ["D-dimer", "GENE_OR_GENE_PRODUCT", 78, 85], ["fibrin degradation products", "SIMPLE_CHEMICAL", 87, 114], ["FDP", "SIMPLE_CHEMICAL", 116, 119], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 126, 136], ["D-dimer", "PROTEIN", 78, 85], ["fibrin degradation products", "PROTEIN", 87, 114], ["FDP", "PROTEIN", 116, 119], ["fibrinogen", "PROTEIN", 126, 136], ["Patients", "SPECIES", 3, 11], ["covid", "TEST", 17, 22], ["D-dimer", "PROBLEM", 78, 85], ["fibrin degradation products", "PROBLEM", 87, 114], ["FDP", "TEST", 116, 119], ["fibrinogen", "TEST", 126, 136], ["fibrin degradation", "OBSERVATION", 87, 105], ["fibrinogen", "ANATOMY", 126, 136]]], ["45 In addition, D-dimer and FDP titres were higher in patients with severe covid-19 than those with milder disease.", [["D-dimer", "SIMPLE_CHEMICAL", 16, 23], ["FDP", "GENE_OR_GENE_PRODUCT", 28, 31], ["patients", "ORGANISM", 54, 62], ["D-dimer", "PROTEIN", 16, 23], ["FDP", "PROTEIN", 28, 31], ["patients", "SPECIES", 54, 62], ["D-dimer", "TEST", 16, 23], ["FDP titres", "TEST", 28, 38], ["severe covid", "PROBLEM", 68, 80], ["milder disease", "PROBLEM", 100, 114], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["milder", "OBSERVATION_MODIFIER", 100, 106], ["disease", "OBSERVATION", 107, 114]]], ["45 A retrospective, multicentre cohort study demonstrated that D-dimer >1 \u00b5g/mL on admission was associated with in-hospital death (OR: 18.4, 95% CI: 2.6 to 128.6, p=0.003).", [["death", "DISEASE", 125, 130], ["D-dimer", "GENE_OR_GENE_PRODUCT", 63, 70], ["multicentre cohort study", "TEST", 20, 44], ["D-dimer", "TEST", 63, 70], ["CI", "TEST", 146, 148], ["p", "TEST", 164, 165]]], ["22 Thus, in the setting of critically ill covid-19 patients with clinical deterioration, VTE (including pulmonary embolism) should be considered.TReATmenT ConsIdeRATIonsThere is currently no proven therapy for covid-19, although many are under investigation.", [["pulmonary", "ANATOMY", 104, 113], ["critically ill", "DISEASE", 27, 41], ["VTE", "DISEASE", 89, 92], ["pulmonary embolism", "DISEASE", 104, 122], ["patients", "ORGANISM", 51, 59], ["pulmonary", "ORGAN", 104, 113], ["patients", "SPECIES", 51, 59], ["clinical deterioration", "PROBLEM", 65, 87], ["VTE", "PROBLEM", 89, 92], ["pulmonary embolism", "PROBLEM", 104, 122], ["covid", "TEST", 210, 215], ["pulmonary", "ANATOMY", 104, 113], ["embolism", "OBSERVATION", 114, 122]]], ["We focus our discussion here on supportive therapies and considerations of potential therapies relevant to the cardiovascular system, summarized in table 6.Anticoagulant therapyDue to the high rate of associated arterial thromboembolism and VTE, prophylactic anticoagulation is essential in the management of hospitalised patients with covid-19, 44 46 although the optimal thromboprophylaxis regimen is unclear.", [["cardiovascular", "ANATOMY", 111, 125], ["arterial", "ANATOMY", 212, 220], ["arterial thromboembolism", "DISEASE", 212, 236], ["VTE", "DISEASE", 241, 244], ["cardiovascular", "ANATOMICAL_SYSTEM", 111, 125], ["arterial", "MULTI-TISSUE_STRUCTURE", 212, 220], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["supportive therapies", "TREATMENT", 32, 52], ["potential therapies", "TREATMENT", 75, 94], ["Anticoagulant therapyDue", "TREATMENT", 156, 180], ["associated arterial thromboembolism", "PROBLEM", 201, 236], ["VTE", "PROBLEM", 241, 244], ["prophylactic anticoagulation", "TREATMENT", 246, 274], ["covid", "TEST", 336, 341], ["the optimal thromboprophylaxis regimen", "TREATMENT", 361, 399], ["cardiovascular system", "ANATOMY", 111, 132], ["arterial", "ANATOMY", 212, 220], ["thromboembolism", "OBSERVATION", 221, 236], ["thromboprophylaxis", "OBSERVATION", 373, 391]]], ["In a retrospective study of 449 patients with severe covid-19, 99 patients received unfractionated heparin or low molecular weight heparin for at least 7 days.", [["heparin", "CHEMICAL", 99, 106], ["heparin", "CHEMICAL", 131, 138], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 66, 74], ["heparin", "SIMPLE_CHEMICAL", 99, 106], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 110, 138], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 66, 74], ["a retrospective study", "TEST", 3, 24], ["severe covid", "TEST", 46, 58], ["unfractionated heparin", "TREATMENT", 84, 106], ["low molecular weight heparin", "TREATMENT", 110, 138]]], ["47 No difference in overall 28-day mortality was observed, but in subgroups of patients with sepsis-induced coagulopathy score \u22654, or D-dimer >sixfold of upper limit of normal, the heparin group had lower mortality compared with the no-heparin group (40.0% vs 64.2%, p=0.029), (32.8% vs 52.4%, p=0.017), respectively.", [["sepsis", "DISEASE", 93, 99], ["coagulopathy", "DISEASE", 108, 120], ["heparin", "CHEMICAL", 181, 188], ["no-heparin", "CHEMICAL", 233, 243], ["no-heparin", "CHEMICAL", 233, 243], ["patients", "ORGANISM", 79, 87], ["D-dimer", "SIMPLE_CHEMICAL", 134, 141], ["upper", "ORGANISM_SUBDIVISION", 154, 159], ["heparin", "SIMPLE_CHEMICAL", 181, 188], ["patients", "SPECIES", 79, 87], ["sepsis", "PROBLEM", 93, 99], ["coagulopathy score", "TEST", 108, 126], ["D-dimer", "TEST", 134, 141], ["the heparin group", "TREATMENT", 177, 194], ["lower mortality", "PROBLEM", 199, 214], ["p", "TEST", 267, 268], ["p", "TEST", 294, 295], ["difference", "OBSERVATION_MODIFIER", 6, 16], ["overall", "OBSERVATION_MODIFIER", 20, 27], ["28-", "OBSERVATION_MODIFIER", 28, 31], ["sepsis", "OBSERVATION", 93, 99], ["coagulopathy", "OBSERVATION", 108, 120], ["upper limit", "OBSERVATION_MODIFIER", 154, 165], ["normal", "OBSERVATION", 169, 175]]], ["47 Another concern regarding thromboprophylaxis is the drug-drug interaction between some antiviral treatments (such as ribavirin, lopinavir and ritonavir) and direct oral anticoagulants.", [["oral", "ANATOMY", 167, 171], ["ribavirin", "CHEMICAL", 120, 129], ["lopinavir and ritonavir", "CHEMICAL", 131, 154], ["ribavirin", "CHEMICAL", 120, 129], ["lopinavir", "CHEMICAL", 131, 140], ["ritonavir", "CHEMICAL", 145, 154], ["ribavirin", "SIMPLE_CHEMICAL", 120, 129], ["lopinavir", "SIMPLE_CHEMICAL", 131, 140], ["ritonavir", "SIMPLE_CHEMICAL", 145, 154], ["oral", "ORGANISM_SUBDIVISION", 167, 171], ["anticoagulants", "SIMPLE_CHEMICAL", 172, 186], ["thromboprophylaxis", "TREATMENT", 29, 47], ["some antiviral treatments", "TREATMENT", 85, 110], ["ribavirin", "TREATMENT", 120, 129], ["lopinavir", "TREATMENT", 131, 140], ["ritonavir", "TREATMENT", 145, 154], ["direct oral anticoagulants", "TREATMENT", 160, 186]]], ["Low molecular weight heparin is likely preferred in critically ill patients with covid-19, if anticoagulation is used.ACe inhibitors and angiotensin receptor blockersSince SARS-CoV-2 uses the ACE2 protein for ligand binding before entering the cell, 10 there are concerns regarding the use of renin-angiotensin-aldosterone system (RAAS) inhibitors that may increase ACE2 expression.", [["cell", "ANATOMY", 244, 248], ["heparin", "CHEMICAL", 21, 28], ["critically ill", "DISEASE", 52, 66], ["angiotensin", "CHEMICAL", 137, 148], ["angiotensin", "CHEMICAL", 299, 310], ["aldosterone", "CHEMICAL", 311, 322], ["aldosterone", "CHEMICAL", 311, 322], ["Low molecular weight heparin", "SIMPLE_CHEMICAL", 0, 28], ["patients", "ORGANISM", 67, 75], ["ACe", "SIMPLE_CHEMICAL", 118, 121], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 137, 166], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 192, 196], ["cell", "CELL", 244, 248], ["renin-angiotensin-aldosterone system", "GENE_OR_GENE_PRODUCT", 293, 329], ["RAAS", "GENE_OR_GENE_PRODUCT", 331, 335], ["ACE2", "GENE_OR_GENE_PRODUCT", 366, 370], ["ACE2 protein", "PROTEIN", 192, 204], ["renin", "PROTEIN", 293, 298], ["ACE2", "PROTEIN", 366, 370], ["patients", "SPECIES", 67, 75], ["Low molecular weight heparin", "TREATMENT", 0, 28], ["covid", "TEST", 81, 86], ["anticoagulation", "TREATMENT", 94, 109], ["ACe inhibitors", "TREATMENT", 118, 132], ["angiotensin receptor blockers", "TREATMENT", 137, 166], ["SARS", "PROBLEM", 172, 176], ["the ACE2 protein", "TREATMENT", 188, 204], ["ligand binding", "PROBLEM", 209, 223], ["renin", "TREATMENT", 293, 298], ["angiotensin-aldosterone system (RAAS) inhibitors", "TREATMENT", 299, 347]]], ["13 48 The relationship between ACE2 expression and SARS-CoV-2 virulence is uncertain.", [["SARS", "DISEASE", 51, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["ACE2", "PROTEIN", 31, 35], ["SARS-CoV", "SPECIES", 51, 59], ["ACE2 expression", "TEST", 31, 46], ["SARS", "TEST", 51, 55]]], ["After cell entry via ACE2, SARS-CoV-2 appears to subsequently downregulate ACE2 expression, which is vital to maintenance of cardiac function.", [["cell", "ANATOMY", 6, 10], ["cardiac", "ANATOMY", 125, 132], ["cell", "CELL", 6, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["cardiac", "ORGAN", 125, 132], ["ACE2", "PROTEIN", 21, 25], ["ACE2", "PROTEIN", 75, 79], ["cell entry", "TEST", 6, 16], ["ACE2", "TEST", 21, 25], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["cardiac", "ANATOMY", 125, 132]]], ["49 In mouse models, reduction in ACE2 expression is associated with increased severity of lung injury induced by influenza.", [["lung", "ANATOMY", 90, 94], ["lung injury", "DISEASE", 90, 101], ["influenza", "DISEASE", 113, 122], ["mouse", "ORGANISM", 6, 11], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["lung", "ORGAN", 90, 94], ["ACE2", "PROTEIN", 33, 37], ["mouse", "SPECIES", 6, 11], ["mouse", "SPECIES", 6, 11], ["reduction in ACE2 expression", "TREATMENT", 20, 48], ["lung injury", "PROBLEM", 90, 101], ["influenza", "PROBLEM", 113, 122], ["reduction", "OBSERVATION_MODIFIER", 20, 29], ["lung", "ANATOMY", 90, 94], ["injury", "OBSERVATION", 95, 101], ["influenza", "OBSERVATION", 113, 122]]], ["50 Whether higher expression of ACE2 increases susceptibility to SARS-CoV-2 infection or confers cardioprotection remains controversial.", [["SARS", "DISEASE", 65, 69], ["infection", "DISEASE", 76, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["SARS-CoV-2", "ORGANISM", 65, 75], ["ACE2", "PROTEIN", 32, 36], ["SARS-CoV", "SPECIES", 65, 73], ["ACE2", "PROBLEM", 32, 36], ["SARS", "PROBLEM", 65, 69], ["CoV", "PROBLEM", 70, 73], ["2 infection", "PROBLEM", 74, 85], ["confers cardioprotection", "TREATMENT", 89, 113]]], ["51 Furthermore, experimental animal models and few studies in humans have yielded conflicting results as to whether RAAS inhibition increases ACE2 expression.", [["humans", "ORGANISM", 62, 68], ["RAAS", "GENE_OR_GENE_PRODUCT", 116, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["ACE2", "PROTEIN", 142, 146], ["humans", "SPECIES", 62, 68], ["humans", "SPECIES", 62, 68], ["experimental animal models", "TEST", 16, 42], ["few studies", "TEST", 47, 58], ["RAAS inhibition", "PROBLEM", 116, 131]]], ["52 53 Based on the uncertainty regarding the overall effect of RAAS inhibitors (ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy) in covid-19, multiple specialty societies currently recommend that RAAS inhibitors be continued in patients in otherwise stable condition.", [["ACE inhibitor", "CHEMICAL", 80, 93], ["ACEI", "CHEMICAL", 95, 99], ["angiotensin receptor blocker", "CHEMICAL", 105, 133], ["ARB", "CHEMICAL", 135, 138], ["RAAS inhibitors", "SIMPLE_CHEMICAL", 63, 78], ["ACE inhibitor", "SIMPLE_CHEMICAL", 80, 93], ["ACEI", "SIMPLE_CHEMICAL", 95, 99], ["angiotensin receptor blocker", "SIMPLE_CHEMICAL", 105, 133], ["ARB", "SIMPLE_CHEMICAL", 135, 138], ["RAAS", "GENE_OR_GENE_PRODUCT", 216, 220], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["RAAS inhibitors", "TREATMENT", 63, 78], ["ACE inhibitor", "TREATMENT", 80, 93], ["ACEI", "TREATMENT", 95, 99], ["angiotensin receptor blocker", "TREATMENT", 105, 133], ["ARB) therapy", "TREATMENT", 135, 147], ["RAAS inhibitors", "TREATMENT", 216, 231], ["stable", "OBSERVATION", 270, 276]]], ["51hydroxychloroquine/Chloroquine and azithromycinChloroquine is a versatile bioactive agent with antiviral activity in vitro against DNA viruses as well as various RNA viruses, including SARS-CoV, MERS-CoV, and SARS-CoV-2, prompting it to be studied for patients with covid-19.", [["hydroxychloroquine", "CHEMICAL", 2, 20], ["Chloroquine", "CHEMICAL", 21, 32], ["azithromycinChloroquine", "CHEMICAL", 37, 60], ["hydroxychloroquine", "CHEMICAL", 2, 20], ["Chloroquine", "CHEMICAL", 21, 32], ["azithromycinChloroquine", "CHEMICAL", 37, 60], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 2, 20], ["Chloroquine", "SIMPLE_CHEMICAL", 21, 32], ["azithromycinChloroquine", "SIMPLE_CHEMICAL", 37, 60], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["SARS-CoV", "ORGANISM", 187, 195], ["MERS-CoV", "ORGANISM", 197, 205], ["SARS-CoV-2", "ORGANISM", 211, 221], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 254, 262], ["SARS-CoV", "SPECIES", 187, 195], ["MERS-CoV", "SPECIES", 197, 205], ["SARS-CoV", "SPECIES", 211, 219], ["hydroxychloroquine", "TREATMENT", 2, 20], ["Chloroquine", "TREATMENT", 21, 32], ["azithromycinChloroquine", "TREATMENT", 37, 60], ["a versatile bioactive agent", "TREATMENT", 64, 91], ["antiviral activity", "TREATMENT", 97, 115], ["DNA viruses", "PROBLEM", 133, 144], ["various RNA viruses", "PROBLEM", 156, 175], ["SARS", "PROBLEM", 187, 191], ["covid", "TEST", 268, 273]]], ["54 Similar to chloroquine, hydroxychloroquine confers antiviral effects and has an additional modulating effect on activated immune cells to decrease IL-6 expression.", [["immune cells", "ANATOMY", 125, 137], ["chloroquine", "CHEMICAL", 14, 25], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["chloroquine", "CHEMICAL", 14, 25], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["chloroquine", "SIMPLE_CHEMICAL", 14, 25], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["immune cells", "CELL", 125, 137], ["IL-6", "GENE_OR_GENE_PRODUCT", 150, 154], ["activated immune cells", "CELL_TYPE", 115, 137], ["IL-6", "PROTEIN", 150, 154], ["chloroquine", "TREATMENT", 14, 25], ["hydroxychloroquine", "TREATMENT", 27, 45], ["antiviral effects", "TREATMENT", 54, 71], ["activated immune cells", "TREATMENT", 115, 137]]], ["55 Non-randomised, observational studies of >100 patients at 10 hospitals in China suggest that chloroquine or hydroxychloroquine is superior to the control treatment in resolving pneumonia (based on clinical and imaging findings), promoting conversion to viral negative status and shortening the disease course.", [["chloroquine", "CHEMICAL", 96, 107], ["hydroxychloroquine", "CHEMICAL", 111, 129], ["pneumonia", "DISEASE", 180, 189], ["chloroquine", "CHEMICAL", 96, 107], ["hydroxychloroquine", "CHEMICAL", 111, 129], ["patients", "ORGANISM", 49, 57], ["chloroquine", "SIMPLE_CHEMICAL", 96, 107], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 111, 129], ["patients", "SPECIES", 49, 57], ["observational studies", "TEST", 19, 40], ["chloroquine", "TREATMENT", 96, 107], ["hydroxychloroquine", "TREATMENT", 111, 129], ["the control treatment", "TREATMENT", 145, 166], ["resolving pneumonia", "PROBLEM", 170, 189], ["imaging findings", "TEST", 213, 229], ["viral negative status", "PROBLEM", 256, 277], ["shortening the disease course", "PROBLEM", 282, 311], ["resolving", "OBSERVATION_MODIFIER", 170, 179], ["pneumonia", "OBSERVATION", 180, 189]]], ["56 In a small open-label, non-randomised study conducted in France, 70% of hydroxychloroquine-treated patients with covid-19 had undetectable viral titres at 6 days, compared with 12.5% in the control group (p=0.001), 57 although there were major methodological concerns with the study.", [["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["non-randomised study", "TEST", 26, 46], ["hydroxychloroquine", "TREATMENT", 75, 93], ["covid", "TEST", 116, 121], ["undetectable viral titres", "PROBLEM", 129, 154], ["the study", "TEST", 276, 285], ["small", "OBSERVATION_MODIFIER", 8, 13], ["viral titres", "OBSERVATION", 142, 154]]], ["Azithromycin, a macrolide antibiotic which acts against Zika and Ebola viruses in vitro 58 and suppresses inflammatory processes, 59 has been proposed as an effective adjunct to hydroxychloroquine in covid-19 through unclear mechanisms.", [["Azithromycin", "CHEMICAL", 0, 12], ["macrolide", "CHEMICAL", 16, 25], ["Zika and Ebola viruses", "DISEASE", 56, 78], ["hydroxychloroquine", "CHEMICAL", 178, 196], ["Azithromycin", "CHEMICAL", 0, 12], ["macrolide", "CHEMICAL", 16, 25], ["hydroxychloroquine", "CHEMICAL", 178, 196], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["macrolide", "SIMPLE_CHEMICAL", 16, 25], ["Zika", "ORGANISM", 56, 60], ["Ebola viruses", "ORGANISM", 65, 78], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 178, 196], ["Ebola viruses", "SPECIES", 65, 78], ["Azithromycin", "TREATMENT", 0, 12], ["a macrolide antibiotic", "TREATMENT", 14, 36], ["Zika", "PROBLEM", 56, 60], ["Ebola viruses", "PROBLEM", 65, 78], ["hydroxychloroquine in covid", "TREATMENT", 178, 205], ["inflammatory", "OBSERVATION_MODIFIER", 106, 118]]], ["57 Although the preliminary evidence for quinoline antimalarials may be promising, it should be taken with caution until randomised clinical trials are completed.", [["quinoline", "CHEMICAL", 41, 50], ["quinoline", "CHEMICAL", 41, 50], ["quinoline", "SIMPLE_CHEMICAL", 41, 50], ["quinoline antimalarials", "TREATMENT", 41, 64]]], ["Both chloroquine and azithromycin have generally favourable safety profiles, but they are known to cause cardiovascular side effects including prolongation of QT interval.", [["cardiovascular", "ANATOMY", 105, 119], ["chloroquine", "CHEMICAL", 5, 16], ["azithromycin", "CHEMICAL", 21, 33], ["prolongation of QT interval", "DISEASE", 143, 170], ["chloroquine", "CHEMICAL", 5, 16], ["azithromycin", "CHEMICAL", 21, 33], ["chloroquine", "SIMPLE_CHEMICAL", 5, 16], ["azithromycin", "SIMPLE_CHEMICAL", 21, 33], ["Both chloroquine", "TREATMENT", 0, 16], ["azithromycin", "TREATMENT", 21, 33], ["cardiovascular side effects", "PROBLEM", 105, 132], ["prolongation of QT interval", "PROBLEM", 143, 170]]], ["60 Although azithromycin interferes minimally with the cytochrome P-450 system in vitro, 61 chloroquine is metabolised by CYP2C8 and CYP3A4/5, 62 and there is a potentially enhanced risk of significant QT prolongation induced by combination therapy.", [["azithromycin", "CHEMICAL", 12, 24], ["cytochrome P-450", "CHEMICAL", 55, 71], ["chloroquine", "CHEMICAL", 92, 103], ["QT prolongation", "DISEASE", 202, 217], ["azithromycin", "CHEMICAL", 12, 24], ["chloroquine", "CHEMICAL", 92, 103], ["azithromycin", "SIMPLE_CHEMICAL", 12, 24], ["cytochrome P-450", "GENE_OR_GENE_PRODUCT", 55, 71], ["chloroquine", "SIMPLE_CHEMICAL", 92, 103], ["CYP2C8", "GENE_OR_GENE_PRODUCT", 122, 128], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 133, 139], ["azithromycin", "TREATMENT", 12, 24], ["the cytochrome P", "TREATMENT", 51, 67], ["chloroquine", "TREATMENT", 92, 103], ["CYP3A4", "TEST", 133, 139], ["significant QT prolongation", "PROBLEM", 190, 217], ["combination therapy", "TREATMENT", 229, 248], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["QT prolongation", "OBSERVATION", 202, 217]]], ["Guidance for managing QTc prolongation in covid-19 pharmacotherapies and other cardiac electrophysiology issues related to covid-19 has recently been published by the Heart Rhythm Society.", [["cardiac", "ANATOMY", 79, 86], ["QTc prolongation", "DISEASE", 22, 38], ["cardiac", "ORGAN", 79, 86], ["managing QTc prolongation", "TREATMENT", 13, 38], ["covid-19 pharmacotherapies", "TREATMENT", 42, 68], ["other cardiac electrophysiology issues", "PROBLEM", 73, 111], ["covid", "TEST", 123, 128], ["cardiac", "ANATOMY", 79, 86], ["Heart", "ANATOMY", 167, 172]]], ["63Immunosuppressive therapyAs for SARS and MERS, corticosteroids are not routinely recommended for covid-19 and might exacerbate the resulting lung injury.", [["lung", "ANATOMY", 143, 147], ["SARS", "DISEASE", 34, 38], ["lung injury", "DISEASE", 143, 154], ["corticosteroids", "CHEMICAL", 49, 64], ["corticosteroids", "SIMPLE_CHEMICAL", 49, 64], ["lung", "ORGAN", 143, 147], ["63Immunosuppressive therapy", "TREATMENT", 0, 27], ["SARS", "PROBLEM", 34, 38], ["corticosteroids", "TREATMENT", 49, 64], ["covid", "TEST", 99, 104], ["the resulting lung injury", "PROBLEM", 129, 154], ["lung", "ANATOMY", 143, 147], ["injury", "OBSERVATION", 148, 154]]], ["64 However, given the detrimental effects of the cytokine release syndrome associated with covid-19 on the cardiopulmonary system, immunosuppressive therapy to dampen the hyperinflammatory response may be beneficial.", [["cardiopulmonary system", "ANATOMY", 107, 129], ["covid-19", "CHEMICAL", 91, 99], ["cytokine", "PROTEIN", 49, 57], ["the cytokine release syndrome", "PROBLEM", 45, 74], ["covid", "TEST", 91, 96], ["the cardiopulmonary system", "TREATMENT", 103, 129], ["immunosuppressive therapy", "TREATMENT", 131, 156], ["the hyperinflammatory response", "PROBLEM", 167, 197], ["cardiopulmonary system", "ANATOMY", 107, 129]]], ["36 Screening patients with covid-19 using laboratory data (increasing ferritin and erythrocyte sedimentation rate, and decreasing platelets) and a proposed score for the hemophagocytic response (HScore) 65 for hyperinflammation may help to identify patients for whom immunosuppression might improve survival.", [["erythrocyte", "ANATOMY", 83, 94], ["platelets", "ANATOMY", 130, 139], ["hemophagocytic", "DISEASE", 170, 184], ["hyperinflammation", "DISEASE", 210, 227], ["patients", "ORGANISM", 13, 21], ["ferritin", "GENE_OR_GENE_PRODUCT", 70, 78], ["erythrocyte", "CELL", 83, 94], ["platelets", "CELL", 130, 139], ["patients", "ORGANISM", 249, 257], ["ferritin", "PROTEIN", 70, 78], ["platelets", "CELL_TYPE", 130, 139], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 249, 257], ["covid", "TEST", 27, 32], ["laboratory data", "TEST", 42, 57], ["increasing ferritin", "PROBLEM", 59, 78], ["erythrocyte sedimentation rate", "TEST", 83, 113], ["decreasing platelets", "TREATMENT", 119, 139], ["the hemophagocytic response", "PROBLEM", 166, 193], ["hyperinflammation", "PROBLEM", 210, 227], ["immunosuppression", "TREATMENT", 267, 284]]], ["36 IL-6 inhibitors may have a role as immunomodulators.", [["IL-6", "GENE_OR_GENE_PRODUCT", 3, 7], ["immunomodulators", "TREATMENT", 38, 54]]], ["Tocilizumab, an inhibitor of the IL-6 receptor, was shown to effectively improve symptoms and prevent clinical deterioration in a retrospective case series study of 21 covid-19 patients with severe or critical disease.", [["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 33, 46], ["patients", "ORGANISM", 177, 185], ["IL-6 receptor", "PROTEIN", 33, 46], ["patients", "SPECIES", 177, 185], ["Tocilizumab", "TREATMENT", 0, 11], ["an inhibitor of the IL-6 receptor", "TREATMENT", 13, 46], ["symptoms", "PROBLEM", 81, 89], ["clinical deterioration", "PROBLEM", 102, 124], ["a retrospective case series study", "TEST", 128, 161], ["severe or critical disease", "PROBLEM", 191, 217], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["critical", "OBSERVATION_MODIFIER", 201, 209], ["disease", "OBSERVATION", 210, 217]]], ["66 Several clinical trials are ongoing to assess the efficacy and safety of tocilizumab (NCT04317092) 67 or sarilumab, another IL-6 inhibitor (NCT04327388) 68 in patients with covid-19.Review mechanical cardiopulmonary supportMechanical cardiopulmonary support in respiratory failure has been reported with variable survival rates.", [["cardiopulmonary", "ANATOMY", 237, 252], ["respiratory", "ANATOMY", 264, 275], ["tocilizumab", "CHEMICAL", 76, 87], ["sarilumab", "CHEMICAL", 108, 117], ["respiratory failure", "DISEASE", 264, 283], ["NCT04317092", "CHEMICAL", 89, 100], ["sarilumab", "CHEMICAL", 108, 117], ["tocilizumab", "SIMPLE_CHEMICAL", 76, 87], ["sarilumab", "SIMPLE_CHEMICAL", 108, 117], ["IL-6", "GENE_OR_GENE_PRODUCT", 127, 131], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["tocilizumab (NCT04317092)", "TREATMENT", 76, 101], ["sarilumab", "TREATMENT", 108, 117], ["another IL", "TREATMENT", 119, 129], ["covid", "TEST", 176, 181], ["mechanical cardiopulmonary support", "TREATMENT", 192, 226], ["Mechanical cardiopulmonary support", "TREATMENT", 226, 260], ["respiratory failure", "PROBLEM", 264, 283], ["cardiopulmonary support", "OBSERVATION", 203, 226], ["cardiopulmonary support", "OBSERVATION", 237, 260], ["respiratory failure", "OBSERVATION", 264, 283]]], ["Extracorporeal Life Support Organization Registry is being adapted to investigate covid-19 in prospective observational studies addressing the role of extracorporeal membrane oxygenation (ECMO) in these critically ill patients.", [["extracorporeal membrane", "ANATOMY", 151, 174], ["critically ill", "DISEASE", 203, 217], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 151, 174], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["prospective observational studies", "TEST", 94, 127], ["extracorporeal membrane oxygenation", "TREATMENT", 151, 186], ["ECMO", "TREATMENT", 188, 192]]], ["69 In the setting of cardiogenic shock related to covid-19, intraaortic balloon pump (IABP), or veno-arterial ECMO should be considered.", [["intraaortic", "ANATOMY", 60, 71], ["veno-arterial", "ANATOMY", 96, 109], ["cardiogenic shock", "DISEASE", 21, 38], ["covid-19", "CHEMICAL", 50, 58], ["intraaortic balloon pump", "GENE_OR_GENE_PRODUCT", 60, 84], ["cardiogenic shock", "PROBLEM", 21, 38], ["covid", "TEST", 50, 55], ["intraaortic balloon pump", "TREATMENT", 60, 84], ["IABP", "TREATMENT", 86, 90], ["veno-arterial ECMO", "TREATMENT", 96, 114], ["cardiogenic shock", "OBSERVATION", 21, 38], ["intraaortic", "ANATOMY", 60, 71], ["balloon pump", "OBSERVATION", 72, 84], ["veno-arterial", "ANATOMY", 96, 109]]], ["During the 2009 H1N1 pandemic in Japan, 9 out of 13 patients with fulminant myocarditis receiving emergent mechanical circulatory support (IABP and/or percutaneous cardiopulmonary support) survived, while all four patients with fulminant myocarditis treated without mechanical circulatory support died.", [["percutaneous", "ANATOMY", 151, 163], ["H1N1 pandemic", "DISEASE", 16, 29], ["myocarditis", "DISEASE", 76, 87], ["myocarditis", "DISEASE", 238, 249], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 214, 222], ["fulminant myocarditis", "PROBLEM", 66, 87], ["emergent mechanical circulatory support", "TREATMENT", 98, 137], ["IABP", "TREATMENT", 139, 143], ["percutaneous cardiopulmonary support", "TREATMENT", 151, 187], ["fulminant myocarditis", "PROBLEM", 228, 249], ["mechanical circulatory support", "TREATMENT", 266, 296], ["fulminant", "OBSERVATION_MODIFIER", 66, 75], ["myocarditis", "OBSERVATION", 76, 87], ["circulatory support", "OBSERVATION", 118, 137], ["fulminant", "OBSERVATION_MODIFIER", 228, 237], ["myocarditis", "OBSERVATION", 238, 249], ["circulatory support", "OBSERVATION", 277, 296]]], ["70 A case has been reported of a patient with covid-19 without respiratory symptoms presenting with cardiogenic shock attributed to acute myopericarditis and successfully treated with IABP support.", [["respiratory", "ANATOMY", 63, 74], ["respiratory symptoms", "DISEASE", 63, 83], ["cardiogenic shock", "DISEASE", 100, 117], ["myopericarditis", "DISEASE", 138, 153], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["covid", "TEST", 46, 51], ["respiratory symptoms", "PROBLEM", 63, 83], ["cardiogenic shock", "PROBLEM", 100, 117], ["acute myopericarditis", "PROBLEM", 132, 153], ["IABP support", "TREATMENT", 184, 196], ["cardiogenic shock", "OBSERVATION", 100, 117], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["myopericarditis", "OBSERVATION", 138, 153]]], ["32 Perhaps a more likely scenario is the conversion of veno-venous ECMO for ARDS to venoarterial-venous ECMO on development of cardiogenic shock, as described in another case report.", [["venoarterial", "ANATOMY", 84, 96], ["venous", "ANATOMY", 97, 103], ["ARDS", "DISEASE", 76, 80], ["cardiogenic shock", "DISEASE", 127, 144], ["venoarterial-venous", "MULTI-TISSUE_STRUCTURE", 84, 103], ["veno-venous ECMO", "TREATMENT", 55, 71], ["ARDS", "PROBLEM", 76, 80], ["venoarterial-venous ECMO", "TREATMENT", 84, 108], ["cardiogenic shock", "PROBLEM", 127, 144], ["veno-venous ECMO", "OBSERVATION", 55, 71], ["venous", "ANATOMY", 97, 103], ["ECMO", "OBSERVATION", 104, 108], ["cardiogenic shock", "OBSERVATION", 127, 144]]], ["32 Regardless of the mode of mechanical support, patient selection should involve consideration of comorbidities and potential complications.ConClusIonCovid-19 is similar to SARS and MERS with regard to host vulnerability, specifically in those with substantial cardiovascular comorbidities.", [["cardiovascular", "ANATOMY", 262, 276], ["SARS", "DISEASE", 174, 178], ["cardiovascular comorbidities", "DISEASE", 262, 290], ["ConClusIonCovid-19", "CHEMICAL", 141, 159], ["patient", "ORGANISM", 49, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 262, 276], ["patient", "SPECIES", 49, 56], ["mechanical support", "TREATMENT", 29, 47], ["patient selection", "TREATMENT", 49, 66], ["comorbidities", "PROBLEM", 99, 112], ["potential complications", "PROBLEM", 117, 140], ["ConClusIonCovid", "TEST", 141, 156], ["SARS", "PROBLEM", 174, 178], ["substantial cardiovascular comorbidities", "PROBLEM", 250, 290], ["substantial", "OBSERVATION_MODIFIER", 250, 261], ["cardiovascular", "ANATOMY", 262, 276], ["comorbidities", "OBSERVATION", 277, 290]]], ["Greater transmissibility of covid-19 has resulted in a worldwide pandemic, a record number of infected individuals and an excess mortality that far exceeded previous coronavirusrelated outbreaks.", [["covid-19", "CHEMICAL", 28, 36], ["covid", "TEST", 28, 33], ["a worldwide pandemic", "PROBLEM", 53, 73], ["infected individuals", "PROBLEM", 94, 114], ["an excess mortality", "PROBLEM", 119, 138], ["worldwide", "OBSERVATION_MODIFIER", 55, 64], ["pandemic", "OBSERVATION", 65, 73], ["infected", "OBSERVATION_MODIFIER", 94, 102]]], ["Myocardial injury is common in covid-19 and portends a worse prognosis.", [["Myocardial", "ANATOMY", 0, 10], ["Myocardial injury", "DISEASE", 0, 17], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["Myocardial injury", "PROBLEM", 0, 17], ["injury", "OBSERVATION", 11, 17]]], ["Differentiating between the various causes of myocardial injury is crucial to determining the treatment course.", [["myocardial", "ANATOMY", 46, 56], ["myocardial injury", "DISEASE", 46, 63], ["myocardial", "MULTI-TISSUE_STRUCTURE", 46, 56], ["myocardial injury", "PROBLEM", 46, 63], ["the treatment course", "TREATMENT", 90, 110], ["myocardial", "ANATOMY", 46, 56], ["injury", "OBSERVATION", 57, 63]]], ["The cardiovascular considerations for treatment, including anticoagulation, ACEI or ARB use, anti-arrhythmic management, immunosuppression/modulation, and haemodynamic support, are important and continue to evolve.", [["cardiovascular", "ANATOMY", 4, 18], ["ACEI", "CHEMICAL", 76, 80], ["ARB", "CHEMICAL", 84, 87], ["ACEI", "SIMPLE_CHEMICAL", 76, 80], ["ARB", "SIMPLE_CHEMICAL", 84, 87], ["treatment", "TREATMENT", 38, 47], ["anticoagulation", "TREATMENT", 59, 74], ["ACEI", "TREATMENT", 76, 80], ["ARB", "TREATMENT", 84, 87], ["anti-arrhythmic management", "TREATMENT", 93, 119], ["immunosuppression/modulation", "TREATMENT", 121, 149], ["haemodynamic support", "TREATMENT", 155, 175]]]], "101f9d51bf500d6f86eacdf68b17838f686845ea": [["INTRODUCTIONNot since its discovery in 2000, 1 2 has the ACE2 receptor attracted as much attention as currently.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 57, 70], ["ACE2 receptor", "PROTEIN", 57, 70], ["the ACE2 receptor", "TREATMENT", 53, 70]]], ["The receptor has been identified as the cellular docking point for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 3 the causative agent of COVID-19, 4 which was declared a pandemic by the WHO 5 and at the time of writing has infected more than 13 million people globally, and more than 580 thousand deaths.", [["cellular", "ANATOMY", 40, 48], ["acute respiratory syndrome coronavirus", "DISEASE", 84, 122], ["deaths", "DISEASE", 324, 330], ["cellular", "CELL", 40, 48], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 77, 124], ["SARS-CoV-2", "ORGANISM", 126, 136], ["people", "ORGANISM", 280, 286], ["people", "SPECIES", 280, 286], ["severe acute respiratory syndrome coronavirus", "SPECIES", 77, 122], ["SARS-CoV-2", "SPECIES", 126, 136], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 67, 122], ["SARS-CoV", "TEST", 126, 134], ["COVID", "TEST", 164, 169], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory syndrome", "OBSERVATION", 90, 110]]], ["6 The renin-angiotensin system is a central mechanism for blood pressure regulation through a diverse system of hormones and receptors (figure 1).INTRODUCTIONThe vasopressive actions of this 'classical' pathway is opposed by the actions of ACE2, a key component of the 'protective (vasodilatory)' arm which converts angiotensin (Ang) II to Ang (1-7).", [["blood", "ANATOMY", 58, 63], ["angiotensin", "CHEMICAL", 12, 23], ["angiotensin", "CHEMICAL", 316, 327], ["Ang", "CHEMICAL", 329, 332], ["Ang", "CHEMICAL", 340, 343], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 6, 23], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 240, 244], ["angiotensin (Ang) II", "GENE_OR_GENE_PRODUCT", 316, 336], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 340, 348], ["renin", "PROTEIN", 6, 11], ["ACE2", "PROTEIN", 240, 244], ["angiotensin (Ang) II", "PROTEIN", 316, 336], ["The renin-angiotensin system", "TREATMENT", 2, 30], ["blood pressure regulation", "TREATMENT", 58, 83], ["ACE2", "TREATMENT", 240, 244], ["the 'protective (vasodilatory)' arm", "TREATMENT", 265, 300], ["angiotensin (Ang) II to Ang", "TREATMENT", 316, 343], ["angiotensin system", "OBSERVATION", 12, 30], ["central mechanism", "OBSERVATION", 36, 53]]], ["Thus, the system is central in a number of pathological processes ranging from cardiovascular and respiratory diseases, to amino acid absorption in the gut and kidney.", [["cardiovascular", "ANATOMY", 79, 93], ["respiratory", "ANATOMY", 98, 109], ["gut", "ANATOMY", 152, 155], ["kidney", "ANATOMY", 160, 166], ["cardiovascular and respiratory diseases", "DISEASE", 79, 118], ["amino acid", "CHEMICAL", 123, 133], ["amino acid", "CHEMICAL", 123, 133], ["cardiovascular", "ANATOMICAL_SYSTEM", 79, 93], ["amino acid", "AMINO_ACID", 123, 133], ["gut", "ORGANISM_SUBDIVISION", 152, 155], ["kidney", "ORGAN", 160, 166], ["pathological processes", "PROBLEM", 43, 65], ["cardiovascular and respiratory diseases", "PROBLEM", 79, 118], ["amino acid absorption in the gut and kidney", "PROBLEM", 123, 166], ["central", "OBSERVATION_MODIFIER", 20, 27], ["respiratory diseases", "OBSERVATION", 98, 118], ["gut", "ANATOMY", 152, 155], ["kidney", "ANATOMY", 160, 166]]], ["Understanding the role of ACE2 has shed light on the pathogenesis of COVID-19 and may potentially explain the myriad of unusual biochemical findings.ACE2 GENE Location and gene productACE2 was discovered independently by two groups in 2000 by homology cloning from a heart failure ventricular complementary DNA (cDNA) library and a lymphoma cDNA library, respectively.", [["heart", "ANATOMY", 267, 272], ["heart failure", "DISEASE", 267, 280], ["lymphoma", "DISEASE", 332, 340], ["COVID-19", "CHEMICAL", 69, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["COVID-19", "CELL", 69, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 149, 153], ["productACE2", "GENE_OR_GENE_PRODUCT", 177, 188], ["heart", "ORGAN", 267, 272], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["lymphoma", "CANCER", 332, 340], ["ACE2", "PROTEIN", 26, 30], ["ACE2", "PROTEIN", 149, 153], ["productACE2", "DNA", 177, 188], ["heart failure ventricular complementary DNA (cDNA) library", "DNA", 267, 325], ["lymphoma cDNA library", "DNA", 332, 353], ["COVID", "TEST", 69, 74], ["a heart failure ventricular complementary DNA (cDNA) library", "PROBLEM", 265, 325], ["a lymphoma cDNA library", "PROBLEM", 330, 353], ["heart", "ANATOMY", 267, 272], ["failure", "OBSERVATION", 273, 280], ["lymphoma", "OBSERVATION", 332, 340]]], ["1 2 The ACE2 gene is 39.98 kB in size, located on Xp22 and contains 18 exons and 20 introns.", [["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["Xp22", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2 gene", "DNA", 8, 17], ["Xp22", "DNA", 50, 54], ["exons", "DNA", 71, 76], ["introns", "DNA", 84, 91], ["The ACE2 gene", "TEST", 4, 17], ["39.98 kB", "OBSERVATION_MODIFIER", 21, 29], ["size", "OBSERVATION_MODIFIER", 33, 37], ["18 exons", "OBSERVATION_MODIFIER", 68, 76]]], ["7 The gene is highly polymorphic [8] [9] [10] and variations may account for differences in enzymatic activity.", [["may account for", "UNCERTAINTY", 61, 76], ["enzymatic activity", "OBSERVATION", 92, 110]]], ["9 The gene undergoes alternative splicing to produce six variants.", [["alternative splicing", "TREATMENT", 21, 41]]], ["10 The final product is an 805 amino acid, 120 kDa monocarboxypeptidase type I transmembrane glycoprotein.", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["monocarboxypeptidase type I transmembrane glycoprotein", "GENE_OR_GENE_PRODUCT", 51, 105], ["120 kDa monocarboxypeptidase type I transmembrane glycoprotein", "PROTEIN", 43, 105], ["amino acid", "TEST", 31, 41]]], ["The first 17 amino acids make up the N-terminal signal peptide followed by a HEXXH zinc-binding metalloprotease motif, a C-terminal collectrin domain and an insulin-like domain that includes a ferredoxin-like neck domain ending with a 22 amino acid hydrophobic transmembrane region anchoring it in the cell membrane 7 10 (figure 2).ACE2 GENE Location and gene productLocation on the X-chromosome implies that expression could be impacted by differences in parental imprinting and escape of X-inactivation in females resulting in dosage discordance in ACE2 expression between males and females.", [["cell membrane", "ANATOMY", 302, 315], ["X-chromosome", "ANATOMY", 383, 395], ["amino acids", "CHEMICAL", 13, 24], ["zinc", "CHEMICAL", 83, 87], ["amino acid", "CHEMICAL", 238, 248], ["amino acids", "CHEMICAL", 13, 24], ["N", "CHEMICAL", 37, 38], ["zinc", "CHEMICAL", 83, 87], ["C", "CHEMICAL", 121, 122], ["amino acid", "CHEMICAL", 238, 248], ["amino acids", "AMINO_ACID", 13, 24], ["insulin", "GENE_OR_GENE_PRODUCT", 157, 164], ["cell membrane", "CELLULAR_COMPONENT", 302, 315], ["ACE2", "GENE_OR_GENE_PRODUCT", 332, 336], ["ACE2", "GENE_OR_GENE_PRODUCT", 551, 555], ["HEXXH zinc-binding metalloprotease motif", "PROTEIN", 77, 117], ["C-terminal collectrin domain", "PROTEIN", 121, 149], ["insulin-like domain", "PROTEIN", 157, 176], ["ferredoxin-like neck domain", "PROTEIN", 193, 220], ["22 amino acid hydrophobic transmembrane region", "PROTEIN", 235, 281], ["ACE2", "PROTEIN", 332, 336], ["X-chromosome", "DNA", 383, 395], ["ACE2", "PROTEIN", 551, 555], ["The first 17 amino acids", "TEST", 0, 24], ["a HEXXH zinc-binding metalloprotease motif", "TREATMENT", 75, 117], ["a C-terminal collectrin domain", "PROBLEM", 119, 149], ["an insulin", "TREATMENT", 154, 164], ["a ferredoxin-like neck domain", "TREATMENT", 191, 220], ["a 22 amino acid hydrophobic transmembrane region", "TREATMENT", 233, 281], ["ACE2 GENE Location and gene productLocation on the X-chromosome", "TREATMENT", 332, 395], ["X-inactivation in females", "PROBLEM", 490, 515], ["dosage discordance", "PROBLEM", 529, 547], ["neck", "ANATOMY", 209, 213], ["cell membrane", "OBSERVATION", 302, 315]]], ["11 Interestingly, analysis of renin-angiotensin metabolites shows a 27% higher plasma renin activity in males.", [["plasma", "ANATOMY", 79, 85], ["angiotensin", "CHEMICAL", 36, 47], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 30, 47], ["plasma", "ORGANISM_SUBSTANCE", 79, 85], ["renin", "GENE_OR_GENE_PRODUCT", 86, 91], ["renin", "PROTEIN", 30, 35], ["renin", "PROTEIN", 86, 91], ["renin", "TEST", 30, 35], ["angiotensin metabolites", "TEST", 36, 59], ["a 27% higher plasma renin activity in males", "PROBLEM", 66, 109], ["activity", "OBSERVATION_MODIFIER", 92, 100]]], ["12 ACE2 shares significant sequence identity with two other proteins, ACE and collectrin (figure 3).Angiotensin converting enzymeThe significant homology, 42% amino acid sequence similarity in the catalytic domains, and the conservation of exon and intron organisation suggest that ACE and ACE2 genes originated from a common ancestor.", [["Angiotensin", "CHEMICAL", 100, 111], ["amino acid", "CHEMICAL", 159, 169], ["amino acid", "CHEMICAL", 159, 169], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["ACE", "GENE_OR_GENE_PRODUCT", 70, 73], ["collectrin", "GENE_OR_GENE_PRODUCT", 78, 88], ["Angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 100, 129], ["amino acid", "AMINO_ACID", 159, 169], ["ACE", "GENE_OR_GENE_PRODUCT", 282, 285], ["ACE2", "GENE_OR_GENE_PRODUCT", 290, 294], ["ACE2", "PROTEIN", 3, 7], ["ACE", "PROTEIN", 70, 73], ["collectrin", "PROTEIN", 78, 88], ["Angiotensin converting enzyme", "PROTEIN", 100, 129], ["catalytic domains", "PROTEIN", 197, 214], ["ACE and ACE2 genes", "DNA", 282, 300], ["ACE and collectrin (figure", "TREATMENT", 70, 96], ["Angiotensin converting enzyme", "TREATMENT", 100, 129], ["42% amino acid sequence similarity in the catalytic domains", "PROBLEM", 155, 214], ["exon and intron organisation", "TREATMENT", 240, 268], ["ACE and ACE2 genes", "TREATMENT", 282, 300]]], ["The ACE gene is located on chromosome 17, spans 21 kB with 26 exons and 25 introns, and codes for a 180 kDa protein anchored to the plasma membrane by a single carboxy-terminal transmembrane domain.", [["chromosome 17", "ANATOMY", 27, 40], ["plasma membrane", "ANATOMY", 132, 147], ["carboxy", "CHEMICAL", 160, 167], ["ACE", "GENE_OR_GENE_PRODUCT", 4, 7], ["chromosome 17", "CELLULAR_COMPONENT", 27, 40], ["plasma membrane", "CELLULAR_COMPONENT", 132, 147], ["ACE gene", "DNA", 4, 12], ["chromosome 17", "DNA", 27, 40], ["21 kB", "DNA", 48, 53], ["exons", "DNA", 62, 67], ["introns", "DNA", 75, 82], ["180 kDa protein", "PROTEIN", 100, 115], ["carboxy-terminal transmembrane domain", "PROTEIN", 160, 197], ["The ACE gene", "TREATMENT", 0, 12], ["exons", "TEST", 62, 67], ["a 180 kDa protein", "TREATMENT", 98, 115], ["a single carboxy-terminal transmembrane domain", "TREATMENT", 151, 197]]], ["13 Two differentially spliced forms are known.", [["differentially spliced", "OBSERVATION", 7, 29]]], ["The single domain testicular form plays an important role in male fertility, and the two-domain somatic form is essential in regulating cardiovascular functions.", [["testicular", "ANATOMY", 18, 28], ["cardiovascular", "ANATOMY", 136, 150], ["testicular", "ORGAN", 18, 28], ["cardiovascular", "ANATOMICAL_SYSTEM", 136, 150], ["testicular", "ANATOMY", 18, 28]]], ["14 Although it was initially thought that ACE and ACE2 have similar functions, this is not the case.", [["ACE", "GENE_OR_GENE_PRODUCT", 42, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE", "PROTEIN", 42, 45], ["ACE2", "PROTEIN", 50, 54], ["ACE and ACE2", "PROBLEM", 42, 54]]], ["The carboxydipeptidase activity of ACE removes Molecules in pathogenesis Figure 1 Central role of the renin-angiotensin system in blood pressure homeostasis.", [["blood", "ANATOMY", 130, 135], ["angiotensin", "CHEMICAL", 108, 119], ["carboxydipeptidase", "SIMPLE_CHEMICAL", 4, 22], ["ACE", "GENE_OR_GENE_PRODUCT", 35, 38], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 102, 119], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["renin", "PROTEIN", 102, 107], ["The carboxydipeptidase activity", "TREATMENT", 0, 31], ["ACE removes Molecules", "TREATMENT", 35, 56], ["the renin-angiotensin system", "TREATMENT", 98, 126], ["blood pressure homeostasis", "TREATMENT", 130, 156]]], ["The cascaded system involves a number of enzymes and receptors.", [["enzymes", "PROTEIN", 41, 48], ["enzymes", "TEST", 41, 48]]], ["Angiotensinogen produced by the liver is converted to angiotensin I (Ang I) by renin secreted by the kidney.", [["liver", "ANATOMY", 32, 37], ["kidney", "ANATOMY", 101, 107], ["Angiotensinogen", "CHEMICAL", 0, 15], ["angiotensin I", "CHEMICAL", 54, 67], ["Ang", "CHEMICAL", 69, 72], ["Angiotensinogen", "CHEMICAL", 0, 15], ["Angiotensinogen", "SIMPLE_CHEMICAL", 0, 15], ["liver", "ORGAN", 32, 37], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 54, 67], ["Ang I", "GENE_OR_GENE_PRODUCT", 69, 74], ["renin", "GENE_OR_GENE_PRODUCT", 79, 84], ["kidney", "ORGAN", 101, 107], ["angiotensin I", "PROTEIN", 54, 67], ["renin", "PROTEIN", 79, 84], ["Angiotensinogen", "TEST", 0, 15], ["angiotensin I (Ang I)", "TREATMENT", 54, 75], ["liver", "ANATOMY", 32, 37], ["kidney", "ANATOMY", 101, 107]]], ["ACE2 is important in the conversion of Ang I to angiotensin (1-9) and angiotensin II (Ang II) to angiotensin (1-7).", [["Ang", "CHEMICAL", 39, 42], ["angiotensin (1-9", "CHEMICAL", 48, 64], ["angiotensin II", "CHEMICAL", 70, 84], ["Ang II", "CHEMICAL", 86, 92], ["angiotensin", "CHEMICAL", 97, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang I", "GENE_OR_GENE_PRODUCT", 39, 44], ["angiotensin (1-9", "GENE_OR_GENE_PRODUCT", 48, 64], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 70, 84], ["Ang II", "GENE_OR_GENE_PRODUCT", 86, 92], ["angiotensin", "SIMPLE_CHEMICAL", 97, 108], ["1-7", "SIMPLE_CHEMICAL", 110, 113], ["ACE2", "PROTEIN", 0, 4], ["Ang I", "PROTEIN", 39, 44], ["ACE2", "TREATMENT", 0, 4], ["Ang I to angiotensin", "TREATMENT", 39, 59], ["angiotensin II (Ang II) to angiotensin", "TREATMENT", 70, 108]]], ["Ang II and angiotensin (1-7) exert a number of actions by binding to AT1, AT2 and MAS receptors.", [["Ang II", "CHEMICAL", 0, 6], ["angiotensin (1-7)", "CHEMICAL", 11, 28], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 11, 27], ["AT1", "GENE_OR_GENE_PRODUCT", 69, 72], ["AT2", "GENE_OR_GENE_PRODUCT", 74, 77], ["MAS receptors", "GENE_OR_GENE_PRODUCT", 82, 95], ["Ang II", "PROTEIN", 0, 6], ["AT1, AT2 and MAS receptors", "PROTEIN", 69, 95], ["Ang II and angiotensin", "TREATMENT", 0, 22]]], ["ACEi, ACE inhibitor; AT1, angiotensin type 1; AT2, angiotensin type 2. the C-terminal dipeptide from the decapeptide Ang I to form the octapeptide Ang II .", [["ACEi", "CHEMICAL", 0, 4], ["ACE inhibitor", "CHEMICAL", 6, 19], ["AT1", "CHEMICAL", 21, 24], ["angiotensin", "CHEMICAL", 26, 37], ["angiotensin", "CHEMICAL", 51, 62], ["Ang", "CHEMICAL", 117, 120], ["Ang II", "CHEMICAL", 147, 153], ["dipeptide", "CHEMICAL", 86, 95], ["ACEi", "SIMPLE_CHEMICAL", 0, 4], ["ACE", "GENE_OR_GENE_PRODUCT", 6, 9], ["AT1", "GENE_OR_GENE_PRODUCT", 21, 24], ["angiotensin type 1", "GENE_OR_GENE_PRODUCT", 26, 44], ["AT2", "GENE_OR_GENE_PRODUCT", 46, 49], ["angiotensin type 2", "GENE_OR_GENE_PRODUCT", 51, 69], ["C-terminal dipeptide", "SIMPLE_CHEMICAL", 75, 95], ["Ang I", "GENE_OR_GENE_PRODUCT", 117, 122], ["Ang II", "GENE_OR_GENE_PRODUCT", 147, 153], ["decapeptide Ang I", "PROTEIN", 105, 122], ["octapeptide Ang II", "PROTEIN", 135, 153], ["ACEi", "TREATMENT", 0, 4], ["ACE inhibitor", "TREATMENT", 6, 19], ["AT1", "TREATMENT", 21, 24], ["angiotensin type 1", "TREATMENT", 26, 44], ["AT2", "PROBLEM", 46, 49], ["angiotensin type 2", "TREATMENT", 51, 69], ["the C-terminal dipeptide", "TREATMENT", 71, 95], ["the decapeptide Ang I", "TREATMENT", 101, 122], ["the octapeptide Ang II", "TREATMENT", 131, 153]]], ["Ang II binds the angiotensin type 1 (AT1) receptors and has a well-established vasopressive role in regulating blood pressure (BP), fluid and electrolyte balance (via aldosterone).", [["blood", "ANATOMY", 111, 116], ["Ang II", "CHEMICAL", 0, 6], ["angiotensin", "CHEMICAL", 17, 28], ["aldosterone", "CHEMICAL", 167, 178], ["aldosterone", "CHEMICAL", 167, 178], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["angiotensin type 1", "GENE_OR_GENE_PRODUCT", 17, 35], ["AT1) receptors", "GENE_OR_GENE_PRODUCT", 37, 51], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["BP", "SIMPLE_CHEMICAL", 127, 129], ["fluid", "ORGANISM_SUBSTANCE", 132, 137], ["electrolyte", "SIMPLE_CHEMICAL", 142, 153], ["aldosterone", "SIMPLE_CHEMICAL", 167, 178], ["Ang II", "PROTEIN", 0, 6], ["angiotensin type 1 (AT1) receptors", "PROTEIN", 17, 51], ["Ang II binds the angiotensin type 1 (AT1) receptors", "TREATMENT", 0, 51], ["blood pressure", "TEST", 111, 125], ["BP", "TEST", 127, 129], ["fluid and electrolyte balance", "TEST", 132, 161], ["aldosterone", "TEST", 167, 178]]], ["11 ACE inhibitors do not affect the ACE2 activity directly but may have indirect effects on ACE2 expression.", [["ACE", "GENE_OR_GENE_PRODUCT", 3, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2", "PROTEIN", 36, 40], ["ACE2", "PROTEIN", 92, 96], ["11 ACE inhibitors", "TREATMENT", 0, 17], ["ACE2 expression", "TREATMENT", 92, 107]]], ["15 Furthermore, ACE plays an important role in the kinin-kallikrein system by inactivating the vasodilator bradykinin.", [["bradykinin", "CHEMICAL", 107, 117], ["bradykinin", "CHEMICAL", 107, 117], ["ACE", "GENE_OR_GENE_PRODUCT", 16, 19], ["kinin", "GENE_OR_GENE_PRODUCT", 51, 56], ["kallikrein", "GENE_OR_GENE_PRODUCT", 57, 67], ["bradykinin", "SIMPLE_CHEMICAL", 107, 117], ["ACE", "PROTEIN", 16, 19], ["ACE", "TREATMENT", 16, 19], ["the kinin-kallikrein system", "TREATMENT", 47, 74], ["the vasodilator bradykinin", "TREATMENT", 91, 117]]], ["16 Collectrin Collectrin has 47.8% sequence similarity to the C-terminal region of ACE2 including the non-catalytic extracellular, transmembrane and cytosolic domains of the protein, but lacks the catalytic domain.", [["extracellular", "ANATOMY", 116, 129], ["transmembrane", "ANATOMY", 131, 144], ["cytosolic", "ANATOMY", 149, 158], ["Collectrin", "CHEMICAL", 14, 24], ["C", "CHEMICAL", 62, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 129], ["transmembrane", "CELLULAR_COMPONENT", 131, 144], ["C-terminal region", "DNA", 62, 79], ["ACE2", "PROTEIN", 83, 87], ["non-catalytic extracellular, transmembrane and cytosolic domains", "PROTEIN", 102, 166], ["catalytic domain", "PROTEIN", 197, 213], ["Collectrin Collectrin", "TREATMENT", 3, 24], ["terminal", "ANATOMY_MODIFIER", 64, 72]]], ["17 Collectrin plays an important role in vesicle transport and membrane fusion.", [["vesicle", "ANATOMY", 41, 48], ["membrane", "ANATOMY", 63, 71], ["Collectrin", "CHEMICAL", 3, 13], ["Collectrin", "GENE_OR_GENE_PRODUCT", 3, 13], ["vesicle", "CELLULAR_COMPONENT", 41, 48], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["Collectrin", "PROTEIN", 3, 13], ["membrane fusion", "TREATMENT", 63, 78], ["membrane fusion", "OBSERVATION", 63, 78]]], ["This is important in the exocytosis of insulin and other membrane proteins and is therefore an attractive possible treatment target for diabetes mellitus, polycystic kidney disease and hypertension.", [["membrane", "ANATOMY", 57, 65], ["kidney", "ANATOMY", 166, 172], ["diabetes mellitus", "DISEASE", 136, 153], ["polycystic kidney disease", "DISEASE", 155, 180], ["hypertension", "DISEASE", 185, 197], ["insulin", "GENE_OR_GENE_PRODUCT", 39, 46], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["kidney", "ORGAN", 166, 172], ["insulin", "PROTEIN", 39, 46], ["membrane proteins", "PROTEIN", 57, 74], ["insulin", "TREATMENT", 39, 46], ["other membrane proteins", "TREATMENT", 51, 74], ["treatment target", "TREATMENT", 115, 131], ["diabetes mellitus", "PROBLEM", 136, 153], ["polycystic kidney disease", "PROBLEM", 155, 180], ["hypertension", "PROBLEM", 185, 197], ["kidney", "ANATOMY", 166, 172], ["disease", "OBSERVATION", 173, 180], ["hypertension", "OBSERVATION", 185, 197]]], ["17 The collectrin gene is regulated by hepatocyte nuclear factor-1\u03b2, and disruption of this factor leads to maturity onset diabetes of the young (MODY) type 5 diabetes mellitus.", [["diabetes of the young", "DISEASE", 123, 144], ["MODY", "DISEASE", 146, 150], ["diabetes mellitus", "DISEASE", 159, 176], ["collectrin", "GENE_OR_GENE_PRODUCT", 7, 17], ["hepatocyte nuclear factor-1\u03b2", "GENE_OR_GENE_PRODUCT", 39, 67], ["collectrin gene", "DNA", 7, 22], ["hepatocyte nuclear factor-1\u03b2", "PROTEIN", 39, 67], ["hepatocyte nuclear factor", "TEST", 39, 64], ["this factor", "PROBLEM", 87, 98], ["maturity onset diabetes", "PROBLEM", 108, 131], ["type 5 diabetes mellitus", "PROBLEM", 152, 176], ["hepatocyte", "ANATOMY", 39, 49], ["diabetes", "OBSERVATION", 123, 131], ["diabetes mellitus", "OBSERVATION", 159, 176]]], ["17Sites of expressionACE2 is expressed in a number of tissues but most abundantly in lung alveolar epithelial cells, kidney, heart, gastrointestinal tract and testes.", [["tissues", "ANATOMY", 54, 61], ["lung alveolar epithelial cells", "ANATOMY", 85, 115], ["kidney", "ANATOMY", 117, 123], ["heart", "ANATOMY", 125, 130], ["gastrointestinal tract", "ANATOMY", 132, 154], ["testes", "ANATOMY", 159, 165], ["expressionACE2", "GENE_OR_GENE_PRODUCT", 11, 25], ["tissues", "TISSUE", 54, 61], ["lung alveolar epithelial cells", "CELL", 85, 115], ["kidney", "ORGAN", 117, 123], ["heart", "ORGAN", 125, 130], ["gastrointestinal tract", "ORGAN", 132, 154], ["testes", "ORGAN", 159, 165], ["17Sites", "PROTEIN", 0, 7], ["expressionACE2", "PROTEIN", 11, 25], ["lung alveolar epithelial cells", "CELL_TYPE", 85, 115], ["expressionACE2", "OBSERVATION", 11, 25], ["lung", "ANATOMY", 85, 89], ["alveolar", "ANATOMY_MODIFIER", 90, 98], ["epithelial cells", "OBSERVATION", 99, 115], ["kidney", "ANATOMY", 117, 123], ["heart", "ANATOMY", 125, 130], ["gastrointestinal tract", "ANATOMY", 132, 154], ["testes", "ANATOMY", 159, 165]]], ["13 18 Soluble ACE2, a form lacking membrane anchors, is shed at very low levels into the circulation following the cleavage action of sheddases ADAM (A Disintegrin and Metalloprotease) 10 and ADAM 17 between amino acids 716 and 741.", [["membrane anchors", "ANATOMY", 35, 51], ["amino acids 716 and 741", "CHEMICAL", 208, 231], ["amino acids", "CHEMICAL", 208, 219], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["membrane", "CELLULAR_COMPONENT", 35, 43], ["ADAM (A Disintegrin and Metalloprotease) 10", "GENE_OR_GENE_PRODUCT", 144, 187], ["ADAM 17", "GENE_OR_GENE_PRODUCT", 192, 199], ["amino acids", "AMINO_ACID", 208, 219], ["ACE2", "PROTEIN", 14, 18], ["membrane anchors", "PROTEIN", 35, 51], ["ADAM", "PROTEIN", 144, 148], ["A Disintegrin and Metalloprotease) 10", "PROTEIN", 150, 187], ["ADAM 17", "PROTEIN", 192, 199], ["amino acids 716 and 741", "PROTEIN", 208, 231], ["Soluble ACE2", "TREATMENT", 6, 18], ["a form lacking membrane anchors", "TREATMENT", 20, 51], ["A Disintegrin and Metalloprotease)", "TREATMENT", 150, 184], ["amino acids", "TEST", 208, 219], ["membrane anchors", "OBSERVATION", 35, 51], ["circulation", "ANATOMY", 89, 100]]], ["This form does not reflect tissue levels and has a very short half-life.", [["tissue", "ANATOMY", 27, 33], ["tissue", "TISSUE", 27, 33], ["tissue levels", "PROBLEM", 27, 40], ["does not reflect", "UNCERTAINTY", 10, 26], ["tissue", "OBSERVATION", 27, 33]]], ["19Figure 3Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel member of the Betacoronavirus genus, and like other coronaviruses, has the characteristic appearance of spikes 'crowning' a lipid membrane enveloped viral particle containing the non-segmented positive-sense single-stranded RNA genome.", [["lipid membrane", "ANATOMY", 206, 220], ["acute respiratory syndrome coronavirus", "DISEASE", 17, 55], ["19Figure 3Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 57], ["SARS-CoV-2", "ORGANISM", 59, 69], ["Betacoronavirus genus", "ORGANISM", 96, 117], ["lipid membrane", "CELLULAR_COMPONENT", 206, 220], ["non-segmented positive-sense single-stranded RNA genome", "DNA", 261, 316], ["19Figure 3Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS-CoV-2", "SPECIES", 59, 69], ["acute respiratory syndrome coronavirus", "PROBLEM", 17, 55], ["SARS", "TEST", 59, 63], ["spikes 'crowning", "PROBLEM", 186, 202], ["a lipid membrane", "TEST", 204, 220], ["viral particle", "TEST", 231, 245], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["viral particle", "OBSERVATION", 231, 245], ["RNA genome", "OBSERVATION", 306, 316]]], ["44 45 Each monomer of the trimeric spike (S)-glycoprotein consists of two subunits, namely S1 and S2, that allows binding to the ACE2 receptor and subsequent fusion of the viral and host cell membranes, respectively.", [["cell membranes", "ANATOMY", 187, 201], ["S1", "GENE_OR_GENE_PRODUCT", 91, 93], ["S2", "GENE_OR_GENE_PRODUCT", 98, 100], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 129, 142], ["cell membranes", "CELLULAR_COMPONENT", 187, 201], ["trimeric spike (S)-glycoprotein", "PROTEIN", 26, 57], ["S1", "PROTEIN", 91, 93], ["S2", "PROTEIN", 98, 100], ["ACE2 receptor", "PROTEIN", 129, 142], ["the trimeric spike", "TEST", 22, 40], ["the ACE2 receptor", "TREATMENT", 125, 142], ["S1", "ANATOMY", 91, 93], ["S2", "ANATOMY", 98, 100], ["fusion", "OBSERVATION", 158, 164], ["viral", "OBSERVATION", 172, 177], ["host cell membranes", "OBSERVATION", 182, 201]]], ["The serine protease, TMPRSS2, plays an integral part in the activation and induction of a conformational change of the S-protein-ACE2 receptor complex to allow the virus particle to fuse with the host cell.Molecules in pathogenesis ROLE OF ACE2 IN PHYSIOLOGY AND PATHOPHYSIOLOGYACE2 regulates the levels of Ang I and Ang II by converting Ang I to Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) , and Ang II to Ang (1-7) which bind the MAS and AT2 receptors forming the 'protective arm' of the renin-angiotensin system resulting in vasodilation, increased nitric oxide synthesis, anti-inflammatory and antifibrotic effects.", [["cell", "ANATOMY", 201, 205], ["Ang", "CHEMICAL", 307, 310], ["Ang II", "CHEMICAL", 317, 323], ["Ang", "CHEMICAL", 338, 341], ["Ang", "CHEMICAL", 347, 350], ["Ang II", "CHEMICAL", 393, 399], ["Ang", "CHEMICAL", 403, 406], ["angiotensin", "CHEMICAL", 492, 503], ["nitric oxide", "CHEMICAL", 548, 560], ["serine", "CHEMICAL", 4, 10], ["Ang (1) (2) (3) (4) (5) (6) (7) (8) (9)", "CHEMICAL", 347, 386], ["nitric oxide", "CHEMICAL", 548, 560], ["serine", "AMINO_ACID", 4, 10], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 21, 28], ["S-protein-ACE2 receptor", "GENE_OR_GENE_PRODUCT", 119, 142], ["host cell", "CELL", 196, 205], ["Ang I", "GENE_OR_GENE_PRODUCT", 307, 312], ["Ang II", "GENE_OR_GENE_PRODUCT", 317, 323], ["Ang I", "GENE_OR_GENE_PRODUCT", 338, 343], ["Ang (1) (2) (3) (4) (5) (6) (7) (8) (9)", "SIMPLE_CHEMICAL", 347, 386], ["Ang II", "GENE_OR_GENE_PRODUCT", 393, 399], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 403, 411], ["AT2 receptors", "GENE_OR_GENE_PRODUCT", 436, 449], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 486, 503], ["nitric oxide", "SIMPLE_CHEMICAL", 548, 560], ["serine protease", "PROTEIN", 4, 19], ["TMPRSS2", "PROTEIN", 21, 28], ["S-protein-ACE2 receptor complex", "PROTEIN", 119, 150], ["host cell", "CELL_TYPE", 196, 205], ["ACE2", "PROTEIN", 240, 244], ["Ang I", "PROTEIN", 307, 312], ["Ang II", "PROTEIN", 317, 323], ["Ang I", "PROTEIN", 338, 343], ["MAS and AT2 receptors", "PROTEIN", 428, 449], ["renin", "PROTEIN", 486, 491], ["The serine protease", "TREATMENT", 0, 19], ["TMPRSS2", "TREATMENT", 21, 28], ["a conformational change", "PROBLEM", 88, 111], ["the S-protein-ACE2 receptor complex", "TREATMENT", 115, 150], ["the virus particle", "TREATMENT", 160, 178], ["PATHOPHYSIOLOGYACE2", "TEST", 263, 282], ["Ang I and Ang II", "TREATMENT", 307, 323], ["converting Ang I to Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) , and Ang II to Ang", "PROBLEM", 327, 406], ["AT2 receptors", "TREATMENT", 436, 449], ["the renin-angiotensin system", "TREATMENT", 482, 510], ["vasodilation", "PROBLEM", 524, 536], ["increased nitric oxide synthesis", "TREATMENT", 538, 570], ["anti-inflammatory and antifibrotic effects", "TREATMENT", 572, 614], ["host cell", "OBSERVATION", 196, 205], ["vasodilation", "OBSERVATION", 524, 536], ["increased", "OBSERVATION_MODIFIER", 538, 547], ["nitric oxide synthesis", "OBSERVATION", 548, 570], ["anti-inflammatory", "OBSERVATION_MODIFIER", 572, 589], ["antifibrotic", "OBSERVATION_MODIFIER", 594, 606]]], ["This counterbalances the 'classical' vasoconstrictive, proinflammatory and profibrotic effects of the Ang II/AT1 arm 20-22 (figure 1).Molecules in pathogenesis ROLE OF ACE2 IN PHYSIOLOGY AND PATHOPHYSIOLOGYACE2 also plays an integral role in neutral amino acid transport as a chaperone for the sodium-dependent amino acid transporter B 0 AT1 in the intestine.", [["intestine", "ANATOMY", 349, 358], ["Ang II", "CHEMICAL", 102, 108], ["amino acid", "CHEMICAL", 250, 260], ["sodium", "CHEMICAL", 294, 300], ["amino acid", "CHEMICAL", 311, 321], ["amino acid", "CHEMICAL", 250, 260], ["sodium", "CHEMICAL", 294, 300], ["amino acid", "CHEMICAL", 311, 321], ["Ang II", "GENE_OR_GENE_PRODUCT", 102, 108], ["amino acid", "AMINO_ACID", 250, 260], ["sodium", "SIMPLE_CHEMICAL", 294, 300], ["B 0 AT1", "GENE_OR_GENE_PRODUCT", 334, 341], ["intestine", "ORGAN", 349, 358], ["Ang II", "PROTEIN", 102, 108], ["ACE2", "PROTEIN", 168, 172], ["sodium-dependent amino acid transporter B 0 AT1", "PROTEIN", 294, 341], ["the Ang II/AT1 arm", "TREATMENT", 98, 116], ["neutral amino acid transport", "TREATMENT", 242, 270], ["a chaperone", "TREATMENT", 274, 285], ["the sodium-dependent amino acid transporter", "TREATMENT", 290, 333], ["profibrotic", "OBSERVATION", 75, 86], ["arm", "ANATOMY", 113, 116], ["intestine", "ANATOMY", 349, 358]]], ["23 Mutations in this system lead to Hartnup disease, an autosomal recessive inborn error of metabolism affecting the absorption of non-polar amino acids characterised by pellagra, cerebellar ataxia and psychosis.", [["cerebellar", "ANATOMY", 180, 190], ["Hartnup disease", "DISEASE", 36, 51], ["inborn error of metabolism", "DISEASE", 76, 102], ["amino acids", "CHEMICAL", 141, 152], ["cerebellar ataxia", "DISEASE", 180, 197], ["psychosis", "DISEASE", 202, 211], ["amino acids", "CHEMICAL", 141, 152], ["amino acids", "AMINO_ACID", 141, 152], ["23 Mutations", "PROBLEM", 0, 12], ["Hartnup disease", "PROBLEM", 36, 51], ["an autosomal recessive inborn error of metabolism", "PROBLEM", 53, 102], ["non-polar amino acids", "TREATMENT", 131, 152], ["pellagra", "PROBLEM", 170, 178], ["cerebellar ataxia", "PROBLEM", 180, 197], ["psychosis", "PROBLEM", 202, 211], ["autosomal", "OBSERVATION_MODIFIER", 56, 65], ["recessive", "OBSERVATION_MODIFIER", 66, 75], ["inborn error", "OBSERVATION", 76, 88], ["cerebellar", "ANATOMY", 180, 190], ["ataxia", "OBSERVATION", 191, 197], ["psychosis", "OBSERVATION", 202, 211]]], ["23 Evidence from mouse models ACE2 gene knockout (KO) KO mouse models have provided some evidence for the role of ACE2 but results have been divergent, depending on the mouse background used.", [["mouse", "ORGANISM", 17, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 114, 118], ["mouse", "ORGANISM", 169, 174], ["ACE2", "PROTEIN", 30, 34], ["ACE2", "PROTEIN", 114, 118], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 169, 174], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 169, 174]]], ["For example, in C57BL/6 KO mice a moderate increase in BP was noticed, whereas in 129/SvEv KO mice no difference in BP was noted.", [["C57BL/6 KO mice", "ORGANISM", 16, 31], ["BP", "SIMPLE_CHEMICAL", 55, 57], ["SvEv KO mice", "ORGANISM", 86, 98], ["BP", "SIMPLE_CHEMICAL", 116, 118], ["BP", "PROTEIN", 55, 57], ["BP", "PROTEIN", 116, 118], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 94, 98], ["a moderate increase in BP", "PROBLEM", 32, 57], ["BP", "TEST", 116, 118], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51]]], ["24 ACE2 appears to be important for normal cardiac function and contractility.", [["cardiac", "ANATOMY", 43, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["cardiac", "ORGAN", 43, 50], ["ACE2", "PROTEIN", 3, 7], ["appears to be", "UNCERTAINTY", 8, 21], ["cardiac", "ANATOMY", 43, 50], ["function", "OBSERVATION", 51, 59]]], ["20 The hearts of the KO mice showed clear structural abnormalities with contractility defects and a reduction in BP was also noticed with no hypertrophic or fibrotic changes.", [["hearts", "ANATOMY", 7, 13], ["hearts", "ORGAN", 7, 13], ["KO mice", "ORGANISM", 21, 28], ["BP", "SIMPLE_CHEMICAL", 113, 115], ["BP", "PROTEIN", 113, 115], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["clear structural abnormalities", "PROBLEM", 36, 66], ["contractility defects", "PROBLEM", 72, 93], ["a reduction in BP", "PROBLEM", 98, 115], ["hypertrophic or fibrotic changes", "PROBLEM", 141, 173], ["hearts", "ANATOMY", 7, 13], ["contractility defects", "OBSERVATION", 72, 93], ["reduction", "OBSERVATION_MODIFIER", 100, 109], ["no", "UNCERTAINTY", 138, 140], ["hypertrophic", "OBSERVATION_MODIFIER", 141, 153], ["fibrotic", "OBSERVATION", 157, 165]]], ["20 Other studies reported contrasting findings with no morphological changes and normal cardiac function.", [["cardiac", "ANATOMY", 88, 95], ["cardiac", "ORGAN", 88, 95], ["Other studies", "TEST", 3, 16], ["morphological changes", "PROBLEM", 55, 76], ["no", "UNCERTAINTY", 52, 54], ["normal", "OBSERVATION", 81, 87], ["cardiac", "ANATOMY", 88, 95]]], ["24 25 They also noted normal fertility and a normal lifespan in their experimental animals.", [["normal", "OBSERVATION", 22, 28]]], ["It is therefore postulated that ACE2 has limited effects on cardiac function and BP control and that other genetic and possibly environmental factors may be important for the function of ACE2.", [["cardiac", "ANATOMY", 60, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["cardiac", "ORGAN", 60, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 187, 191], ["ACE2", "PROTEIN", 32, 36], ["ACE2", "PROTEIN", 187, 191], ["cardiac function", "TEST", 60, 76], ["BP control", "TREATMENT", 81, 91]]], ["The difference in findings may be due to the mice strains used, and results therefore remain controversial.", [["mice", "ORGANISM", 45, 49], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["the mice strains", "PROBLEM", 41, 57], ["may be due to", "UNCERTAINTY", 27, 40]]], ["24 In lung tissue, ACE2 KO mice had significantly worse outcome in induced acute respiratory distress syndrome with increased vascular permeability and pulmonary oedema.", [["lung tissue", "ANATOMY", 6, 17], ["respiratory", "ANATOMY", 81, 92], ["vascular", "ANATOMY", 126, 134], ["pulmonary", "ANATOMY", 152, 161], ["respiratory distress syndrome", "DISEASE", 81, 110], ["pulmonary oedema", "DISEASE", 152, 168], ["lung tissue", "TISSUE", 6, 17], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["vascular", "MULTI-TISSUE_STRUCTURE", 126, 134], ["pulmonary oedema", "PATHOLOGICAL_FORMATION", 152, 168], ["ACE2", "PROTEIN", 19, 23], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["acute respiratory distress syndrome", "PROBLEM", 75, 110], ["increased vascular permeability", "PROBLEM", 116, 147], ["pulmonary oedema", "PROBLEM", 152, 168], ["lung", "ANATOMY", 6, 10], ["tissue", "ANATOMY_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory distress", "OBSERVATION", 81, 101], ["syndrome", "OBSERVATION", 102, 110], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["vascular", "ANATOMY", 126, 134], ["permeability", "OBSERVATION_MODIFIER", 135, 147], ["pulmonary", "ANATOMY", 152, 161], ["oedema", "OBSERVATION", 162, 168]]], ["Treatment with recombinant ACE2 rescued this phenotype, underlining the protective role of ACE2 in contrast with the disease-promoting effects of ACE, Ang II and AT1 receptor stimulation.", [["Ang II", "CHEMICAL", 151, 157], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["ACE", "GENE_OR_GENE_PRODUCT", 146, 149], ["Ang II", "GENE_OR_GENE_PRODUCT", 151, 157], ["AT1 receptor", "GENE_OR_GENE_PRODUCT", 162, 174], ["recombinant ACE2", "PROTEIN", 15, 31], ["ACE2", "PROTEIN", 91, 95], ["Ang II", "PROTEIN", 151, 157], ["AT1 receptor", "PROTEIN", 162, 174], ["Treatment", "TREATMENT", 0, 9], ["recombinant ACE2", "TREATMENT", 15, 31], ["this phenotype", "PROBLEM", 40, 54], ["the disease", "PROBLEM", 113, 124], ["ACE", "TREATMENT", 146, 149], ["Ang II and AT1 receptor stimulation", "TREATMENT", 151, 186], ["disease", "OBSERVATION", 117, 124]]], ["25 ACE2 KO in renal disease showed exacerbation of existing hypertension-induced kidney disease.", [["renal", "ANATOMY", 14, 19], ["kidney", "ANATOMY", 81, 87], ["renal disease", "DISEASE", 14, 27], ["hypertension", "DISEASE", 60, 72], ["kidney disease", "DISEASE", 81, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["renal", "ORGAN", 14, 19], ["kidney", "ORGAN", 81, 87], ["ACE2", "PROTEIN", 3, 7], ["renal disease", "PROBLEM", 14, 27], ["exacerbation", "PROBLEM", 35, 47], ["existing hypertension", "PROBLEM", 51, 72], ["kidney disease", "PROBLEM", 81, 95], ["renal", "ANATOMY", 14, 19], ["disease", "OBSERVATION", 20, 27], ["exacerbation", "OBSERVATION", 35, 47], ["hypertension", "OBSERVATION", 60, 72], ["kidney", "ANATOMY", 81, 87], ["disease", "OBSERVATION", 88, 95]]], ["20 24 Furthermore, ACE2 appears to play a protective role in diabetic kidney disease.", [["kidney", "ANATOMY", 70, 76], ["diabetic kidney disease", "DISEASE", 61, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["kidney", "ORGAN", 70, 76], ["ACE2", "PROTEIN", 19, 23], ["diabetic kidney disease", "PROBLEM", 61, 84], ["diabetic", "OBSERVATION", 61, 69], ["kidney", "ANATOMY", 70, 76], ["disease", "OBSERVATION", 77, 84]]], ["20 24 Overexpression of ACE2 gene in transgenic modelsMolecules in pathogenesis ROLE OF ACE2 IN PHYSIOLOGY AND PATHOPHYSIOLOGYThere are limited data from transgenic models.", [["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ACE2 gene", "DNA", 24, 33], ["ACE2 gene", "TREATMENT", 24, 33]]], ["When overexpressed in heart tissue, ventricular tachycardia and sudden death was observed.", [["heart tissue", "ANATOMY", 22, 34], ["ventricular", "ANATOMY", 36, 47], ["ventricular tachycardia", "DISEASE", 36, 59], ["sudden death", "DISEASE", 64, 76], ["heart tissue", "TISSUE", 22, 34], ["ventricular", "MULTI-TISSUE_STRUCTURE", 36, 47], ["overexpressed in heart tissue", "PROBLEM", 5, 34], ["ventricular tachycardia", "PROBLEM", 36, 59], ["sudden death", "PROBLEM", 64, 76], ["heart tissue", "ANATOMY", 22, 34], ["ventricular", "ANATOMY", 36, 47], ["tachycardia", "OBSERVATION", 48, 59], ["sudden", "OBSERVATION_MODIFIER", 64, 70], ["death", "OBSERVATION", 71, 76]]], ["26 In the kidney, overexpression of ACE2 appeared to be protective against diabetic kidney disease.", [["kidney", "ANATOMY", 10, 16], ["kidney", "ANATOMY", 84, 90], ["diabetic kidney disease", "DISEASE", 75, 98], ["kidney", "ORGAN", 10, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["kidney", "ORGAN", 84, 90], ["ACE2", "PROTEIN", 36, 40], ["overexpression of ACE2", "PROBLEM", 18, 40], ["diabetic kidney disease", "PROBLEM", 75, 98], ["kidney", "ANATOMY", 10, 16], ["diabetic", "OBSERVATION", 75, 83], ["kidney", "ANATOMY", 84, 90], ["disease", "OBSERVATION", 91, 98]]], ["27 28 Transgenic mice were also found to be more susceptible to SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 64, 82], ["mice", "ORGANISM", 17, 21], ["SARS-CoV", "ORGANISM", 64, 72], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["SARS-CoV", "SPECIES", 64, 72], ["SARS", "PROBLEM", 64, 68], ["CoV infection", "PROBLEM", 69, 82], ["SARS", "OBSERVATION", 64, 68], ["CoV", "OBSERVATION_MODIFIER", 69, 72], ["infection", "OBSERVATION", 73, 82]]], ["28 Function of ACE2 and polymorphisms in disease Cardiovascular system ACE2 expression was found to be decreased in patients with heart failure and levels correlated with disease severity.", [["heart", "ANATOMY", 130, 135], ["heart failure", "DISEASE", 130, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["patients", "ORGANISM", 116, 124], ["heart", "ORGAN", 130, 135], ["ACE2", "PROTEIN", 15, 19], ["ACE2", "PROTEIN", 71, 75], ["patients", "SPECIES", 116, 124], ["polymorphisms in disease", "PROBLEM", 24, 48], ["ACE2 expression", "TEST", 71, 86], ["heart failure", "PROBLEM", 130, 143], ["disease severity", "PROBLEM", 171, 187], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["heart", "ANATOMY", 130, 135], ["failure", "OBSERVATION", 136, 143]]], ["29 It was postulated that higher ACE2 levels may be cardioprotective, as cardiac dysfunction was noted in ACE2 KO mice.", [["cardiac", "ANATOMY", 73, 80], ["cardiac dysfunction", "DISEASE", 73, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["cardiac", "ORGAN", 73, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ACE2", "PROTEIN", 33, 37], ["ACE2", "PROTEIN", 106, 110], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["higher ACE2 levels", "PROBLEM", 26, 44], ["cardiac dysfunction", "PROBLEM", 73, 92], ["dysfunction", "OBSERVATION", 81, 92]]], ["30 ACE2 deficiency upregulates mediators of atherogenesis and ACE2 suppresses vascular inflammation with subsequent development of atherosclerosis.", [["vascular", "ANATOMY", 78, 86], ["inflammation", "DISEASE", 87, 99], ["atherosclerosis", "DISEASE", 131, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["vascular", "MULTI-TISSUE_STRUCTURE", 78, 86], ["ACE2", "PROTEIN", 3, 7], ["ACE2", "PROTEIN", 62, 66], ["ACE2 deficiency", "PROBLEM", 3, 18], ["atherogenesis", "PROBLEM", 44, 57], ["ACE2 suppresses vascular inflammation", "PROBLEM", 62, 99], ["atherosclerosis", "PROBLEM", 131, 146], ["deficiency", "OBSERVATION", 8, 18], ["atherogenesis", "OBSERVATION", 44, 57], ["vascular", "ANATOMY", 78, 86], ["inflammation", "OBSERVATION", 87, 99], ["atherosclerosis", "OBSERVATION", 131, 146]]], ["31 ACE2, via Ang (1-7), increases nitric oxide which has vasodilatory and antithrombogenic effects.", [["Ang (1-7)", "CHEMICAL", 13, 22], ["nitric oxide", "CHEMICAL", 34, 46], ["nitric oxide", "CHEMICAL", 34, 46], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 13, 21], ["nitric oxide", "SIMPLE_CHEMICAL", 34, 46], ["ACE2", "PROTEIN", 3, 7], ["increases nitric oxide", "TREATMENT", 24, 46], ["vasodilatory and antithrombogenic effects", "TREATMENT", 57, 98], ["nitric oxide", "OBSERVATION", 34, 46], ["antithrombogenic effects", "OBSERVATION", 74, 98]]], ["32 The apelin peptide family protects against the development of cardiovascular disease.", [["cardiovascular", "ANATOMY", 65, 79], ["cardiovascular disease", "DISEASE", 65, 87], ["apelin peptide", "GENE_OR_GENE_PRODUCT", 7, 21], ["cardiovascular", "ANATOMICAL_SYSTEM", 65, 79], ["apelin peptide family", "PROTEIN", 7, 28], ["cardiovascular disease", "PROBLEM", 65, 87], ["cardiovascular", "ANATOMY", 65, 79], ["disease", "OBSERVATION", 80, 87]]], ["Apelin KO mice have reduced ACE2 messenger RNA and ACE2 protein levels.", [["Apelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["mice", "ORGANISM", 10, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ACE2 messenger RNA", "RNA", 28, 46], ["ACE2", "PROTEIN", 51, 55], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["Apelin KO mice", "TEST", 0, 14], ["reduced ACE2 messenger RNA", "PROBLEM", 20, 46], ["ACE2 protein levels", "TEST", 51, 70]]], ["33 Apelin deficiency can potentially lead to cardiovascular disease including heart failure and hypertension with impaired contractibility and hypertrophy.", [["cardiovascular", "ANATOMY", 45, 59], ["heart", "ANATOMY", 78, 83], ["cardiovascular disease", "DISEASE", 45, 67], ["heart failure", "DISEASE", 78, 91], ["hypertension", "DISEASE", 96, 108], ["impaired contractibility", "DISEASE", 114, 138], ["hypertrophy", "DISEASE", 143, 154], ["Apelin", "GENE_OR_GENE_PRODUCT", 3, 9], ["heart", "ORGAN", 78, 83], ["Apelin deficiency", "PROBLEM", 3, 20], ["cardiovascular disease", "PROBLEM", 45, 67], ["heart failure", "PROBLEM", 78, 91], ["hypertension", "PROBLEM", 96, 108], ["impaired contractibility", "PROBLEM", 114, 138], ["hypertrophy", "PROBLEM", 143, 154], ["deficiency", "OBSERVATION", 10, 20], ["potentially lead to", "UNCERTAINTY", 25, 44], ["cardiovascular disease", "OBSERVATION", 45, 67], ["heart", "ANATOMY", 78, 83], ["failure", "OBSERVATION", 84, 91], ["hypertension", "OBSERVATION", 96, 108], ["impaired", "OBSERVATION_MODIFIER", 114, 122], ["contractibility", "OBSERVATION_MODIFIER", 123, 138], ["hypertrophy", "OBSERVATION", 143, 154]]], ["33 When AT1 was also inhibited in apelin KO mice, the induced phenotype was rescued.", [["AT1", "GENE_OR_GENE_PRODUCT", 8, 11], ["apelin", "GENE_OR_GENE_PRODUCT", 34, 40], ["KO mice", "ORGANISM", 41, 48], ["AT1", "PROTEIN", 8, 11], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["the induced phenotype", "PROBLEM", 50, 71]]], ["This was accompanied by an increase in ACE2 underlining its possible protective traits.", [["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["ACE2", "PROTEIN", 39, 43], ["an increase in ACE2", "PROBLEM", 24, 43], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["34 Studies investigating the effects of single nucleotide polymorphisms (SNPs) of ACE2 in hypertension showed mixed results.", [["hypertension", "DISEASE", 90, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["ACE2", "PROTEIN", 82, 86], ["single nucleotide polymorphisms (SNPs", "TREATMENT", 40, 77], ["ACE2 in hypertension", "PROBLEM", 82, 102], ["hypertension", "OBSERVATION", 90, 102]]], ["A number of SNPs of the ACE2 gene are associated with essential hypertension (EH) in humans, as the gene is located in area on the X chromosome 20 35 known to be associated with hypertension disorders on the X-chromosome.", [["X chromosome", "ANATOMY", 131, 143], ["essential hypertension", "DISEASE", 54, 76], ["EH", "DISEASE", 78, 80], ["hypertension disorders", "DISEASE", 178, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["humans", "ORGANISM", 85, 91], ["ACE2 gene", "DNA", 24, 33], ["X chromosome 20 35", "DNA", 131, 149], ["X-chromosome", "DNA", 208, 220], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["the ACE2 gene", "TREATMENT", 20, 33], ["essential hypertension (EH) in humans", "PROBLEM", 54, 91], ["hypertension disorders", "PROBLEM", 178, 200], ["the X-chromosome", "TREATMENT", 204, 220], ["essential", "OBSERVATION_MODIFIER", 54, 63], ["hypertension", "OBSERVATION", 64, 76], ["hypertension", "OBSERVATION", 178, 190]]], ["ACE2 downregulation results in BP dysregulation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["BP", "SIMPLE_CHEMICAL", 31, 33], ["ACE2", "PROTEIN", 0, 4], ["BP", "PROTEIN", 31, 33], ["ACE2 downregulation", "TEST", 0, 19], ["BP dysregulation", "PROBLEM", 31, 47], ["BP dysregulation", "OBSERVATION", 31, 47]]], ["33 ACE2 deletion in rats led to impaired baroreflex sensitivity and autonomic dysfunction.", [["impaired baroreflex sensitivity", "DISEASE", 32, 63], ["autonomic dysfunction", "DISEASE", 68, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["rats", "ORGANISM", 20, 24], ["ACE2", "PROTEIN", 3, 7], ["rats", "SPECIES", 20, 24], ["ACE2 deletion in rats", "PROBLEM", 3, 24], ["impaired baroreflex sensitivity", "PROBLEM", 32, 63], ["autonomic dysfunction", "PROBLEM", 68, 89], ["impaired baroreflex sensitivity", "OBSERVATION", 32, 63], ["autonomic dysfunction", "OBSERVATION", 68, 89]]], ["36 ACE2 polymorphisms in dyslipidaemia have also been studied.", [["dyslipidaemia", "DISEASE", 25, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["ACE2", "PROTEIN", 3, 7], ["ACE2 polymorphisms in dyslipidaemia", "PROBLEM", 3, 38], ["dyslipidaemia", "OBSERVATION", 25, 38]]], ["A variant ACE2 rs4646188 was found to be a potential marker of susceptibility for EH, dyslipidaemia and related ischaemic stroke in Asian communities.", [["EH", "DISEASE", 82, 84], ["dyslipidaemia", "DISEASE", 86, 99], ["ischaemic stroke", "DISEASE", 112, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ACE2", "PROTEIN", 10, 14], ["A variant ACE2", "TEST", 0, 14], ["EH", "PROBLEM", 82, 84], ["dyslipidaemia", "PROBLEM", 86, 99], ["related ischaemic stroke", "PROBLEM", 104, 128], ["dyslipidaemia", "OBSERVATION", 86, 99], ["ischaemic", "OBSERVATION_MODIFIER", 112, 121], ["stroke", "OBSERVATION", 122, 128]]], ["37 However, another study found that this variant was not correlated with a dyslipidaemia in Uyghur communities.", [["dyslipidaemia", "DISEASE", 76, 89], ["another study", "TEST", 12, 25], ["a dyslipidaemia", "PROBLEM", 74, 89], ["dyslipidaemia", "OBSERVATION", 76, 89]]], ["8 Therefore, variant effects differ in various populations and environmental and genetic factors are important.Respiratory systemThe role of ACE2 in COVID-19 is now well established and there is intense interest in how it influences the unusual pathophysiology seen.", [["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["COVID-19", "GENE_OR_GENE_PRODUCT", 149, 157], ["ACE2", "PROTEIN", 141, 145], ["variant effects", "PROBLEM", 13, 28], ["ACE2 in COVID", "TREATMENT", 141, 154]]], ["Lung ACE2 levels decline with age in rat models 36 and this decline is higher in males.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["rat", "ORGANISM", 37, 40], ["ACE2", "PROTEIN", 5, 9], ["rat", "SPECIES", 37, 40], ["Lung ACE2 levels", "TEST", 0, 16], ["age in rat models", "TEST", 30, 47], ["higher", "OBSERVATION_MODIFIER", 71, 77]]], ["This supports the observation that older men are more susceptible to SARS-CoV-2 infection.Respiratory systemCertain variations in ACE2 may increase individual susceptibility to COVID-19 infection, but these are very rare.", [["SARS-CoV-2 infection", "DISEASE", 69, 89], ["infection", "DISEASE", 186, 195], ["men", "ORGANISM", 41, 44], ["SARS-CoV-2", "ORGANISM", 69, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["ACE2", "PROTEIN", 130, 134], ["men", "SPECIES", 41, 44], ["SARS-CoV", "SPECIES", 69, 77], ["COVID-19", "SPECIES", 177, 185], ["SARS", "PROBLEM", 69, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["Respiratory systemCertain variations in ACE2", "PROBLEM", 90, 134], ["COVID", "TEST", 177, 182], ["19 infection", "PROBLEM", 183, 195], ["infection", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 186, 195]]], ["38 It has been postulated that downregulation of ACE2 may reduce the susceptibility to COVID-19, but in animal models it was found that lower levels of ACE2 were also associated with lung oedema and worsening acute lung injury.", [["lung", "ANATOMY", 183, 187], ["lung", "ANATOMY", 215, 219], ["COVID-19", "CHEMICAL", 87, 95], ["lung oedema", "DISEASE", 183, 194], ["acute lung injury", "DISEASE", 209, 226], ["COVID-19", "CHEMICAL", 87, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["lung", "ORGAN", 183, 187], ["lung", "ORGAN", 215, 219], ["ACE2", "PROTEIN", 49, 53], ["ACE2", "PROTEIN", 152, 156], ["downregulation of ACE2", "PROBLEM", 31, 53], ["COVID", "TEST", 87, 92], ["lower levels of ACE2", "PROBLEM", 136, 156], ["lung oedema", "PROBLEM", 183, 194], ["worsening acute lung injury", "PROBLEM", 199, 226], ["associated with", "UNCERTAINTY", 167, 182], ["lung", "ANATOMY", 183, 187], ["oedema", "OBSERVATION", 188, 194], ["worsening", "OBSERVATION_MODIFIER", 199, 208], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["lung", "ANATOMY", 215, 219], ["injury", "OBSERVATION", 220, 226]]], ["39Endocrine system and metabolismSome polymorphisms of ACE2 may be useful markers for type 2 diabetes mellitus and some polymorphisms are associated with cardiovascular complications in this setting.", [["cardiovascular", "ANATOMY", 154, 168], ["type 2 diabetes mellitus", "DISEASE", 86, 110], ["cardiovascular complications", "DISEASE", 154, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 154, 168], ["ACE2", "PROTEIN", 55, 59], ["39Endocrine system", "TREATMENT", 0, 18], ["metabolismSome polymorphisms of ACE2", "TREATMENT", 23, 59], ["type 2 diabetes mellitus", "PROBLEM", 86, 110], ["some polymorphisms", "PROBLEM", 115, 133], ["cardiovascular complications", "PROBLEM", 154, 182], ["complications", "OBSERVATION", 169, 182]]], ["40 In the pancreas, ACE2 has glycaemia-protective properties, 41 and in the kidney low ACE2 levels are associated with worsening diabetic nephropathy.", [["pancreas", "ANATOMY", 10, 18], ["kidney", "ANATOMY", 76, 82], ["diabetic nephropathy", "DISEASE", 129, 149], ["pancreas", "ORGAN", 10, 18], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["kidney", "ORGAN", 76, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 87, 91], ["ACE2", "TEST", 20, 24], ["glycaemia", "TEST", 29, 38], ["worsening diabetic nephropathy", "PROBLEM", 119, 149], ["pancreas", "ANATOMY", 10, 18], ["ACE2", "ANATOMY", 20, 24], ["glycaemia", "OBSERVATION", 29, 38], ["protective properties", "OBSERVATION_MODIFIER", 39, 60], ["kidney", "ANATOMY", 76, 82], ["low ACE2", "OBSERVATION_MODIFIER", 83, 91], ["associated with", "UNCERTAINTY", 103, 118], ["worsening", "OBSERVATION_MODIFIER", 119, 128], ["diabetic", "OBSERVATION_MODIFIER", 129, 137], ["nephropathy", "OBSERVATION", 138, 149]]], ["42 Diabetic retinopathy is associated with the activation of the classical arm of the renin-angiotensin system and the proinflammatory, profibrotic and activation of oxidative stress of this arm can be counteracted by ACE2/ Ang (1-7) .", [["Diabetic retinopathy", "DISEASE", 3, 23], ["angiotensin", "CHEMICAL", 92, 103], ["Ang", "CHEMICAL", 224, 227], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 86, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["Ang", "GENE_OR_GENE_PRODUCT", 224, 227], ["1-7", "GENE_OR_GENE_PRODUCT", 229, 232], ["renin", "PROTEIN", 86, 91], ["ACE2", "PROTEIN", 218, 222], ["Diabetic retinopathy", "PROBLEM", 3, 23], ["oxidative stress of this arm", "PROBLEM", 166, 194], ["Diabetic", "OBSERVATION_MODIFIER", 3, 11], ["retinopathy", "OBSERVATION", 12, 23], ["angiotensin system", "ANATOMY", 92, 110], ["proinflammatory", "OBSERVATION_MODIFIER", 119, 134], ["profibrotic", "OBSERVATION_MODIFIER", 136, 147], ["oxidative stress", "OBSERVATION", 166, 182], ["arm", "ANATOMY", 191, 194]]], ["43 ACE2 also plays an important role in the browning of adipose tissue leading to favourable metabolic effects and weight loss.", [["adipose tissue", "ANATOMY", 56, 70], ["weight loss", "DISEASE", 115, 126], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["adipose tissue", "TISSUE", 56, 70], ["ACE2", "PROTEIN", 3, 7], ["adipose tissue", "PROBLEM", 56, 70], ["weight loss", "PROBLEM", 115, 126], ["adipose tissue", "OBSERVATION", 56, 70], ["favourable", "OBSERVATION_MODIFIER", 82, 92], ["metabolic effects", "OBSERVATION", 93, 110]]], ["33 Renal system ACE2 is extensively expressed in tubular epithelial cells and also the vascular components and glomerular epithelium.", [["Renal system", "ANATOMY", 3, 15], ["tubular epithelial cells", "ANATOMY", 49, 73], ["vascular components", "ANATOMY", 87, 106], ["glomerular epithelium", "ANATOMY", 111, 132], ["Renal", "ORGAN", 3, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["tubular epithelial cells", "CELL", 49, 73], ["vascular components", "TISSUE", 87, 106], ["glomerular epithelium", "TISSUE", 111, 132], ["ACE2", "PROTEIN", 16, 20], ["tubular epithelial cells", "CELL_TYPE", 49, 73], ["Renal system ACE2", "TREATMENT", 3, 20], ["glomerular epithelium", "PROBLEM", 111, 132], ["system", "ANATOMY", 9, 15], ["ACE2", "OBSERVATION", 16, 20], ["tubular epithelial cells", "OBSERVATION", 49, 73], ["vascular", "ANATOMY", 87, 95], ["components", "ANATOMY_MODIFIER", 96, 106], ["glomerular", "ANATOMY_MODIFIER", 111, 121], ["epithelium", "ANATOMY_MODIFIER", 122, 132]]], ["44 In hypertensive kidney disease, ACE2 levels were decreased.", [["kidney", "ANATOMY", 19, 25], ["hypertensive kidney disease", "DISEASE", 6, 33], ["kidney", "ORGAN", 19, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE2", "PROTEIN", 35, 39], ["hypertensive kidney disease", "PROBLEM", 6, 33], ["ACE2 levels", "TEST", 35, 46], ["hypertensive", "OBSERVATION", 6, 18], ["kidney", "ANATOMY", 19, 25], ["disease", "OBSERVATION", 26, 33], ["decreased", "OBSERVATION_MODIFIER", 52, 61]]], ["20 Although ACE inhibitors and angiotensin receptor blockers do not affect the enzymatic activity of ACE2, they increase ACE2 gene expression in animal studies.", [["angiotensin", "CHEMICAL", 31, 42], ["ACE", "GENE_OR_GENE_PRODUCT", 12, 15], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 31, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["ACE2", "PROTEIN", 101, 105], ["ACE2", "PROTEIN", 121, 125], ["ACE inhibitors", "TREATMENT", 12, 26], ["angiotensin receptor blockers", "TREATMENT", 31, 60], ["ACE2", "TEST", 101, 105], ["animal studies", "TEST", 145, 159]]], ["45 In diabetic kidney disease, ACE2 is protective and overexpression of ACE2 in podocytes reduces diabetic kidney disease in animal models.", [["kidney", "ANATOMY", 15, 21], ["podocytes", "ANATOMY", 80, 89], ["kidney", "ANATOMY", 107, 113], ["diabetic kidney disease", "DISEASE", 6, 29], ["diabetic kidney disease", "DISEASE", 98, 121], ["kidney", "ORGAN", 15, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["podocytes", "CELL", 80, 89], ["kidney", "ORGAN", 107, 113], ["ACE2", "PROTEIN", 31, 35], ["ACE2", "PROTEIN", 72, 76], ["podocytes", "CELL_TYPE", 80, 89], ["diabetic kidney disease", "PROBLEM", 6, 29], ["ACE2", "PROBLEM", 31, 35], ["ACE2 in podocytes", "PROBLEM", 72, 89], ["diabetic kidney disease in animal models", "PROBLEM", 98, 138], ["diabetic", "OBSERVATION", 6, 14], ["kidney", "ANATOMY", 15, 21], ["disease", "OBSERVATION", 22, 29], ["diabetic", "OBSERVATION_MODIFIER", 98, 106], ["kidney", "ANATOMY", 107, 113], ["disease", "OBSERVATION", 114, 121]]], ["27Neurological systemThe ability of ACE and ACE2 to cleave amyloid-\u03b2-peptidase and the use of inhibitor drugs of the renin-angiotensin system and their role in the development Alzheimer's disease have been investigated with no concrete conclusions at this stage.", [["angiotensin", "CHEMICAL", 123, 134], ["Alzheimer's disease", "DISEASE", 176, 195], ["ACE", "GENE_OR_GENE_PRODUCT", 36, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["amyloid-\u03b2-peptidase", "GENE_OR_GENE_PRODUCT", 59, 78], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 117, 134], ["ACE", "PROTEIN", 36, 39], ["ACE2", "PROTEIN", 44, 48], ["amyloid-\u03b2-peptidase", "PROTEIN", 59, 78], ["renin", "PROTEIN", 117, 122], ["ACE", "TREATMENT", 36, 39], ["ACE2", "TREATMENT", 44, 48], ["amyloid-\u03b2-peptidase", "TREATMENT", 59, 78], ["inhibitor drugs", "TREATMENT", 94, 109], ["the renin-angiotensin system", "TREATMENT", 113, 141], ["the development Alzheimer's disease", "PROBLEM", 160, 195], ["Alzheimer", "OBSERVATION", 176, 185]]], ["46 Gastrointestinal system ACE2 is important in regulating intestinal amino acid transportation and plays a vital role in the expression of antimicrobial peptides and prevention of gut dysbiosis.", [["intestinal", "ANATOMY", 59, 69], ["gut", "ANATOMY", 181, 184], ["amino acid", "CHEMICAL", 70, 80], ["gut dysbiosis", "DISEASE", 181, 194], ["amino acid", "CHEMICAL", 70, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["intestinal", "ORGAN", 59, 69], ["amino acid", "AMINO_ACID", 70, 80], ["gut", "ORGANISM_SUBDIVISION", 181, 184], ["ACE2", "PROTEIN", 27, 31], ["intestinal amino acid transportation", "TREATMENT", 59, 95], ["antimicrobial peptides", "TREATMENT", 140, 162], ["gut dysbiosis", "PROBLEM", 181, 194], ["Gastrointestinal system", "ANATOMY", 3, 26], ["intestinal", "ANATOMY", 59, 69], ["amino acid", "OBSERVATION", 70, 80], ["gut", "ANATOMY", 181, 184], ["dysbiosis", "OBSERVATION", 185, 194]]], ["47 ACE2 deficiency resulted in increased susceptibility for intestinal inflammation.", [["intestinal", "ANATOMY", 60, 70], ["intestinal inflammation", "DISEASE", 60, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["intestinal", "ORGAN", 60, 70], ["ACE2", "PROTEIN", 3, 7], ["ACE2 deficiency", "PROBLEM", 3, 18], ["increased susceptibility", "PROBLEM", 31, 55], ["intestinal inflammation", "PROBLEM", 60, 83], ["deficiency", "OBSERVATION", 8, 18], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["susceptibility", "OBSERVATION_MODIFIER", 41, 55], ["intestinal", "ANATOMY", 60, 70], ["inflammation", "OBSERVATION", 71, 83]]], ["47 In the liver, ACE2 is protective against the development of fibrosis via Ang (1-7) .", [["liver", "ANATOMY", 10, 15], ["fibrosis", "DISEASE", 63, 71], ["Ang", "CHEMICAL", 76, 79], ["liver", "ORGAN", 10, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ang", "GENE_OR_GENE_PRODUCT", 76, 79], ["1-7", "GENE_OR_GENE_PRODUCT", 81, 84], ["ACE2", "PROTEIN", 17, 21], ["fibrosis", "PROBLEM", 63, 71], ["Ang", "TEST", 76, 79], ["liver", "ANATOMY", 10, 15], ["ACE2", "ANATOMY", 17, 21], ["fibrosis", "OBSERVATION", 63, 71], ["Ang", "OBSERVATION", 76, 79]]], ["48 In ACE2 KO mice, there was significant worsening of liver fibrosis in chronic induced liver conditions.", [["liver", "ANATOMY", 55, 60], ["liver", "ANATOMY", 89, 94], ["fibrosis", "DISEASE", 61, 69], ["chronic induced liver conditions", "DISEASE", 73, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["mice", "ORGANISM", 14, 18], ["liver", "ORGAN", 55, 60], ["liver", "ORGAN", 89, 94], ["ACE2", "PROTEIN", 6, 10], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["liver fibrosis", "PROBLEM", 55, 69], ["chronic induced liver conditions", "PROBLEM", 73, 105], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["worsening", "OBSERVATION_MODIFIER", 42, 51], ["liver", "ANATOMY", 55, 60], ["fibrosis", "OBSERVATION", 61, 69], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["liver", "ANATOMY", 89, 94], ["conditions", "OBSERVATION", 95, 105]]], ["Interestingly, this was not observed in acute liver injury.", [["liver", "ANATOMY", 46, 51], ["acute liver injury", "DISEASE", 40, 58], ["liver", "ORGAN", 46, 51], ["acute liver injury", "PROBLEM", 40, 58], ["not observed", "UNCERTAINTY", 24, 36], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["liver", "ANATOMY", 46, 51], ["injury", "OBSERVATION", 52, 58]]], ["48NeoplasmsOverexpression of ACE2 and DNA hypomethylation was observed in tumours including colon adenocarcinoma, kidney papillary cell adenocarcinoma, pancreatic, rectum, stomach and rectum adenocarcinoma.", [["tumours", "ANATOMY", 74, 81], ["colon adenocarcinoma", "ANATOMY", 92, 112], ["kidney papillary cell adenocarcinoma", "ANATOMY", 114, 150], ["pancreatic", "ANATOMY", 152, 162], ["rectum", "ANATOMY", 164, 170], ["stomach", "ANATOMY", 172, 179], ["rectum adenocarcinoma", "ANATOMY", 184, 205], ["colon adenocarcinoma", "DISEASE", 92, 112], ["kidney papillary cell adenocarcinoma, pancreatic, rectum, stomach and rectum adenocarcinoma", "DISEASE", 114, 205], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["tumours", "CANCER", 74, 81], ["colon adenocarcinoma", "CANCER", 92, 112], ["kidney papillary cell adenocarcinoma", "CANCER", 114, 150], ["pancreatic", "CANCER", 152, 162], ["rectum", "ORGAN", 164, 170], ["stomach", "ORGAN", 172, 179], ["rectum adenocarcinoma", "CANCER", 184, 205], ["ACE2", "PROTEIN", 29, 33], ["ACE2", "PROBLEM", 29, 33], ["DNA hypomethylation", "PROBLEM", 38, 57], ["colon adenocarcinoma", "PROBLEM", 92, 112], ["kidney papillary cell adenocarcinoma", "PROBLEM", 114, 150], ["pancreatic, rectum, stomach and rectum adenocarcinoma", "PROBLEM", 152, 205], ["DNA hypomethylation", "OBSERVATION", 38, 57], ["colon", "ANATOMY", 92, 97], ["adenocarcinoma", "OBSERVATION", 98, 112], ["kidney", "ANATOMY", 114, 120], ["papillary cell adenocarcinoma", "OBSERVATION", 121, 150], ["pancreatic", "ANATOMY", 152, 162], ["rectum", "ANATOMY", 164, 170], ["stomach", "ANATOMY", 172, 179], ["rectum", "ANATOMY", 184, 190], ["adenocarcinoma", "OBSERVATION", 191, 205]]], ["49 Lung adenocarcinoma had significant upregulation of ACE2 RNA expression.", [["Lung adenocarcinoma", "ANATOMY", 3, 22], ["Lung adenocarcinoma", "DISEASE", 3, 22], ["Lung adenocarcinoma", "CANCER", 3, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2 RNA", "RNA", 55, 63], ["Lung adenocarcinoma", "PROBLEM", 3, 22], ["ACE2 RNA expression", "PROBLEM", 55, 74], ["Lung", "ANATOMY", 3, 7], ["adenocarcinoma", "OBSERVATION", 8, 22], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["upregulation", "OBSERVATION_MODIFIER", 39, 51], ["ACE2 RNA expression", "OBSERVATION", 55, 74]]], ["49 Furthermore, histone modification and glycosylation may be involved in abnormal ACE2 expression in tumour development.", [["tumour", "ANATOMY", 102, 108], ["tumour", "DISEASE", 102, 108], ["histone", "GENE_OR_GENE_PRODUCT", 16, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["tumour", "CANCER", 102, 108], ["histone", "PROTEIN", 16, 23], ["ACE2", "PROTEIN", 83, 87], ["histone modification", "TREATMENT", 16, 36], ["glycosylation", "TREATMENT", 41, 54], ["abnormal ACE2 expression in tumour development", "PROBLEM", 74, 120], ["tumour", "OBSERVATION", 102, 108]]], ["49 Pregnancy and fertility ACE2 and Ang (1-7) are present in uteroplacental tissue and are important in placentation of normal pregnancy via vasoactive regulatory action.", [["uteroplacental tissue", "ANATOMY", 61, 82], ["Ang", "CHEMICAL", 36, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 36, 44], ["uteroplacental tissue", "TISSUE", 61, 82], ["ACE2", "PROTEIN", 27, 31], ["Pregnancy and fertility ACE2", "PROBLEM", 3, 31], ["Ang", "TEST", 36, 39], ["vasoactive regulatory action", "TREATMENT", 141, 169], ["uteroplacental tissue", "ANATOMY", 61, 82]]], ["ACE2 and Ang (1-7) expression is similar in uncomplicated and pre-eclamptic pregnancies.", [["Ang", "CHEMICAL", 9, 12], ["pre-eclamptic", "DISEASE", 62, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 9, 17], ["ACE2", "PROTEIN", 0, 4], ["Ang (1-7", "PROTEIN", 9, 17], ["ACE2 and Ang", "TREATMENT", 0, 12], ["pre-eclamptic pregnancies", "PROBLEM", 62, 87], ["uncomplicated", "OBSERVATION_MODIFIER", 44, 57], ["pre-eclamptic pregnancies", "OBSERVATION", 62, 87]]], ["50 ACE2 also appears to be important in the regulation of renal adaptations in pregnancy by enhancing the increased expression of renal Ang (1-7).", [["renal", "ANATOMY", 58, 63], ["renal", "ANATOMY", 130, 135], ["Ang", "CHEMICAL", 136, 139], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["renal", "ORGAN", 58, 63], ["renal Ang", "GENE_OR_GENE_PRODUCT", 130, 139], ["1-7", "GENE_OR_GENE_PRODUCT", 141, 144], ["ACE2", "PROTEIN", 3, 7], ["renal adaptations", "TREATMENT", 58, 75], ["renal Ang", "TREATMENT", 130, 139], ["appears to be", "UNCERTAINTY", 13, 26], ["renal", "ANATOMY", 58, 63], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["expression", "OBSERVATION", 116, 126], ["renal", "ANATOMY", 130, 135], ["Ang", "OBSERVATION", 136, 139]]], ["51CONCLUSIONACE2 plays a complex role in disease that has relevance beyond the cardiovascular and respiratory systems.", [["cardiovascular", "ANATOMY", 79, 93], ["cardiovascular", "ANATOMICAL_SYSTEM", 79, 93], ["51CONCLUSIONACE2", "PROTEIN", 0, 16], ["disease", "PROBLEM", 41, 48], ["complex", "OBSERVATION_MODIFIER", 25, 32], ["disease", "OBSERVATION", 41, 48], ["cardiovascular", "ANATOMY", 79, 93], ["respiratory systems", "ANATOMY", 98, 117]]], ["Its role in the pathophysiology of COVID-19 is a source of ongoing research and makes it an attractive possible therapeutic target.", [["COVID-19", "CHEMICAL", 35, 43], ["COVID-19", "CHEMICAL", 35, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 35, 43], ["COVID", "TEST", 35, 40]]], ["Of recent interest is the effect of tobacco smoking on ACE2 expression in the lung which implies that smoking could increase the susceptibility to lung infection by SARS-CoV-2.", [["lung", "ANATOMY", 78, 82], ["lung", "ANATOMY", 147, 151], ["smoking", "CHEMICAL", 44, 51], ["smoking", "CHEMICAL", 102, 109], ["lung infection", "DISEASE", 147, 161], ["tobacco", "ORGANISM", 36, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["lung", "ORGAN", 78, 82], ["lung", "ORGAN", 147, 151], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["ACE2", "PROTEIN", 55, 59], ["tobacco", "SPECIES", 36, 43], ["SARS-CoV", "SPECIES", 165, 173], ["ACE2 expression", "TREATMENT", 55, 70], ["lung infection", "PROBLEM", 147, 161], ["lung", "ANATOMY", 78, 82], ["lung", "ANATOMY", 147, 151], ["infection", "OBSERVATION", 152, 161]]], ["52 It is clear that further studies of its genetic and physiological roles will be required to fully understand how it could be therapeutically modulated in disease.Handling editor Des Richardson.Contributors OW wrote the first and subsequent drafts and prepared the figures.", [["further studies", "TEST", 20, 35], ["disease", "PROBLEM", 157, 164], ["clear", "OBSERVATION", 9, 14]]], ["Images created with Biorender. com.FundingThe authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.FundingCompeting interests None declared.Patient consent for publication Not required.Provenance and peer review Not commissioned; internally peer reviewed.Patient consent for publication Not required.This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ.", [["Patient", "SPECIES", 224, 231], ["Patient", "SPECIES", 339, 346], ["Images", "TEST", 0, 6]]], ["You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.ORCID iDTahir S Pillay http:// orcid. org/ 0000-0002-9982-9710", [["org/ 0000-0002-9982-9710", "SPECIES", 219, 243]]]], "f0dfdf25a4ad0ee36d48aed8e2b8f2c8bc7e3ac6": [["Approximately 1.2 billion school children have had their education put on hold due to COVID-related school closures (UNESCO 2020) .", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41]]]], "33d167ebde750f4ebe4a1984c07ff3f42914c862": [["Emerging infectious diseasesInfectious diseases are the second leading cause of death annually across the globe.", [["infectious diseases", "DISEASE", 9, 28], ["Infectious diseases", "DISEASE", 28, 47], ["death", "DISEASE", 80, 85], ["Emerging infectious diseasesInfectious diseases", "PROBLEM", 0, 47], ["death", "PROBLEM", 80, 85], ["infectious", "OBSERVATION_MODIFIER", 9, 19], ["globe", "ANATOMY", 106, 111]]], ["The causative agent of most emerging infectious diseases is viruses; every year approximately more than two novel viral pathogens are identified, which can cause illness in a human.", [["infectious diseases", "DISEASE", 37, 56], ["illness", "DISEASE", 162, 169], ["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["viruses", "PROBLEM", 60, 67], ["two novel viral pathogens", "PROBLEM", 104, 129], ["infectious", "OBSERVATION", 37, 47]]], ["Since the 1970s, an average of 40 infectious diseases has been emerged and known to cause pandemics such as Ebola, swine flu, chikungunya, and Zika (Table 17\u00c01 ) [4] .", [["infectious diseases", "DISEASE", 34, 53], ["Ebola", "DISEASE", 108, 113], ["swine flu", "DISEASE", 115, 124], ["chikungunya", "DISEASE", 126, 137], ["Ebola", "ORGANISM", 108, 113], ["Ebola", "SPECIES", 108, 113], ["swine flu", "SPECIES", 115, 124], ["pandemics", "PROBLEM", 90, 99], ["Ebola", "PROBLEM", 108, 113], ["chikungunya", "PROBLEM", 126, 137]]], ["The emergence of infectious diseases has severe health and socioeconomic impacts; thus the following section discusses the various infectious disease that emerged within the last two decades and presenting few pandemic viral diseases as a suitable example [5, 7] .", [["infectious diseases", "DISEASE", 17, 36], ["infectious disease", "DISEASE", 131, 149], ["viral diseases", "DISEASE", 219, 233], ["severe health and socioeconomic impacts", "PROBLEM", 41, 80], ["the various infectious disease", "PROBLEM", 119, 149], ["few pandemic viral diseases", "PROBLEM", 206, 233], ["infectious", "OBSERVATION", 17, 27], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["infectious", "OBSERVATION", 131, 141], ["few", "OBSERVATION_MODIFIER", 206, 209], ["pandemic", "OBSERVATION_MODIFIER", 210, 218], ["viral diseases", "OBSERVATION", 219, 233]]], ["Factors for emergence include natural process (evolution of pathogen), infectious agents transfer from vertebrate to mammals, antimicrobial resistance (AMR), and climate change.", [["AMR", "DISEASE", 152, 155], ["natural process", "PROBLEM", 30, 45], ["pathogen", "PROBLEM", 60, 68], ["infectious agents", "TREATMENT", 71, 88], ["antimicrobial resistance", "OBSERVATION", 126, 150]]], ["The factors responsible for the emergence of infectious diseases such as (1) the evolution of new strain, (2) the introduction of a host to enzootic, (3) translocation of infected wildlife, (4) farming practices, and (5) others were provided.Emerging virus diseasesThe viral evolution rate occurs through mutation and adaption, which are much faster than any other microscopic organisms that is why a large fraction of emerging and reemerging pathogens are viruses (37%).", [["infectious diseases", "DISEASE", 45, 64], ["Emerging virus diseases", "DISEASE", 242, 265], ["infectious diseases", "PROBLEM", 45, 64], ["new strain", "PROBLEM", 94, 104], ["Emerging virus diseases", "PROBLEM", 242, 265], ["The viral evolution rate", "PROBLEM", 265, 289], ["mutation", "PROBLEM", 305, 313], ["any other microscopic organisms", "PROBLEM", 355, 386], ["infectious", "OBSERVATION", 45, 55], ["new", "OBSERVATION_MODIFIER", 94, 97], ["virus diseases", "OBSERVATION", 251, 265], ["viral", "OBSERVATION", 269, 274], ["large", "OBSERVATION_MODIFIER", 401, 406]]], ["Among these 37% of emerging viruses, RNA viruses are prominent one because of their higher nucleotide substitution rate which enables them to invade and amplify in broad host range [22] .", [["nucleotide", "CHEMICAL", 91, 101], ["nucleotide", "CHEMICAL", 91, 101], ["emerging viruses", "PROBLEM", 19, 35], ["RNA viruses", "PROBLEM", 37, 48], ["their higher nucleotide substitution rate", "TREATMENT", 78, 119], ["viruses", "OBSERVATION", 28, 35]]], ["The environment changes, social condition, and their interaction are the important factors which lead to the viral evolution and ultimately to disease emergence.", [["the viral evolution", "PROBLEM", 105, 124]]], ["The decrease in biological diversity due to deforestation, prevalence of micropollutant in natural environment, and climate change triggers the evolution of opportunistic pathogen [23] .", [["The decrease in biological diversity", "PROBLEM", 0, 36], ["deforestation", "PROBLEM", 44, 57], ["micropollutant in natural environment", "PROBLEM", 73, 110], ["opportunistic pathogen", "PROBLEM", 157, 179], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["biological diversity", "OBSERVATION", 16, 36]]], ["For instance, the outbreak of Nipah virus diseases was occurred due Anaplasma phagocytophilum [7] Buruli ulcers Mycobacterium ulcerans [8] to the extensive deforestation of a forest of Southeast Asia [24] .", [["Nipah virus diseases", "DISEASE", 30, 50], ["Anaplasma phagocytophilum", "DISEASE", 68, 93], ["ulcers", "DISEASE", 105, 111], ["Mycobacterium ulcerans", "DISEASE", 112, 134], ["Nipah virus", "ORGANISM", 30, 41], ["Anaplasma phagocytophilum", "ORGANISM", 68, 93], ["Nipah virus", "SPECIES", 30, 41], ["Anaplasma phagocytophilum", "SPECIES", 68, 93], ["Mycobacterium ulcerans", "SPECIES", 112, 134], ["Nipah virus", "SPECIES", 30, 41], ["Anaplasma phagocytophilum", "SPECIES", 68, 93], ["Mycobacterium ulcerans", "SPECIES", 112, 134], ["Nipah virus diseases", "PROBLEM", 30, 50], ["Anaplasma phagocytophilum", "PROBLEM", 68, 93], ["Buruli ulcers Mycobacterium ulcerans", "PROBLEM", 98, 134], ["Nipah virus", "OBSERVATION", 30, 41], ["Buruli", "OBSERVATION_MODIFIER", 98, 104], ["ulcers", "OBSERVATION_MODIFIER", 105, 111], ["Mycobacterium ulcerans", "OBSERVATION", 112, 134], ["extensive", "OBSERVATION_MODIFIER", 146, 155], ["deforestation", "OBSERVATION", 156, 169]]], ["The deforestation leads to migration of fruit bats for food quest to the agriculture land.", [["The deforestation", "TREATMENT", 0, 17], ["deforestation", "OBSERVATION", 4, 17], ["migration", "OBSERVATION_MODIFIER", 27, 36], ["fruit bats", "OBSERVATION", 40, 50]]], ["These fruit bats are natural reservoir (host) of Nipah virus and their migration to cultivable land lead to transmission of Nipah virus disease in farm animals and subsequently in humans [24] .", [["Nipah virus disease", "DISEASE", 124, 143], ["Nipah virus", "ORGANISM", 49, 60], ["Nipah virus", "ORGANISM", 124, 135], ["humans", "ORGANISM", 180, 186], ["Nipah virus", "SPECIES", 49, 60], ["Nipah virus", "SPECIES", 124, 135], ["humans", "SPECIES", 180, 186], ["Nipah virus", "SPECIES", 49, 60], ["Nipah virus", "SPECIES", 124, 135], ["humans", "SPECIES", 180, 186], ["natural reservoir", "TREATMENT", 21, 38], ["Nipah virus", "PROBLEM", 49, 60], ["Nipah virus disease", "PROBLEM", 124, 143], ["fruit bats", "OBSERVATION", 6, 16], ["Nipah virus", "OBSERVATION", 49, 60], ["Nipah virus disease", "OBSERVATION", 124, 143]]], ["The increase in temperature due to climate change affects the ecology, survival, and behavior of arthropod vectors, which subsequently changes population dynamic with increased disease transmission rate.", [["The increase in temperature", "PROBLEM", 0, 27], ["behavior of arthropod vectors", "PROBLEM", 85, 114], ["increased disease transmission rate", "PROBLEM", 167, 202], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["disease", "OBSERVATION", 177, 184]]], ["For example, the rise in temperature from 10 C to 15 C decreases the proliferation time of Plasmodium falciparum in Anopheline mosquitoes vector from 20 to 13 days.", [["Plasmodium falciparum", "DISEASE", 91, 112], ["Plasmodium falciparum", "ORGANISM", 91, 112], ["Anopheline mosquitoes", "ORGANISM", 116, 137], ["Plasmodium falciparum", "SPECIES", 91, 112], ["Plasmodium falciparum", "SPECIES", 91, 112], ["Anopheline mosquitoes", "SPECIES", 116, 137], ["the rise in temperature", "PROBLEM", 13, 36], ["Plasmodium falciparum", "TREATMENT", 91, 112], ["Anopheline mosquitoes vector", "TREATMENT", 116, 144], ["rise", "OBSERVATION_MODIFIER", 17, 21]]], ["Usually, P. falciparum requires 20 days to proliferate in the vector at 20 C. However, the high temperature reduces its proliferation time by increasing egg production, by increasing metabolic rate, and by reducing the larval and pupal period duration [25] .", [["egg", "ANATOMY", 153, 156], ["P. falciparum", "DISEASE", 9, 22], ["P. falciparum", "ORGANISM", 9, 22], ["egg", "ORGANISM_SUBDIVISION", 153, 156], ["P. falciparum", "SPECIES", 9, 22], ["P. falciparum", "SPECIES", 9, 22], ["the high temperature", "PROBLEM", 87, 107], ["increasing egg production", "PROBLEM", 142, 167], ["increasing metabolic rate", "PROBLEM", 172, 197], ["falciparum", "OBSERVATION", 12, 22], ["egg production", "OBSERVATION", 153, 167], ["increasing", "OBSERVATION_MODIFIER", 172, 182], ["metabolic rate", "OBSERVATION", 183, 197]]], ["Moreover, the proximity of natural host such as Rodents and human is the ease and travel aids for the spread of emerging viruses.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["natural host", "OBSERVATION", 27, 39], ["viruses", "OBSERVATION", 121, 128]]], ["The viral infection begins from binding of virus to the receptor of host cell, and during the emergence of new disease, viruses develop either the ability to bind the new receptor or use homologue receptor in new host species.", [["cell", "ANATOMY", 73, 77], ["viral infection", "DISEASE", 4, 19], ["host cell", "CELL", 68, 77], ["host cell", "CELL_TYPE", 68, 77], ["homologue receptor", "PROTEIN", 187, 205], ["The viral infection", "PROBLEM", 0, 19], ["binding of virus", "PROBLEM", 32, 48], ["new disease", "PROBLEM", 107, 118], ["viruses", "PROBLEM", 120, 127], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19], ["host cell", "OBSERVATION", 68, 77], ["new", "OBSERVATION_MODIFIER", 107, 110], ["disease", "OBSERVATION", 111, 118], ["host species", "OBSERVATION", 213, 225]]], ["The spread of coronavirus (CoV) which causes severe acute respiratory syndrome (SARS) in human occurs due to cross-species transmission from raccoon dogs and Chinese ferret badgers [1] .", [["coronavirus (CoV)", "DISEASE", 14, 31], ["acute respiratory syndrome", "DISEASE", 52, 78], ["SARS", "DISEASE", 80, 84], ["coronavirus", "ORGANISM", 14, 25], ["CoV", "ORGANISM", 27, 30], ["human", "ORGANISM", 89, 94], ["raccoon", "ORGANISM", 141, 148], ["dogs", "ORGANISM_SUBDIVISION", 149, 153], ["human", "SPECIES", 89, 94], ["dogs", "SPECIES", 149, 153], ["ferret", "SPECIES", 166, 172], ["CoV", "SPECIES", 27, 30], ["human", "SPECIES", 89, 94], ["Chinese ferret badgers", "SPECIES", 158, 180], ["coronavirus (CoV)", "TREATMENT", 14, 31], ["severe acute respiratory syndrome", "PROBLEM", 45, 78], ["raccoon dogs", "TREATMENT", 141, 153], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["coronavirus", "OBSERVATION", 14, 25], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78]]], ["The examination of wild species of CoV did not have the sign of SARS\u00c0CoV infection but the CoV viruses isolated from horseshoe bats have SARS\u00c0CoV infection.", [["infection", "DISEASE", 73, 82], ["SARS\u00c0CoV infection", "DISEASE", 137, 155], ["CoV", "ORGANISM", 35, 38], ["SARS\u00c0CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["CoV viruses", "ORGANISM", 91, 102], ["horseshoe bats", "ORGANISM", 117, 131], ["CoV viruses", "SPECIES", 91, 102], ["The examination", "TEST", 0, 15], ["wild species of CoV", "PROBLEM", 19, 38], ["SARS\u00c0CoV infection", "PROBLEM", 64, 82], ["the CoV viruses", "PROBLEM", 87, 102], ["horseshoe bats", "PROBLEM", 117, 131], ["SARS\u00c0CoV infection", "PROBLEM", 137, 155], ["infection", "OBSERVATION", 73, 82], ["CoV viruses", "OBSERVATION", 91, 102], ["horseshoe bats", "OBSERVATION", 117, 131], ["SARS\u00c0CoV", "OBSERVATION_MODIFIER", 137, 145], ["infection", "OBSERVATION", 146, 155]]], ["The CoV binds to angiotensin-converting enzyme 2 (ACE2) receptor to infect humans.", [["angiotensin", "CHEMICAL", 17, 28], ["CoV", "GENE_OR_GENE_PRODUCT", 4, 7], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 17, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["humans", "ORGANISM", 75, 81], ["CoV", "PROTEIN", 4, 7], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 17, 64], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["The CoV binds", "PROBLEM", 0, 13], ["angiotensin", "TEST", 17, 28], ["enzyme", "TEST", 40, 46]]], ["However, in bats, ACE2 viral receptor is not use for infection by CoV.", [["infection", "DISEASE", 53, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["CoV", "ORGANISM", 66, 69], ["ACE2 viral receptor", "PROTEIN", 18, 37], ["ACE2 viral receptor", "TREATMENT", 18, 37], ["infection", "PROBLEM", 53, 62]]], ["Later it was studied that the mutation in ACE2 receptor aids the adaptation of CoV in human cells.", [["cells", "ANATOMY", 92, 97], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 42, 55], ["CoV", "ORGANISM", 79, 82], ["human", "ORGANISM", 86, 91], ["cells", "CELL", 92, 97], ["ACE2 receptor", "PROTEIN", 42, 55], ["human cells", "CELL_TYPE", 86, 97], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["the mutation", "PROBLEM", 26, 38], ["ACE2 receptor", "TREATMENT", 42, 55], ["CoV in human cells", "TREATMENT", 79, 97], ["human cells", "OBSERVATION", 86, 97]]], ["The spread of Ebola, Marburg, and measles viruses is some of the example of virus evolution and which contributes to the emergence of disease.", [["Ebola, Marburg", "DISEASE", 14, 28], ["measles viruses", "DISEASE", 34, 49], ["Ebola", "ORGANISM", 14, 19], ["measles viruses", "ORGANISM", 34, 49], ["measles viruses", "SPECIES", 34, 49], ["Ebola", "PROBLEM", 14, 19], ["Marburg", "PROBLEM", 21, 28], ["measles viruses", "PROBLEM", 34, 49], ["virus evolution", "PROBLEM", 76, 91], ["disease", "PROBLEM", 134, 141], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["Ebola", "OBSERVATION", 14, 19], ["virus", "OBSERVATION", 76, 81], ["disease", "OBSERVATION", 134, 141]]], ["The virus evolution and adaptation is difficult to predict and thus raises a question how the effect of emerging viral infection can be reduced.", [["viral infection", "DISEASE", 113, 128], ["The virus evolution", "PROBLEM", 0, 19], ["emerging viral infection", "PROBLEM", 104, 128], ["virus", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 119, 128]]], ["This requires a holistic approach to identify the drivers of emergence with effective surveillance.Emergence of Bunyvirus in ChinaIn 2009 an increased cases of severe fever with thrombocytopenia syndrome (SFTS) were frequently reported in rural areas of China.", [["fever", "DISEASE", 167, 172], ["thrombocytopenia", "DISEASE", 178, 194], ["SFTS", "DISEASE", 205, 209], ["a holistic approach", "TREATMENT", 14, 33], ["effective surveillance", "TEST", 76, 98], ["severe fever", "PROBLEM", 160, 172], ["thrombocytopenia syndrome", "PROBLEM", 178, 203], ["SFTS", "PROBLEM", 205, 209], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["fever", "OBSERVATION", 167, 172], ["thrombocytopenia syndrome", "OBSERVATION", 178, 203]]], ["The associated pathogens of thrombocytopenia and other similar diseases were not detected in majority of the pathogen samples which implies that the pathogen associated with SFTS was newly evolved.", [["samples", "ANATOMY", 118, 125], ["thrombocytopenia", "DISEASE", 28, 44], ["SFTS", "DISEASE", 174, 178], ["SFTS", "CANCER", 174, 178], ["thrombocytopenia", "PROBLEM", 28, 44], ["other similar diseases", "PROBLEM", 49, 71], ["the pathogen", "PROBLEM", 145, 157], ["SFTS", "PROBLEM", 174, 178], ["pathogens", "OBSERVATION_MODIFIER", 15, 24], ["thrombocytopenia", "OBSERVATION", 28, 44], ["similar", "OBSERVATION_MODIFIER", 55, 62], ["diseases", "OBSERVATION", 63, 71], ["pathogen", "OBSERVATION", 109, 117], ["SFTS", "OBSERVATION", 174, 178]]], ["The emergence of this unknown infection having average fatality rate of 10% due to organ failure leads to the implementation of enhanced surveillance to identify causative agent of SFTS infection [2] .", [["organ", "ANATOMY", 83, 88], ["infection", "DISEASE", 30, 39], ["organ failure", "DISEASE", 83, 96], ["SFTS infection", "DISEASE", 181, 195], ["organ", "ORGAN", 83, 88], ["SFTS", "SPECIES", 181, 185], ["this unknown infection", "PROBLEM", 17, 39], ["organ failure", "PROBLEM", 83, 96], ["enhanced surveillance", "TEST", 128, 149], ["SFTS infection", "PROBLEM", 181, 195], ["infection", "OBSERVATION", 30, 39], ["organ", "ANATOMY", 83, 88], ["failure", "OBSERVATION", 89, 96]]], ["The surveillance data revealed 20 strain of viruses as causative of SFTS infection and regarded as SFTS viruses (SFTSVs).", [["SFTS infection", "DISEASE", 68, 82], ["SFTS", "CANCER", 68, 72], ["SFTSVs", "CANCER", 113, 119], ["SFTS", "SPECIES", 68, 72], ["The surveillance data", "TEST", 0, 21], ["20 strain of viruses", "PROBLEM", 31, 51], ["SFTS infection", "PROBLEM", 68, 82], ["SFTS viruses", "PROBLEM", 99, 111], ["SFTS infection", "OBSERVATION", 68, 82]]], ["SFTSVs are RNA virus with three single-stranded RNA genomes.", [["SFTSVs", "GENE_OR_GENE_PRODUCT", 0, 6], ["single-stranded RNA genomes", "DNA", 32, 59], ["RNA virus", "PROBLEM", 11, 20], ["RNA virus", "OBSERVATION", 11, 20], ["stranded RNA genomes", "OBSERVATION", 39, 59]]], ["The complete sequencing of SFTSV, RNA genome reveals that they belong to genus Phlebovirus, family Bunyaviriade.Emergence of Bunyvirus in ChinaThe SFTSV is transmitted in human through infected ticks and transmission of blood and other body fluid of infected person lead to human-to-human transmission of infection.", [["blood", "ANATOMY", 220, 225], ["body fluid", "ANATOMY", 236, 246], ["Bunyaviriade", "CHEMICAL", 99, 111], ["Bunyvirus", "CHEMICAL", 125, 134], ["SFTSV", "CHEMICAL", 147, 152], ["infection", "DISEASE", 305, 314], ["SFTSV", "GENE_OR_GENE_PRODUCT", 27, 32], ["human", "ORGANISM", 171, 176], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["body", "ORGANISM_SUBDIVISION", 236, 240], ["fluid", "ORGANISM_SUBSTANCE", 241, 246], ["human", "ORGANISM", 274, 279], ["human", "ORGANISM", 283, 288], ["SFTSV", "DNA", 27, 32], ["RNA genome", "DNA", 34, 44], ["human", "SPECIES", 171, 176], ["person", "SPECIES", 259, 265], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 283, 288], ["SFTSV", "SPECIES", 27, 32], ["SFTSV", "SPECIES", 147, 152], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 283, 288], ["SFTSV", "PROBLEM", 27, 32], ["RNA genome", "PROBLEM", 34, 44], ["infection", "PROBLEM", 305, 314], ["SFTSV", "OBSERVATION", 27, 32], ["genus Phlebovirus", "OBSERVATION", 73, 90], ["Bunyvirus", "OBSERVATION", 125, 134], ["SFTSV", "OBSERVATION", 147, 152], ["infected ticks", "OBSERVATION", 185, 199], ["infected", "OBSERVATION", 250, 258], ["infection", "OBSERVATION", 305, 314]]], ["TheEmergence of Bunyvirus in ChinaPhlebovirus infection in human results in mild febrile illness.", [["Bunyvirus", "CHEMICAL", 16, 25], ["ChinaPhlebovirus infection", "DISEASE", 29, 55], ["febrile illness", "DISEASE", 81, 96], ["ChinaPhlebovirus", "ORGANISM", 29, 45], ["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["Bunyvirus", "PROBLEM", 16, 25], ["ChinaPhlebovirus infection", "PROBLEM", 29, 55], ["mild febrile illness", "PROBLEM", 76, 96], ["ChinaPhlebovirus", "ANATOMY", 29, 45], ["infection", "OBSERVATION", 46, 55], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["febrile", "OBSERVATION_MODIFIER", 81, 88], ["illness", "OBSERVATION", 89, 96]]], ["However, the major symptoms of SFTS include thrombocytopenia, high fever, leukocytopenia, and lymphadenopathy.", [["SFTS", "DISEASE", 31, 35], ["thrombocytopenia", "DISEASE", 44, 60], ["fever", "DISEASE", 67, 72], ["leukocytopenia", "DISEASE", 74, 88], ["lymphadenopathy", "DISEASE", 94, 109], ["SFTS", "CANCER", 31, 35], ["the major symptoms", "PROBLEM", 9, 27], ["SFTS", "PROBLEM", 31, 35], ["thrombocytopenia", "PROBLEM", 44, 60], ["high fever", "PROBLEM", 62, 72], ["leukocytopenia", "PROBLEM", 74, 88], ["lymphadenopathy", "PROBLEM", 94, 109], ["SFTS", "OBSERVATION", 31, 35], ["thrombocytopenia", "OBSERVATION", 44, 60], ["high", "OBSERVATION_MODIFIER", 62, 66], ["fever", "OBSERVATION", 67, 72], ["leukocytopenia", "OBSERVATION", 74, 88], ["lymphadenopathy", "OBSERVATION", 94, 109]]], ["Currently, it is believed that the vertical transmission of Phlebovirus in arthropod vector (ticks such as Haemaphysalis longicornis) helps in maintenance cycle of virus and amplification of virus occur in vertebrate host (human).", [["Phlebovirus", "CHEMICAL", 60, 71], ["Phlebovirus", "GENE_OR_GENE_PRODUCT", 60, 71], ["Haemaphysalis longicornis", "ORGANISM", 107, 132], ["human", "ORGANISM", 223, 228], ["Haemaphysalis longicornis", "SPECIES", 107, 132], ["human", "SPECIES", 223, 228], ["Haemaphysalis longicornis", "SPECIES", 107, 132], ["human", "SPECIES", 223, 228], ["Phlebovirus in arthropod vector", "TREATMENT", 60, 91], ["Haemaphysalis longicornis", "PROBLEM", 107, 132], ["virus", "PROBLEM", 164, 169], ["amplification of virus", "PROBLEM", 174, 196], ["vertical", "OBSERVATION_MODIFIER", 35, 43], ["Phlebovirus", "OBSERVATION", 60, 71]]], ["The laboratory diagnosis of body fluid samples of SFTS patient showed elevated level of serum and important enzymes and cofactor such as creatine kinase, alanine aminotransferase, lactate dehydrogenase, and aspartate aminotransferase.", [["body fluid samples", "ANATOMY", 28, 46], ["serum", "ANATOMY", 88, 93], ["creatine", "CHEMICAL", 137, 145], ["alanine", "CHEMICAL", 154, 161], ["lactate", "CHEMICAL", 180, 187], ["aspartate", "CHEMICAL", 207, 216], ["creatine", "CHEMICAL", 137, 145], ["alanine", "CHEMICAL", 154, 161], ["lactate", "CHEMICAL", 180, 187], ["aspartate", "CHEMICAL", 207, 216], ["body fluid samples", "ORGANISM_SUBSTANCE", 28, 46], ["patient", "ORGANISM", 55, 62], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 137, 152], ["alanine", "AMINO_ACID", 154, 161], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 162, 178], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 180, 201], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 207, 233], ["enzymes", "PROTEIN", 108, 115], ["cofactor", "PROTEIN", 120, 128], ["creatine kinase", "PROTEIN", 137, 152], ["alanine aminotransferase", "PROTEIN", 154, 178], ["lactate dehydrogenase", "PROTEIN", 180, 201], ["aspartate aminotransferase", "PROTEIN", 207, 233], ["patient", "SPECIES", 55, 62], ["body fluid samples", "TEST", 28, 46], ["SFTS", "TEST", 50, 54], ["elevated level of serum", "PROBLEM", 70, 93], ["cofactor", "TEST", 120, 128], ["creatine kinase", "TEST", 137, 152], ["alanine aminotransferase", "TEST", 154, 178], ["lactate dehydrogenase", "TEST", 180, 201], ["aspartate aminotransferase", "TEST", 207, 233]]], ["The SFTSV replicates in the spleen of infected patient which increases the number of macrophages and platelets.", [["spleen", "ANATOMY", 28, 34], ["macrophages", "ANATOMY", 85, 96], ["platelets", "ANATOMY", 101, 110], ["spleen", "ORGAN", 28, 34], ["patient", "ORGANISM", 47, 54], ["macrophages", "CELL", 85, 96], ["platelets", "CELL", 101, 110], ["macrophages", "CELL_TYPE", 85, 96], ["platelets", "CELL_TYPE", 101, 110], ["patient", "SPECIES", 47, 54], ["The SFTSV", "PROBLEM", 0, 9], ["platelets", "TEST", 101, 110], ["SFTSV", "OBSERVATION", 4, 9], ["spleen", "ANATOMY", 28, 34], ["infected", "OBSERVATION", 38, 46], ["macrophages", "OBSERVATION", 85, 96]]], ["The in vitro assay revealed that SFTSV facilitates the phagocytosis of platelets by adhering on the surface of platelets and ultimately causing thrombocytopenia.", [["platelets", "ANATOMY", 71, 80], ["surface", "ANATOMY", 100, 107], ["platelets", "ANATOMY", 111, 120], ["SFTSV", "CHEMICAL", 33, 38], ["thrombocytopenia", "DISEASE", 144, 160], ["SFTSV", "SIMPLE_CHEMICAL", 33, 38], ["platelets", "CELL", 71, 80], ["surface", "CELLULAR_COMPONENT", 100, 107], ["platelets", "CELL", 111, 120], ["SFTSV", "PROTEIN", 33, 38], ["platelets", "CELL_TYPE", 71, 80], ["platelets", "CELL_TYPE", 111, 120], ["The in vitro assay", "TEST", 0, 18], ["SFTSV", "PROBLEM", 33, 38], ["the phagocytosis of platelets", "PROBLEM", 51, 80], ["platelets", "TEST", 111, 120], ["thrombocytopenia", "PROBLEM", 144, 160], ["SFTSV", "OBSERVATION", 33, 38], ["causing", "UNCERTAINTY", 136, 143], ["thrombocytopenia", "OBSERVATION", 144, 160]]], ["The spread of SFTSV in China and the detection of SFTSV like viruses in other parts of world such as in the United States and Europe emphasized on the urgent need of understanding of pathogenesis and transmission cycle of virus which help in the development of efficient vaccine.Pathogen\u00c0host\u00c0environment interplayThe changes in the host\u00c0environment lead to the evolution of opportunistic and novel pathogens due to which infectious diseases emerge.", [["SFTSV", "CHEMICAL", 14, 19], ["infectious diseases", "DISEASE", 422, 441], ["SFTSV", "ORGANISM", 50, 55], ["SFTSV", "SPECIES", 14, 19], ["SFTSV", "SPECIES", 50, 55], ["SFTSV", "PROBLEM", 14, 19], ["the detection", "TEST", 33, 46], ["SFTSV like viruses", "PROBLEM", 50, 68], ["pathogenesis", "PROBLEM", 183, 195], ["transmission cycle of virus", "PROBLEM", 200, 227], ["efficient vaccine", "TREATMENT", 261, 278], ["opportunistic and novel pathogens", "PROBLEM", 375, 408], ["infectious diseases emerge", "PROBLEM", 422, 448], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["SFTSV", "OBSERVATION", 14, 19], ["SFTSV", "OBSERVATION", 50, 55], ["viruses", "OBSERVATION", 61, 68], ["host\u00c0environment", "OBSERVATION", 333, 349]]], ["The forces which shape the emergence of disease in human are similar to the drivers found in wildlife and domestic animals.", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["disease in human", "PROBLEM", 40, 56], ["forces", "OBSERVATION_MODIFIER", 4, 10], ["shape", "OBSERVATION_MODIFIER", 17, 22], ["disease", "OBSERVATION", 40, 47]]], ["These drivers alter the interplay of hosts, environment, and pathogen thereby modulating disease ecology and developing or acclimatizing pathogen in hosts.", [["acclimatizing pathogen in hosts", "PROBLEM", 123, 154]]], ["The drivers alter interaction pattern of pathogen\u00c0host and environment which to either of three events (1) altering the genetic trait of pathogen which causes severe disease in same host; (2) emergence of pathogen in new hosts; and (3) redistribution of pathogens that result in its establishment in new geographical area.Pathogen\u00c0host\u00c0environment interplayFrequent use of antimicrobial compounds and mass rearing of animals result in AMR and eventually increase virulence pathogenicity of a pathogen.", [["AMR", "DISEASE", 435, 438], ["pathogen", "PROBLEM", 41, 49], ["pathogen", "PROBLEM", 137, 145], ["severe disease in same host", "PROBLEM", 159, 186], ["pathogen", "PROBLEM", 205, 213], ["pathogens", "PROBLEM", 254, 263], ["antimicrobial compounds", "TREATMENT", 373, 396], ["mass", "PROBLEM", 401, 405], ["AMR", "PROBLEM", 435, 438], ["a pathogen", "PROBLEM", 490, 500], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["disease", "OBSERVATION", 166, 173], ["pathogens", "OBSERVATION", 254, 263], ["new", "OBSERVATION_MODIFIER", 300, 303]]], ["Mass rearing of food animals to meet the demand of growing population results in intensification of genetically similar animals of same sex and age at confined place.", [["Mass", "PROBLEM", 0, 4]]], ["This leads to transmission of pathogen with increases population turnover which supports emergence of novel trait.", [["pathogen", "PROBLEM", 30, 38], ["increases population turnover", "PROBLEM", 44, 73], ["novel trait", "PROBLEM", 102, 113], ["pathogen", "OBSERVATION", 30, 38], ["increases", "OBSERVATION_MODIFIER", 44, 53]]], ["The transmission of Highly Pathogenic Asian Avian Influenza A (H5N1 HPAI) is the well-known example of mass rearing [26] .Pathogen\u00c0host\u00c0environment interplayThe drivers which are responsible for the disease emergence in new host include interspecies contact, wildlife migration, and increase contact between different hosts.", [["Influenza A", "DISEASE", 50, 61], ["HPAI", "DISEASE", 68, 72], ["Asian", "ORGANISM", 38, 43], ["Avian", "ORGANISM", 44, 49], ["Influenza A", "ORGANISM", 50, 61], ["H5N1 HPAI", "ORGANISM", 63, 72], ["Avian Influenza A", "SPECIES", 44, 61], ["H5N1 HPAI", "SPECIES", 63, 72], ["Asian Avian Influenza A (H5N1 HPAI", "SPECIES", 38, 72], ["Highly Pathogenic Asian Avian Influenza A (H5N1 HPAI", "PROBLEM", 20, 72], ["mass rearing", "PROBLEM", 103, 115], ["the disease emergence", "PROBLEM", 195, 216], ["mass", "OBSERVATION", 103, 107]]], ["The worldwide change in ecological landscape results in close contact between human and animals which eventually lead to transmission of microbial reservoir of animals (birds, rodents, and bats) to human.", [["human", "ORGANISM", 78, 83], ["birds", "ORGANISM_SUBDIVISION", 169, 174], ["human", "ORGANISM", 198, 203], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 198, 203], ["microbial reservoir of animals", "TREATMENT", 137, 167], ["worldwide", "OBSERVATION_MODIFIER", 4, 13], ["change", "OBSERVATION_MODIFIER", 14, 20], ["ecological landscape", "OBSERVATION", 24, 44]]], ["For instance, the emergence of Nipah virus in human was due to transmission of virus from foraging fruit bat to pigs [7] .", [["Nipah virus", "DISEASE", 31, 42], ["Nipah virus", "ORGANISM", 31, 42], ["human", "ORGANISM", 46, 51], ["pigs", "ORGANISM", 112, 116], ["Nipah virus", "SPECIES", 31, 42], ["human", "SPECIES", 46, 51], ["fruit bat", "SPECIES", 99, 108], ["pigs", "SPECIES", 112, 116], ["Nipah virus", "SPECIES", 31, 42], ["human", "SPECIES", 46, 51], ["Nipah virus", "PROBLEM", 31, 42], ["virus", "PROBLEM", 79, 84]]], ["The transport of food, live animals, plants with accompany insects for international trade, migration of birds, and wild animals results in geographical jump of pathogens.", [["migration of birds", "TREATMENT", 92, 110], ["pathogens", "PROBLEM", 161, 170], ["pathogens", "OBSERVATION", 161, 170]]], ["The bacterium Ralstonia solanacearum hitchhikes to the United States via geranium plant which is imported from Kenya [7] .Persisters and multidrug tolerancePersisters are slow growing or nongrowing organisms which remain in stagnant during the presence of antimicrobial compound but have the capacity to resuscitate and grow under specific conditions.", [["Ralstonia solanacearum", "ORGANISM", 14, 36], ["Ralstonia solanacearum", "SPECIES", 14, 36], ["Ralstonia solanacearum", "SPECIES", 14, 36], ["The bacterium Ralstonia solanacearum", "PROBLEM", 0, 36], ["multidrug tolerance", "PROBLEM", 137, 156], ["slow growing", "PROBLEM", 171, 183], ["nongrowing organisms", "PROBLEM", 187, 207], ["antimicrobial compound", "PROBLEM", 256, 278], ["bacterium", "OBSERVATION_MODIFIER", 4, 13], ["Ralstonia solanacearum", "OBSERVATION", 14, 36], ["multidrug tolerance", "OBSERVATION", 137, 156], ["slow", "OBSERVATION_MODIFIER", 171, 175], ["growing", "OBSERVATION_MODIFIER", 176, 183], ["nongrowing organisms", "OBSERVATION", 187, 207]]], ["The persisters formation is mediated by variety of stress such as due to nutrient depletion, oxidative stress heat, acidic pH, and the presence of toxic compound (antibiotics).", [["persisters", "ANATOMY", 4, 14], ["stress", "PROBLEM", 51, 57], ["nutrient depletion", "PROBLEM", 73, 91], ["oxidative stress heat", "PROBLEM", 93, 114], ["acidic pH", "PROBLEM", 116, 125], ["toxic compound (antibiotics", "TREATMENT", 147, 174], ["nutrient depletion", "OBSERVATION", 73, 91], ["toxic", "OBSERVATION_MODIFIER", 147, 152]]], ["Antibiotics such as tetracycline, rifampin, and ciprofloxacin were shown to enrich persisters formation by inhibiting protein synthesis, RNA synthesis, or by antioxidative defense [5] .Persisters and multidrug tolerancePersisters are the cause of biofilm infection, recurrent infection, and chronic infection and contribute toward prolongation of therapy time (e.g., tuberculosis, Lyme disease).", [["persisters", "ANATOMY", 83, 93], ["biofilm", "ANATOMY", 247, 254], ["tetracycline", "CHEMICAL", 20, 32], ["rifampin", "CHEMICAL", 34, 42], ["ciprofloxacin", "CHEMICAL", 48, 61], ["Persisters", "DISEASE", 219, 229], ["biofilm infection", "DISEASE", 247, 264], ["infection", "DISEASE", 276, 285], ["infection", "DISEASE", 299, 308], ["tuberculosis", "DISEASE", 367, 379], ["Lyme disease", "DISEASE", 381, 393], ["tetracycline", "CHEMICAL", 20, 32], ["rifampin", "CHEMICAL", 34, 42], ["ciprofloxacin", "CHEMICAL", 48, 61], ["tetracycline", "SIMPLE_CHEMICAL", 20, 32], ["rifampin", "SIMPLE_CHEMICAL", 34, 42], ["ciprofloxacin", "SIMPLE_CHEMICAL", 48, 61], ["Antibiotics", "TREATMENT", 0, 11], ["tetracycline", "TREATMENT", 20, 32], ["rifampin", "TREATMENT", 34, 42], ["ciprofloxacin", "TREATMENT", 48, 61], ["inhibiting protein synthesis", "PROBLEM", 107, 135], ["RNA synthesis", "PROBLEM", 137, 150], ["multidrug tolerance", "PROBLEM", 200, 219], ["biofilm infection", "PROBLEM", 247, 264], ["recurrent infection", "PROBLEM", 266, 285], ["chronic infection", "PROBLEM", 291, 308], ["therapy time", "TREATMENT", 347, 359], ["tuberculosis", "PROBLEM", 367, 379], ["Lyme disease)", "PROBLEM", 381, 394], ["multidrug tolerance", "OBSERVATION", 200, 219], ["biofilm", "OBSERVATION_MODIFIER", 247, 254], ["infection", "OBSERVATION", 255, 264], ["recurrent", "OBSERVATION_MODIFIER", 266, 275], ["infection", "OBSERVATION", 276, 285], ["chronic", "OBSERVATION_MODIFIER", 291, 298], ["infection", "OBSERVATION", 299, 308], ["Lyme disease", "OBSERVATION", 381, 393]]], ["The repeated treatment of persistent infection may result in the development of drug-resistance microbes, often seen in the case of tuberculosis.", [["infection", "DISEASE", 37, 46], ["drug-resistance microbes", "DISEASE", 80, 104], ["tuberculosis", "DISEASE", 132, 144], ["The repeated treatment", "TREATMENT", 0, 22], ["persistent infection", "PROBLEM", 26, 46], ["drug-resistance microbes", "PROBLEM", 80, 104], ["tuberculosis", "PROBLEM", 132, 144], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["infection", "OBSERVATION", 37, 46], ["resistance microbes", "OBSERVATION", 85, 104], ["tuberculosis", "OBSERVATION", 132, 144]]], ["Persistent could be pre-or postantibiotic depending on its development in the host.", [["postantibiotic", "OBSERVATION_MODIFIER", 27, 41]]], ["The capacity of formation of persisters varies greatly among the bacterial species.", [["persisters varies", "PROBLEM", 29, 46], ["the bacterial species", "PROBLEM", 61, 82], ["capacity", "OBSERVATION_MODIFIER", 4, 12], ["persisters", "OBSERVATION_MODIFIER", 29, 39], ["bacterial species", "OBSERVATION", 65, 82]]], ["For instance, persisters of Mycobacterium tuberculosis are not removed from the host even after chemotherapy, while the single antibiotic treatment is sufficient for curing infection caused by Streptococcus pneumoniae.", [["Mycobacterium tuberculosis", "DISEASE", 28, 54], ["infection", "DISEASE", 173, 182], ["Streptococcus pneumoniae", "DISEASE", 193, 217], ["Mycobacterium tuberculosis", "ORGANISM", 28, 54], ["Streptococcus pneumoniae", "ORGANISM", 193, 217], ["Mycobacterium tuberculosis", "SPECIES", 28, 54], ["Streptococcus pneumoniae", "SPECIES", 193, 217], ["Mycobacterium tuberculosis", "SPECIES", 28, 54], ["Streptococcus pneumoniae", "SPECIES", 193, 217], ["Mycobacterium tuberculosis", "PROBLEM", 28, 54], ["chemotherapy", "TREATMENT", 96, 108], ["the single antibiotic treatment", "TREATMENT", 116, 147], ["curing infection", "PROBLEM", 166, 182], ["Streptococcus pneumoniae", "PROBLEM", 193, 217], ["Mycobacterium tuberculosis", "OBSERVATION", 28, 54], ["Streptococcus pneumoniae", "OBSERVATION", 193, 217]]], ["The physical and psychological stress, host immune and hormonal factor, and coinfection also affect the persisters formation in the host.Persisters and multidrug toleranceThe mechanism behind the persisters formation is not well understood.", [["coinfection", "DISEASE", 76, 87], ["hormonal factor", "PROTEIN", 55, 70], ["hormonal factor", "PROBLEM", 55, 70], ["coinfection", "PROBLEM", 76, 87], ["multidrug tolerance", "PROBLEM", 152, 171], ["multidrug tolerance", "OBSERVATION", 152, 171]]], ["However, it is believed that epigenetic changes, changes in DNA modification, and posttranslational modification induce expression of persisters gene.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["persisters", "GENE_OR_GENE_PRODUCT", 134, 144], ["persisters gene", "DNA", 134, 149], ["epigenetic changes", "PROBLEM", 29, 47], ["DNA modification", "TREATMENT", 60, 76], ["posttranslational modification", "TREATMENT", 82, 112]]], ["The genes which involve in persisters formation are relA, sucB, hipA, ubiF, and phoU.", [["persisters", "ANATOMY", 27, 37], ["persisters", "GENE_OR_GENE_PRODUCT", 27, 37], ["relA", "GENE_OR_GENE_PRODUCT", 52, 56], ["sucB", "GENE_OR_GENE_PRODUCT", 58, 62], ["hipA", "GENE_OR_GENE_PRODUCT", 64, 68], ["ubiF", "GENE_OR_GENE_PRODUCT", 70, 74], ["phoU", "GENE_OR_GENE_PRODUCT", 80, 84], ["relA", "PROTEIN", 52, 56], ["sucB", "DNA", 58, 62], ["hipA", "DNA", 64, 68], ["ubiF", "DNA", 70, 74], ["phoU", "DNA", 80, 84]]], ["The mutagenesis approach is used to study genes involved in persisters formation; however, the short antibiotic exposure, screening of partial mutant library, and aeration during antibiotic exposure are factors which result in failure of mutagenesis process for identifying persisters genes.Vector borne zoonotic diseasesZoonotic diseases are vector (mosquito, ticks, and bugs) aided or nonaided disease caused by bacteria, virus, parasites, prions and fungi, and transmitted from animals to human.", [["persisters", "ANATOMY", 60, 70], ["zoonotic diseases", "DISEASE", 304, 321], ["Zoonotic diseases", "DISEASE", 321, 338], ["persisters", "PATHOLOGICAL_FORMATION", 60, 70], ["human", "ORGANISM", 492, 497], ["persisters genes", "DNA", 274, 290], ["human", "SPECIES", 492, 497], ["human", "SPECIES", 492, 497], ["The mutagenesis approach", "TREATMENT", 0, 24], ["the short antibiotic exposure", "PROBLEM", 91, 120], ["screening", "TEST", 122, 131], ["partial mutant library", "PROBLEM", 135, 157], ["antibiotic exposure", "TREATMENT", 179, 198], ["failure of mutagenesis process", "PROBLEM", 227, 257], ["Vector borne zoonotic diseasesZoonotic diseases", "PROBLEM", 291, 338], ["nonaided disease", "PROBLEM", 387, 403], ["bacteria", "PROBLEM", 414, 422], ["virus", "PROBLEM", 424, 429], ["parasites", "PROBLEM", 431, 440], ["prions", "PROBLEM", 442, 448], ["fungi", "PROBLEM", 453, 458], ["zoonotic", "OBSERVATION_MODIFIER", 304, 312], ["bacteria", "OBSERVATION", 414, 422]]], ["Various modes of transmission are direct contact between infected animal and human, via arthropod vector, consumption of contaminated animal food (meat and pork), and ingestion of aerosolized pathogens present in the environment.", [["meat", "ANATOMY", 147, 151], ["pork", "ANATOMY", 156, 160], ["human", "ORGANISM", 77, 82], ["meat", "ORGANISM_SUBDIVISION", 147, 151], ["pork", "ORGANISM_SUBDIVISION", 156, 160], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["pork", "SPECIES", 156, 160], ["arthropod vector", "TREATMENT", 88, 104], ["aerosolized pathogens", "PROBLEM", 180, 201]]], ["In last two decades, many vector borne pathogens spread in new geographical regions.", [["many vector borne pathogens spread", "PROBLEM", 21, 55], ["many", "OBSERVATION_MODIFIER", 21, 25], ["vector", "OBSERVATION_MODIFIER", 26, 32], ["borne", "OBSERVATION_MODIFIER", 33, 38], ["pathogens", "OBSERVATION_MODIFIER", 39, 48], ["spread", "OBSERVATION_MODIFIER", 49, 55], ["new", "OBSERVATION_MODIFIER", 59, 62], ["geographical", "OBSERVATION_MODIFIER", 63, 75]]], ["The emergence and reemergence rate of zoonotic infection has increased inescapably due to urbanization, deforestation, climate change, international trade (frequent travel), population movement, and encroachment into animal habitats.", [["zoonotic infection", "DISEASE", 38, 56], ["deforestation", "DISEASE", 104, 117], ["zoonotic infection", "PROBLEM", 38, 56], ["deforestation", "PROBLEM", 104, 117], ["encroachment into animal habitats", "PROBLEM", 199, 232], ["zoonotic", "OBSERVATION_MODIFIER", 38, 46], ["infection", "OBSERVATION", 47, 56], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["The most emerging zoonotic vector borne diseases in the United States and Canada include tick borne Lyme disease, Babesiosis, human granulocytic anaplasmosis and mosquito borne West nile virus (WNV), California serogroup viruses, and cache valley virus [7] .Vector borne zoonotic diseasesThe change in land use alters the abundance and interaction of vectors and hosts (wildlife and domestic animals) which results in emergence of vectors.", [["zoonotic vector borne diseases", "DISEASE", 18, 48], ["tick borne Lyme disease", "DISEASE", 89, 112], ["Babesiosis", "DISEASE", 114, 124], ["human granulocytic anaplasmosis", "DISEASE", 126, 157], ["zoonotic diseases", "DISEASE", 271, 288], ["human", "ORGANISM", 126, 131], ["granulocytic anaplasmosis", "ORGANISM", 132, 157], ["mosquito borne", "ORGANISM", 162, 176], ["West nile virus", "ORGANISM", 177, 192], ["WNV", "ORGANISM", 194, 197], ["California serogroup viruses", "ORGANISM", 200, 228], ["cache valley virus", "ORGANISM", 234, 252], ["human", "SPECIES", 126, 131], ["West nile virus", "SPECIES", 177, 192], ["cache valley virus", "SPECIES", 234, 252], ["human granulocytic anaplasmosis", "SPECIES", 126, 157], ["West nile virus", "SPECIES", 177, 192], ["WNV", "SPECIES", 194, 197], ["California serogroup viruses", "SPECIES", 200, 228], ["cache valley virus", "SPECIES", 234, 252], ["tick borne Lyme disease", "PROBLEM", 89, 112], ["Babesiosis", "PROBLEM", 114, 124], ["human granulocytic anaplasmosis", "PROBLEM", 126, 157], ["mosquito borne West nile virus (WNV", "PROBLEM", 162, 197], ["California serogroup viruses", "PROBLEM", 200, 228], ["cache valley virus", "PROBLEM", 234, 252], ["Vector borne zoonotic diseases", "PROBLEM", 258, 288], ["granulocytic anaplasmosis", "OBSERVATION", 132, 157], ["zoonotic", "OBSERVATION_MODIFIER", 271, 279], ["diseases", "OBSERVATION", 280, 288], ["change", "OBSERVATION_MODIFIER", 292, 298]]], ["For instance, deforestation in amazon and eastern Africa enhances the breeding of anopheles' mosquito due to sunlight and standing water.", [["amazon", "CHEMICAL", 31, 37], ["anopheles", "ORGANISM", 82, 91], ["amazon", "TREATMENT", 31, 37]]], ["Similarly in North America, increased hunting changes the predator community and results in increased abundance of small animals such as mice, chipmunks, and shrew which are main host of spirochete Borrelia burgdorferi, causative agent of Lyme disease [6] .", [["chipmunks", "ANATOMY", 143, 152], ["Borrelia burgdorferi", "DISEASE", 198, 218], ["Lyme disease", "DISEASE", 239, 251], ["mice", "ORGANISM", 137, 141], ["spirochete", "ORGANISM", 187, 197], ["Borrelia burgdorferi", "ORGANISM", 198, 218], ["mice", "SPECIES", 137, 141], ["Borrelia burgdorferi", "SPECIES", 198, 218], ["mice", "SPECIES", 137, 141], ["shrew", "SPECIES", 158, 163], ["Borrelia burgdorferi", "SPECIES", 198, 218], ["Lyme disease", "PROBLEM", 239, 251], ["North", "OBSERVATION_MODIFIER", 13, 18], ["America", "OBSERVATION_MODIFIER", 19, 26], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["hunting", "OBSERVATION", 38, 45], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["abundance", "OBSERVATION_MODIFIER", 102, 111], ["small", "OBSERVATION_MODIFIER", 115, 120]]], ["Socioeconomic changes and human activities are the another factor which governs spread and emergence of pathogen.", [["human", "ORGANISM", 26, 31], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["Socioeconomic changes", "PROBLEM", 0, 21], ["pathogen", "PROBLEM", 104, 112]]], ["The Lyme disease was reported to occur more in high-income people in Europe due to the more recreational activity and living in new homes in broad-leaf woodlands with cooccurrence of wildlife result in frequent exposure to vector.", [["Lyme disease", "DISEASE", 4, 16], ["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["The Lyme disease", "PROBLEM", 0, 16], ["Lyme disease", "OBSERVATION", 4, 16], ["leaf woodlands", "OBSERVATION", 147, 161]]], ["Vector born zoonotic disease could be controlled by prompt identification of cause with subsequent action which requires integration of public health officials, researchers, and public [23] .Emergence of arbovirusesArbovirus is an acronym for arthropod-borne viruses.", [["zoonotic disease", "DISEASE", 12, 28], ["arbovirusesArbovirus", "DISEASE", 204, 224], ["arthropod-borne viruses", "DISEASE", 243, 266], ["arbovirusesArbovirus", "ORGANISM", 204, 224], ["Vector born zoonotic disease", "PROBLEM", 0, 28], ["arbovirusesArbovirus", "PROBLEM", 204, 224], ["arthropod-borne viruses", "PROBLEM", 243, 266], ["zoonotic disease", "OBSERVATION", 12, 28], ["arboviruses", "OBSERVATION", 204, 215]]], ["Dengue virus, WNV, and chikungunya virus are recent examples of arboviruses which are transmitted from the arthropods (ticks, bugs, and mosquito) to vertebrate.", [["Dengue", "DISEASE", 0, 6], ["chikungunya virus", "DISEASE", 23, 40], ["Dengue virus", "ORGANISM", 0, 12], ["WNV", "ORGANISM", 14, 17], ["chikungunya virus", "ORGANISM", 23, 40], ["arboviruses", "ORGANISM", 64, 75], ["ticks", "ORGANISM_SUBDIVISION", 119, 124], ["Dengue virus", "SPECIES", 0, 12], ["chikungunya virus", "SPECIES", 23, 40], ["Dengue virus", "SPECIES", 0, 12], ["WNV", "SPECIES", 14, 17], ["chikungunya virus", "SPECIES", 23, 40], ["Dengue virus", "PROBLEM", 0, 12], ["WNV", "PROBLEM", 14, 17], ["chikungunya virus", "PROBLEM", 23, 40], ["arboviruses", "PROBLEM", 64, 75], ["chikungunya virus", "OBSERVATION", 23, 40], ["arboviruses", "OBSERVATION", 64, 75]]], ["Arboviruses use arthropods as a vector (carrier) for transmission and do not causes any sickness in them.", [["a vector (carrier", "TREATMENT", 30, 47], ["any sickness in them", "PROBLEM", 84, 104], ["sickness", "OBSERVATION", 88, 96]]], ["Bunyaviridae, Reoviridae, Flaviviridae, and Togaviridae are the most prevailing arboviruses families that cause diseases in human and animals [27] .Emergence of arbovirusesThe emergence of arboviruses is governed by three factors, that is, high mutation frequency, varying anthropological behavior, and climate change.", [["Bunyaviridae", "DISEASE", 0, 12], ["arboviruses", "DISEASE", 161, 172], ["arboviruses", "DISEASE", 189, 200], ["Bunyaviridae", "ORGANISM", 0, 12], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 14, 24], ["Togaviridae", "GENE_OR_GENE_PRODUCT", 44, 55], ["human", "ORGANISM", 124, 129], ["arboviruses", "ORGANISM", 161, 172], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["Bunyaviridae", "TREATMENT", 0, 12], ["Reoviridae", "TREATMENT", 14, 24], ["Flaviviridae", "TREATMENT", 26, 38], ["Togaviridae", "TREATMENT", 44, 55], ["diseases in human", "PROBLEM", 112, 129], ["arboviruses", "PROBLEM", 161, 172], ["arboviruses", "PROBLEM", 189, 200], ["high mutation frequency", "PROBLEM", 240, 263], ["varying anthropological behavior", "PROBLEM", 265, 297], ["arboviruses", "OBSERVATION", 161, 172], ["arboviruses", "OBSERVATION", 189, 200]]], ["For instance, emergence of chikungunya virus in Asia due to mutation in surface protein which increases its reproduction, transmission, and infection efficiency in Aedes albopictus.", [["surface", "ANATOMY", 72, 79], ["chikungunya virus", "DISEASE", 27, 44], ["infection", "DISEASE", 140, 149], ["chikungunya virus", "ORGANISM", 27, 44], ["Aedes albopictus", "ORGANISM", 164, 180], ["surface protein", "PROTEIN", 72, 87], ["Aedes albopictus", "SPECIES", 164, 180], ["chikungunya virus", "SPECIES", 27, 44], ["Aedes albopictus", "SPECIES", 164, 180], ["chikungunya virus", "PROBLEM", 27, 44], ["mutation in surface protein", "PROBLEM", 60, 87], ["infection efficiency", "PROBLEM", 140, 160], ["chikungunya virus", "OBSERVATION", 27, 44], ["infection efficiency", "OBSERVATION", 140, 160]]], ["They are able to maintain themselves for years in mosquito eggs or via attaining transstadial stages in ticks.", [["eggs", "ANATOMY", 59, 63], ["mosquito", "ORGANISM", 50, 58], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 59, 63]]], ["Domestic animals, livestock, and human are not important part of arbovirus life cycle because of nonviraemic transmission of arbovirus between ticks without infecting vertebrate host.", [["arbovirus", "DISEASE", 125, 134], ["human", "ORGANISM", 33, 38], ["arbovirus", "ORGANISM", 125, 134], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["arbovirus life cycle", "TREATMENT", 65, 85], ["arbovirus between ticks", "PROBLEM", 125, 148]]], ["This feature of arbovirus adds additional limitation for controlling disease emergence [27] .Emergence of arbovirusesMosquito eradication, development of live-attenuated vaccines, antiviral drugs, and molecule are few methods used to control and prevent arboviral infection.", [["arbovirus", "DISEASE", 16, 25], ["infection", "DISEASE", 264, 273], ["arbovirus", "ORGANISM", 16, 25], ["arbovirus", "PROBLEM", 16, 25], ["controlling disease emergence", "PROBLEM", 57, 86], ["arbovirusesMosquito eradication", "TREATMENT", 106, 137], ["live-attenuated vaccines", "TREATMENT", 154, 178], ["antiviral drugs", "TREATMENT", 180, 195], ["molecule", "TREATMENT", 201, 209], ["few methods", "TREATMENT", 214, 225], ["arboviral infection", "PROBLEM", 254, 273], ["arbovirus", "OBSERVATION", 16, 25], ["arboviruses", "OBSERVATION", 106, 117], ["antiviral drugs", "OBSERVATION", 180, 195], ["arboviral", "OBSERVATION_MODIFIER", 254, 263], ["infection", "OBSERVATION", 264, 273]]], ["However, high mutational frequency will result in emergence of new pathogenic arboviruses.", [["arboviruses", "DISEASE", 78, 89], ["arboviruses", "ORGANISM", 78, 89], ["high mutational frequency", "PROBLEM", 9, 34], ["new pathogenic arboviruses", "PROBLEM", 63, 89]]], ["Since it has been proven by genome sequencing of mosquitoes that they are the carrier of various known and unknown viruses, control of localized arthropod during endemic could be a possible solution for regulating the emergence of arbovirus [24] .Emergence of Buruli ulcerBuruli ulcer (BU) is necrotizing skin disease caused by Mycobacterium ulcerans recognized as one of most neglected tropical disease by World Health Organization (WHO).", [["skin", "ANATOMY", 305, 309], ["arbovirus", "DISEASE", 231, 240], ["Buruli ulcerBuruli ulcer", "DISEASE", 260, 284], ["BU", "DISEASE", 286, 288], ["necrotizing skin disease", "DISEASE", 293, 317], ["Mycobacterium ulcerans", "DISEASE", 328, 350], ["ulcerBuruli ulcer", "PATHOLOGICAL_FORMATION", 267, 284], ["skin", "ORGAN", 305, 309], ["Mycobacterium ulcerans", "ORGANISM", 328, 350], ["Mycobacterium ulcerans", "SPECIES", 328, 350], ["Mycobacterium ulcerans", "SPECIES", 328, 350], ["unknown viruses", "PROBLEM", 107, 122], ["Buruli ulcerBuruli ulcer", "PROBLEM", 260, 284], ["necrotizing skin disease", "PROBLEM", 293, 317], ["Mycobacterium ulcerans", "PROBLEM", 328, 350], ["viruses", "OBSERVATION", 115, 122], ["Buruli", "OBSERVATION_MODIFIER", 260, 266], ["ulcerBuruli ulcer", "OBSERVATION", 267, 284], ["necrotizing", "OBSERVATION_MODIFIER", 293, 304], ["skin", "ANATOMY", 305, 309], ["disease", "OBSERVATION", 310, 317], ["Mycobacterium ulcerans", "OBSERVATION", 328, 350], ["disease", "OBSERVATION", 396, 403]]], ["The BU lead to the formation of skin ulcers which results in osteomyelitis.", [["skin ulcers", "ANATOMY", 32, 43], ["BU", "CHEMICAL", 4, 6], ["skin ulcers", "DISEASE", 32, 43], ["osteomyelitis", "DISEASE", 61, 74], ["BU", "SIMPLE_CHEMICAL", 4, 6], ["skin ulcers", "PATHOLOGICAL_FORMATION", 32, 43], ["skin ulcers", "PROBLEM", 32, 43], ["osteomyelitis", "PROBLEM", 61, 74], ["skin", "ANATOMY", 32, 36], ["ulcers", "OBSERVATION", 37, 43], ["osteomyelitis", "OBSERVATION", 61, 74]]], ["It causes pandemic in humid tropical and subtopical region, often where humans are in proximity with slow moving or stagnant contaminated water.", [["humans", "ORGANISM", 72, 78], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["pandemic in humid tropical and subtopical region", "PROBLEM", 10, 58], ["pandemic", "OBSERVATION_MODIFIER", 10, 18], ["humid", "OBSERVATION_MODIFIER", 22, 27], ["tropical", "OBSERVATION_MODIFIER", 28, 36], ["subtopical", "ANATOMY_MODIFIER", 41, 51], ["region", "ANATOMY_MODIFIER", 52, 58]]], ["The transmission of M. ulcerans follows multihost transmission dynamics, that is, multiple hosts of aquatic environment such as scrapers, scavengers, and predators become contaminated with M. ulcerans and result in its passive dissemination via organism-to-organism contact.", [["scrapers", "ANATOMY", 128, 136], ["M. ulcerans", "ORGANISM", 20, 31], ["M. ulcerans", "ORGANISM", 189, 200], ["M. ulcerans", "SPECIES", 20, 31], ["M. ulcerans", "SPECIES", 189, 200], ["M. ulcerans", "SPECIES", 20, 31], ["M. ulcerans", "SPECIES", 189, 200], ["M. ulcerans", "PROBLEM", 20, 31], ["scavengers", "TREATMENT", 138, 148], ["M. ulcerans", "PROBLEM", 189, 200], ["M. ulcerans", "OBSERVATION", 20, 31], ["ulcerans", "OBSERVATION", 192, 200]]], ["Phylogenetic studies revealed that the M. ulcerans was emerged from species Mycobacterium marinum which causes cutaneous disease in human and also shown to infect fish.", [["cutaneous", "ANATOMY", 111, 120], ["Mycobacterium marinum", "DISEASE", 76, 97], ["cutaneous disease", "DISEASE", 111, 128], ["M. ulcerans", "ORGANISM", 39, 50], ["Mycobacterium marinum", "ORGANISM", 76, 97], ["human", "ORGANISM", 132, 137], ["fish", "ORGANISM", 163, 167], ["M. ulcerans", "SPECIES", 39, 50], ["Mycobacterium marinum", "SPECIES", 76, 97], ["human", "SPECIES", 132, 137], ["M. ulcerans", "SPECIES", 39, 50], ["Mycobacterium marinum", "SPECIES", 76, 97], ["human", "SPECIES", 132, 137], ["Phylogenetic studies", "TEST", 0, 20], ["the M. ulcerans", "PROBLEM", 35, 50], ["species Mycobacterium marinum", "PROBLEM", 68, 97], ["cutaneous disease in human", "PROBLEM", 111, 137], ["M.", "OBSERVATION_MODIFIER", 39, 41], ["ulcerans", "OBSERVATION", 42, 50], ["species", "OBSERVATION_MODIFIER", 68, 75], ["Mycobacterium marinum", "OBSERVATION", 76, 97], ["cutaneous disease", "OBSERVATION", 111, 128]]], ["M. ulcerans are widely distributed in Africa; however, the BU cases reported in specific geographical villages.", [["BU", "DISEASE", 59, 61], ["M. ulcerans", "ORGANISM", 0, 11], ["M. ulcerans", "SPECIES", 0, 11], ["M. ulcerans", "SPECIES", 0, 11], ["M. ulcerans", "PROBLEM", 0, 11], ["the BU cases", "TEST", 55, 67], ["ulcerans", "OBSERVATION", 3, 11], ["widely", "OBSERVATION_MODIFIER", 16, 22], ["distributed", "OBSERVATION_MODIFIER", 23, 34], ["Africa", "OBSERVATION_MODIFIER", 38, 44]]], ["Researchers postulates that a specific M. ulcerans strain might have pathogenicity or virulence to cause BU [8] .", [["BU", "DISEASE", 105, 107], ["M. ulcerans", "ORGANISM", 39, 50], ["M. ulcerans", "SPECIES", 39, 50], ["M. ulcerans", "SPECIES", 39, 50], ["a specific M. ulcerans strain", "PROBLEM", 28, 57], ["pathogenicity", "PROBLEM", 69, 82]]], ["The current knowledge lacks the understanding of spatiotemporal distribution of M. ulcerans and required detailed scenario of diversity of M. ulcerans strains existing in environment [2] .Age of superbugsSuperbug is a term coined for bacterial species which confers resistant toward majority of antibiotics.", [["M. ulcerans", "ORGANISM", 80, 91], ["M. ulcerans", "ORGANISM", 139, 150], ["M. ulcerans", "SPECIES", 80, 91], ["M. ulcerans", "SPECIES", 139, 150], ["M. ulcerans", "SPECIES", 80, 91], ["M. ulcerans", "SPECIES", 139, 150], ["M. ulcerans", "PROBLEM", 80, 91], ["M. ulcerans strains", "PROBLEM", 139, 158], ["bacterial species", "PROBLEM", 234, 251], ["antibiotics", "TREATMENT", 295, 306], ["M. ulcerans", "OBSERVATION", 80, 91], ["ulcerans strains", "OBSERVATION", 142, 158]]], ["Emergence of superbugs implies the frequent detection of novel bacterial pathogens which caused unrecognized life-threatening infections.", [["superbugs", "DISEASE", 13, 22], ["infections", "DISEASE", 126, 136], ["novel bacterial pathogens", "PROBLEM", 57, 82], ["unrecognized life-threatening infections", "PROBLEM", 96, 136], ["bacterial pathogens", "OBSERVATION", 63, 82], ["threatening", "OBSERVATION_MODIFIER", 114, 125], ["infections", "OBSERVATION", 126, 136]]], ["The frequent emergence and spread of superbugs worldwide causes a concern that human life is heading back, toward the preantibiotic era, where the entire population of a society was wipe out due to the simple infection.", [["superbugs", "DISEASE", 37, 46], ["infection", "DISEASE", 209, 218], ["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["the simple infection", "PROBLEM", 198, 218], ["frequent", "OBSERVATION_MODIFIER", 4, 12], ["simple", "OBSERVATION_MODIFIER", 202, 208], ["infection", "OBSERVATION", 209, 218]]], ["United Nation (UN) General Assembly of 2016 addresses the AMR [28] as a health emergency and acknowledge that AMR has deleterious effect on human health and sustainable development.", [["AMR", "DISEASE", 58, 61], ["AMR", "DISEASE", 110, 113], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145]]], ["WHO identified a group of AMR resistant \"priority pathogens\" that requires urgent strategic action (Table 17\u00c02) .", [["AMR", "DISEASE", 26, 29], ["AMR resistant \"priority pathogens", "PROBLEM", 26, 59]]], ["WHO categorize these priority pathogens into three categories, that is, critical, high, and medium priority based on the need for new antibiotics.", [["new antibiotics", "TREATMENT", 130, 145], ["high", "OBSERVATION_MODIFIER", 82, 86]]], ["The criteria for prioritization of pathogens were developed using multicriteria decision analysis technique which includes AMR pathogens which causes mortality, prevalence of resistance, transmissibility, treatability, healthcare and community burden, 10-year trend of resistance, preventability in hospital and community settings, and current pipeline [9] .Age of superbugsTo fight against increasing prevalence of antibiotic-resistant superbugs and to limit the indiscriminate use of antibiotics, WHO prepared three groups of antibiotics namely ACCESS, WATCH, and RESERVE group to ensure appropriate prescription and use.", [["superbugs", "DISEASE", 437, 446], ["pathogens", "PROBLEM", 35, 44], ["multicriteria decision analysis technique", "TEST", 66, 107], ["AMR pathogens", "PROBLEM", 123, 136], ["antibiotic", "TREATMENT", 416, 426], ["resistant superbugs", "PROBLEM", 427, 446], ["antibiotics", "TREATMENT", 486, 497], ["antibiotics", "TREATMENT", 528, 539]]], ["Access group comprises of antibiotics which are prescribe as in common infection as first and second choice.", [["infection", "DISEASE", 71, 80], ["antibiotics", "TREATMENT", 26, 37], ["common infection", "PROBLEM", 64, 80], ["infection", "OBSERVATION", 71, 80]]], ["The first-choice antibiotics are narrow spectrum with low-resistant potential, whereas the second-choice antibiotics are broad spectrum having higher resistant potential.", [["The first-choice antibiotics", "TREATMENT", 0, 28], ["antibiotics", "TREATMENT", 105, 116], ["low-resistant", "OBSERVATION_MODIFIER", 54, 67], ["higher resistant", "OBSERVATION_MODIFIER", 143, 159]]], ["Antibiotics such as \u03b2-lactam, chloramphenicol, and clindamycin come under this category.", [["\u03b2-lactam", "CHEMICAL", 20, 28], ["chloramphenicol", "CHEMICAL", 30, 45], ["clindamycin", "CHEMICAL", 51, 62], ["\u03b2-lactam", "CHEMICAL", 20, 28], ["chloramphenicol", "CHEMICAL", 30, 45], ["clindamycin", "CHEMICAL", 51, 62], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 20, 28], ["chloramphenicol", "SIMPLE_CHEMICAL", 30, 45], ["clindamycin", "SIMPLE_CHEMICAL", 51, 62], ["Antibiotics", "TREATMENT", 0, 11], ["\u03b2-lactam", "TREATMENT", 20, 28], ["chloramphenicol", "TREATMENT", 30, 45], ["clindamycin", "TREATMENT", 51, 62]]], ["Watch group identifies pharmacological antibiotic classes which prescribes as first or second choice but have a limited number of indication.", [["pharmacological antibiotic classes", "TREATMENT", 23, 57]]], ["The watch group has higher resistance potential compared with the access group.", [["higher resistance", "OBSERVATION_MODIFIER", 20, 37]]], ["Watch group comprises macrolides, quinolones and fluoroquinolones, and glycopeptides class of antibiotics [29] .Age of superbugsWHO created reserve group of antibiotics to reserve some antibiotics as the last resort in superbug infection.", [["macrolides", "CHEMICAL", 22, 32], ["quinolones", "CHEMICAL", 34, 44], ["fluoroquinolones", "CHEMICAL", 49, 65], ["infection", "DISEASE", 228, 237], ["macrolides", "CHEMICAL", 22, 32], ["quinolones", "CHEMICAL", 34, 44], ["fluoroquinolones", "CHEMICAL", 49, 65], ["macrolides", "SIMPLE_CHEMICAL", 22, 32], ["quinolones", "SIMPLE_CHEMICAL", 34, 44], ["fluoroquinolones", "SIMPLE_CHEMICAL", 49, 65], ["macrolides", "TREATMENT", 22, 32], ["quinolones", "TREATMENT", 34, 44], ["fluoroquinolones", "TREATMENT", 49, 65], ["glycopeptides class of antibiotics", "TREATMENT", 71, 105], ["antibiotics", "TREATMENT", 157, 168], ["some antibiotics", "TREATMENT", 180, 196], ["superbug infection", "PROBLEM", 219, 237], ["infection", "OBSERVATION", 228, 237]]], ["This group of antibiotics should be recommended as \"last resort,\" in case of life-threatening infection when other alternatives are failed in treatment.", [["infection", "DISEASE", 94, 103], ["antibiotics", "TREATMENT", 14, 25], ["life-threatening infection", "PROBLEM", 77, 103], ["treatment", "TREATMENT", 142, 151], ["infection", "OBSERVATION", 94, 103]]], ["Reserve groups include eight antibiotic or antibiotic class which are aztreonam, fosfomycin, fourth-generation cephalosporins (cefepime), oxazolidinones (linezolid), fifth-generation cephalosporins (ceftaroline), tigecycline, polymyxins (polymyxin-B, colistin), and daptomycin [6] .", [["aztreonam", "CHEMICAL", 70, 79], ["fosfomycin", "CHEMICAL", 81, 91], ["cephalosporins", "CHEMICAL", 111, 125], ["cefepime", "CHEMICAL", 127, 135], ["oxazolidinones", "CHEMICAL", 138, 152], ["linezolid", "CHEMICAL", 154, 163], ["cephalosporins", "CHEMICAL", 183, 197], ["ceftaroline", "CHEMICAL", 199, 210], ["tigecycline", "CHEMICAL", 213, 224], ["polymyxins", "CHEMICAL", 226, 236], ["polymyxin-B", "CHEMICAL", 238, 249], ["colistin", "CHEMICAL", 251, 259], ["daptomycin", "CHEMICAL", 266, 276], ["aztreonam", "CHEMICAL", 70, 79], ["fosfomycin", "CHEMICAL", 81, 91], ["cephalosporins", "CHEMICAL", 111, 125], ["cefepime", "CHEMICAL", 127, 135], ["oxazolidinones", "CHEMICAL", 138, 152], ["linezolid", "CHEMICAL", 154, 163], ["cephalosporins", "CHEMICAL", 183, 197], ["ceftaroline", "CHEMICAL", 199, 210], ["tigecycline", "CHEMICAL", 213, 224], ["polymyxins", "CHEMICAL", 226, 236], ["polymyxin-B", "CHEMICAL", 238, 249], ["colistin", "CHEMICAL", 251, 259], ["daptomycin", "CHEMICAL", 266, 276], ["aztreonam", "SIMPLE_CHEMICAL", 70, 79], ["fosfomycin", "SIMPLE_CHEMICAL", 81, 91], ["fourth-generation cephalosporins", "SIMPLE_CHEMICAL", 93, 125], ["cefepime", "SIMPLE_CHEMICAL", 127, 135], ["oxazolidinones", "SIMPLE_CHEMICAL", 138, 152], ["linezolid", "SIMPLE_CHEMICAL", 154, 163], ["fifth-generation cephalosporins", "SIMPLE_CHEMICAL", 166, 197], ["ceftaroline", "SIMPLE_CHEMICAL", 199, 210], ["tigecycline", "SIMPLE_CHEMICAL", 213, 224], ["polymyxins", "SIMPLE_CHEMICAL", 226, 236], ["polymyxin-B", "SIMPLE_CHEMICAL", 238, 249], ["colistin", "SIMPLE_CHEMICAL", 251, 259], ["daptomycin", "SIMPLE_CHEMICAL", 266, 276], ["Reserve groups", "TREATMENT", 0, 14], ["eight antibiotic", "TREATMENT", 23, 39], ["antibiotic class", "TREATMENT", 43, 59], ["aztreonam", "TREATMENT", 70, 79], ["fosfomycin", "TREATMENT", 81, 91], ["fourth-generation cephalosporins", "TREATMENT", 93, 125], ["cefepime)", "TREATMENT", 127, 136], ["oxazolidinones", "TREATMENT", 138, 152], ["linezolid", "TREATMENT", 154, 163], ["fifth-generation cephalosporins", "TREATMENT", 166, 197], ["ceftaroline", "TREATMENT", 199, 210], ["tigecycline", "TREATMENT", 213, 224], ["polymyxins", "TREATMENT", 226, 236], ["polymyxin", "TREATMENT", 238, 247], ["colistin", "TREATMENT", 251, 259], ["daptomycin", "TREATMENT", 266, 276]]], ["Recently, among these eight antibiotic classes, resistant determinant against colistin was detected in people of rural Vietnam.", [["colistin", "CHEMICAL", 78, 86], ["colistin", "CHEMICAL", 78, 86], ["colistin", "SIMPLE_CHEMICAL", 78, 86], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["these eight antibiotic classes", "TREATMENT", 16, 46], ["colistin", "TREATMENT", 78, 86]]], ["The prevalence of colistin resistant Escherichia coli in intestine of resident of Vietnam was extremely high, that is, approximately 70%.", [["intestine", "ANATOMY", 57, 66], ["colistin", "CHEMICAL", 18, 26], ["colistin", "CHEMICAL", 18, 26], ["colistin", "SIMPLE_CHEMICAL", 18, 26], ["Escherichia coli", "ORGANISM", 37, 53], ["intestine", "ORGAN", 57, 66], ["Escherichia coli", "SPECIES", 37, 53], ["Escherichia coli", "SPECIES", 37, 53], ["colistin resistant Escherichia coli", "PROBLEM", 18, 53], ["colistin", "OBSERVATION_MODIFIER", 18, 26], ["resistant", "OBSERVATION_MODIFIER", 27, 36], ["Escherichia coli", "OBSERVATION", 37, 53], ["intestine", "ANATOMY", 57, 66], ["high", "OBSERVATION_MODIFIER", 104, 108]]], ["Previously, mutation that causes colistin resistant was not transferable; thus it is not considered as pathogenic, as intestinal E. coli is nonpathogenic.", [["colistin", "CHEMICAL", 33, 41], ["colistin", "CHEMICAL", 33, 41], ["colistin", "SIMPLE_CHEMICAL", 33, 41], ["intestinal E. coli", "ORGANISM", 118, 136], ["E. coli", "SPECIES", 129, 136], ["E. coli", "SPECIES", 129, 136], ["mutation", "PROBLEM", 12, 20], ["colistin resistant", "PROBLEM", 33, 51], ["pathogenic", "PROBLEM", 103, 113], ["intestinal E. coli", "PROBLEM", 118, 136], ["nonpathogenic", "PROBLEM", 140, 153], ["colistin resistant", "OBSERVATION_MODIFIER", 33, 51], ["not considered", "UNCERTAINTY", 85, 99], ["intestinal", "ANATOMY", 118, 128], ["E. coli", "OBSERVATION", 129, 136], ["nonpathogenic", "OBSERVATION_MODIFIER", 140, 153]]], ["Finally, a transmissible colistin resistance gene (mcr) was detected in China, which has the potential to transfer colistin resistant to pathogenic microbes.", [["colistin", "CHEMICAL", 25, 33], ["colistin", "CHEMICAL", 115, 123], ["colistin", "CHEMICAL", 25, 33], ["colistin", "CHEMICAL", 115, 123], ["colistin", "SIMPLE_CHEMICAL", 25, 33], ["mcr", "GENE_OR_GENE_PRODUCT", 51, 54], ["colistin", "SIMPLE_CHEMICAL", 115, 123], ["transmissible colistin resistance gene", "DNA", 11, 49], ["mcr", "DNA", 51, 54], ["a transmissible colistin resistance gene (mcr", "TREATMENT", 9, 54], ["colistin", "TREATMENT", 115, 123], ["pathogenic microbes", "PROBLEM", 137, 156], ["colistin resistance", "OBSERVATION", 25, 44]]], ["The prevalence of mcr gene represents a serious concern regarding the emergence of superbugs that are resistant to last resort of antibiotic [30] .", [["superbugs", "DISEASE", 83, 92], ["mcr", "GENE_OR_GENE_PRODUCT", 18, 21], ["mcr gene", "DNA", 18, 26], ["antibiotic", "TREATMENT", 130, 140]]], ["Currently, there are only fewer option (such as last resort antibiotics) to tackle antibiotic-resistant superbugs, and the finding of mcr gene indicates toward the needs of innovative research which results in better understanding of superbug emergence and also to research and development on quality, safe, efficacious, and affordable antimicrobial medicines, especially new antibiotics and alternative therapies, vaccines, and diagnostics.ThreatsThe various chapters of this book discussed about the occurrence and prevalence of human and veterinary pharmaceuticals (antibiotics, antidepressant, antidiabetic, radioactive agents, etc.) at different environmental sites.", [["superbugs", "DISEASE", 104, 113], ["antidepressant", "CHEMICAL", 582, 596], ["mcr", "GENE_OR_GENE_PRODUCT", 134, 137], ["human", "ORGANISM", 531, 536], ["radioactive agents", "SIMPLE_CHEMICAL", 612, 630], ["mcr gene", "DNA", 134, 142], ["human", "SPECIES", 531, 536], ["human", "SPECIES", 531, 536], ["antibiotics", "TREATMENT", 60, 71], ["tackle antibiotic", "TREATMENT", 76, 93], ["resistant superbugs", "PROBLEM", 94, 113], ["affordable antimicrobial medicines", "TREATMENT", 325, 359], ["new antibiotics", "TREATMENT", 372, 387], ["alternative therapies", "TREATMENT", 392, 413], ["vaccines", "TREATMENT", 415, 423], ["diagnostics", "TEST", 429, 440], ["human and veterinary pharmaceuticals", "TREATMENT", 531, 567], ["antibiotics", "TREATMENT", 569, 580], ["antidepressant", "TREATMENT", 582, 596], ["antidiabetic", "TREATMENT", 598, 610], ["radioactive agents", "TREATMENT", 612, 630]]], ["These pharmaceutical compounds are biologically active compounds that are known to have a specific mode of action (MOA) in human and animals even at low concentration.", [["human", "ORGANISM", 123, 128], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128]]], ["Due to genetic relatedness (presence of conserved gene) across species, these compounds interact with protein and cell lineage of nontarget organisms (conserved therapeutic drug targets) and elicit a response in their body (targets metabolic pathway, enzyme or mediators of cell signaling molecule).", [["cell lineage", "ANATOMY", 114, 126], ["body", "ANATOMY", 218, 222], ["cell", "ANATOMY", 274, 278], ["cell", "CELL", 114, 118], ["body", "ORGANISM_SUBDIVISION", 218, 222], ["cell", "CELL", 274, 278], ["cell signaling molecule", "PROTEIN", 274, 297], ["genetic relatedness", "PROBLEM", 7, 26], ["conserved gene) across species", "PROBLEM", 40, 70], ["nontarget organisms", "PROBLEM", 130, 149], ["metabolic pathway", "TEST", 232, 249], ["enzyme", "TEST", 251, 257], ["cell signaling molecule", "PROBLEM", 274, 297]]], ["For instance, ibuprofen which is a cyclooxygenase inhibitor was found to interfere with arachidonic acid signaling pathway in marine clams Ruditapes philippinarum [31] .", [["ibuprofen", "CHEMICAL", 14, 23], ["arachidonic acid", "CHEMICAL", 88, 104], ["ibuprofen", "CHEMICAL", 14, 23], ["arachidonic acid", "CHEMICAL", 88, 104], ["ibuprofen", "SIMPLE_CHEMICAL", 14, 23], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 35, 49], ["arachidonic acid", "SIMPLE_CHEMICAL", 88, 104], ["Ruditapes philippinarum", "SPECIES", 139, 162], ["Ruditapes philippinarum", "SPECIES", 139, 162], ["ibuprofen", "TREATMENT", 14, 23], ["a cyclooxygenase inhibitor", "TREATMENT", 33, 59], ["arachidonic acid signaling pathway", "TREATMENT", 88, 122]]], ["However, the effect of pharmaceuticals may vary from species to species due to difference in gene expression of the same gene across species or due to change in solubility or potency of drugs because of binding of pharmaceuticals with organic molecules present at environmental sites.", [["pharmaceuticals", "TREATMENT", 23, 38], ["species to species", "PROBLEM", 53, 71], ["the same gene across species", "PROBLEM", 112, 140], ["change in solubility", "PROBLEM", 151, 171], ["drugs", "TREATMENT", 186, 191], ["binding of pharmaceuticals", "PROBLEM", 203, 229], ["organic molecules", "PROBLEM", 235, 252], ["organic molecules", "OBSERVATION", 235, 252]]], ["Therefore to understand the environmental risk posed by these contaminants, conceptual model of MOA of pharmaceuticals was used.", [["MOA of pharmaceuticals", "TREATMENT", 96, 118]]], ["The MOA [15] approach involves the assessment of drug targets and its evolution between mammals and the model species.", [["the assessment", "TEST", 31, 45], ["drug targets", "PROBLEM", 49, 61], ["model species", "OBSERVATION", 104, 117]]], ["The conceptual model of MOA approach in marine organisms reveals the presence of fluoxetine at environmental concentration was able to control the serotonin signaling pathway, and this alteration in physiological signaling pathway results in defects in reproduction, locomotion, and metabolism of aquatic organisms [31] .", [["fluoxetine", "CHEMICAL", 81, 91], ["serotonin", "CHEMICAL", 147, 156], ["fluoxetine", "CHEMICAL", 81, 91], ["serotonin", "CHEMICAL", 147, 156], ["fluoxetine", "SIMPLE_CHEMICAL", 81, 91], ["serotonin", "GENE_OR_GENE_PRODUCT", 147, 156], ["fluoxetine", "TREATMENT", 81, 91], ["the serotonin signaling pathway", "PROBLEM", 143, 174], ["this alteration in physiological signaling pathway", "PROBLEM", 180, 230], ["defects in reproduction", "PROBLEM", 242, 265], ["aquatic organisms", "PROBLEM", 297, 314], ["defects", "OBSERVATION", 242, 249]]], ["Many short-term toxicity studies reported that the drug molecules do not have an acute toxic effect on aquatic organisms because of their presence in low concentration (ng/L to low \u03bcg/L), but their constant release and exposure to aquatic biota have long-term chronic effects [32, 33] .", [["toxicity", "DISEASE", 16, 24], ["Many short-term toxicity studies", "PROBLEM", 0, 32], ["the drug molecules", "PROBLEM", 47, 65], ["an acute toxic effect", "PROBLEM", 78, 99], ["aquatic organisms", "PROBLEM", 103, 120], ["long-term chronic effects", "PROBLEM", 250, 275], ["short-term toxicity", "OBSERVATION_MODIFIER", 5, 24], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["toxic", "OBSERVATION", 87, 92], ["long-term chronic", "OBSERVATION_MODIFIER", 250, 267]]], ["However, many laboratory studies at high concentration of pharmaceutical compounds report direct lethal effects.", [["many laboratory studies", "TEST", 9, 32], ["pharmaceutical compounds", "TREATMENT", 58, 82]]], ["Tetracycline concentration around 10\u00c0100 \u03bcg/L leads to low periphyton (nematode, bacteria, and algae) concentration in mesocosm stream [34] .", [["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "SIMPLE_CHEMICAL", 0, 12], ["Tetracycline concentration", "TREATMENT", 0, 26], ["bacteria", "PROBLEM", 81, 89], ["low periphyton", "OBSERVATION_MODIFIER", 55, 69]]], ["Structure disruption in kidney and intestine of rainbow trout and brown trout due to diclofenac (5 \u03bcg/L) was reported [35] .", [["kidney", "ANATOMY", 24, 30], ["intestine", "ANATOMY", 35, 44], ["diclofenac", "CHEMICAL", 85, 95], ["diclofenac", "CHEMICAL", 85, 95], ["kidney", "ORGAN", 24, 30], ["intestine", "ORGAN", 35, 44], ["rainbow", "ORGANISM", 48, 55], ["trout", "ORGANISM", 56, 61], ["brown trout", "ORGANISM", 66, 77], ["diclofenac", "SIMPLE_CHEMICAL", 85, 95], ["rainbow trout", "SPECIES", 48, 61], ["brown trout", "SPECIES", 66, 77], ["rainbow trout", "SPECIES", 48, 61], ["brown trout", "SPECIES", 66, 77], ["Structure disruption in kidney and intestine of rainbow trout", "PROBLEM", 0, 61], ["diclofenac", "TREATMENT", 85, 95], ["disruption", "OBSERVATION", 10, 20], ["kidney", "ANATOMY", 24, 30], ["intestine", "ANATOMY", 35, 44], ["diclofenac", "OBSERVATION", 85, 95]]], ["Prolonged exposure to pharmaceuticals in low concentration leads to the change in species trait and behavior of aquatic organisms.", [["Prolonged exposure to pharmaceuticals", "TREATMENT", 0, 37], ["the change in species trait", "PROBLEM", 68, 95], ["aquatic organisms", "PROBLEM", 112, 129], ["low concentration", "OBSERVATION_MODIFIER", 41, 58], ["species trait", "OBSERVATION", 82, 95]]], ["Antidepressant and psychiatric drugs such as fluoxetine and oxazepam cause disruption in ecological interaction even in low concentration [9] .", [["Antidepressant", "CHEMICAL", 0, 14], ["psychiatric", "DISEASE", 19, 30], ["fluoxetine", "CHEMICAL", 45, 55], ["oxazepam", "CHEMICAL", 60, 68], ["fluoxetine", "CHEMICAL", 45, 55], ["oxazepam", "CHEMICAL", 60, 68], ["fluoxetine", "SIMPLE_CHEMICAL", 45, 55], ["oxazepam", "SIMPLE_CHEMICAL", 60, 68], ["Antidepressant", "TREATMENT", 0, 14], ["psychiatric drugs", "TREATMENT", 19, 36], ["fluoxetine", "TREATMENT", 45, 55], ["oxazepam", "TREATMENT", 60, 68]]], ["Indeed, even by considering that these drugs are diluted after their release, it is evident that they have a toxic effect on the aquatic ecosystem.ThreatsThe widespread occurrences of pharmaceuticals at various environmental sites such as in ocean, river, and groundwater raise a concern regarding the risk associated with human health.", [["human", "ORGANISM", 323, 328], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 323, 328], ["these drugs", "TREATMENT", 33, 44], ["a toxic effect on the aquatic ecosystem", "PROBLEM", 107, 146], ["toxic effect", "OBSERVATION", 109, 121], ["widespread", "OBSERVATION_MODIFIER", 158, 168], ["occurrences", "OBSERVATION_MODIFIER", 169, 180], ["pharmaceuticals", "OBSERVATION", 184, 199]]], ["For instance, the birth control and growth stimulator agent like estrogen have the potential to cause prostate and breast cancer in humans (If the estrogen concentration is used above the threshold limit).", [["prostate", "ANATOMY", 102, 110], ["breast cancer", "ANATOMY", 115, 128], ["estrogen", "CHEMICAL", 65, 73], ["prostate and breast cancer", "DISEASE", 102, 128], ["estrogen", "CHEMICAL", 147, 155], ["estrogen", "CHEMICAL", 65, 73], ["estrogen", "CHEMICAL", 147, 155], ["estrogen", "SIMPLE_CHEMICAL", 65, 73], ["prostate", "CANCER", 102, 110], ["breast cancer", "CANCER", 115, 128], ["humans", "ORGANISM", 132, 138], ["estrogen", "SIMPLE_CHEMICAL", 147, 155], ["humans", "SPECIES", 132, 138], ["humans", "SPECIES", 132, 138], ["the birth control", "TREATMENT", 14, 31], ["growth stimulator agent", "TREATMENT", 36, 59], ["prostate and breast cancer in humans", "PROBLEM", 102, 138], ["the estrogen concentration", "TREATMENT", 143, 169], ["prostate", "ANATOMY", 102, 110], ["breast", "ANATOMY", 115, 121], ["cancer", "OBSERVATION", 122, 128]]], ["The worldwide discharge of estrogen from livestock and human ranges approximately 86,000 and 30,000 kg/year, respectively.", [["estrogen", "CHEMICAL", 27, 35], ["estrogen", "CHEMICAL", 27, 35], ["estrogen", "SIMPLE_CHEMICAL", 27, 35], ["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["The US National Toxicology Program declared estrogen as carcinogen, the no adverse effect concentration of estrogen in human is 0.3 mg/day and frequent detection of estrogen in drinking water concentration ranging from 0.1 to 2.0 ng/L represent a health risk [33] .", [["estrogen", "CHEMICAL", 44, 52], ["estrogen", "CHEMICAL", 107, 115], ["estrogen", "CHEMICAL", 165, 173], ["estrogen", "CHEMICAL", 44, 52], ["estrogen", "CHEMICAL", 107, 115], ["estrogen", "CHEMICAL", 165, 173], ["estrogen", "SIMPLE_CHEMICAL", 44, 52], ["estrogen", "SIMPLE_CHEMICAL", 107, 115], ["human", "ORGANISM", 119, 124], ["estrogen", "SIMPLE_CHEMICAL", 165, 173], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["estrogen in human", "TREATMENT", 107, 124], ["estrogen in drinking water concentration", "TREATMENT", 165, 205]]], ["Estrogen was reported to cause abnormalities in animals such as permanent infertility (clover disease in sheep due to feeding on clover plant which has high phytoestrogen level) [33] .", [["permanent infertility", "DISEASE", 64, 85], ["clover disease", "DISEASE", 87, 101], ["phytoestrogen", "CHEMICAL", 157, 170], ["Estrogen", "CHEMICAL", 0, 8], ["phytoestrogen", "CHEMICAL", 157, 170], ["Estrogen", "GENE_OR_GENE_PRODUCT", 0, 8], ["clover", "ORGANISM_SUBDIVISION", 87, 93], ["sheep", "ORGANISM", 105, 110], ["phytoestrogen", "SIMPLE_CHEMICAL", 157, 170], ["sheep", "SPECIES", 105, 110], ["sheep", "SPECIES", 105, 110], ["Estrogen", "TREATMENT", 0, 8], ["abnormalities in animals", "PROBLEM", 31, 55], ["permanent infertility", "PROBLEM", 64, 85], ["clover disease in sheep", "PROBLEM", 87, 110]]], ["However, human health risk assessment studies reported no appreciable risk to human due to exposure of pharmaceuticals mixture [32] .Required research action and proposed remediesDue to emergence of antibiotic-resistant pathogens and unavoidable use of antibiotics, concomitant environmental perturbation caused by climate change might make the earth is not suitable for humans and other livings.", [["human", "ORGANISM", 9, 14], ["human", "ORGANISM", 78, 83], ["humans", "ORGANISM", 371, 377], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 371, 377], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 371, 377], ["human health risk assessment studies", "TEST", 9, 45], ["exposure of pharmaceuticals mixture", "TREATMENT", 91, 126], ["research action", "TREATMENT", 142, 157], ["proposed remedies", "TREATMENT", 162, 179], ["antibiotic", "TREATMENT", 199, 209], ["resistant pathogens", "PROBLEM", 210, 229], ["antibiotics", "TREATMENT", 253, 264], ["concomitant environmental perturbation", "PROBLEM", 266, 304]]], ["Thus researchers focus on finding alternative methods to avoid use of antibiotics and developing novel treatment technologies to degrade and remove the pharmaceutical compounds.Prediction of emergence microbesPrediction of emerging signals by theoretical and bioinformatics tool will highly help to alarm the researchers, hospitals, and public about the nearby occurrence of resistant bug.", [["antibiotics", "TREATMENT", 70, 81], ["novel treatment technologies", "TREATMENT", 97, 125], ["bioinformatics tool", "TEST", 259, 278], ["resistant bug", "PROBLEM", 375, 388], ["pharmaceutical compounds", "OBSERVATION", 152, 176]]], ["Such predictions are underway by monitoring microbial community dynamics in different environmental samples; however, these studies facing enormous challenges in the developmental face [28,36\u00c043] .", [["community", "ANATOMY", 54, 63], ["these studies", "TEST", 118, 131]]], ["Several research studies have been conducted to observe a change in microbial metabolic pathways for a while.", [["Several research studies", "TEST", 0, 24], ["a change in microbial metabolic pathways", "PROBLEM", 56, 96]]], ["Such study results could predict microbial interactions and route of evolution, and might apply to precisely pinpoint the emerging organism in the mixed microbial community.", [["Such study", "TEST", 0, 10]]], ["These studies are still under research stage, such studies are using genomic, metabolomic, and trancsriptomic tools to predict the bug emergence.", [["These studies", "TEST", 0, 13], ["such studies", "TEST", 46, 58], ["genomic, metabolomic, and trancsriptomic tools", "PROBLEM", 69, 115]]], ["Recently, Geoghegan and Holmes [44] attempted predicting the virus emergence with an interest of biomedicine and preventing unpredicted incidence [44] .", [["the virus emergence", "TREATMENT", 57, 76]]], ["They have monitored the evolution of viruses in short-term period to highlight the cross-species transmission and emergence.", [["viruses", "PROBLEM", 37, 44], ["viruses", "OBSERVATION", 37, 44], ["short-term", "OBSERVATION_MODIFIER", 48, 58]]], ["They have concluded that predicting emergence requires a new mechanistic and integrated approach, which might permit or stop the emerging viral spread into new hosts [44] .World Health Organization's global action plan-resistant bacteriaWith the fact that microbial resistant to pharmaceuticals, the treatment options are reduced; however, alternative methods have been explored to protect human and animal from microbial illness.", [["microbial illness", "DISEASE", 412, 429], ["human", "ORGANISM", 390, 395], ["human", "SPECIES", 390, 395], ["human", "SPECIES", 390, 395], ["a new mechanistic and integrated approach", "TREATMENT", 55, 96], ["resistant bacteriaWith", "PROBLEM", 219, 241], ["pharmaceuticals", "TREATMENT", 279, 294], ["the treatment options", "TREATMENT", 296, 317], ["alternative methods", "TREATMENT", 340, 359], ["microbial illness", "PROBLEM", 412, 429], ["microbial resistant", "OBSERVATION_MODIFIER", 256, 275]]], ["The microbial drug resistance leads to direct and indirect consequences as described by WHO report 2015 [45] .", [["The microbial drug resistance", "TREATMENT", 0, 29], ["microbial", "OBSERVATION", 4, 13], ["drug resistance", "OBSERVATION", 14, 29]]], ["The severe direct consequences are prolonged illness, impossible to protect the patients undergoing surgery and augmented treatment cost.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["The severe direct consequences", "PROBLEM", 0, 30], ["prolonged illness", "PROBLEM", 35, 52], ["surgery", "TREATMENT", 100, 107], ["augmented treatment cost", "TREATMENT", 112, 136], ["severe", "OBSERVATION_MODIFIER", 4, 10]]], ["Whereas the indirect impacts of AMR are depleting the global economy (due to the loss of productivity by sickness) and higher costs of treatment.", [["AMR", "DISEASE", 32, 35], ["sickness", "DISEASE", 105, 113], ["AMR", "PROBLEM", 32, 35], ["the loss of productivity", "PROBLEM", 77, 101], ["sickness", "PROBLEM", 105, 113], ["treatment", "TREATMENT", 135, 144], ["impacts", "OBSERVATION_MODIFIER", 21, 28], ["AMR", "OBSERVATION_MODIFIER", 32, 35], ["global", "OBSERVATION_MODIFIER", 54, 60], ["economy", "OBSERVATION_MODIFIER", 61, 68]]], ["Thus WHO proposed a global action plan to assure preventing the transmission of infectious disease and providing complete treatment with the help of safe and effective medicines [45] .", [["infectious disease", "DISEASE", 80, 98], ["infectious disease", "PROBLEM", 80, 98], ["complete treatment", "TREATMENT", 113, 131], ["safe and effective medicines", "TREATMENT", 149, 177], ["infectious", "OBSERVATION", 80, 90]]], ["To achieve the global action plan successfully, five objectives have been proposed by WHO: (1) to improve awareness and understanding of AMR; (2) to strengthen knowledge through surveillance and research;World Health Organization's global action plan-resistant bacteria(3) to reduce the incidence of infection; (4) to optimize the use of antimicrobial agents; and (5) to ensure sustainable investment in countering AMR.", [["AMR", "DISEASE", 137, 140], ["infection", "DISEASE", 300, 309], ["AMR", "DISEASE", 415, 418], ["AMR", "PROBLEM", 137, 140], ["resistant bacteria", "PROBLEM", 251, 269], ["infection", "PROBLEM", 300, 309], ["antimicrobial agents", "TREATMENT", 338, 358], ["infection", "OBSERVATION", 300, 309]]], ["These objectives are likely to be met through political leaders, Member States, the Secretariat, and international and national partners across multiple sectors.", [["likely to be", "UNCERTAINTY", 21, 33]]], ["Notably, individual responsibilities like recycling unused medicines, intake of only prescribed medicines, and keeping the environment clean would highly help to achieve the WHO's global action plan for the betterment of human and animal health.Phage therapy to fight against multidrug-resistant pathogensIncreasing resistance to antibiotics and the emergence of \"superbugs\" that are resistant to drugs of last resort have highlighted the great need for alternative treatments of bacterial disease.", [["bacterial disease", "DISEASE", 480, 497], ["human", "ORGANISM", 221, 226], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["recycling unused medicines", "TREATMENT", 42, 68], ["medicines", "TREATMENT", 96, 105], ["Phage therapy", "TREATMENT", 245, 258], ["multidrug-resistant pathogens", "PROBLEM", 276, 305], ["antibiotics", "TREATMENT", 330, 341], ["drugs", "TREATMENT", 397, 402], ["alternative treatments", "TREATMENT", 454, 476], ["bacterial disease", "PROBLEM", 480, 497], ["bacterial disease", "OBSERVATION", 480, 497]]], ["This has led to renewed interest in the potential of phage to treat bacterial pathogens.", [["phage", "TREATMENT", 53, 58], ["bacterial pathogens", "PROBLEM", 68, 87]]], ["The term \"phage therapy\" usually refers to the treatment of bacterial infections with intact phage; however, there are other ways in which phage can be used as antibacterials.Therapy delivery systemsPhage can be used as \"lethal agent delivery systems\" to introduce nonspecific or toxic antimicrobials [46, 47] , or genes encoding antimicrobials [48] into selected pathogenic bacteria.", [["bacterial infections", "DISEASE", 60, 80], ["The term \"phage therapy", "TREATMENT", 0, 23], ["bacterial infections", "PROBLEM", 60, 80], ["intact phage", "TREATMENT", 86, 98], ["antibacterials", "TREATMENT", 160, 174], ["Therapy delivery systems", "TREATMENT", 175, 199], ["Phage", "TREATMENT", 199, 204], ["lethal agent delivery systems", "TREATMENT", 221, 250], ["nonspecific or toxic antimicrobials", "PROBLEM", 265, 300], ["selected pathogenic bacteria", "PROBLEM", 355, 383], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["infections", "OBSERVATION", 70, 80], ["intact phage", "OBSERVATION_MODIFIER", 86, 98]]], ["In another method (targeted gene transfer), filamentous phage can be modified to carry therapeutic genes and to target cell surface antigens or receptors on mammalian cells, transducing them by receptor-mediated endocytosis [49] .", [["cell surface", "ANATOMY", 119, 131], ["cells", "ANATOMY", 167, 172], ["cell", "CELL", 119, 123], ["mammalian cells", "CELL", 157, 172], ["cell surface antigens", "PROTEIN", 119, 140], ["mammalian cells", "CELL_TYPE", 157, 172], ["filamentous phage", "TREATMENT", 44, 61], ["mammalian cells", "TREATMENT", 157, 172]]], ["Although phages are not an antimicrobial tool in itself, this approach could be used to deliver antimicrobials to intracellular bacterial pathogens.Lytic enzymesPhage secrets lysins enzymes which lyse the host bacteria.", [["intracellular", "ANATOMY", 114, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["lysins", "GENE_OR_GENE_PRODUCT", 175, 181], ["Lytic enzymes", "PROTEIN", 148, 161], ["lysins enzymes", "PROTEIN", 175, 189], ["phages", "PROBLEM", 9, 15], ["this approach", "TREATMENT", 57, 70], ["antimicrobials", "TREATMENT", 96, 110], ["intracellular bacterial pathogens", "PROBLEM", 114, 147], ["Lytic enzymes", "TEST", 148, 161], ["Phage secrets lysins enzymes", "TEST", 161, 189], ["the host bacteria", "PROBLEM", 201, 218], ["bacterial pathogens", "OBSERVATION", 128, 147], ["host bacteria", "OBSERVATION", 205, 218]]], ["Lysins are host specific and use cell wall components that are essential for viability as receptors; therefore bacterial resistance is rare [50] .", [["cell wall", "ANATOMY", 33, 42], ["Lysins", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell", "CELL", 33, 37], ["cell wall components", "TREATMENT", 33, 53], ["bacterial resistance", "PROBLEM", 111, 131], ["bacterial resistance", "OBSERVATION", 111, 131]]], ["Initial tests of lysins against clinically relevant Gram-positive bacteria, such as methicillin-resistance Staphylococcus aureus, look promising [51, 52] .", [["methicillin", "CHEMICAL", 84, 95], ["Staphylococcus aureus", "DISEASE", 107, 128], ["methicillin", "CHEMICAL", 84, 95], ["methicillin-resistance Staphylococcus aureus", "ORGANISM", 84, 128], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Initial tests of lysins", "TEST", 0, 23], ["Gram-positive bacteria", "PROBLEM", 52, 74], ["methicillin-resistance Staphylococcus aureus", "PROBLEM", 84, 128], ["positive bacteria", "OBSERVATION", 57, 74], ["Staphylococcus aureus", "OBSERVATION", 107, 128]]], ["The use of multiple phage lysins with different cleavage sites could increase therapeutic effectiveness and further reduce the chance of bacteria developing resistance.", [["multiple phage lysins", "TREATMENT", 11, 32], ["different cleavage sites", "TREATMENT", 38, 62], ["bacteria developing resistance", "PROBLEM", 137, 167], ["bacteria", "OBSERVATION", 137, 145]]], ["Lysins can also be used to make bacterial ghost vaccines.Pathogen removal in treated effluentTo produce better quality of treated sludge, wastewater treatment processes must achieve a minimum 6 log reduction in E. coli loads and a final end product (sludge) with a maximum admissible concentration of E. coli 1 3 10 3 CFU/g [dry solids (DS)] and zero Salmonella in 2 g (DS).", [["Lysins", "CHEMICAL", 0, 6], ["Lysins", "SIMPLE_CHEMICAL", 0, 6], ["E. coli", "ORGANISM", 211, 218], ["E. coli", "SPECIES", 211, 218], ["E. coli", "SPECIES", 301, 308], ["E. coli", "SPECIES", 211, 218], ["E. coli", "SPECIES", 301, 308], ["Lysins", "TREATMENT", 0, 6], ["bacterial ghost vaccines", "TREATMENT", 32, 56], ["Pathogen removal", "TREATMENT", 57, 73], ["treated sludge", "PROBLEM", 122, 136], ["wastewater treatment processes", "TREATMENT", 138, 168], ["a minimum 6 log reduction", "TREATMENT", 182, 207], ["E. coli loads", "PROBLEM", 211, 224], ["a maximum admissible concentration of E. coli", "TREATMENT", 263, 308], ["DS", "TEST", 337, 339], ["zero Salmonella", "PROBLEM", 346, 361], ["effluent", "OBSERVATION_MODIFIER", 85, 93], ["sludge", "OBSERVATION", 130, 136], ["coli loads", "OBSERVATION", 214, 224], ["sludge", "OBSERVATION", 250, 256]]], ["Similarly, United States Environmental Protection Agency regulations are categorized into Class A and Class B sludges.", [["sludges", "OBSERVATION", 110, 117]]], ["Class A pathogen reduction requirements are more stringent than those of Class B sludges which are subject to application restrictions.", [["A pathogen reduction requirements", "TREATMENT", 6, 39], ["Class B sludges", "PROBLEM", 73, 88], ["pathogen", "OBSERVATION_MODIFIER", 8, 16], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["sludges", "OBSERVATION", 81, 88]]], ["Class A sludges are required to reduce pathogens to below the detectable limit (,3 most probable number of Salmonella, ,1 plaque forming unit of enteric viruses, and ,1 viable helminth ovum per 4 g DS).", [["plaque", "ANATOMY", 122, 128], ["Class A sludges", "TREATMENT", 0, 15], ["pathogens", "PROBLEM", 39, 48], ["Salmonella", "PROBLEM", 107, 117], ["enteric viruses", "TREATMENT", 145, 160], ["sludges", "OBSERVATION", 8, 15], ["Salmonella", "OBSERVATION", 107, 117], ["enteric viruses", "ANATOMY", 145, 160]]], ["Treatment processes designed to achieve pathogen reduction to a required level can incur substantial capital and operating costs [53] .", [["Treatment processes", "TREATMENT", 0, 19], ["pathogen reduction", "TREATMENT", 40, 58]]], ["Development of phage treatment of sludge may provide long-term and cost-effective control of potentially pathogenic bacteria (e.g., E. coli and Salmonella).", [["E. coli", "ORGANISM", 132, 139], ["Salmonella)", "ORGANISM", 144, 155], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 132, 139], ["phage treatment", "TREATMENT", 15, 30], ["sludge", "PROBLEM", 34, 40], ["long-term", "TREATMENT", 53, 62], ["pathogenic bacteria", "PROBLEM", 105, 124], ["E. coli", "PROBLEM", 132, 139], ["Salmonella", "PROBLEM", 144, 154], ["phage treatment", "OBSERVATION", 15, 30], ["sludge", "OBSERVATION", 34, 40], ["long-term", "OBSERVATION_MODIFIER", 53, 62]]], ["Successful phage treatment of wastewater bacterial pathogens would be dependent on the prevalence and diversity of pathogen species within wastewater.", [["Successful phage treatment", "TREATMENT", 0, 26], ["wastewater bacterial pathogens", "PROBLEM", 30, 60], ["pathogen species", "PROBLEM", 115, 131], ["wastewater bacterial pathogens", "OBSERVATION", 30, 60], ["pathogen species", "OBSERVATION", 115, 131]]], ["It would be virtually impossible to produce phage targeted at all pathogenic serotypes.", [["phage", "PROBLEM", 44, 49], ["pathogenic serotypes", "OBSERVATION", 66, 86]]], ["For example, there is a high diversity of E. coli serotypes [54] and around 2400 known Salmonella serotypes [55] .", [["E. coli", "ORGANISM", 42, 49], ["E. coli", "SPECIES", 42, 49], ["E. coli", "SPECIES", 42, 49], ["E. coli serotypes", "PROBLEM", 42, 59], ["Salmonella serotypes", "PROBLEM", 87, 107], ["high", "OBSERVATION_MODIFIER", 24, 28], ["diversity", "OBSERVATION_MODIFIER", 29, 38], ["E. coli serotypes", "OBSERVATION", 42, 59], ["Salmonella serotypes", "OBSERVATION", 87, 107]]], ["However, wastewater treatment conditions intrinsically reduce the numbers of some pathogenic bacteria.", [["wastewater treatment conditions", "TREATMENT", 9, 40], ["some pathogenic bacteria", "PROBLEM", 77, 101], ["pathogenic bacteria", "OBSERVATION", 82, 101]]], ["Therefore there is potential for phage treatment to be used successfully in combination with biological sludge stabilization processes to reduce the abundance of specific pathogenic bacterial strains such as E. coli O157.", [["E. coli", "ORGANISM", 208, 215], ["O157", "ORGANISM", 216, 220], ["E. coli", "SPECIES", 208, 215], ["E. coli", "SPECIES", 208, 215], ["phage treatment", "TREATMENT", 33, 48], ["biological sludge stabilization processes", "TREATMENT", 93, 134], ["specific pathogenic bacterial strains", "PROBLEM", 162, 199], ["E. coli O157", "PROBLEM", 208, 220], ["potential for", "UNCERTAINTY", 19, 32], ["pathogenic", "OBSERVATION_MODIFIER", 171, 181], ["bacterial strains", "OBSERVATION", 182, 199], ["E. coli", "OBSERVATION", 208, 215]]], ["Indeed, research on phage therapy for reduction of this pathogen in animal reservoirs is already underway [53] .Phage and antibiotics mixed with polymer compositeAlthough phage-derived therapies have several advantages compared with antibiotics, the combined use of phage, or phage lysins, and antibiotics is an attractive treatment regime.", [["phage therapy", "TREATMENT", 20, 33], ["reduction", "TREATMENT", 38, 47], ["this pathogen", "PROBLEM", 51, 64], ["animal reservoirs", "TREATMENT", 68, 85], ["Phage", "TREATMENT", 112, 117], ["antibiotics", "TREATMENT", 122, 133], ["polymer composite", "TREATMENT", 145, 162], ["therapies", "TREATMENT", 185, 194], ["antibiotics", "TREATMENT", 233, 244], ["phage", "TREATMENT", 266, 271], ["phage lysins", "TREATMENT", 276, 288], ["antibiotics", "TREATMENT", 294, 305], ["an attractive treatment regime", "TREATMENT", 309, 339]]], ["Indeed, such a product is available commercially in Georgia: PhagoBioDerm is a biodegradable polymer composite impregnated with a lytic phage cocktail and ciprofloxacin [56] .", [["PhagoBioDerm", "CHEMICAL", 61, 73], ["ciprofloxacin", "CHEMICAL", 155, 168], ["ciprofloxacin", "CHEMICAL", 155, 168], ["PhagoBioDerm", "SIMPLE_CHEMICAL", 61, 73], ["ciprofloxacin", "SIMPLE_CHEMICAL", 155, 168], ["a biodegradable polymer composite", "TREATMENT", 77, 110], ["a lytic phage cocktail", "TREATMENT", 128, 150], ["ciprofloxacin", "TREATMENT", 155, 168]]], ["Using phage with antibiotics should increase the efficiency of treatment and reduce the emergence of resistant mutants because the surviving bacteria would need to acquire at least two separate resistance mechanisms.Phage and antibiotics mixed with polymer compositeTo kill the multidrug-resistant bacteria researchers from IBN (Institute of Bioengineering and Nanotechnology), Chin et al. [57] developed a novel synthetic molecule and demonstrated selectively destroying five multidrug-resistant bacteria [57] .", [["phage", "TREATMENT", 6, 11], ["antibiotics", "TREATMENT", 17, 28], ["treatment", "TREATMENT", 63, 72], ["resistant mutants", "PROBLEM", 101, 118], ["the surviving bacteria", "PROBLEM", 127, 149], ["Phage", "TREATMENT", 216, 221], ["antibiotics", "TREATMENT", 226, 237], ["polymer composite", "TREATMENT", 249, 266], ["a novel synthetic molecule", "PROBLEM", 405, 431], ["selectively destroying five multidrug-resistant bacteria", "PROBLEM", 449, 505]]], ["Recently polymer-based advanced drug designing to combat multidrug resistances is widely explored, which are described in detail [58, 59] .Effect of global warming on pathogens survivalDue to climate change, a steady increase in temperature (about 0.75 C) was recorded in the past 100 years, which was clearly observed on lands than the ocean in recent days [60] .", [["combat multidrug resistances", "TREATMENT", 50, 78], ["global warming", "TREATMENT", 149, 163], ["pathogens survival", "TREATMENT", 167, 185], ["a steady increase in temperature", "PROBLEM", 208, 240], ["multidrug resistances", "OBSERVATION", 57, 78], ["global", "OBSERVATION_MODIFIER", 149, 155], ["warming", "OBSERVATION_MODIFIER", 156, 163], ["steady", "OBSERVATION_MODIFIER", 210, 216], ["increase", "OBSERVATION_MODIFIER", 217, 225]]], ["However, ice melting in north pole, increase in sea level, and alteration in raining patterns are clear and known effects of examples of global warming.", [["ice melting in north pole", "PROBLEM", 9, 34], ["increase in sea level", "PROBLEM", 36, 57], ["alteration in raining patterns", "PROBLEM", 63, 93], ["global warming", "TREATMENT", 137, 151], ["ice melting", "OBSERVATION_MODIFIER", 9, 20], ["pole", "ANATOMY_MODIFIER", 30, 34], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["sea level", "OBSERVATION", 48, 57], ["alteration", "OBSERVATION_MODIFIER", 63, 73], ["clear", "OBSERVATION", 98, 103]]], ["Climate change affects the water cycle in the following aspects: (1) poor water quality, (2) less availability (quantity for consumption and use), (3) evaporation leads increases the microbial load (concentration) and toxic ions concentration, (4) water depletion in animal-farming and agriculture (leads to food scarcity), and (5) effects on freshwater biodiversity is still undetermined.", [["the microbial load (concentration)", "TREATMENT", 179, 213], ["toxic ions concentration", "TREATMENT", 218, 242], ["water depletion", "TREATMENT", 248, 263], ["water cycle", "OBSERVATION_MODIFIER", 27, 38]]], ["Ultimately, these changes will hugely affect wastewater microbiome (including beneficial and pathogenic microbes), the concentration of toxic pollutants and biological process performance, which was discussed in detail in Chapter 13, Treatment of wastewater containing pharmaceuticals: biological treatment.", [["toxic pollutants", "PROBLEM", 136, 152], ["biological treatment", "TREATMENT", 286, 306], ["toxic pollutants", "OBSERVATION", 136, 152]]], ["Recently, WHO reported that climate change affects the infectious disease transmission pattern (Fig. 17\u00c01) .Effect of global warming on pathogens survivalVarious infectious diseases and their agents (viruses, bacteria, protozoa, and multicellular parasites) have adapted (via evolution) humans as a primary host, which raises serious threat mankind to face in near future.", [["infectious diseases", "DISEASE", 162, 181], ["humans", "ORGANISM", 287, 293], ["humans", "SPECIES", 287, 293], ["humans", "SPECIES", 287, 293], ["the infectious disease transmission pattern", "PROBLEM", 51, 94], ["global warming", "TREATMENT", 118, 132], ["pathogens survival", "TREATMENT", 136, 154], ["Various infectious diseases", "PROBLEM", 154, 181], ["their agents", "TREATMENT", 186, 198], ["bacteria", "PROBLEM", 209, 217], ["protozoa", "PROBLEM", 219, 227], ["multicellular parasites", "PROBLEM", 233, 256], ["infectious", "OBSERVATION_MODIFIER", 55, 65], ["global", "OBSERVATION_MODIFIER", 118, 124], ["warming", "OBSERVATION_MODIFIER", 125, 132], ["infectious", "OBSERVATION", 162, 172]]], ["Due to the negligent, persistent and accidental activities of humans (industrial) raised the environmental pollution (chemicals including pharmaceuticals), which led to inseparable effect like climate change.", [["humans", "ORGANISM", 62, 68], ["humans", "SPECIES", 62, 68], ["humans", "SPECIES", 62, 68], ["the negligent", "PROBLEM", 7, 20], ["persistent", "OBSERVATION_MODIFIER", 22, 32]]], ["Furthermore, development of drug-resistant organisms and increased pathogen survival rate, only raising panic about the human, animal, and environmental health.", [["panic", "DISEASE", 104, 109], ["human", "ORGANISM", 120, 125], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["drug-resistant organisms", "PROBLEM", 28, 52], ["increased pathogen survival rate", "PROBLEM", 57, 89], ["panic", "PROBLEM", 104, 109], ["resistant organisms", "OBSERVATION", 33, 52], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["pathogen", "OBSERVATION_MODIFIER", 67, 75], ["survival", "OBSERVATION_MODIFIER", 76, 84]]], ["Thus researchers are continuously searching alternatives to these environmental problems.Conclusions and perspectivesDue to pharmaceuticals release in the environment and climate change, the survival of pathogens prolongs.", [["pharmaceuticals", "TREATMENT", 124, 139], ["pathogens prolongs", "TREATMENT", 203, 221], ["pharmaceuticals", "OBSERVATION", 124, 139]]], ["High load of infectious bacterial strains dwelling in wastewater further favors the transfer of antibiotic-resistance gene.", [["antibiotic-resistance gene", "DNA", 96, 122], ["High load of infectious bacterial strains dwelling", "PROBLEM", 0, 50], ["antibiotic-resistance gene", "TREATMENT", 96, 122], ["infectious", "OBSERVATION_MODIFIER", 13, 23], ["bacterial strains", "OBSERVATION", 24, 41]]], ["This could be a classical example for multidrug-resistant bacterial strains that are prevalence in tropical countries (like China and India).", [["multidrug-resistant bacterial strains", "PROBLEM", 38, 75], ["resistant", "OBSERVATION_MODIFIER", 48, 57], ["bacterial strains", "OBSERVATION", 58, 75]]], ["This draws immediate attention of public, health, and international sectors to fight against, pollution, climate change, and drug resistance.Conclusions and perspectivesThe advancement in medicinal research helps in control and elimination of various infectious diseases such as smallpox.", [["infectious diseases", "DISEASE", 251, 270], ["smallpox", "DISEASE", 279, 287], ["medicinal research", "TREATMENT", 188, 206], ["various infectious diseases", "PROBLEM", 243, 270], ["smallpox", "PROBLEM", 279, 287], ["drug resistance", "OBSERVATION", 125, 140], ["various", "OBSERVATION_MODIFIER", 243, 250], ["infectious", "OBSERVATION", 251, 261]]], ["However, emergence and reemergence of infectious diseases due to various factors, that is, natural evolution, climate change, AMR, and many more, is a matter of concern.", [["infectious diseases", "DISEASE", 38, 57], ["AMR", "DISEASE", 126, 129], ["infectious diseases", "PROBLEM", 38, 57], ["various factors", "PROBLEM", 65, 80], ["AMR", "PROBLEM", 126, 129], ["infectious", "OBSERVATION", 38, 48]]], ["The knowledge about the evolution and life cycle of pathogens (bacteria, virus, or parasite) using omics study (proteome, metabolome, epigenome, and transcriptome) and via next-generation sequencing could help in the prevention and control of infectious diseases.", [["infectious diseases", "DISEASE", 243, 262], ["pathogens", "PROBLEM", 52, 61], ["bacteria", "PROBLEM", 63, 71], ["virus", "PROBLEM", 73, 78], ["parasite", "PROBLEM", 83, 91], ["omics study", "TEST", 99, 110], ["next-generation sequencing", "TREATMENT", 172, 198], ["infectious diseases", "PROBLEM", 243, 262], ["infectious", "OBSERVATION", 243, 253]]], ["The implantation of ecological approaches, network, and system biology approaches could provide a better understanding of the environmental factors of disease-emergence and drug-resistance mechanisms.", [["The implantation", "TREATMENT", 0, 16], ["disease", "PROBLEM", 151, 158], ["drug-resistance mechanisms", "TREATMENT", 173, 199], ["implantation", "OBSERVATION", 4, 16]]], ["The information gained from these approaches could help in assessing the immune mechanisms of pathogen and a developing treatment strategy.", [["these approaches", "TREATMENT", 28, 44], ["pathogen", "PROBLEM", 94, 102], ["a developing treatment strategy", "TREATMENT", 107, 138]]]], "bcbeee32b5ea6ab9c50c12f28c4bc1e0bb772cff": [["IntroductionOur group has focused on development of a carbohydrate-based microarray technology to facilitate investigation of carbohydrate-mediated molecular recognition and anticarbohydrate immune responses (1-3).", [["carbohydrate", "CHEMICAL", 54, 66], ["carbohydrate", "CHEMICAL", 126, 138], ["carbohydrate", "SIMPLE_CHEMICAL", 126, 138], ["carbohydrate", "TEST", 126, 138]]], ["Like nucleic acids and proteins, carbohydrates are another class of the essential biological molecules.", [["nucleic acids", "CHEMICAL", 5, 18], ["carbohydrates", "CHEMICAL", 33, 46], ["nucleic acids", "SIMPLE_CHEMICAL", 5, 18], ["carbohydrates", "SIMPLE_CHEMICAL", 33, 46], ["nucleic acids", "TEST", 5, 18], ["carbohydrates", "TREATMENT", 33, 46], ["nucleic acids", "OBSERVATION", 5, 18], ["biological molecules", "OBSERVATION", 82, 102]]], ["Because of their unique physicochemical properties, carbohydrates are capable of generating structural diversity, and so they are prominent in display on the surfaces of cell membranes or on the exposed regions of macromolecules (4-6).", [["cell membranes", "ANATOMY", 170, 184], ["carbohydrates", "CHEMICAL", 52, 65], ["carbohydrates", "SIMPLE_CHEMICAL", 52, 65], ["cell membranes", "CELLULAR_COMPONENT", 170, 184], ["carbohydrates", "TREATMENT", 52, 65], ["cell membranes", "TREATMENT", 170, 184], ["physicochemical properties", "OBSERVATION", 24, 50], ["structural diversity", "OBSERVATION", 92, 112], ["prominent", "OBSERVATION_MODIFIER", 130, 139], ["cell membranes", "OBSERVATION", 170, 184], ["macromolecules", "OBSERVATION", 214, 228]]], ["As a result, carbohydrate moieties are suitable for storing biological signals in the forms that are identifiable by other biological systems.", [["carbohydrate", "CHEMICAL", 13, 25], ["carbohydrate moieties", "SIMPLE_CHEMICAL", 13, 34], ["carbohydrate moieties", "TREATMENT", 13, 34]]], ["In this chapter, we discuss 1) our theoretical consideration for developing high-throughput carbohydrate microarrays, 2) a unique approach we took to establish carbohydrate microarrays, 3) a practical carbohydrate microarray platform that is currently in use by our laboratory, and 4) an example that illustrates a highly promising area for carbohydrate microarray technology to explore.Theoretical Considerations in Developing Carbohydrate MicroarraysThe Genome Project has led to the discovery that only approx 30,000 genes in the human genome must account for all the complexity of the human organism.", [["carbohydrate", "CHEMICAL", 92, 104], ["carbohydrate", "CHEMICAL", 160, 172], ["carbohydrate", "CHEMICAL", 201, 213], ["carbohydrate", "CHEMICAL", 341, 353], ["Carbohydrate", "CHEMICAL", 428, 440], ["human", "ORGANISM", 533, 538], ["human", "ORGANISM", 589, 594], ["approx 30,000 genes", "DNA", 506, 525], ["human genome", "DNA", 533, 545], ["human", "SPECIES", 533, 538], ["human", "SPECIES", 589, 594], ["human", "SPECIES", 533, 538], ["human", "SPECIES", 589, 594], ["carbohydrate microarrays", "TREATMENT", 160, 184], ["a practical carbohydrate microarray platform", "TREATMENT", 189, 233], ["carbohydrate microarray technology", "TREATMENT", 341, 375], ["the human organism", "PROBLEM", 585, 603], ["human genome", "OBSERVATION", 533, 545], ["human organism", "OBSERVATION", 589, 603]]], ["This discovery raised an important question about the roles of protein processing and structural modification in modulating the biological activities of proteins and cellular functions.", [["cellular", "ANATOMY", 166, 174], ["cellular", "CELL", 166, 174], ["protein processing", "TREATMENT", 63, 81], ["structural modification", "PROBLEM", 86, 109], ["cellular functions", "OBSERVATION", 166, 184]]], ["In higher eukaryotic species, most secretory and membrane-bound proteins are decorated with sugar moieties, which is achieved by a critically important posttranslational protein modification, called glycosylation.", [["membrane", "ANATOMY", 49, 57], ["sugar", "CHEMICAL", 92, 97], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["sugar moieties", "SIMPLE_CHEMICAL", 92, 106], ["secretory and membrane-bound proteins", "PROTEIN", 35, 72], ["higher eukaryotic species", "PROBLEM", 3, 28], ["a critically important posttranslational protein modification", "TREATMENT", 129, 190], ["higher", "OBSERVATION_MODIFIER", 3, 9], ["eukaryotic species", "OBSERVATION", 10, 28]]], ["In many physiological and pathophysiological conditions, expression of cellular glycans, in the form of either glycoproteins or glycolipids, is differentially regulated.", [["cellular", "ANATOMY", 71, 79], ["cellular glycans", "GENE_OR_GENE_PRODUCT", 71, 87], ["glycoproteins", "PROTEIN", 111, 124], ["many physiological and pathophysiological conditions", "PROBLEM", 3, 55], ["cellular glycans", "PROBLEM", 71, 87], ["glycolipids", "TREATMENT", 128, 139], ["pathophysiological conditions", "OBSERVATION", 26, 55], ["cellular glycans", "OBSERVATION", 71, 87]]], ["There are documented examples that show that cell display of precise complex carbohydrates is characteristically associated with the stages or steps of embryonic development, cell differentiation, and transformation of normal cell to abnormally differentiated tumor or cancer cells (7-10).", [["cell", "ANATOMY", 45, 49], ["embryonic", "ANATOMY", 152, 161], ["cell", "ANATOMY", 175, 179], ["cell", "ANATOMY", 226, 230], ["tumor", "ANATOMY", 260, 265], ["cancer cells", "ANATOMY", 269, 281], ["tumor", "DISEASE", 260, 265], ["cancer", "DISEASE", 269, 275], ["carbohydrates", "CHEMICAL", 77, 90], ["cell", "CELL", 45, 49], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 152, 161], ["cell", "CELL", 175, 179], ["cell", "CELL", 226, 230], ["tumor", "CELL", 260, 265], ["cancer cells", "CELL", 269, 281], ["normal cell", "CELL_TYPE", 219, 230], ["abnormally differentiated tumor or cancer cells", "CELL_TYPE", 234, 281], ["embryonic development", "PROBLEM", 152, 173], ["cell differentiation", "PROBLEM", 175, 195], ["abnormally differentiated tumor", "PROBLEM", 234, 265], ["cancer cells", "PROBLEM", 269, 281], ["complex", "OBSERVATION_MODIFIER", 69, 76], ["carbohydrates", "OBSERVATION", 77, 90], ["cell differentiation", "OBSERVATION", 175, 195], ["normal cell", "OBSERVATION", 219, 230], ["abnormally", "OBSERVATION_MODIFIER", 234, 244], ["differentiated", "OBSERVATION_MODIFIER", 245, 259], ["tumor", "OBSERVATION", 260, 265], ["cancer cells", "OBSERVATION", 269, 281]]], ["Sugar moieties are also abundantly expressed on the outer surfaces of the mass majority of viral, bacterial, protozoan, and fungal pathogens.", [["outer surfaces", "ANATOMY", 52, 66], ["Sugar", "CHEMICAL", 0, 5], ["Sugar moieties", "SIMPLE_CHEMICAL", 0, 14], ["outer surfaces", "CELLULAR_COMPONENT", 52, 66], ["viral, bacterial, protozoan", "PROBLEM", 91, 118], ["fungal pathogens", "PROBLEM", 124, 140], ["moieties", "OBSERVATION_MODIFIER", 6, 14], ["outer surfaces", "OBSERVATION_MODIFIER", 52, 66], ["mass", "OBSERVATION", 74, 78], ["viral", "OBSERVATION", 91, 96], ["bacterial", "OBSERVATION_MODIFIER", 98, 107], ["protozoan", "OBSERVATION_MODIFIER", 109, 118], ["fungal pathogens", "OBSERVATION", 124, 140]]], ["Many sugar structures are pathogen specific, which makes them important molecular targets for pathogen recognition, diagnosis of infectious diseases, and vaccine development (4, [11] [12] [13] [14] [15] .Theoretical Considerations in Developing Carbohydrate MicroarraysIn spite of the biological magnitude of carbohydrate molecules, the characterization of carbohydrate structures and the exposition of their function have lagged compared with other major classes of biological molecules, such as nucleic acids and proteins.", [["infectious diseases", "DISEASE", 129, 148], ["sugar", "CHEMICAL", 5, 10], ["Carbohydrate", "CHEMICAL", 245, 257], ["carbohydrate", "CHEMICAL", 309, 321], ["carbohydrate", "CHEMICAL", 357, 369], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 178, 202], ["nucleic acids", "SIMPLE_CHEMICAL", 497, 510], ["carbohydrate molecules", "PROTEIN", 309, 331], ["nucleic acids and proteins", "PROTEIN", 497, 523], ["pathogen", "PROBLEM", 26, 34], ["infectious diseases", "PROBLEM", 129, 148], ["Carbohydrate Microarrays", "TEST", 245, 269], ["carbohydrate molecules", "TREATMENT", 309, 331], ["carbohydrate structures", "PROBLEM", 357, 380], ["nucleic acids", "TEST", 497, 510], ["biological molecules", "OBSERVATION", 467, 487]]], ["For example, whereas the microarray-based high-throughput technologies for nucleic acids (16,17) and proteins (18, 19) were developed years ago, the first carbohydrate microarray research was published in 2002 (1,20-24).Theoretical Considerations in Developing Carbohydrate MicroarraysOur endeavor has focused on establishment of a high-throughput carbohydrate microarray platform that is technically equivalent to the state-of-the-art technologies of the cDNA microarray.", [["nucleic acids", "CHEMICAL", 75, 88], ["carbohydrate", "CHEMICAL", 155, 167], ["Carbohydrate", "CHEMICAL", 261, 273], ["carbohydrate", "CHEMICAL", 348, 360], ["nucleic acids", "SIMPLE_CHEMICAL", 75, 88], ["the microarray", "TEST", 21, 35], ["nucleic acids", "TEST", 75, 88], ["proteins", "TEST", 101, 109], ["a high-throughput carbohydrate microarray platform", "PROBLEM", 330, 380]]], ["Carbohydrates are strikingly different from nucleic acids in structure, physicochemical properties, and cellular function.", [["cellular", "ANATOMY", 104, 112], ["nucleic acids", "CHEMICAL", 44, 57], ["nucleic acids", "SIMPLE_CHEMICAL", 44, 57], ["cellular", "CELL", 104, 112], ["Carbohydrates", "TREATMENT", 0, 13], ["nucleic acids", "TEST", 44, 57], ["different", "OBSERVATION_MODIFIER", 29, 38], ["nucleic acids", "OBSERVATION", 44, 57], ["physicochemical properties", "OBSERVATION", 72, 98], ["cellular function", "OBSERVATION", 104, 121]]], ["Thus, the fundamental principles that are at the basis of establishment of a carbohydrate-based assay differ from the basic principles of the nucleic acid-based assays, such as the cDNA microarray and oligonucleotide biochips.", [["nucleic acid", "CHEMICAL", 142, 154], ["carbohydrate", "CHEMICAL", 77, 89], ["the nucleic acid", "TEST", 138, 154], ["the cDNA microarray", "TEST", 177, 196], ["oligonucleotide biochips", "TREATMENT", 201, 225]]], ["For the nucleic acid-based biochips, the detection specificity is determined by the A::T and C::G base pairing, and there is no need to preserve the three-dimensional (3D) structures of the nucleic acid molecules.", [["nucleic acid", "CHEMICAL", 8, 20], ["nucleic acid", "CHEMICAL", 190, 202], ["nucleic acid molecules", "PROTEIN", 190, 212], ["the nucleic acid", "TEST", 4, 20], ["the detection specificity", "TEST", 37, 62], ["G base pairing", "PROBLEM", 96, 110], ["the nucleic acid molecules", "PROBLEM", 186, 212], ["no", "UNCERTAINTY", 125, 127], ["nucleic", "OBSERVATION", 190, 197], ["acid molecules", "OBSERVATION", 198, 212]]], ["By contrast, carbohydrate microarrays require preservation of the 3D conformations and topological configurations of sugar moieties on a chip to permit a targeted molecular recognition by the corresponding cellular receptors to take place (4,5).Theoretical Considerations in Developing Carbohydrate MicroarraysTherefore, several technical difficulties must conquer to establish a high-throughput carbohydrate microarray technology.", [["cellular", "ANATOMY", 206, 214], ["carbohydrate", "CHEMICAL", 13, 25], ["sugar", "CHEMICAL", 117, 122], ["Carbohydrate", "CHEMICAL", 286, 298], ["carbohydrate", "CHEMICAL", 396, 408], ["sugar moieties", "SIMPLE_CHEMICAL", 117, 131], ["cellular", "CELL", 206, 214], ["cellular receptors", "PROTEIN", 206, 224], ["carbohydrate microarrays", "TREATMENT", 13, 37], ["a chip", "TREATMENT", 135, 141], ["Carbohydrate Microarrays", "TREATMENT", 286, 310], ["several technical difficulties", "PROBLEM", 321, 351]]], ["These difficulties take into account whether carbohydrate macromolecules of hydrophilic character can be immobilized on a chip surface by methods that are suitable for high-throughput production of microarrays; whether immobilized carbohydrate-containing macromolecules preserve their immunological properties, such as expression of carbohydrate-epitopes or antigenic determinants and their solvent accessibility; whether the carbohydrate microarray system reaches the sensitivity, specificity, and capacity to detect a broad range of antibody specificities in clinical specimens; and eventually whether this technology can be applied to investigate the carbohydrate-mediated molecular recognition on a titanic scale that was previously impossible.Experimental Approach to Establishment of High-Throughput Carbohydrate MicroarraysOur intent was to introduce immunological specificity to microarray technology to establish a microarray-based broad-range immunosensor for the exploration of immunological diversity of carbohydrates and the immune responses to carbohydrate antigens.", [["specimens", "ANATOMY", 570, 579], ["carbohydrate", "CHEMICAL", 45, 57], ["carbohydrate", "CHEMICAL", 231, 243], ["carbohydrate", "CHEMICAL", 333, 345], ["carbohydrate", "CHEMICAL", 426, 438], ["carbohydrate", "CHEMICAL", 654, 666], ["carbohydrates", "CHEMICAL", 1016, 1029], ["carbohydrate", "CHEMICAL", 1058, 1070], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 1058, 1079], ["carbohydrate-epitopes", "PROTEIN", 333, 354], ["antigenic determinants", "PROTEIN", 358, 380], ["carbohydrate antigens", "PROTEIN", 1058, 1079], ["These difficulties", "PROBLEM", 0, 18], ["carbohydrate macromolecules of hydrophilic character", "PROBLEM", 45, 97], ["a chip surface", "TREATMENT", 120, 134], ["high-throughput production of microarrays", "TREATMENT", 168, 209], ["immobilized carbohydrate", "TREATMENT", 219, 243], ["macromolecules", "TREATMENT", 255, 269], ["carbohydrate-epitopes", "TREATMENT", 333, 354], ["the carbohydrate microarray system", "TEST", 422, 456], ["antibody specificities in clinical specimens", "PROBLEM", 535, 579], ["a titanic scale", "TREATMENT", 701, 716], ["microarray technology", "TEST", 887, 908], ["a microarray", "TEST", 922, 934], ["the exploration", "TEST", 970, 985], ["immunological diversity of carbohydrates", "PROBLEM", 989, 1029], ["hydrophilic character", "OBSERVATION_MODIFIER", 76, 97]]], ["In experimental design, we applied a well-studied model system of carbohydrateanticarbohydrate interaction, (1,6)dextran and anti-(1,6)dextran antibodies (25-27), for our initial investigation (1).", [["carbohydrateanticarbohydrate", "CHEMICAL", 66, 94], ["dextran", "CHEMICAL", 113, 120], ["dextran", "CHEMICAL", 135, 142], ["carbohydrateanticarbohydrate", "CHEMICAL", 66, 94], ["carbohydrateanticarbohydrate", "SIMPLE_CHEMICAL", 66, 94], ["(1,6)dextran", "SIMPLE_CHEMICAL", 108, 120], ["anti-(1,6)dextran antibodies", "SIMPLE_CHEMICAL", 125, 153], ["carbohydrateanticarbohydrate interaction", "TREATMENT", 66, 106], ["dextran", "TREATMENT", 113, 120], ["anti", "TEST", 125, 129], ["dextran antibodies", "TEST", 135, 153], ["our initial investigation", "TEST", 167, 192]]], ["To address whether carbohydrate macromolecules of hydrophilic character can be immobilized on a chip surface, we applied the fluorescein isothiocyanate (FITC)-conjugated (1, 6) dextrans as probes to screen available chip substrates that were produced for printing cDNA microarrays for their potential use in carbohydrate microarrays.", [["fluorescein isothiocyanate", "CHEMICAL", 125, 151], ["1, 6) dextrans", "CHEMICAL", 171, 185], ["carbohydrate", "CHEMICAL", 19, 31], ["fluorescein isothiocyanate", "CHEMICAL", 125, 151], ["FITC", "CHEMICAL", 153, 157], ["carbohydrate", "CHEMICAL", 308, 320], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 125, 151], ["FITC", "SIMPLE_CHEMICAL", 153, 157], ["conjugated (1, 6) dextrans", "SIMPLE_CHEMICAL", 159, 185], ["cDNA microarrays", "DNA", 264, 280], ["carbohydrate macromolecules of hydrophilic character", "PROBLEM", 19, 71], ["a chip surface", "TREATMENT", 94, 108], ["the fluorescein isothiocyanate (FITC)-conjugated (1, 6) dextrans", "TREATMENT", 121, 185], ["chip substrates", "TREATMENT", 216, 231], ["printing cDNA microarrays", "TREATMENT", 255, 280], ["carbohydrate microarrays", "TREATMENT", 308, 332], ["hydrophilic character", "OBSERVATION_MODIFIER", 50, 71]]], ["This investigation guided us to the discovery that the nitrocellulose-coated glass slides are suitable for immobilization of carbohydrate-containing macromolecules.Experimental Approach to Establishment of High-Throughput Carbohydrate MicroarraysTo test whether the size and molecular weight of polysaccharides influence their surface immobilization, FITC-(1,6)dextran preparations of different molecular weights and of similar molar ratios of FITC/glucose were applied.", [["surface", "ANATOMY", 327, 334], ["dextran", "CHEMICAL", 361, 368], ["glucose", "CHEMICAL", 449, 456], ["nitrocellulose", "CHEMICAL", 55, 69], ["carbohydrate", "CHEMICAL", 125, 137], ["Carbohydrate", "CHEMICAL", 222, 234], ["FITC", "CHEMICAL", 351, 355], ["FITC", "CHEMICAL", 444, 448], ["glucose", "CHEMICAL", 449, 456], ["nitrocellulose", "SIMPLE_CHEMICAL", 55, 69], ["polysaccharides", "SIMPLE_CHEMICAL", 295, 310], ["FITC-(1,6)dextran", "SIMPLE_CHEMICAL", 351, 368], ["FITC", "SIMPLE_CHEMICAL", 444, 448], ["glucose", "SIMPLE_CHEMICAL", 449, 456], ["the nitrocellulose-coated glass slides", "TREATMENT", 51, 89], ["immobilization of carbohydrate", "TREATMENT", 107, 137], ["High-Throughput Carbohydrate Microarrays", "TREATMENT", 206, 246], ["the size", "TEST", 262, 270], ["polysaccharides", "TREATMENT", 295, 310], ["their surface immobilization", "TREATMENT", 321, 349], ["FITC", "TEST", 351, 355], ["dextran preparations", "TREATMENT", 361, 381], ["different molecular weights", "TREATMENT", 385, 412], ["FITC/glucose", "TREATMENT", 444, 456], ["size", "OBSERVATION_MODIFIER", 266, 270]]], ["A structurally distinct polysaccharide, inulin, was chosen as a control to see whether surface immobilization of polysaccharides is restricted to a specific carbohydrate structure.", [["surface", "ANATOMY", 87, 94], ["inulin", "CHEMICAL", 40, 46], ["carbohydrate", "CHEMICAL", 157, 169], ["inulin", "SIMPLE_CHEMICAL", 40, 46], ["inulin", "TREATMENT", 40, 46], ["surface immobilization of polysaccharides", "TREATMENT", 87, 128], ["structurally", "OBSERVATION_MODIFIER", 2, 14], ["distinct", "OBSERVATION_MODIFIER", 15, 23], ["polysaccharide", "OBSERVATION_MODIFIER", 24, 38]]], ["This investigation demonstrated that dextran preparations of different molecular weights, ranging from 20 to 2000 kDa, and inulin of 3.3 kDa could be printed and immobilized on the nitrocellulose-coated slide without chemical conjugation.", [["dextran", "CHEMICAL", 37, 44], ["inulin", "CHEMICAL", 123, 129], ["nitrocellulose", "CHEMICAL", 181, 195], ["dextran", "SIMPLE_CHEMICAL", 37, 44], ["inulin", "SIMPLE_CHEMICAL", 123, 129], ["This investigation", "TEST", 0, 18], ["dextran preparations", "TREATMENT", 37, 57], ["different molecular weights", "TEST", 61, 88], ["inulin", "TEST", 123, 129], ["the nitrocellulose-coated slide", "TREATMENT", 177, 208], ["chemical conjugation", "TREATMENT", 217, 237]]], ["The linear range of the material transferred and surface immobilized, however, differs significantly among dextran preparations of different molecular weights (1).Experimental Approach to Establishment of High-Throughput Carbohydrate MicroarraysTo investigate whether immobilized carbohydrate antigens preserve their antigenic determinants, dextran preparations of different linkage compositions and with different ratios of terminal to internal epitopes were printed on nitrocellulose-coated glass slides.", [["surface", "ANATOMY", 49, 56], ["dextran", "CHEMICAL", 107, 114], ["dextran", "CHEMICAL", 341, 348], ["Carbohydrate", "CHEMICAL", 221, 233], ["carbohydrate", "CHEMICAL", 280, 292], ["nitrocellulose", "CHEMICAL", 471, 485], ["surface", "CELLULAR_COMPONENT", 49, 56], ["dextran", "SIMPLE_CHEMICAL", 107, 114], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 280, 301], ["dextran", "SIMPLE_CHEMICAL", 341, 348], ["carbohydrate antigens", "PROTEIN", 280, 301], ["terminal to internal epitopes", "PROTEIN", 425, 454], ["dextran preparations", "TREATMENT", 107, 127], ["Experimental Approach", "TREATMENT", 163, 184], ["High-Throughput Carbohydrate Microarrays", "TREATMENT", 205, 245], ["immobilized carbohydrate antigens", "TREATMENT", 268, 301], ["dextran preparations", "TREATMENT", 341, 361], ["different linkage compositions", "TREATMENT", 365, 395], ["nitrocellulose-coated glass slides", "TREATMENT", 471, 505], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["range", "OBSERVATION_MODIFIER", 11, 16], ["material", "OBSERVATION_MODIFIER", 24, 32], ["surface", "OBSERVATION_MODIFIER", 49, 56], ["immobilized", "OBSERVATION_MODIFIER", 57, 68]]], ["These preparations included N279, displaying both internal linear and terminal nonreducing end epitopes, B1299S, heavily branched and expressing predominantly terminal epitopes, and LD7, a synthetic dextran composed of 100% (1,6)-linked internal linear chain structure.", [["N279", "CHEMICAL", 28, 32], ["dextran", "CHEMICAL", 199, 206], ["N279", "SIMPLE_CHEMICAL", 28, 32], ["LD7", "SIMPLE_CHEMICAL", 182, 185], ["dextran", "SIMPLE_CHEMICAL", 199, 206], ["internal linear and terminal nonreducing end epitopes", "PROTEIN", 50, 103], ["B1299S", "PROTEIN", 105, 111], ["terminal epitopes", "PROTEIN", 159, 176], ["LD7", "PROTEIN", 182, 185], ["internal linear chain structure", "PROTEIN", 237, 268], ["internal linear and terminal nonreducing end epitopes", "PROBLEM", 50, 103], ["LD7", "TEST", 182, 185], ["a synthetic dextran", "TREATMENT", 187, 206], ["linked internal linear chain structure", "PROBLEM", 230, 268], ["internal", "ANATOMY_MODIFIER", 50, 58], ["linear", "OBSERVATION_MODIFIER", 59, 65], ["terminal", "OBSERVATION_MODIFIER", 70, 78], ["nonreducing", "OBSERVATION_MODIFIER", 79, 90], ["end epitopes", "OBSERVATION", 91, 103], ["heavily", "OBSERVATION_MODIFIER", 113, 120], ["branched", "OBSERVATION_MODIFIER", 121, 129], ["predominantly", "OBSERVATION_MODIFIER", 145, 158], ["terminal", "OBSERVATION_MODIFIER", 159, 167], ["epitopes", "OBSERVATION", 168, 176], ["internal", "ANATOMY_MODIFIER", 237, 245], ["linear", "OBSERVATION_MODIFIER", 246, 252], ["chain structure", "OBSERVATION", 253, 268]]], ["The dextran microarrays were incubated with monoclonal antibodies of defined specificities, either a groove-type anti-(1,6)dextran 4.3F1 (IgG3) (28) or a cavity-type anti-(1,6)dextran 16.4.12E (IgA) (29).", [["dextran", "CHEMICAL", 4, 11], ["dextran", "CHEMICAL", 123, 130], ["dextran", "CHEMICAL", 176, 183], ["dextran", "SIMPLE_CHEMICAL", 4, 11], ["anti-(1,6)dextran 4.3F1", "SIMPLE_CHEMICAL", 113, 136], ["IgG3", "SIMPLE_CHEMICAL", 138, 142], ["anti-(1,6)dextran 16.4", "SIMPLE_CHEMICAL", 166, 188], ["12E", "SIMPLE_CHEMICAL", 189, 192], ["IgA", "GENE_OR_GENE_PRODUCT", 194, 197], ["monoclonal antibodies", "PROTEIN", 44, 65], ["IgG3", "PROTEIN", 138, 142], ["12E", "PROTEIN", 189, 192], ["IgA", "PROTEIN", 194, 197], ["The dextran microarrays", "TREATMENT", 0, 23], ["monoclonal antibodies", "TEST", 44, 65], ["a groove-type anti", "TEST", 99, 117], ["dextran", "TREATMENT", 123, 130], ["a cavity", "TEST", 152, 160], ["dextran", "TREATMENT", 176, 183], ["cavity", "ANATOMY", 154, 160]]], ["The former recognizes the internal linear chain of (1,6)dextrans, whereas the latter is specific for the terminal nonreducing end structure of the polysaccharide.Experimental Approach to Establishment of High-Throughput Carbohydrate MicroarraysThe groove-type monoclonal antibody (mAb), 4.3F1, bound well to the dextran preparations with predominantly linear chain structures, N279 and LD7, but bound poorly to the heavily branched (1.6)dextran, B1299S.", [["dextran", "CHEMICAL", 312, 319], ["dextran", "CHEMICAL", 437, 444], ["B1299S", "CHEMICAL", 446, 452], ["Carbohydrate", "CHEMICAL", 220, 232], ["(1,6)dextrans", "SIMPLE_CHEMICAL", 51, 64], ["dextran", "SIMPLE_CHEMICAL", 312, 319], ["N279", "SIMPLE_CHEMICAL", 377, 381], ["LD7", "SIMPLE_CHEMICAL", 386, 389], ["(1.6)dextran", "SIMPLE_CHEMICAL", 432, 444], ["terminal nonreducing end structure", "PROTEIN", 105, 139], ["groove-type monoclonal antibody", "PROTEIN", 248, 279], ["mAb", "PROTEIN", 281, 284], ["dextrans", "TREATMENT", 56, 64], ["the polysaccharide", "TREATMENT", 143, 161], ["High-Throughput Carbohydrate Microarrays", "TREATMENT", 204, 244], ["The groove-type monoclonal antibody", "TEST", 244, 279], ["the dextran preparations", "TREATMENT", 308, 332], ["predominantly linear chain structures", "PROBLEM", 338, 375], ["LD7", "TEST", 386, 389], ["dextran", "TREATMENT", 437, 444], ["internal", "ANATOMY_MODIFIER", 26, 34], ["linear", "OBSERVATION_MODIFIER", 35, 41], ["chain", "OBSERVATION_MODIFIER", 42, 47], ["polysaccharide", "OBSERVATION_MODIFIER", 147, 161], ["groove", "ANATOMY_MODIFIER", 248, 254], ["monoclonal antibody", "OBSERVATION", 260, 279], ["predominantly", "OBSERVATION_MODIFIER", 338, 351], ["linear", "OBSERVATION_MODIFIER", 352, 358], ["chain structures", "OBSERVATION", 359, 375]]], ["By contrast, when the cavitytype mAb 16.4.12E was applied, it bound to the immobilized dextran preparations with branches (N279 and B1299S) but not to those with only internal linear chain structure (LD7).", [["dextran", "CHEMICAL", 87, 94], ["12E", "SIMPLE_CHEMICAL", 42, 45], ["dextran", "SIMPLE_CHEMICAL", 87, 94], ["cavitytype mAb", "PROTEIN", 22, 36], ["12E", "PROTEIN", 42, 45], ["internal linear chain structure", "PROTEIN", 167, 198], ["LD7", "PROTEIN", 200, 203], ["the cavitytype mAb", "TEST", 18, 36], ["the immobilized dextran preparations", "TREATMENT", 71, 107], ["internal linear chain structure", "PROBLEM", 167, 198], ["branches", "ANATOMY_MODIFIER", 113, 121], ["internal", "ANATOMY_MODIFIER", 167, 175], ["linear", "OBSERVATION_MODIFIER", 176, 182], ["chain structure", "OBSERVATION", 183, 198]]], ["These patterns of antigen-antibody reactivities are typically identical to those recognized by an ELISA binding assay for either the groove type or cavity type of antidextran mAbs.", [["antigen", "GENE_OR_GENE_PRODUCT", 18, 25], ["antidextran mAbs", "GENE_OR_GENE_PRODUCT", 163, 179], ["antidextran mAbs", "PROTEIN", 163, 179], ["antigen-antibody reactivities", "TEST", 18, 47], ["an ELISA binding assay", "TEST", 95, 117], ["antidextran mAbs", "TREATMENT", 163, 179], ["antibody reactivities", "OBSERVATION", 26, 47], ["cavity", "OBSERVATION", 148, 154]]], ["Therefore, the immunological properties of dextran molecules are well preserved when immobilized on a nitrocellulose-coated glass slide.", [["dextran", "CHEMICAL", 43, 50], ["nitrocellulose", "CHEMICAL", 102, 116], ["dextran molecules", "SIMPLE_CHEMICAL", 43, 60], ["dextran molecules", "TREATMENT", 43, 60], ["a nitrocellulose-coated glass slide", "TREATMENT", 100, 135], ["dextran molecules", "OBSERVATION", 43, 60]]], ["Their nonreducing end structure, recognized by the cavity-type anti-(1,6)dextrans as well as the internal linear chain epitopes bound by the groove-type anti-(1,6)dextrans are displayed on the surface after immobilization and are accessible to antibodies in an aqueous solution.", [["surface", "ANATOMY", 193, 200], ["1,6)dextrans", "SIMPLE_CHEMICAL", 69, 81], ["anti-(1,6)dextrans", "SIMPLE_CHEMICAL", 153, 171], ["surface", "CELLULAR_COMPONENT", 193, 200], ["internal linear chain epitopes", "PROTEIN", 97, 127], ["antibodies", "PROTEIN", 244, 254], ["type anti-(1,6)dextrans", "TREATMENT", 58, 81], ["the internal linear chain epitopes bound", "TREATMENT", 93, 133], ["dextrans", "TREATMENT", 163, 171], ["immobilization", "TREATMENT", 207, 221], ["an aqueous solution", "TREATMENT", 258, 277], ["cavity", "OBSERVATION_MODIFIER", 51, 57], ["internal", "ANATOMY_MODIFIER", 97, 105], ["groove", "OBSERVATION_MODIFIER", 141, 147]]], ["This approach was then extended to test a large panel of carbohydrate-containing macromolecules to assess their immobilization on chip and to evaluate expression of antigenic structures for antibody detection.", [["carbohydrate", "CHEMICAL", 57, 69], ["carbohydrate-containing macromolecules", "TREATMENT", 57, 95], ["their immobilization on chip", "TREATMENT", 106, 134], ["antibody detection", "TEST", 190, 208]]], ["We demonstrated that polysaccharides and glycoconjugates of distinct structural configurations and of diverse sugar chain contents were applicable for this biochip platform, i.e., a method of nitrocellulose-based noncovalent immobilization for high-throughput construction of carbohydrate microarrays (1).Experimental Approach to Establishment of High-Throughput Carbohydrate MicroarraysNitrocellulose polymer is a fully nitrated derivative of cellulose in which free hydroxyl groups are substituted by nitro groups, and it is thus hydrophobic in character.", [["Nitrocellulose polymer", "CHEMICAL", 387, 409], ["hydroxyl", "CHEMICAL", 468, 476], ["nitro", "CHEMICAL", 503, 508], ["sugar", "CHEMICAL", 110, 115], ["nitrocellulose", "CHEMICAL", 192, 206], ["carbohydrate", "CHEMICAL", 276, 288], ["Carbohydrate", "CHEMICAL", 363, 375], ["hydroxyl", "CHEMICAL", 468, 476], ["nitro", "CHEMICAL", 503, 508], ["polysaccharides", "SIMPLE_CHEMICAL", 21, 36], ["sugar", "SIMPLE_CHEMICAL", 110, 115], ["Nitrocellulose polymer", "SIMPLE_CHEMICAL", 387, 409], ["cellulose", "SIMPLE_CHEMICAL", 444, 453], ["free hydroxyl groups", "SIMPLE_CHEMICAL", 463, 483], ["polysaccharides", "PROBLEM", 21, 36], ["diverse sugar chain contents", "PROBLEM", 102, 130], ["this biochip platform", "TEST", 151, 172], ["a method of nitrocellulose", "TREATMENT", 180, 206], ["noncovalent immobilization", "TREATMENT", 213, 239], ["carbohydrate microarrays", "TREATMENT", 276, 300], ["Experimental Approach", "TREATMENT", 305, 326], ["High-Throughput Carbohydrate MicroarraysNitrocellulose polymer", "TREATMENT", 347, 409], ["a fully nitrated derivative of cellulose", "TREATMENT", 413, 453], ["free hydroxyl groups", "TREATMENT", 463, 483], ["polysaccharides", "OBSERVATION_MODIFIER", 21, 36], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["structural configurations", "OBSERVATION", 69, 94], ["diverse", "OBSERVATION_MODIFIER", 102, 109], ["sugar chain contents", "OBSERVATION", 110, 130]]], ["Documented investigations have suggested that immobilization of proteins on a nitrocellulose membrane requires revelation of their hydrophobic surfaces to the membrane (30,31) .", [["membrane", "ANATOMY", 93, 101], ["membrane", "ANATOMY", 159, 167], ["nitrocellulose", "CHEMICAL", 78, 92], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["Documented investigations", "TEST", 0, 25], ["immobilization of proteins", "TREATMENT", 46, 72], ["a nitrocellulose membrane", "TREATMENT", 76, 101], ["membrane", "ANATOMY_MODIFIER", 159, 167]]], ["The molecular forces for the carbohydrate-nitrocellulose interaction remain to be characterized.", [["carbohydrate", "CHEMICAL", 29, 41], ["nitrocellulose", "CHEMICAL", 42, 56], ["carbohydrate", "SIMPLE_CHEMICAL", 29, 41], ["the carbohydrate-nitrocellulose interaction", "TREATMENT", 25, 68], ["forces", "OBSERVATION_MODIFIER", 14, 20]]], ["Perhaps the 3D microporous configuration of the nitrocellulose coating on the slides, the macropolymer characteristics of polysaccharides and the polyamphypathic properties of many carbohydrate-containing macromolecules are key factors for the stable immobilization of carbohydrate antigens on the slide.", [["nitrocellulose", "CHEMICAL", 48, 62], ["carbohydrate", "CHEMICAL", 181, 193], ["carbohydrate", "CHEMICAL", 269, 281], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 269, 290], ["carbohydrate antigens", "PROTEIN", 269, 290], ["the nitrocellulose coating", "TREATMENT", 44, 70], ["the slides", "TEST", 74, 84], ["polysaccharides", "PROBLEM", 122, 137], ["microporous configuration", "OBSERVATION", 15, 40], ["polysaccharides", "OBSERVATION", 122, 137], ["stable", "OBSERVATION_MODIFIER", 244, 250], ["immobilization", "OBSERVATION", 251, 265]]], ["Given the structural diversity of carbohydrate antigens, we highly recommend that each preparation must be tested on this chip substrate.Practical Platform of Carbohydrate MicroarraysThe aforementioned experimental investigations have guided our research to the establishment of a high-throughput platform of carbohydrate microarrays.", [["carbohydrate", "CHEMICAL", 34, 46], ["Carbohydrate", "CHEMICAL", 159, 171], ["carbohydrate", "CHEMICAL", 309, 321], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 34, 55], ["carbohydrate antigens", "PROTEIN", 34, 55], ["this chip substrate", "TREATMENT", 117, 136], ["Carbohydrate Microarrays", "TREATMENT", 159, 183], ["carbohydrate microarrays", "TREATMENT", 309, 333], ["carbohydrate antigens", "OBSERVATION", 34, 55]]], ["As illustrated in the Fig. 1 , this approach applies to existing cDNA microarray systems, including spotter and scanner, for carbohydrate array production and applications.", [["carbohydrate", "CHEMICAL", 125, 137], ["this approach", "TREATMENT", 31, 44], ["existing cDNA microarray systems", "TREATMENT", 56, 88], ["carbohydrate array production", "TREATMENT", 125, 154]]], ["A key technical element of this array platform is the introduction of nitrocellulose-coated microglass slides to immobilize unmodified carbohydrate antigens on the chip surface.Practical Platform of Carbohydrate MicroarraysA high-precision robot designed to produce cDNA microarrays was used to spot carbohydrate antigens onto a chemically modified glass slide.", [["surface", "ANATOMY", 169, 176], ["nitrocellulose", "CHEMICAL", 70, 84], ["carbohydrate", "CHEMICAL", 135, 147], ["Carbohydrate", "CHEMICAL", 199, 211], ["carbohydrate", "CHEMICAL", 300, 312], ["microglass slides", "SIMPLE_CHEMICAL", 92, 109], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 135, 156], ["unmodified carbohydrate antigens", "PROTEIN", 124, 156], ["cDNA microarrays", "DNA", 266, 282], ["carbohydrate antigens", "PROTEIN", 300, 321], ["nitrocellulose-coated microglass slides", "TREATMENT", 70, 109], ["Carbohydrate MicroarraysA", "TEST", 199, 224], ["cDNA microarrays", "TEST", 266, 282], ["a chemically modified glass slide", "TREATMENT", 327, 360]]], ["The antibody-stained slides were then scanned for fluorescent signals with a Biochip scanner that was developed for cDNA microarrays.Practical Platform of Carbohydrate MicroarraysFor microspotting, antigens and antibodies were printed using PIXSYS 5500C (Cartesian Technologies, Irvine, CA).", [["Carbohydrate", "CHEMICAL", 155, 167], ["cDNA microarrays", "DNA", 116, 132], ["antigens", "PROTEIN", 198, 206], ["antibodies", "PROTEIN", 211, 221], ["The antibody", "TEST", 0, 12], ["stained slides", "TEST", 13, 27], ["fluorescent signals", "TEST", 50, 69], ["a Biochip scanner", "TEST", 75, 92], ["cDNA microarrays", "TEST", 116, 132], ["Carbohydrate Microarrays", "TEST", 155, 179], ["microspotting", "TEST", 183, 196], ["antigens", "TEST", 198, 206], ["antibodies", "TEST", 211, 221], ["PIXSYS", "TREATMENT", 241, 247]]], ["For immunofluorescence staining, the staining procedure used is essentially identical to regular immunofluorescent staining of tissue sections.", [["tissue sections", "ANATOMY", 127, 142], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 127, 142], ["immunofluorescence staining", "TEST", 4, 31], ["the staining procedure", "TREATMENT", 33, 55], ["tissue sections", "OBSERVATION", 127, 142]]], ["For microarray scanning, a ScanArray 5000 Standard Biochip Scanning System and its QuantArray software (Perkin-Elmer, Boston, MA) were used for scanning and data capture.An Eight-Chamber Subarray System for Customized ArraysWe have designed an eight-chamber subarray system to create customized carbohydrate microarrays for defined purposes.", [["carbohydrate", "CHEMICAL", 295, 307], ["microarray scanning", "TEST", 4, 23], ["a ScanArray", "TEST", 25, 36], ["scanning and data capture", "TEST", 144, 169], ["An Eight-Chamber Subarray System", "TREATMENT", 170, 202], ["Customized Arrays", "TREATMENT", 207, 224], ["an eight-chamber subarray system", "TREATMENT", 241, 273], ["customized carbohydrate microarrays", "TREATMENT", 284, 319]]], ["As illustrated in the Fig. 2 , each microglass slide contains eight separated subarrays.", [["each microglass slide", "TREATMENT", 31, 52], ["eight separated", "OBSERVATION_MODIFIER", 62, 77]]], ["The microarray capacity is approx 600 microspots per subarray.", [["The microarray capacity", "TEST", 0, 23]]], ["A single slide is designed to enable eight microarray analyses.", [["eight microarray analyses", "TEST", 37, 62]]], ["A similar design with array capacity of approx 100 microspots is also commer- cially available (Whatman Schleicher and Schuell).", [["array capacity", "TEST", 22, 36]]], ["For eight-chamber subarrays.", [["eight-chamber subarrays", "TREATMENT", 4, 27], ["chamber subarrays", "OBSERVATION", 10, 27]]], ["Each microglass slide contains eight subarrays of identical content.", [["Each microglass slide", "TREATMENT", 0, 21], ["eight subarrays", "OBSERVATION_MODIFIER", 31, 46], ["identical content", "OBSERVATION", 50, 67]]], ["There is chip space for 600 microspots per subarray, with spot sizes of approx 200-and 300-\u00b5m intervals, center to center.", [["chip space", "PROBLEM", 9, 19], ["chip space", "OBSERVATION", 9, 19]]], ["For repeats and dilutions, each antigen will be printed at 0.5-1.0 mg/mL and also at a 1:10 dilution of the initial concentration.", [["repeats and dilutions", "TREATMENT", 4, 25], ["each antigen", "TREATMENT", 27, 39], ["the initial concentration", "TREATMENT", 104, 129]]], ["A given concentration of each preparation will be repeated at least three times to allow statistical analysis of detection of identical preparation at given antigen concentration.", [["A given concentration of each preparation", "TREATMENT", 0, 41], ["statistical analysis", "TEST", 89, 109], ["identical preparation", "TREATMENT", 126, 147], ["antigen concentration", "TREATMENT", 157, 178]]], ["For antibody isotype standard curves, antibodies of IgG, IgA, and IgM isotype of corresponding species serve as standard curves for antibody detection and normalization.Examination of the Presence of Antigens and Antibodies on the ArrayTo verify that we have successfully \"printed\" proteins, synthetic peptides, and carbohydrates, we incubate microarrays with antibodies, receptors, or lectins known to react with the printed substance.", [["carbohydrates", "CHEMICAL", 316, 329], ["IgG", "GENE_OR_GENE_PRODUCT", 52, 55], ["IgA", "GENE_OR_GENE_PRODUCT", 57, 60], ["antibody isotype", "PROTEIN", 4, 20], ["antibodies", "PROTEIN", 38, 48], ["IgG", "PROTEIN", 52, 55], ["IgA", "PROTEIN", 57, 60], ["IgM isotype", "PROTEIN", 66, 77], ["Antigens", "PROTEIN", 200, 208], ["Antibodies", "PROTEIN", 213, 223], ["antibodies", "PROTEIN", 360, 370], ["lectins", "PROTEIN", 386, 393], ["antibody isotype standard curves", "TEST", 4, 36], ["antibodies", "TEST", 38, 48], ["IgG", "TEST", 52, 55], ["IgA", "TEST", 57, 60], ["IgM isotype of corresponding species", "PROBLEM", 66, 102], ["standard curves", "TEST", 112, 127], ["antibody detection", "TEST", 132, 150], ["Examination", "TEST", 169, 180], ["Antigens", "PROBLEM", 200, 208], ["synthetic peptides", "TREATMENT", 292, 310], ["carbohydrates", "TREATMENT", 316, 329], ["IgM isotype", "OBSERVATION", 66, 77]]], ["The reaction is detected either directly by conjugating with a fluorochrome to the \"detector\" or by a second-step staining procedure.Staining and Scanning of Carbohydrate MicroarraysImmediately before use, the printed microarrays are rinsed with phosphate-buffered saline (PBS), pH 7.4, with 0.05% Tween 20 and then blocked by incubating the slides in 1% bovine serum albumin in PBS containing 0.05% NaN 3 at 37 C for 30 min.", [["serum", "ANATOMY", 362, 367], ["phosphate", "CHEMICAL", 246, 255], ["NaN", "CHEMICAL", 400, 403], ["Carbohydrate", "CHEMICAL", 158, 170], ["phosphate", "CHEMICAL", 246, 255], ["Tween 20", "CHEMICAL", 298, 306], ["fluorochrome", "SIMPLE_CHEMICAL", 63, 75], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 246, 271], ["bovine", "ORGANISM", 355, 361], ["serum", "ORGANISM_SUBSTANCE", 362, 367], ["albumin", "SIMPLE_CHEMICAL", 368, 375], ["PBS", "SIMPLE_CHEMICAL", 379, 382], ["bovine", "SPECIES", 355, 361], ["bovine", "SPECIES", 355, 361], ["The reaction", "PROBLEM", 0, 12], ["a fluorochrome", "TREATMENT", 61, 75], ["a second-step staining procedure", "TREATMENT", 100, 132], ["Carbohydrate Microarrays", "TREATMENT", 158, 182], ["the printed microarrays", "TREATMENT", 206, 229], ["phosphate-buffered saline (PBS", "TREATMENT", 246, 276], ["pH", "TEST", 279, 281], ["1% bovine serum albumin in PBS", "TREATMENT", 352, 382]]], ["They are then incubated at room temperature with serum specimens at given dilutions in 1% bovine serum albumin PBS containing 0.05% NaN 3 and 0.05% Tween-20.", [["serum specimens", "ANATOMY", 49, 64], ["serum", "ANATOMY", 97, 102], ["NaN", "CHEMICAL", 132, 135], ["Tween-20", "CHEMICAL", 148, 156], ["serum specimens", "ORGANISM_SUBSTANCE", 49, 64], ["bovine", "ORGANISM", 90, 96], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["albumin", "SIMPLE_CHEMICAL", 103, 110], ["Tween-20", "SIMPLE_CHEMICAL", 148, 156], ["bovine", "SPECIES", 90, 96], ["bovine", "SPECIES", 90, 96], ["serum specimens", "TEST", 49, 64], ["dilutions", "TEST", 74, 83], ["1% bovine serum albumin PBS", "TREATMENT", 87, 114]]], ["Next, antihuman (or other species) IgG, IgM, or IgA antibodies with distinct specific fluorescent tags (Cy3, Cy5, or FITC) are applied to reveal the bound antibodies according to their Ig heavy chain isotypes.", [["FITC", "CHEMICAL", 117, 121], ["antihuman", "GENE_OR_GENE_PRODUCT", 6, 15], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgA", "GENE_OR_GENE_PRODUCT", 48, 51], ["Cy3", "SIMPLE_CHEMICAL", 104, 107], ["Cy5", "SIMPLE_CHEMICAL", 109, 112], ["FITC", "SIMPLE_CHEMICAL", 117, 121], ["Ig heavy chain isotypes", "GENE_OR_GENE_PRODUCT", 185, 208], ["antihuman", "PROTEIN", 6, 15], ["IgG", "PROTEIN", 35, 38], ["IgM", "PROTEIN", 40, 43], ["IgA antibodies", "PROTEIN", 48, 62], ["bound antibodies", "PROTEIN", 149, 165], ["Ig heavy chain isotypes", "PROTEIN", 185, 208], ["antihuman", "TEST", 6, 15], ["other species", "TEST", 20, 33], ["IgG", "TEST", 35, 38], ["IgM", "TEST", 40, 43], ["IgA antibodies", "TEST", 48, 62], ["fluorescent tags", "TEST", 86, 102], ["Cy3, Cy5, or FITC)", "TEST", 104, 122], ["the bound antibodies", "PROBLEM", 145, 165], ["heavy", "OBSERVATION_MODIFIER", 188, 193], ["chain isotypes", "OBSERVATION", 194, 208]]], ["The stained slides are rinsed five times with PBS with 0.05% Tween-20 after each staining step.", [["Tween-20", "CHEMICAL", 61, 69], ["Tween-20", "SIMPLE_CHEMICAL", 61, 69], ["The stained slides", "TEST", 0, 18], ["PBS", "TEST", 46, 49]]], ["ScanArray 5000A is used to scan the microarray.", [["ScanArray 5000A", "DNA", 0, 15], ["ScanArray", "TEST", 0, 9], ["scan the microarray", "TEST", 27, 46]]], ["This instrument is a standard biochip scanning system (Perkin-Elmer) equipped with multiple lasers, emission filters and ScanArray acquisition software.Analysis of Microarray DataFluorescence intensity values for each array spot and its background are calculated using QuantArray software analysis packages.", [["a standard biochip scanning system", "TREATMENT", 19, 53], ["multiple lasers", "TREATMENT", 83, 98], ["emission filters", "TREATMENT", 100, 116], ["ScanArray acquisition software", "TEST", 121, 151], ["Microarray DataFluorescence intensity values", "TEST", 164, 208], ["each array spot", "TEST", 213, 228]]], ["Data for at least three replicates for each substance analyzed are collected on each chip (\"triple spotting\").Validation and Further Investigation of Microarray ObservationsIt is always astute to verify microarray data by other experimental approaches.", [["Microarray Observations", "TEST", 150, 173], ["microarray data", "TEST", 203, 218]]], ["We check our carbohydrate microararry findings by doing conventional immunoassays, e.g., ELISA, dot blot, Western blot, flow cytometry, and immunohistology.", [["carbohydrate", "CHEMICAL", 13, 25], ["conventional immunoassays", "TEST", 56, 81], ["ELISA", "TEST", 89, 94], ["dot blot", "TEST", 96, 104], ["Western blot", "TEST", 106, 118], ["flow cytometry", "TEST", 120, 134], ["immunohistology", "TEST", 140, 155]]], ["Examples of such investigations were described in our recent publications (1,3) .Promising Areas for Exploring Carbohydrate Microarray TechnologyAs described above, carbohydrates of multiple molecular configurations and of diverse sugar chain structures can be stably immobilized on a nitrocellulose-coated glass slide without chemical conjugation (1,3) .", [["Carbohydrate", "CHEMICAL", 111, 123], ["carbohydrates", "CHEMICAL", 165, 178], ["sugar", "CHEMICAL", 231, 236], ["nitrocellulose", "CHEMICAL", 285, 299], ["such investigations", "TEST", 12, 31], ["Carbohydrate Microarray Technology", "TREATMENT", 111, 145], ["diverse sugar chain structures", "PROBLEM", 223, 253], ["a nitrocellulose-coated glass slide", "TREATMENT", 283, 318], ["chemical conjugation", "TREATMENT", 327, 347], ["multiple", "OBSERVATION_MODIFIER", 182, 190], ["molecular configurations", "OBSERVATION", 191, 215]]], ["A direct application of this technology is in exploring the repertoires of human antibodies with anticarbohydrate activities.", [["human", "ORGANISM", 75, 80], ["human antibodies", "PROTEIN", 75, 91], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["this technology", "TREATMENT", 24, 39], ["human antibodies", "TREATMENT", 75, 91], ["anticarbohydrate activities", "TREATMENT", 97, 124]]], ["When a large collection of microbial carbohydrate antigens is arrayed on a sugar chip, such array would allow a simultaneous detection and characterization of a wide range of antibody reactivities and provide specific diagnostic information of infectious diseases.", [["infectious diseases", "DISEASE", 244, 263], ["carbohydrate", "CHEMICAL", 37, 49], ["sugar", "CHEMICAL", 75, 80], ["microbial carbohydrate antigens", "PROTEIN", 27, 58], ["a large collection of microbial carbohydrate antigens", "PROBLEM", 5, 58], ["a sugar chip", "TREATMENT", 73, 85], ["a simultaneous detection", "TEST", 110, 134], ["antibody reactivities", "PROBLEM", 175, 196], ["infectious diseases", "PROBLEM", 244, 263], ["large", "OBSERVATION_MODIFIER", 7, 12], ["collection", "OBSERVATION_MODIFIER", 13, 23], ["microbial carbohydrate antigens", "OBSERVATION", 27, 58]]], ["In combination with the use of semisynthetic glycoconjugates, which display unique oligosaccharide chains, a biochip-based characterization of the epitope-binding specificity of a single antibody or lectin and determination of the dominant antigenic responses elicited by a natural infection or a vaccination would be practically achievable.", [["infection", "DISEASE", 282, 291], ["lectin", "GENE_OR_GENE_PRODUCT", 199, 205], ["epitope", "PROTEIN", 147, 154], ["lectin", "PROTEIN", 199, 205], ["semisynthetic glycoconjugates", "TREATMENT", 31, 60], ["a biochip", "TEST", 107, 116], ["a single antibody or lectin", "PROBLEM", 178, 205], ["the dominant antigenic responses", "PROBLEM", 227, 259], ["a natural infection", "PROBLEM", 272, 291], ["a vaccination", "TREATMENT", 295, 308], ["oligosaccharide chains", "OBSERVATION", 83, 105], ["infection", "OBSERVATION", 282, 291]]], ["Similarly, this technology can be extended to monitor autoantibodies and tumorspecific or -associated anticarbohydrate activities.Promising Areas for Exploring Carbohydrate Microarray TechnologyThis novel approach can be applied to other biological systems in which a carbohydrate-carbohydrate or carbohydrate-protein interaction plays a significant role.", [["Carbohydrate", "CHEMICAL", 160, 172], ["carbohydrate", "CHEMICAL", 268, 280], ["carbohydrate", "CHEMICAL", 281, 293], ["carbohydrate", "CHEMICAL", 297, 309], ["carbohydrate", "SIMPLE_CHEMICAL", 297, 309], ["autoantibodies", "PROTEIN", 54, 68], ["autoantibodies", "TEST", 54, 68], ["Carbohydrate Microarray Technology", "TREATMENT", 160, 194], ["This novel approach", "TREATMENT", 194, 213], ["a carbohydrate-carbohydrate", "TREATMENT", 266, 293], ["carbohydrate-protein interaction", "TREATMENT", 297, 329]]], ["For example, a sugar chip can be applied in screening for the carbohydrate-based cellular receptors of a microorganism.", [["cellular", "ANATOMY", 81, 89], ["sugar", "CHEMICAL", 15, 20], ["carbohydrate", "CHEMICAL", 62, 74], ["cellular", "CELL", 81, 89], ["carbohydrate-based cellular receptors", "PROTEIN", 62, 99], ["a sugar chip", "TREATMENT", 13, 25], ["screening", "TEST", 44, 53], ["a microorganism", "PROBLEM", 103, 118]]], ["Experimentally, a candidate protein or the whole cell of a microbe can be placed on a sugar chip to probe the carbohydrate structures that a microbial pathogen may bind and selectively colonize in certain type of host cells or tissue environments.", [["cell", "ANATOMY", 49, 53], ["cells", "ANATOMY", 218, 223], ["tissue", "ANATOMY", 227, 233], ["sugar", "CHEMICAL", 86, 91], ["carbohydrate", "CHEMICAL", 110, 122], ["cell", "CELL", 49, 53], ["host cells", "CELL", 213, 223], ["tissue", "TISSUE", 227, 233], ["candidate protein", "PROTEIN", 18, 35], ["host cells", "CELL_TYPE", 213, 223], ["a sugar chip", "TREATMENT", 84, 96], ["a microbial pathogen", "PROBLEM", 139, 159], ["host cells", "OBSERVATION", 213, 223]]], ["Such investigation is noteworthy, because it may lead to a better understanding of the host-microbe biological relationship as well as the pathogenesis mechanism of human pathogens.", [["human", "ORGANISM", 165, 170], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["human pathogens", "PROBLEM", 165, 180]]], ["A reverse type of application is to print a large panel of structurally uncharacterized polysaccharides or glycoconjugates, such as those isolated from mixtures of natural herbs of traditional eastern medicines, to react with antibodies or lectins of known carbohydrate-binding specificities.", [["carbohydrate", "CHEMICAL", 257, 269], ["antibodies", "PROTEIN", 226, 236], ["glycoconjugates", "PROBLEM", 107, 122], ["natural herbs", "TREATMENT", 164, 177], ["traditional eastern medicines", "TREATMENT", 181, 210], ["known carbohydrate-binding specificities", "PROBLEM", 251, 291], ["large", "OBSERVATION_MODIFIER", 44, 49], ["structurally", "OBSERVATION_MODIFIER", 59, 71], ["uncharacterized", "OBSERVATION_MODIFIER", 72, 87], ["polysaccharides", "OBSERVATION_MODIFIER", 88, 103]]], ["In this way, the sugar chain epitope profile of these printed preparations can be rapidly recognized, providing important clues for drug discovery.", [["sugar", "CHEMICAL", 17, 22], ["the sugar chain epitope profile", "TEST", 13, 44]]], ["In addition, such sugar chain epitope mapping strategy is technically straightforward and is suitable to serve as a scanning method to verify and control the quality of a complex formula of herbal medicine or nutrition additives, which contain significant quantities of glycan components or lectins with carbohydrate-binding reactivities.Promising Areas for Exploring Carbohydrate Microarray TechnologyRecently, we have focused on the establishment of a glycomics strategy to facilitate identification of the sugar moieties of biological significance.", [["sugar", "CHEMICAL", 18, 23], ["carbohydrate", "CHEMICAL", 304, 316], ["Carbohydrate", "CHEMICAL", 368, 380], ["sugar", "CHEMICAL", 509, 514], ["lectins", "GENE_OR_GENE_PRODUCT", 291, 298], ["carbohydrate", "SIMPLE_CHEMICAL", 304, 316], ["sugar", "SIMPLE_CHEMICAL", 509, 514], ["such sugar chain epitope mapping strategy", "TREATMENT", 13, 54], ["a scanning method", "TEST", 114, 131], ["herbal medicine", "TREATMENT", 190, 205], ["nutrition additives", "TREATMENT", 209, 228], ["Carbohydrate Microarray TechnologyRecently", "TREATMENT", 368, 410], ["a glycomics strategy", "TREATMENT", 452, 472], ["significant", "OBSERVATION_MODIFIER", 244, 255]]], ["We proposed to take advantage of the highly evolved immune systems of mammals to recognize the immunogenic sugar moieties of microbes.", [["sugar", "CHEMICAL", 107, 112]]], ["Specifically, we use carbohydrate microarrays to capture specific antibodies elicited by a microorganism (see Fig. 3 for a schematic illustration of this approach).", [["carbohydrate", "CHEMICAL", 21, 33], ["antibodies", "PROTEIN", 66, 76], ["carbohydrate microarrays", "TREATMENT", 21, 45], ["specific antibodies", "TEST", 57, 76], ["a microorganism", "PROBLEM", 89, 104], ["this approach", "TREATMENT", 149, 162]]], ["To critically evaluate this strategy, we have chosen a previous unrecognized viral pathogen, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (32-34), as a model for our investigation.", [["viral pathogen", "DISEASE", 77, 91], ["acute respiratory syndrome-associated coronavirus", "DISEASE", 100, 149], ["SARS", "DISEASE", 151, 155], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 93, 149], ["SARS-CoV", "ORGANISM", 151, 159], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 93, 149], ["SARS-CoV", "SPECIES", 151, 159], ["a previous unrecognized viral pathogen", "PROBLEM", 53, 91], ["severe acute respiratory syndrome", "PROBLEM", 93, 126], ["associated coronavirus", "PROBLEM", 127, 149], ["our investigation", "TEST", 185, 202], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126], ["coronavirus", "OBSERVATION_MODIFIER", 138, 149]]], ["This task was difficult and challenging, because information regarding the sugar moieties of this virus was entirely unavailable.", [["sugar", "CHEMICAL", 75, 80], ["sugar", "SIMPLE_CHEMICAL", 75, 80], ["this virus", "PROBLEM", 93, 103]]], ["This information is, however, very important for our consideration of vaccination strategy against SARS-CoV as well as investigation of pathogenic mechanisms of SARS.", [["SARS-CoV", "DISEASE", 99, 107], ["SARS", "DISEASE", 161, 165], ["SARS-CoV", "ORGANISM", 99, 107], ["SARS-CoV", "SPECIES", 99, 107], ["vaccination strategy", "TREATMENT", 70, 90], ["SARS", "PROBLEM", 99, 103], ["SARS", "PROBLEM", 161, 165]]], ["Therefore, we constructed glycan arrays to display carbohydrate antigens of defined structures and subsequently applied these tools to detect carbohydrate-specific antibody \"fingerprints\" that were elicited by a SARS vaccine.", [["SARS", "DISEASE", 212, 216], ["carbohydrate", "CHEMICAL", 51, 63], ["carbohydrate", "CHEMICAL", 142, 154], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 51, 72], ["carbohydrate", "SIMPLE_CHEMICAL", 142, 154], ["carbohydrate antigens", "PROTEIN", 51, 72], ["carbohydrate antigens of defined structures", "PROBLEM", 51, 94], ["these tools", "TEST", 120, 131], ["carbohydrate", "TEST", 142, 154], ["a SARS vaccine", "TREATMENT", 210, 224]]], ["Our rational was that if SARS-CoV expressed antigenic carbohydrate structures, then immunizing animals by using the whole virus-based vaccines would have the possibility to elicit antibodies specific for these structures.", [["carbohydrate", "CHEMICAL", 54, 66], ["SARS-CoV", "ORGANISM", 25, 33], ["antibodies", "PROTEIN", 180, 190], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["immunizing animals", "TREATMENT", 84, 102], ["the whole virus-based vaccines", "TREATMENT", 112, 142]]], ["In addition, if SARS-CoV displayed a carbohydrate structure that mimics host cellular glycans, then vaccinated animals may develop antibodies with autoimmune reactivity to their corresponding cellular glycans.Promising Areas for Exploring Carbohydrate Microarray TechnologyBy characterizing the SARS-CoV neutralizing antibodies elicited by an inactivated SARS-CoV vaccine, we detected autoantibody reactivity specific for the carbohydrate moieties of an abundant human serum glycoprotein asialo-orosomucoid (ASOR) (Fig. 3B) .", [["cellular", "ANATOMY", 77, 85], ["cellular", "ANATOMY", 192, 200], ["serum", "ANATOMY", 469, 474], ["SARS", "DISEASE", 16, 20], ["carbohydrate", "CHEMICAL", 37, 49], ["Carbohydrate", "CHEMICAL", 239, 251], ["carbohydrate", "CHEMICAL", 426, 438], ["SARS-CoV", "ORGANISM", 16, 24], ["cellular", "CELL", 77, 85], ["cellular", "CELL", 192, 200], ["SARS-CoV", "ORGANISM", 295, 303], ["SARS-CoV", "ORGANISM", 355, 363], ["human", "ORGANISM", 463, 468], ["serum", "ORGANISM_SUBSTANCE", 469, 474], ["asialo-orosomucoid", "GENE_OR_GENE_PRODUCT", 488, 506], ["ASOR", "GENE_OR_GENE_PRODUCT", 508, 512], ["antibodies", "PROTEIN", 131, 141], ["SARS-CoV neutralizing antibodies", "PROTEIN", 295, 327], ["carbohydrate moieties", "PROTEIN", 426, 447], ["human serum glycoprotein asialo", "PROTEIN", 463, 494], ["orosomucoid", "PROTEIN", 495, 506], ["ASOR", "PROTEIN", 508, 512], ["human", "SPECIES", 463, 468], ["SARS-CoV", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 295, 303], ["SARS-CoV", "SPECIES", 355, 363], ["human", "SPECIES", 463, 468], ["SARS", "PROBLEM", 16, 20], ["CoV", "PROBLEM", 21, 24], ["host cellular glycans", "PROBLEM", 72, 93], ["antibodies", "PROBLEM", 131, 141], ["autoimmune reactivity", "PROBLEM", 147, 168], ["Carbohydrate Microarray", "TEST", 239, 262], ["the SARS", "PROBLEM", 291, 299], ["CoV neutralizing antibodies", "TEST", 300, 327], ["an inactivated SARS", "PROBLEM", 340, 359], ["CoV vaccine", "TREATMENT", 360, 371], ["autoantibody reactivity", "TEST", 385, 408], ["the carbohydrate moieties", "TEST", 422, 447]]], ["For array I (Fig. 3A,B) , a glycan array that contains 51 antigens (0.5 ng/microspot) was constructed and applied to scan horse anti-Pn 18 serum (Fig. 3A) as well as anti-SARS neutralizing antibodies (Fig. 3B) .Promising Areas for Exploring Carbohydrate Microarray TechnologyFor array II (Fig. 3C,D) , a glycan array that displays 24 antigens, many of preparations of Gal-containing carbohydrate antigens, was stained by lectin PHA-L (Fig. 3C) , which is specific for Gal 1,4-N-acetylglucosamine-linked units, and by lectin GS1-B4 (Fig. 3D) , which is considered to be specific for This surveillance provides important clues for the selection of specific immunological probes to further examine whether SARS-CoV expresses antigenic structures that imitate the host glycan.", [["serum", "ANATOMY", 139, 144], ["Gal 1,4-N-acetylglucosamine", "CHEMICAL", 468, 495], ["Carbohydrate", "CHEMICAL", 241, 253], ["carbohydrate", "CHEMICAL", 383, 395], ["Gal 1,4-N-acetylglucosamine", "CHEMICAL", 468, 495], ["horse", "ORGANISM", 122, 127], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["anti-SARS neutralizing antibodies", "GENE_OR_GENE_PRODUCT", 166, 199], ["Gal-containing carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 368, 404], ["PHA-L", "GENE_OR_GENE_PRODUCT", 428, 433], ["Fig. 3C", "GENE_OR_GENE_PRODUCT", 435, 442], ["Gal 1,4-N-acetylglucosamine", "SIMPLE_CHEMICAL", 468, 495], ["GS1-B4", "GENE_OR_GENE_PRODUCT", 524, 530], ["SARS-CoV", "ORGANISM", 703, 711], ["51 antigens", "PROTEIN", 55, 66], ["anti-SARS neutralizing antibodies", "PROTEIN", 166, 199], ["Fig. 3B", "PROTEIN", 201, 208], ["Gal-containing carbohydrate antigens", "PROTEIN", 368, 404], ["lectin PHA-L (Fig. 3C", "PROTEIN", 421, 442], ["Gal 1,4-N-acetylglucosamine-linked units", "PROTEIN", 468, 508], ["GS1", "PROTEIN", 524, 527], ["B4", "PROTEIN", 528, 530], ["horse", "SPECIES", 122, 127], ["SARS-CoV", "SPECIES", 703, 711], ["a glycan array", "TREATMENT", 26, 40], ["scan horse anti-Pn", "TEST", 117, 135], ["anti-SARS neutralizing antibodies", "TREATMENT", 166, 199], ["Carbohydrate Microarray Technology", "TREATMENT", 241, 275], ["a glycan array", "TEST", 302, 316], ["Gal-containing carbohydrate antigens", "PROBLEM", 368, 404], ["lectin PHA", "TEST", 421, 431], ["Gal", "TEST", 468, 471], ["N-acetylglucosamine", "TREATMENT", 476, 495], ["This surveillance", "TEST", 582, 599], ["SARS", "PROBLEM", 703, 707], ["CoV expresses antigenic structures", "PROBLEM", 708, 742]]], ["We found that lectin PHA-L (for Phaseolus vulgaris L.) is specific for a defined complex carbohydrate of ASOR (Fig. 3C,D) .", [["PHA-L", "CHEMICAL", 21, 26], ["carbohydrate", "CHEMICAL", 89, 101], ["lectin PHA-L", "GENE_OR_GENE_PRODUCT", 14, 26], ["Phaseolus vulgaris L.", "ORGANISM", 32, 53], ["PHA", "PROTEIN", 21, 24], ["ASOR", "PROTEIN", 105, 109], ["Fig. 3C,D", "PROTEIN", 111, 120], ["Phaseolus vulgaris", "SPECIES", 32, 50], ["L.", "SPECIES", 51, 53], ["Phaseolus vulgaris L.", "SPECIES", 32, 53], ["lectin PHA", "TEST", 14, 24], ["Phaseolus vulgaris L.", "PROBLEM", 32, 53]]], ["Using this reagent as a probe, we confirmed that only the SARS-CoV-infected cells express a PHA-L-reactive antigenic structure (see ref.", [["cells", "ANATOMY", 76, 81], ["PHA", "CHEMICAL", 92, 95], ["SARS-CoV", "ORGANISM", 58, 66], ["cells", "CELL", 76, 81], ["PHA", "SIMPLE_CHEMICAL", 92, 95], ["SARS-CoV-infected cells", "CELL_LINE", 58, 81], ["PHA-L-reactive antigenic structure", "PROTEIN", 92, 126], ["SARS-CoV", "SPECIES", 58, 66], ["this reagent", "TREATMENT", 6, 18], ["the SARS", "TEST", 54, 62], ["infected cells", "PROBLEM", 67, 81], ["a PHA", "TEST", 90, 95], ["reactive antigenic structure", "PROBLEM", 98, 126], ["infected cells", "OBSERVATION", 67, 81], ["reactive", "OBSERVATION_MODIFIER", 98, 106], ["antigenic structure", "OBSERVATION", 107, 126]]], ["We obtained, therefore, immunologic evidences that a carbohydrate structure of SARS-CoV shares antigenic similarity with host glycan complex carbohydrates.", [["SARS", "DISEASE", 79, 83], ["carbohydrate", "CHEMICAL", 53, 65], ["carbohydrates", "CHEMICAL", 141, 154], ["SARS-CoV", "ORGANISM", 79, 87], ["SARS-CoV", "SPECIES", 79, 87], ["SARS", "PROBLEM", 79, 83], ["host glycan complex carbohydrates", "TREATMENT", 121, 154]]], ["This viral component is probably responsible for the stimulation of the autoantibodies directed at a cellular glycan complex carbohydrate.Promising Areas for Exploring Carbohydrate Microarray TechnologyThese observations raise important questions about whether autoimmune responses are indeed elicited by SARS-CoV infection and whether such autoimmunogenicity contributes to SARS pathogenesis.", [["cellular", "ANATOMY", 101, 109], ["SARS-CoV infection", "DISEASE", 305, 323], ["SARS", "DISEASE", 375, 379], ["carbohydrate", "CHEMICAL", 125, 137], ["Carbohydrate", "CHEMICAL", 168, 180], ["cellular", "CELL", 101, 109], ["SARS-CoV", "ORGANISM", 305, 313], ["autoantibodies", "PROTEIN", 72, 86], ["cellular glycan complex carbohydrate", "PROTEIN", 101, 137], ["SARS-CoV", "SPECIES", 305, 313], ["This viral component", "PROBLEM", 0, 20], ["the autoantibodies", "PROBLEM", 68, 86], ["Carbohydrate Microarray Technology", "TREATMENT", 168, 202], ["autoimmune responses", "PROBLEM", 261, 281], ["SARS", "PROBLEM", 305, 309], ["CoV infection", "PROBLEM", 310, 323], ["such autoimmunogenicity", "PROBLEM", 336, 359], ["SARS pathogenesis", "PROBLEM", 375, 392], ["probably responsible for", "UNCERTAINTY", 24, 48], ["infection", "OBSERVATION", 314, 323]]], ["ASOR is an abundant human serum glycoprotein and the ASOR-type complex carbohydrates are also expressed by other host glycoproteins (35,36) .", [["serum", "ANATOMY", 26, 31], ["carbohydrates", "CHEMICAL", 71, 84], ["ASOR", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 20, 25], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["ASOR", "GENE_OR_GENE_PRODUCT", 53, 57], ["ASOR", "PROTEIN", 0, 4], ["human serum glycoprotein", "PROTEIN", 20, 44], ["ASOR", "PROTEIN", 53, 57], ["host glycoproteins", "PROTEIN", 113, 131], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["an abundant human serum glycoprotein", "PROBLEM", 8, 44], ["the ASOR-type complex carbohydrates", "TREATMENT", 49, 84]]], ["Thus, the human immune system is generally nonresponsive to these selfcarbohydrate structures.", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["the human immune system", "TEST", 6, 29]]], ["However, when similar sugar moieties were expressed by a viral glycoprotein, their cluster configuration could differ significantly from those displayed by a cellular glycan, and in this manner, generate a novel nonself antigenic structure.", [["cellular", "ANATOMY", 158, 166], ["sugar", "CHEMICAL", 22, 27], ["sugar moieties", "SIMPLE_CHEMICAL", 22, 36], ["cellular", "CELL", 158, 166], ["viral glycoprotein", "PROTEIN", 57, 75], ["nonself antigenic structure", "PROTEIN", 212, 239], ["similar sugar moieties", "PROBLEM", 14, 36], ["a viral glycoprotein", "PROBLEM", 55, 75], ["viral glycoprotein", "OBSERVATION", 57, 75], ["cellular glycan", "OBSERVATION", 158, 173]]], ["A documented example of such antigenic structure is a broad-range HIV-1 neutralization epitope recognized by a monoclonal antibody 2G12.", [["HIV-1", "ORGANISM", 66, 71], ["monoclonal antibody 2G12", "PROTEIN", 111, 135], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["such antigenic structure", "PROBLEM", 24, 48], ["1 neutralization epitope", "TREATMENT", 70, 94], ["a monoclonal antibody 2G12", "TREATMENT", 109, 135]]], ["This antibody is specific for a unique cluster of sugar chains displayed by the gp120 glycoprotein of HIV-1 (37).", [["sugar", "CHEMICAL", 50, 55], ["HIV-1", "ORGANISM", 102, 107], ["sugar chains", "PROTEIN", 50, 62], ["gp120 glycoprotein", "PROTEIN", 80, 98], ["HIV-1", "SPECIES", 102, 107], ["HIV-1", "SPECIES", 102, 107], ["This antibody", "TEST", 0, 13], ["sugar chains", "TEST", 50, 62], ["HIV", "TEST", 102, 105], ["sugar chains", "OBSERVATION", 50, 62]]], ["It is, hence, important to examine whether naturally occurring SARS-CoV expresses the ASOR-type autoimmune reactive sugar moieties.", [["SARS", "DISEASE", 63, 67], ["sugar", "CHEMICAL", 116, 121], ["SARS-CoV", "ORGANISM", 63, 71], ["ASOR", "GENE_OR_GENE_PRODUCT", 86, 90], ["reactive sugar moieties", "SIMPLE_CHEMICAL", 107, 130], ["ASOR", "PROTEIN", 86, 90], ["SARS-CoV", "SPECIES", 63, 71], ["naturally occurring SARS", "PROBLEM", 43, 67]]], ["During a SARS epidemic spread, the viruses replicate in human cells.", [["cells", "ANATOMY", 62, 67], ["SARS", "DISEASE", 9, 13], ["human", "ORGANISM", 56, 61], ["cells", "CELL", 62, 67], ["human cells", "CELL_TYPE", 56, 67], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["a SARS epidemic spread", "PROBLEM", 7, 29], ["the viruses replicate in human cells", "PROBLEM", 31, 67], ["viruses", "OBSERVATION", 35, 42], ["human cells", "OBSERVATION", 56, 67]]], ["Their sugar chain expression may differ from the monkey cell-produced viral particles.", [["cell", "ANATOMY", 56, 60], ["sugar", "CHEMICAL", 6, 11], ["sugar chain", "GENE_OR_GENE_PRODUCT", 6, 17], ["monkey", "ORGANISM", 49, 55], ["cell", "CELL", 56, 60], ["monkey cell", "CELL_TYPE", 49, 60], ["viral particles", "PROBLEM", 70, 85], ["viral particles", "OBSERVATION", 70, 85]]], ["Scanning of the serum antibodies of SARS patients by using glycan arrays or other specific immunological tools may endow with information to shed light on this question.Promising Areas for Exploring Carbohydrate Microarray TechnologyIn synopsis, recent establishment of carbohydrate-based microarrays, and especially the availability of different technological platforms to meet the multiple needs of carbohydrate research, marks an important developmental stage of postgenomic research (1,20-24,38).", [["serum", "ANATOMY", 16, 21], ["SARS", "DISEASE", 36, 40], ["Carbohydrate", "CHEMICAL", 199, 211], ["carbohydrate", "CHEMICAL", 270, 282], ["carbohydrate", "CHEMICAL", 401, 413], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["patients", "ORGANISM", 41, 49], ["serum antibodies", "PROTEIN", 16, 32], ["patients", "SPECIES", 41, 49], ["Scanning", "TEST", 0, 8], ["the serum antibodies", "TEST", 12, 32], ["SARS", "PROBLEM", 36, 40], ["glycan arrays", "TREATMENT", 59, 72], ["other specific immunological tools", "PROBLEM", 76, 110], ["Carbohydrate Microarray Technology", "TREATMENT", 199, 233], ["carbohydrate-based microarrays", "TREATMENT", 270, 300], ["carbohydrate research", "TREATMENT", 401, 422], ["developmental stage", "OBSERVATION_MODIFIER", 443, 462]]], ["Our laboratory has established a simple, precise, and highly efficient experimental approach for the construction of carbohydrate microarrays (1-3) .", [["carbohydrate", "CHEMICAL", 117, 129], ["carbohydrate microarrays", "TREATMENT", 117, 141]]], ["This approach makes use of existing cDNA microarray system, including spotter and scanner, for carbohydrate array production.", [["carbohydrate", "CHEMICAL", 95, 107], ["existing cDNA microarray system", "TREATMENT", 27, 58], ["carbohydrate array production", "TREATMENT", 95, 124]]], ["A key technical element of this array platform is the introduction of nitrocellulose-coated microglass slides to immobilize unmodified carbohydrate antigens on the chip surface noncovalently.", [["surface", "ANATOMY", 169, 176], ["nitrocellulose", "CHEMICAL", 70, 84], ["carbohydrate", "CHEMICAL", 135, 147], ["microglass slides", "SIMPLE_CHEMICAL", 92, 109], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 135, 156], ["unmodified carbohydrate antigens", "PROTEIN", 124, 156], ["nitrocellulose-coated microglass slides", "TREATMENT", 70, 109], ["the chip surface noncovalently", "TREATMENT", 160, 190]]], ["This technology has achieved the sensitivity to recognize the profiles of human anti-carbohydrate antibodies with as little as a few microliters of serum specimen and reached the chip capacity to include the antigenic preparations of most common pathogens (~20,000 microspots per biochip).", [["serum specimen", "ANATOMY", 148, 162], ["human", "ORGANISM", 74, 79], ["anti-carbohydrate antibodies", "GENE_OR_GENE_PRODUCT", 80, 108], ["serum specimen", "ORGANISM_SUBSTANCE", 148, 162], ["human anti-carbohydrate antibodies", "PROTEIN", 74, 108], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["human anti-carbohydrate antibodies", "TREATMENT", 74, 108], ["serum specimen", "TEST", 148, 162], ["the chip capacity", "PROBLEM", 175, 192], ["the antigenic preparations", "TREATMENT", 204, 230], ["most common pathogens", "PROBLEM", 234, 255]]], ["We described also an eight-chamber subarray system to produce carbohydrate microarrays of relative smaller scale, which is more frequently applied in our laboratory's routine research activities.", [["carbohydrate", "CHEMICAL", 62, 74], ["carbohydrate microarrays", "TREATMENT", 62, 86], ["relative smaller scale", "TREATMENT", 90, 112], ["smaller", "OBSERVATION_MODIFIER", 99, 106]]], ["Of late, we applied this system to assemble glycan arrays to probe the immunogenic sugar moieties of a recently discovered viral pathogen, SARS-CoV.", [["SARS", "DISEASE", 139, 143], ["sugar", "CHEMICAL", 83, 88], ["SARS-CoV", "ORGANISM", 139, 147], ["SARS-CoV", "SPECIES", 139, 147], ["this system", "TREATMENT", 20, 31], ["glycan arrays", "TREATMENT", 44, 57], ["viral pathogen", "PROBLEM", 123, 137], ["viral pathogen", "OBSERVATION", 123, 137]]], ["This research approach is probably applicable for the identification of immunological targets of other microorganisms and for the exploration of complex carbohydrates that are differentially expressed by host cells, including stem cells at various stages of differentiation and human cancers.", [["cells", "ANATOMY", 209, 214], ["stem cells", "ANATOMY", 226, 236], ["cancers", "ANATOMY", 284, 291], ["cancers", "DISEASE", 284, 291], ["carbohydrates", "CHEMICAL", 153, 166], ["host cells", "CELL", 204, 214], ["stem cells", "CELL", 226, 236], ["human", "ORGANISM", 278, 283], ["cancers", "CANCER", 284, 291], ["host cells", "CELL_TYPE", 204, 214], ["stem cells", "CELL_TYPE", 226, 236], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 278, 283], ["This research approach", "TREATMENT", 0, 22], ["other microorganisms", "PROBLEM", 97, 117], ["the exploration", "TEST", 126, 141], ["complex carbohydrates", "PROBLEM", 145, 166], ["host cells", "PROBLEM", 204, 214], ["stem cells", "PROBLEM", 226, 236], ["human cancers", "PROBLEM", 278, 291], ["host cells", "OBSERVATION", 204, 214], ["stem cells", "OBSERVATION", 226, 236], ["human cancers", "OBSERVATION", 278, 291]]]]}